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Abstract 
When cannabis-based medicine was withdrawn in the UK in 1973 it appeared 
cannabis' career as a medicine had ended, but even as cannabis became regulated solely 
as an illicit drug, it appeared it was being re-medicalized. This thesis, framed as a history 
of science and policy-making, studied cannabis' re-medicalization from 1973 and in 
so doing analysed the process whereby boundaries shift between illicit 'drug' and licit 
'medicine' and the issues and interests involved. 
It argues that changing scientific knowledge, from the synthesis ofTHC to the 
discovery of the endocannabinoid system, spurred by individual scientists, developing 
scientific disciplines, and advances in technology all contributed to a shifting 
environment around cannabis and opened-up new avenues for cannabis as a medicine. 
Initially, interest and funding were directed to the cannabis field through political and 
social fears over cannabis' recreational. Driven by drug control imperatives expert 
committees, in particular, the working groups of the Advisory Council on the Misuse of 
Drugs provided an early arena for discussion and stimulated research on cannabis which 
led ultimately to increased research on medical applications. The study reveals that 
although international and domestic drug control systems acted as countervailing forces, 
they provided spurs to re-medicalization as pressure mounted to isolate calls for medical 
cannabis from legalization arguments. In transforming the concept of cannabis, the drug, 
into cannabis, the medicine, the pharmaceutical industry was fundamental, through the 
provision of synthetic cannabinoids and finally plant extracts with the development of 
OW Phannaceuticals and their product Sativex. The incentive to study cannabis as a 
medicine would not have emerged, as it did, without user activism and the thesis argues 
that in the UK it was pressure from Multiple Sclerosis sufferers that encouraged research 
and its direction. Once legitimacy was conferred by influential professional bodies, such 
as the BMA, and the House of Lords there was a concerted effort to place cannabis into 
the clinical trial system and through regulatory processes. Re-medicalization could exist 
within the drug control system and discourse shifted towards the drug control framework 
and the relative positions of both licit and illicit drugs. 
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Introduction 
'Britain's drugs crisis: Recipe for dangerous medicine. H 
The psychiatrists Griffith Edwards and John Strang used this catchy headline in 1994 
to make their case for the maintenance of the drug control system and to emphasize 
the dangers of drug legalization. However, the phrase could apply equally to cannabis 
in its role as a therapeutic within the drug control framework. Cannabis is a complex 
substance, both because of its own structure and the baggage that it carries. The 
position of cannabis in society has been determined by different stakeholders at different 
times, each claiming different roles for the plant. In the twentieth century cannabis 
constituted a headache for both medical and illicit drug regulators. Its multifaceted 
and fluid role has meant that cannabis proved difficult to classify definitively and yet 
its relationship to other drugs, medical and recreational, is important as its borderline 
position acts as a spotlight onto drug policy. 
Cannabis was introduced to the UK as a medical product in the nineteenth 
century. Questions quickly emerged over its safety, efficacy and its relative position, 
in terms of harm, to other drugs. However, as it was not widely used as a medicine 
or even recreationally, and it quickly became caught up in developing drug legislation 
aimed at more widely used drugs like opium. Its medical role had diminished by the 
1950s and cannabis became viewed mainly as a drug of misuse as regulation around 
medical and recreational drugs was tightened. Both frameworks were in flux and 
their development eroded cannabis' role as a medical product. In 1961 cannabis was 
brought under the control of the UN Single Convention on Narcotic Substances. The 
convention introduced four Schedules into which drugs were classified, with Schedule 
I and IV the most stringent. Cannabis and cannabis resin along with heroin were listed 
in Schedule I and Schedule IV, which entitled parties to adopt 'special measures of 
control' , and to ban them altogether apart from medical or scientific research. Cannabis, 
in the form of extracts or tinctures, was placed in the slightly less restrictive Schedule 
I alongside morphine. The UK ratified this convention and the Dangerous Drugs Act 
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of 1964 enacted the provisions necessary for compliance and created the offence of 
the cultivation of cannabis. This was succeeded by subsequent Dangerous Drugs Acts 
(DDA) such as the DDA of 1965 which consolidated previous acts and the DDA of 
1967 which introduced policies of stop and search. Many drugs had dual structures 
and drugs within the Act could be made available as medicines as there existed some 
overlap between controlled illicit drugs and the regulation of medicines. Cannabis 
as a medicine was still permissible and when the 1968 Medicines Control Act was 
introduced, extracts of cannabis, in the form of tinctures were made available on 
prescription via a 'product licence of right', (PLR). However, in the 1970s cannabis lost 
its dual structure. In 1971 the UN Convention on Psychotropic Substances consolidated 
previous legislation and incorporated emergent synthetic psychotropic drugs. Cannabis-
based drugs were placed in Schedule I which included substances that had no, or very 
limited, medical value. Cannabis remained controlled under the Single Convention.2 
These conventions were open to interpretation and parties to the conventions, 
such as the UK, US and Holland, took different approaches to drug control. The 
US domestic legislation, for example, excluded medical use for substances listed in 
Schedule I oftheir domestic Controlled Substances Act, although the international 
conventions permitted limited use. The Misuse of Drugs Act of 1971 was enacted in 
the UK and introduced the term 'controlled drugs.' The main purpose of the Act was to 
prevent the misuse of controlled drugs and it imposed a complete ban on the possession, 
supply, manufacture, import and export of controlled drugs except as allowed by 
regulations or by licence from the Secretary of State. It introduced the statutory body, 
the Advisory Council on the Misuse of Drugs (ACMD) to advise government. Schedule 
II of the Act identified the drugs that were to be controlled and these were divided into 
three classes: A, Band C. The level of classification determined the gravity of penalties 
that could be imposed under criminal law for an infringement of the Act. Drugs derived 
from cannabis, for example, cannabinoids such as cannabinol (CBD) and THC were 
placed in Class A. Cannabis and cannabis resin were listed as Class B, which enabled 
cannabis to be used under licence from the Home Office for research purposes or for 
clinical trials with permission from the Medicines Control Agency. Regulations to the 
Act permitted exemptions for legitimate activities such as the medical use of controlled 
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drugs but the medical chest was stripped of the last remaining cannabis ingredient 
when these came into force. 3 When the "product licences of right' were reviewed by the 
Medicines Control Agency, cannabis' licence was not renewed and when the oriainal 
b 
regulations of the Misuse of Drugs Act were enacted in 1973 cannabis was placed 
in Schedule 4, now Schedule I of Misuse of Drugs Regulations, which comprised of 
substances with no known or limited medical use, and was therefore not exempted 
under the regulations. Cannabis, in any form, could no longer be prescribed and 
therefore was left under the sole control of illicit drug regulation. 
At face value these moves could have closed down cannabis' career as a medical 
drug but, even as it was removed, cannabis was beginning its comeback as a licit 
medicine and concerns were raised over the illicit drug classification system. The 
situation that existed in 1973 was open to re-evaluation and the removal of cannabis-
based medicine from the medicine cabinet was perhaps a hiatus in the plant's history. 
Scientific and lay knowledge around cannabis expanded from the 1960s onwards and 
cannabis re-appeared in different therapeutic forms for a range of uses including, as 
an anti-emetic, as an appetite stimulate for AIDS related wasting, as an anti-glaucoma 
agent, for the treatment of asthma, and for neurological disorders including epilepsy 
and Multiple Sclerosis (MS) as well as an analgesic. Different forms of cannabis were 
important at different stages. Two primary phytotherapeutic cannabinoids emerged, 
THC and CBD followed by synthetic cannabinoids such as nabilone. Within ten years 
of cannabis tinctures' removal in the UK, synthetic cannabis-based drugs entered 
the clinic. These drugs were little used and had numerous problems, not least their 
placement in the most restrictive schedules of drug control systems, and patient pressure 
drove demand for additional products. Cannabis, in a botanical form, appeared to offer 
a more effective way forward for patients who self-medicated and for a small start-up 
UK pharmaceutical firm which was developed specifically to look at herbal cannabis. It 
developed a cannabis-based medicine, Sativex, in an attempt to bring cannabis extracts 
back to the medical market. Expert committees and professional bodies delved into 
therapeutic cannabis and clinical trials were initiated to move anecdotal reports of 
efficacy onto an evidence-base for both synthetic and plant derived cannabis-based 
drugs. Emergent medical use helped to re-open debates on cannabis and drug policy. 
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With cannabis' twin roles being re-instated, the concept of cannabis therapeutics became 
tied up with drug control discussions from the 1970s onwards. Cannabis' position in 
the Misuse of Drugs Act had always been controversial in the UK and it appeared that 
the policy environment around cannabis had shifted when it was downgraded in 2004 
to Class C. Sativex was licensed in Canada and provided to patients, in the UK, on a 
named-patient basis, circumventing the UK regulatory process and it appeared that it 
might shortly be made a licensed medicine in Europe. Highly controlled pharmaceutical 
cannabis derivatives like dronabinol were transferred to less restrictive schedules in 
the international and US scheduling systems to facilitate their entry into the market. In 
the US one previously abandoned cannabis-based drug, nabilone, was returned to the 
market in May 2006 by Valeant Pharmaceuticals and was licensed by the FDA as an 
anti-nausea drug in cancer chemotherapy management.4 1t appeared that cannabis was 
moving more in-line with opium and morphine in that it could exist legitimately in both 
the controlled illicit drug and licit medical structures. 
Re-medicalizing cannabis 
The process of re-medicalization raises many questions. Why was cannabis re-
considered as a medicine? To what extent was it re-medicalized and how did this 
process take place? What was the impact of cannabis' role as a medicine on discussions 
of drug policy and vice versa? Yet, while there is useful existent research on the history 
of cannabis and related themes such as user activism and the pharmaceutical industry, 
there is little research on the therapeutic use of cannabis in the UK from 1973-2004 
when cannabis therapeutics developed within the context of fluid drug control policies. 
This thesis was framed therefore as a history of science and policy-making. It began 
from the hypothesis that the re-medicalization of cannabis was underway and was 
important for the environment in which UK policy on cannabis was constructed. 
Re-medicalization was defined as the introduction of medical uses and structures for 
the drug, as distinct from non-medical illicit usage and control structures. It recognized 
that full re-medicalization had not been established but rather sought to examine the 
intervening stages of that transition, from research, to product development, to clinical 
trials, and regulation. The project aimed to study the process whereby boundaries 
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shift between illicit 'drug' and licit 'medicine'. It considered what kind of 'borderline 
substance' (the regulatory term used for tobacco) cannabis had become. To understand 
the process of re-medicalization the thesis aimed to analyze the trajectory of scientific 
research after the removal of cannabis tincture in 1973 and the interests involved , 
in particular, the role of scientific research and allied professions; industry; drug 
technology; and user activism. Within this it sought to consider the interaction of 
science and medicine with policy through an examination of the policy role of expert 
committees and the impact of re-medicalization on the policy environment. It focused 
primarily on the UK, although some account was taken of different national contexts. 
Its main focus was from 1973 when cannabis was dropped as a medicine to 2004 when 
cannabis was downgraded to Class C and follow-up clinical trials had been initiated 
and an additional submission for Sativex to the European Agency for the Evaluation of 
Medicinal Products was about to begin. It did, however, take account of developments 
just prior to 1973 which enabled research in the 1970s to take-off, as well as important 
developments that occurred after the main research period of the thesis but whilst 
research and writing-up took place. It drew inspiration from a rich supply of archival 
material and key informant interviews. 
Defining cannabis 
If the process of re-medicalizing cannabis was complex so too is the terminology used 
to describe what was happening during the process. The terms drug, cannabis, and 
even medicine can have a multitude of different meanings. Medicine and drug have 
often been used interchangeably but this is not always appropriate. The term drug has 
become increasingly linked to illicit recreational substances, whereas traditionally the 
term would have been applied to the active ingredient of a medicine. The use of terms 
such as pharmaceutics, and therapeutics also confuse the issue.5 In direct relation to 
cannabis there are different terms in common use for the plant: cannabis; marihuana; 
marijuana; ganja; as well as the more common parlance of pot; weed; grass; or skunk. 
These terms are used generally to refer to the dried flowers, stems or leaves of female 
cannabis plants. I have used the UK version throughout, referring to cannabis even 
when discussion of American developments refers to marijuana or marihuana. Then 
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there are the different terms which refer to parts of cannabis usually in relation to their 
non-medical use such as cannabis resin or hashish, a substance produced from the resin 
of the flowers which produces a more potent substance than the dried leaves. The term 
cannabis can also cover a number of different cannabis species: Cannabis indica and 
Cannabis sativa. Different versions have been more popular at different times and 
places and have different components and activities. Hemp, for example, refers to the 
variant which does not contain a psychoactive element and in Europe was most widely 
used in rigging for ship's sails. 
Cannabis can contain over sixty compounds termed cannabinoids (or since 1999 the 
term phytocannabinoids has been suggested) such as cannabidiol (CBD) or cannabinol 
(CBN) and delta-9 tetrahydrocannabinol (THC), each with different functions. 
Phytocannabinoids or phytomedicines are those extracted from a plant as opposed 
to a synthetic chemical. Different variants and different growing conditions can 
lead to the production of different amounts of these constituents. Several medicines 
have been developed from cannabis. In the thesis for the sake of simplicity I refer to 
cannabis-based medicines, but this term can cover a variety of different types. From 
1973, interest focused on the active psychoactive principle of cannabis, THe. This 
was followed by the development of synthetic rather than phytocannabinoids such as 
synthetic versions ofTHC usually administered in tablet form. The flowers, stems or 
leaves of cannabis were originally used as a medicine, either smoked often combined 
with tobacco or taken as a tea. In this instance I have used the term: herbal cannabis. 
Common in the nineteenth century was the use of cannabis extract, that is, extracts 
of cannabis in alcohol prepared by percolation, or cannabis tincture prepared by a 
dilution of cannabis extract. The latest form of a cannabis-based medicine, Sativex is a 
cannabis-based medicine extract (CBME), one that contains a mix of phytocannabinoids 
including CBD and CBN and is delivered in a spray form. 
The Structure of the Thesis 
The thesis is divided thematically and is largely chronological although some chapters 
overlap in time. The following section provides an explanation of how the thesis is 
structured and how the themes under investigation fit together. 
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Chapter one sets the background to the thesis and describes the methodology 
utilised in this project. The initial section provides an overview of the history of 
cannabis prior to 1973 and places the thesis within the context of the historiography of 
cannabis. The literature review indicates useful concepts from history and the social 
sciences that have been applied to this thesis. The remainder of the chapter describes 
the historical methodology used to build on the literature review through the use of 
archival, documentary, media, and interview sources. 
The opening two chapters of the main body of the thesis concentrate on the 
trajectory of cannabis research through a study of the role of scientific knowledge, 
professional communities and individual scientists. The first of these, chapter two, 
considers the emergence of interest in cannabis research just prior to the removal 
of cannabis tincture's PLR in 1973. Through an analysis of archival material, the 
chapter focuses on a case study of the work of Sir William Paton, an influential British 
pharmacologist of the period. The chapter considers, through a study of his research, 
how awareness about cannabis was raised through increased recreational use and the 
subsequent need for drug control and how understandings of cannabis filtered through 
to discussions over cannabis' position in the developing control mechanisms. It looks 
at how major scientific advances, such as in medicinal chemistry and the discovery 
ofTHC, opened up new avenues for research. It explains how hindrances to research 
were partially overcome which allowed laboratory research on the chemistry and 
pharmacology of cannabis to progress and expand the fundamental understanding of 
cannabis. In particular, this section raises the problem of the availability and quality 
of the raw material for researchers. It analyses how new research placed emphasis on 
the harms associated with cannabis, especially potential detrimental long-term effects. 
Finally, it reveals early concerns around the concept of therapeutic cannabis and how 
this influenced debates over drug policy and the relative harms of illicit substances. 
Chapter three concentrates on the initial re-interest in cannabis' therapeutic 
properties by British pharmacologists in the 1970s. It focuses on the development of 
clinical pharmacology and considers the role played by JDP Graham a pharmacologist 
who began to write more positively about the drug and who was influential in expert 
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discussions on cannabis in the 1970s. It looks at how forces of necessity in the clinic 
led to acceptance of cannabis as a therapeutic for the alleviation of the nausea associated 
with cancer chemotherapy. In particular, the chapter highlights the importance of the 
form of cannabis under study and its mode of administration. The chapter concludes in 
1982 with the re-establishment of cannabis as a medicine through the limited approval 
of a single entity chemical, cannabis-based medicine in the UK and a slowdown in 
the development of the cannabis research field due to a failure to understand cannabis' 
mode of action and changing public health priorities that drew researchers away from 
cannabis research. 
The interplay between science and policy is considered in chapter four. This 
chapter focuses on 1972-1982 a period that saw the development of expert advice in the 
illicit drugs field and this section concentrates on the role of the Advisory Council on the 
Misuse of Drugs at the time when Paton and Graham were carrying out their research. 
Through an examination of three distinct periods the chapter considers shifting attitudes 
in the policy environment towards the control of cannabis, the interplay between science 
and policy and in particular the growing role of therapeutics within discussions as well 
as the impact of the policy environment on the process of re-medicalization. 
The following four chapters (5-8) deal with industry, user activism, the 
further development of expert advice and the development of clinical trials. They 
concentrate mainly on the period after 1997 which saw increased incentives for the 
re-medicalization of cannabis, though they also provide the background to these 
developments. These chapters overlap in time but they provide a thematic approach to 
pivotal events and developments from the perspective of different stakeholders. 
The first of these four chapters, chapter five, takes account of the pharmaceutical 
industry'S role in the transition of cannabis as a therapeutic from kitchen physic or self-
help into the clinic and then into the marketplace. The chapter charts a progression 
from the initial lack of interest in cannabis by industry, to a temporary interest by the 
phalmaceutical industry which yielded the first licensed synthetic cannabis-based drugs 
and provided important materials for academic research and facilitated the breakthrough 
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in the understanding of cannabis' mode of action. This breakthrough provided the: 
foundation for a more sustained interest in cannabis therapeutics in the 1990s and 
industry involvement increased worldwide. This chapter focuses on the involvement of 
a small UK biotechnology firm, GW Pharmaceuticals and places it within the context 
of the rise of phytopharmacy. GW Pharmaceuticals represented the realisation of a 
domestic pharmaceutical industry interest in cannabis. It drew inspiration from an 
interest in botanical substances and re-focused the spotlight towards extracts of cannabis 
rather than single-entity chemical substances. The impact of the form of cannabis 
utilized developments in technology and delivery systems, and standardization are 
considered. 
Lay knowledge and activism underpinned some of the discourse in science, policy 
and industry. Chapter six traces activism, from campaigns for drug liberalisation of 
which therapeutic cannabis was one aspect, to the development of specific campaigns 
for cannabis therapeutics and in the US the development of the concept of medical 
necessity in relation to glaucoma, cancer and AIDS in the 1980s and early 1990s. It 
focuses on a case study of the role of multiple sclerosis (MS) patient associations in the 
UK which campaigned for research and access to cannabis in the 1990s and considers 
their impact on the scientific, clinical, industrial, and policy spheres. 
Chapter seven takes the story of expert advice and the relationship between 
science and policy forward to consider the role of professional bodies and expert advice 
in the period 1997-2004. It traces the expert discussions through the release of pivotal 
reports that emerged from the BMA and the House of Lords in the late 1990s and 
discussions over the scheduling of cannabis in the Misuse of Drugs Act after the tum of 
millennium. Through an examination of these expert discussions the chapter explores 
the impact of developments in the medical use of cannabis on the policy environment 
and their impact on the debates upon the process of re-medicalization itself. 
'Evidence', clinical trials and regulation are the subject of chapter eight. After the 
expert discussion of the 1990s, the government agreed to permit the licensing of 
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cannabis-based medicines if sucessful in clinical trials. This chapter charts the 
initiation and development of the clinical trials, and their outcomes. It looks at the issue 
of 'evidence' and the problems that clinical trials posed for cannabis and the issues 
around regulation of cannabis-based medicines. The chapter concludes at the point 
at which Sativex, a CBME, was in the process of passing through the medical drug 
licensing system and as a new series of clincal trials were due to commence. 
Chapter nine, the conclusion, draws together these various interlocking themes 
providing an overview of the process of the re-medicalization of cannabis and links the 
history to a few important developments that took place just after the main research 
period of this project. Cannabis was viewed as a 'peculiar' or 'borderline substance', 
one whose position as a medical and or recreational product was fluid and dependent 
on a myriad of developing and competing factors. In addition to a story of a plant, an 
illicit drug and medicine it is also the story of developing disciplines, national interests, 
commercial interests, patient perspectives, and 'evidence'. Uncertainty has been 
crucial in the story of the process of re-medicalization and where therapeutic cannabis 
will go from the point at which this study ends is uncertain but this thesis provides a 
window into an ongoing process. Emergent cannabis-based medicines appeared to 
be able to exist within the drug control systems, and questions shifted to the broader 
picture of the relative positions in terms of harm of both ill icit and licit drugs and to the 
entire framework of control. 
I G. Edwards, and 1. Strange, 'Britains Drug Crisis,' the Independent, Thursday, 3 March 1994: 
http://www.independent.co.uklnews/uklbritains-drugs-crisis-recipe-for-dangerous-medicine-
viewpoint-1426619.html 
2 See appendix 3. 
3 See appendix 5. 
4 See appendix 6. 
5 See A. Anderson, Makings Medicines (London: Pharmaceutical Press, 2005), p. 4-5. 
Chapter One 
Historiography 
'Cannabis spray beats MS spasms' Daily Mail, March 13th 2007. 
Each of these five simple words headlined in a newspaper article in 2007 carries a 
heavy load of baggage and such succinct headlines that have emerged in recent years 
mask a very complicated history. Cannabis-based medicine ceased to be licit medicine 
in 1973 in the UK, so why did it appear to be re-starting a successful career as a 
medicine? Furthermore, cannabis is more noted for its administration through smoking 
so how and why did a new delivery method emerge? Cannabis has been perceived 
as having applications for many complaints, so why was it used to treat MS and to 
what extent did it beat MS spasms? This raises further questions such as the extent to 
which cannabis has been re-medicalized, how has this process taken place and how 
has it been incorporated within the drugs policy environment? The thesis is framed 
as a history of science and policy-making and has employed standard contemporary 
historical methodology. The subject of history itself has undergone development and 
has moved beyond narrative to analytical approaches and from a passive subject to 
taking greater role in contemporary debate. This has been highlighted in recent years 
as the application of an historical approach has become increasingly important in 
the public health field. This chapter highlights useful approaches and lacuna in the 
existent literature around cannabis, public health and drug control. It concludes with a 
description of the methodology utilised for this study. 
Literature Review 
In turning to existent literature for explanations of the process ofre-medicalization even 
a cursory scan of most libraries or bookshops will reveal a range of books on cannabis: 
from how to grow it; to popular histories of its medical and recreational uses: scientific 
tomes on its pharmacology and the legalization/prohibition debate. 
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The angles of interest to writers on cannabis have also undergone development over 
time. A literature review revealed useful approaches and interesting questions that 
had already been utilized in the historical study of cannabis and established where 
further research could contribute to the historical understanding of cannabis. Social 
science literature on cannabis and related themes also provided useful methodologies to 
apply to this study. Catalogue and database searches included: the Wellcome Library. 
British Library, Senate House, University of London, Pubmed; Historical Abstracts. 
and JSTOR. Further material was garnered from bibliographies and PhD databases 
and by word of mouth. Search terms incorporated the myriad of words related directly 
to cannabis but also relevant topics such as expert advice and the pharmaceutical 
industry. Search terms were kept under review throughout the research process. 1 The 
initial search was wide ranging and encompassed all time periods and captured texts on 
both the UK and international context. Finding more than enough material for a UK 
based study, international comparisons such as with the US and Australia were scaled 
back and remain a potential area for future work. Material was stored in an Endnote 
database. 
A variety of approaches to the study of cannabis emerged from the literature review 
as did useful methodologies from related themes which had not been applied to the 
historical study of cannabis. These have been categorized into eleven topics within 
which salient themes for this thesis are discussed. 
Popular histories of cannabis 
When popular, policy and scientific interest in cannabis re-emerged in the 1960s 
numerous popular histories of cannabis emerged to provide brief overviews of its 
history, and or detailed explanations of the techniques for using cannabis recreationally.2 
'Cannabis culture' emerged through popular texts and many focused on the legalization/ 
prohibition axis of the debate. David Soloman edited a collection of essays in 1969 
on the historical, sociological, and cultural aspects of cannabis, in which he argued for 
the legalization of cannabis.3 However popular histories tended to be US-centric and 
focused on the role of cannabis as a recreational drug. They proyide a start point but 
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are perhaps more useful as a primary source for attitudes towards cannabis. They do 
indicate however that medical use of cannabis needs to be studied in the context of the 
prohibition and legalization debates. 
Cannabis from ancient times. 
Academic historical interest focused initially on the long-term history of cannabis and 
sought to bring an historical perspective to contemporary drug problems. Interest in the 
1970s focused on the ancient use of cannabis or its long history of use throughout the 
world.4 Theodore Brunner, for example, analysed the literary evidence for cannabis use 
in ancient Greece and in Rome, and contributed an in-depth analysis of the evidence 
for specific incidences of cannabis use in specific ancient populations.5 Historical 
use of cannabis was co-opted sometimes to support contemporary arguments for and 
against the use of cannabis.6 The presumed relationship between cannabis, violence 
and crime pushed by Henry Anslinger, Head of the Federal Narcotics Control Board 
(!NCB) in the US was given support by the supposed use of cannabis by the Assassins, 
a sect of Shia Muslims, who were alleged to have taken cannabis prior to assassination 
attempts. Casto challenged the view that history could be used in such a manner to 
support policy and he attempted to debunk the Assassin's tale as myth.7 More recent 
material by Berridge has also considered the relationship between history and policy 
and challenged the assumption of Queen Victoria's use of cannabis for dysmenorrhoea 
and its utilization in policy debate.8 
Other academic writing in the 1970s and early 1980s traced the long history of 
cannabis from ancient times to the modem day.9 One feature of the medical history of 
cannabis has been the publication of histories by the scientists involved in the 
re-investigation of cannabis. In the US, Mikuriya, a former director of marihuana 
research for the National Institute of Mental Health (NIMH) and consultant to the 
National Commission of Marihuana and Drug Abuse, wrote in the mid-1970s of the 
amnesia suffered around cannabis' original uses.1O The re-investigation of old literature 
in the light of contemporary knowledge and the similarities between contemporary and 
historical concerns over issues such as toxicity. delivery methods, and dosage has been a 
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another facet of historical research. 11 That cannabis was not always viewed as an illicit 
dangerous substance but was initially prized as a food, fibre and medicine \\as shO\\n 
by Ernst Abel. I2 Abel described how Emperor Shen Nung (2700BC) was credited with 
the discovery of cannabis' therapeutic uses. The world's oldest pharmacopoeia dating 
from the first or second century AD - Shen-nng pen ts'ao ching, based on the work 
of Shen Nung - recognised the psychoactive properties of cannabis and later editions 
recommended that cannabis be used for treating gout, malaria, and rheumatism. Hua 
To, founder of Chinese surgery, was said to have used cannabis mixed with wine to 
anaesthetise patients. In Europe, hemp, the non-psychoactive variant of cannabis, 
had been cultivated since Roman times, but little was known about cannabis' medical 
uses, though Galen, the second century Roman physician, wrote of its use in the 
elimination of intestinal gas and as an analgesic. From the sixteenth century hemp was 
widely cultivated to supply fibre for textiles and for ships' rigging and sails. Due to the 
European growing conditions little was known about cannabis' psychoactive properties 
until cannabis was introduced from the East in the nineteenth century. Abel went on to 
trace the interweaving of cannabis into the development of prohibitive legislation in the 
twentieth century. Such histories demonstrate how perspectives on substances fluctuate. 
Perhaps the attempt to frame cannabis exclusively as an illicit substance is a brief 
departure from the norm rather than a defining feature of its history. This thesis aims 
therefore to give an idea of greater complexity around cannabis rather than the more 
dominant preconception of cannabis as an illicit substance. These texts require updating 
to take into account developments after the 1980s and to provide a history focused on 
the medical aspects of the debate. Utilizing such contemporary history allows also the 
use of contemporary historical methodology, such as oral history techniques, for the 
supplementation of documentary sources. 
Cannabis in the UK. From 'wonder drug' to sidelined substance 
The nineteenth century European use of cannabis has been of particular interest 
to historians. 13 Lewis highlighted how debates and fears raised in the 1960s over 
drugs such as cannabis and heroin bore striking similarities to those generated in the 
nineteenth century.14 Historians' interest fell on the use of cannabis by literar: figures. 
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for instance, Dumas. International comparisons of the recreational use of cannabis have 
been made. ls Medical use was also of interest and Berridge in the 1980s described the 
introduction of cannabis to the UK as a therapeutic. 16 It was introduced from India 
in the 1840s by William O'Shaughnessy, an Irish doctor, who served as Professor of 
Chemistry and Medicine in the Medical College in Calcutta. In studying the Indian 
use of cannabis he wrote on its analgesic and sedative properties, and he found major 
success in treating muscle spasm caused by tetanus and rabies and with vomiting from 
cholera. His work attracted considerable attention as these diseases were much feared at 
the time. This 'medical necessity' was an important incentive for cannabis therapeutics 
post- 1973 such as in the case of HI VIA IDS. Commercial success for cannabis was 
achieved when O'Shaughnessy gave cannabis indica to the pharmacist Peter Squire 
who produced an extract, Squire's Extract that became readily available for many 
ailments. Official recognition was achieved and quality standards set when cannabis-
based medicines were included in UK and US pharmacopeias in the 1850s.17 By the 
nineteenth century the medicinal value of a plant was linked to its 'active principle' 
rather than the use of the plant itself and a major trend in chemistry in the nineteenth 
century was the quest for active natural products. IS Numerous alkaloids were isolated 
in pure form plants, for instance, morphine from the poppy was purified and used for 
medicine. Such alkaloids were relatively easy to isolate. but the cannabinoids, forms 
ofterpenoids, from cannabis proved more difficult. 19 Cannabis' value as a medicine 
increased in the 1890's when a group of chemists Wood, Spivey and Eastemeld at 
Cambridge University succeeded in obtaining a relatively pure extraction of a terpene 
and which was thought to be the active principle of cannabis which they called 
cannabino1.20 This discovery facilitated further research and articles appeared on its 
use as an antibiotic, appetite stimulant and antidepressant, and for opium addiction. 
Smoking was recommended as the fastest and most effective method of delivery. 
At this stage, it was generally regarded as a safe medicine. Pre-empting 
controversial contemporary comparisons with other drugs, Walter Ernest Dixon, a 
leading member of the Rolleston Committee on Morphine and Heroin Addiction in 
the 1920s and an opponent of the penal narcotic policy of the American model, placed 
cannabis in the same category as tea and coffee rather than with drugs like heroin. 
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Cannabis-based medicines such as cannabis tincture were available as over-the-counter 
products and cannabis extracts were found in many proprietary medicines. It was 
often combined with opium and capsicum extracts as a pain killer.21 Histories of the 
introduction of cannabis as a medicine therefore raise important concepts for a study of 
its re-medicalization post-l 973 . The thesis considered if the diseases cannabis was used 
to treat were important to its survival as a medicine. Who produced cannabis-based 
drugs and how were they supplied? How were safety and quality standards set? In what 
form was cannabis used and how was it delivered? Discussion of the safety of cannabis 
raised questions as to the perception of cannabis' harm relative to other drugs such as 
heroin and to widely used licit substances like tea, coffee and alcohol. 
Historical research in the 1980s also demonstrated that cannabis as a medicine 
was limited and medical usage had declined rapidly by the end of the nineteenth 
century. Berridge offered explanations for its limited use, namely problems with its 
uncertainty of action, irregular supply, and its inability to compete with opium products 
in terms of availability and mode of delivery.22 The pure active principle had not been 
isolated, a major problem at a time when the pharmaceutical sector was developing 
around the production of single chemical entities. Its chemical structure meant it was 
not water soluble, unlike a major competitor, morphine. This meant cannabis could not 
be administered via new drug delivery systems such as the hypodermic syringe which 
was rapidly gaining currency. Issues of standardization posed further complications. In 
the nineteenth century and for most of the twentieth the plant could not be standardized 
and therefore a standardized medical product could not be produced. There was no 
standard for either the total content of cannabinoids or the proportions of individual 
cannabinoids, leaving the product in a weakened position compared to emergent 
synthetic single entity chemicals such as aspirin. All these factors limited its utility as a 
therapeutic in a marketplace increasingly controlled by the developing pharmaceutical 
industry. Therefore the thesis considered if overcoming these problems allowed the 
process of re-medicalization to take off. 
Histories of nineteenth century use highlighted another key issue around cannabis. 
that of the psychoactive impact of the plant and the fear that this posed for the safety of 
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individuals and society. Cannabis became linked to mental health problems, especially 
insanity, and crime. Much of the evidence for this came from India where it was feared 
that hospitals were full of patients with mental health problems allegedly caused by 
cannabis use. A major inquiry, the Indian Hemp Drugs Commission of the 18905 
examined the trade in hemp drugs and whether cannabis use should be prohibited. The 
commission came out against a link between cannabis and crime, and any need for 
prohibition. The link between cannabis and mental health is as hotly debated today, 
as it was in the nineteenth century, and the conundrum over cannabis' role both in the 
treatment and cause of insanity has occupied historians.23 Though the commission's 
report was largely ignored at the time in the UK, it became of interest to historians and 
scientists from the 1970s onwards, particularly in relation to the link with insanity.2-l 
Kalant reviewed the report and reflected on its relevance to contemporary problemsY 
Interest in the mental health aspects re-emerged from 2000 onwards as debates over 
the alleged link were revived most notably by British psychiatrists. Basu wrote on the 
alleged evidence from the Hemp Drugs Commission for the link to insanity.26 Mills 
worked on the growth of lunatic asylums in India in the nineteenth century, and placed 
cannabis within the colonial discussions of madness and the impact of these discussions 
upon the UK discourseY A clearer picture is required of the impact of this controversy 
on drug policy at both the national and the international level and how it acted as a 
countervailing force to re-medicalization. Existent historical reviews tended to be 
confined to a brief description within more general histories of other drugs or within 
social histories of cannabis. Further work was required to look at cannabis specifically; 
in relation to the latter half of the twentieth and early twenty-first century; and with a 
focus on medical rather than recreational use. 
Cannabis and American drug control policy in the twentieth century 
One of the more contentious facets of the historiography is the discussion surrounding 
the development of prohibitive drug legislation, especially in the US. Increased use 
of cannabis in that country during the 19605. and especially after the Vietnam \\ar. led 
to an increased interest in the history of the rationale behind the prohibitive polices. 
Policy history flourished in the 1970s and 1980s but was primarily focused on c\ents 
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in the US and centred on the 1930s when early prohibitive policies were implemented. 
The US enacted its own legislation via the Marijuana (Cannabis) Tax Act (MTA) 
of 1937 against cannabis through the Federal Bureau of Narcotics headed by Harry 
Anslinger. Historical debates revolved around the reasons behind the establishment of 
the MTA. Arguments ranged over the relative importance of anti-Mexican sentiment, 
the link to crime and insanity, and role of the individual in the shape of Anslinaer and b , 
the Federal Bureau of Narcotics. Musto in a review of the MTA argued for a greater 
synthesis in understanding.28 Himmelstein queried the argument that the MTA was due 
to anti-Mexican sentiment or the moralistic polices of Anslinger and raised the question 
of the ideology surrounding the drug and drug contro1.29 Alternatively, Saper suggested 
that American narcotic laws had developed more through accident, and the acceptance 
of drug myths, rather than through rational decision-making.30 Bonnie and Whitebread 
brought a legal perspective to the history of cannabis, with the use of historical 
documents surrounding the cannabis laws and the public policy response.3l They sought 
cannabis law reform and moved the emphasis from public safety to public health and 
in the process they elucidated why contemporary laws were established. Their book 
provided an early example of a comprehensive history of cannabis prohibition in the 
US. It highlighted the construction of cannabis as a 'monster'; the 'politics of fact 
finding'; the establishment of the Marijuana Tax Act; the stepping stone theory: the idea 
that cannabis use led on the use of 'harder' drugs; the escalation of punitive responses 
to cannabis use in the post-war period; and the creation of the United Nations Single 
Convention on Narcotic Drugs of 1961. This legal history has been developed with 
further texts such as Erlen's review of the Federal drug control system from the 1870s 
to 2000 via a study of Supreme Court cases. He revealed the gradual increase in power 
accorded to the criminal justice system.32 The incorporation of cannabis within criminal 
justice is an important aspect within discussion of the process of re-medicalization. 
These works provide one slice of policy history at defining moments in American 
history in relation to cannabis. They provide useful themes to consider such as the 
competing interests involved in the formulation of policy, and the hindrances to rational 
decision making. The re-medicalization of cannabis took place within the context 
offtuctuating drug policy both internationally and in the UK yet an in-depth policy 
discussion that is UK centric is lacking. 
2~ 
Cannabis and international agencies and policy 
The rise of international organisations and associated drug control policies of 
which cannabis has been a part since the 1920s is an important contextual basis for 
understanding the process ofre-medicalization, since for most of the twentieth century 
cannabis has been viewed as an illicit drug. Cannabis' medical utility was eroded 
in stages, through the development of mechanisms of control, and cannabis became 
reframed as an illicit rather than medical substance. Since 2000 historians of public 
health have argued for further research on the globalization of the governance of 
health and the treatment of illicit drugs.33 Berridge has highlighted the importance of 
understanding this historical context. Recent research, such as by Mills, has expanded 
our knowledge of colonial production and supply and the development of initial 
prohibitive international and domestic legislation. He demonstrated how the politics 
of Empire led to the prohibitive drug policies and scientific evaluation was pushed to 
the sidelines in contrast to the demands of supply and trade.34 He revealed the battle 
between the producer and the trader and how producers sought to avoid tax imposed 
by the British Administration which led to cannabis becoming associated with crime 
by the British Government. In domestic policy he demonstrated how 'policy seems to 
have been driven by mistakes and misunderstanding rather than well-informed debate. '35 
Kendell's work provided a discussion of the development of initial international 
regulation and demonstrated how cannabis became caught up in international drugs 
control. 36 Through such work historians indicated how, in the early twentieth century, 
multi-lateral agreements had developed around narcotic drugs and replaced the earlier 
bi-Iateral agreements such as existed between Britain and China and were largely 
concerned with issue of trade and supply. The 1912 International Opium Convention 
(Hague) laid the foundation of international drug control systems. Cannabis was not 
included in that Convention though Italy, South Africa and the US applied pressure for 
it to be considered. The Convention led to the introduction of regulations in Britain 
around 'dangerous drugs' with the Dangerous Drugs Act of 1920. In 1925 the Geneva 
Convention marked the start of a sustained focus on drug control. Essentially focused 
on opium, cannabis was included under pressure from South Africa and Egypt and this 
impacted on the manufacture, sale and movement of crud~ cannabis ie cannabis resin 
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for purposes other than medical or scientific purposes.37 The Convention was relatively 
weak and cannabis, for example, could still be shipped through non-signatory countries. 
Britain, as a signatory, introduced the Dangerous Drugs Act of 1928 which banned 
recreational use of cannabis. With little use of cannabis in the UK at this time there was 
little opposition to these moves. Cannabis as a medicine was unaffected and cannabis 
tinctures, for example, were still available.38 
Much historical work on the development of prohibitive drug policy is on pre-
Second World War developments although Bruun looked at the Nordic experience of 
control of medicines and at international drug control after the Second World War.39 
The influence of the US on global drugs control after the Second World War has been 
studied, in particular, the development of two United Nations Conventions: the 1961 
Single Convention on Narcotic Substances and the follow-up 1971 Convention on 
Psychotropic Substances.4o The impact ofthe US on the evolution of drugs control 
has been considered by Bewley-Taylor. He discussed the initial development of 
international control up to the Second World War, to the export of US drug control 
policies with US pressure for the Single Convention in the post-war period. He 
highlighted the impact of the US on the UN and argued that US influence was possible 
due to its hegemonic superiority in the post-war period. He demonstrated the US 
dissatisfaction with the alleged weakness and functioning of the global drugs regime 
post-1961. He went on to suggest that drug control policy was largely ineffective and 
led to the destructive 'war on drugs' approach. The framing of regulatory frameworks 
has been analysed by McAllister. He provided an historical account of the development 
of global drug control regimes and considered the involvement in policy formation 
of various interests: colonial concerns; pharmaceutical interests; and the role of 
interpersonal relationships. Of particular interest for this study is his discussion of the 
development in the West of a split between licit medical use and illicit recreational 
use, a divide that cannabis appeared to straddle. Of relevance too was the growing 
perception that society had a responsibility to intervene to prevent illicit-non medical 
use or the abuse of drugs, an intervention which led to increased illicit manufacture and 
trade.41 This division between medical and recreational use requires consideration in 
the context of the re-medicalization of cannabis. So too does the discussion between a 
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precautionary and paternalistic approach and liberal principles. McAllister highlighted 
the role of the pharmaceutical industry as an interest group important in the formation 
of drug control policy and demonstrated how the 1961 Convention favoured a medical-
industrial complex and focused on control of raw material affecting the producer rather 
than the control of new synthetic derivatives, an exclusion which largely continued 
in the 1971 Convention.42 This leads to important questions; what is the impact of 
cannabis being a plant-based medicine? What is the importance of the placement of 
cannabis and its derivatives within the scheduling system? What impact has this had on 
the development of cannabis-based extracts? Finally, the impact of international control 
on contemporary concerns including: patient and health care advocacy; the renewed 
interest in herbs and alternative medicine; harm reduction polices and the environmental 
and natural foods movements have been considered by Mead. She also notes how the 
conventions were open to interpretation, a factor important for the treatment of medical 
use of cannabis in signatory countries such as the UK:B 
There is limited work on setting these developments into the institutional context 
in which these conventions were designed. Histories exist ofthe initial developments 
of the international agencies such as the Red Cross. Weindling's edited collection of 
essays on international health organizations charted the inter-war development of the 
international agencies such as the League of Nations. The work highlighted tensions 
between national interests, ideals, class, and realpolitik.44 There are some histories 
ofthe World Health Organisation (WHO) focused on the initial attempt to establish a 
scientific basis for the cause of poverty and disease and the role of outside expertise, 
but a definitive history has not been produced nor is there a comprehensive history 
of the drug agencies such as the INCB.45 This leaves unanswered questions such as 
what response did each of these organisations take to the medical use of cannabis? Did 
attitudes change over time and how did they interact? 
UK policy and the role of expert advice 
Various responses to the international conventions were introduced by the di fferent 
parties. In the UK the framing of cannabis and its derivatives in drug policy has 
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been reviewed by governmental expert bodies. These have included the closed in-
house discussions of the Advisory Council on the Misuse of Drugs (ACMD). and the 
more public discussions that emerged in 1990s through the House of Lords Science 
and Technology Committee and professional bodies such as the British Medical 
Association (BMA), all of which published influential reports on the medical use of 
cannabis.46 However, the role of professional bodies and expert committees has been 
relatively little studied in relation to cannabis despite their crucial importance in the 
cannabis story and rich archival material. In the UK, after the publication and initial 
government dismissal of the Wootton Report in 1969, Abrams, a founding member of 
the cannabis activist group, SOMA, considered the development of cannabis policy in 
the UK:n Popular histories have touched on the developments of national UK policy 
history in the latter part of the twentieth century, but the focus of historians has been 
the development of policy in the nineteenth and early twentieth centuries. Mills, for 
example, in Cannabis Britannica considered the initial development of British policy 
on cannabis up to 1928 and demonstrated how cannabis was caught up in policy on 
medical and intoxicant substances through political and moral agendas rather than 
through 'evidenced-based policy' and that the foundation of policy was frequently 
based on incorrect assumptions.48 Hall has considered the public policy debate and 
the relationship between health policy, public health and the law in Australia, the UK 
and US.49 Historical and social science work from the broader literature provides 
methods of looking at the role of expert advice which can be applied to the cannabis 
field. The term expert advice covers a variety of structures, as Barker and Peters have 
described, ranging from, from institutional expert civil servants, advisory committees, 
to more informal information networks and contacts.50 In the UK context, MacLeod has 
shown how the role of the professional and the expert developed in the mid Victorian 
period while Hamlin has described how disputes flared between these experts.51 Expert 
advice evolved into a more formalized setting in the twentieth century and Berridge in 
her analysis of smoking policy in Britain has discussed the development of advisory 
bodies or expert committees.51 She placed deliberations over smoking in the context 
of developing relationships between experts and the state, and the growing demand for 
the 'rational expertise-based model' within government, especially within the context 
of health policy and developments in the NHS. As Berridge has shown the model of 
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channelling scientific advice into policy was utilized in the illicit drugs field, and the 
formula was developed in detail during the I 970s, with the formation of the Advisory 
Council on the Misuse of DrugS.53 As will be discussed, it was during the 1960s that we 
see some of the initial expert committees established in the illicit drugs field, on an ad 
hoc basis, and in the 1970s the formation of statutory committees which became deeply 
concerned with the cannabis question. The formal structure of an expert committee 
may be seen as one of the better ways of achieving evidence-based policy. For instance. 
Bulmer has shown how it provides a method of neutralizing a subject by taking it out 
of the political arena.54 This is especially important with a highly divisive issue such as 
cannabis. How far a committee can be successful in this is open to question. 
One important theme that emerges from the literature is the role of uncertainty. 
Jasanoff, for example, in looking at the role of expert committees in the US, in relation 
to carcinogens in the 1970s and 1980s, has shown their growing importance to policy-
makers, and she illustrates how the technocratic model is by no means value-free. 55 
Her work considers what lies behind the construction of 'evidence' or expert advice, 
and the 'trade ofJbetween risks to health/environment and the economic/social costs of 
regulating.'56 Jasanoff demonstrated how 'scientific uncertainty is a resource that can be 
mobilized by regulators ... in efJect to influence policy. '57 This is particularly interesting 
in the case of cannabis, where uncertainty over its medical benefits and potential 
hazards, were utilized by those on both sides of the debate. Hilgartner in a review of 
expert advice, in relation to diet and cancer, demonstrated how uncertainty could be 
invoked to justify action or inaction.58 Hilgartner raises another issue, that of the role of 
private/public discussions. Hilgartner likened the work of expert advice to the world of 
the theatre with the performance or report/publication on view at the front of the stage, 
whilst backstage the actors, or in this case the experts, could discuss and rehearse their 
'performance' in a private enclosed space. Leaks blurring the division between this 
public and private space are viewed by Hilgartner as a breakdown in stage management. 
This approach is useful in the case of cannabis where uncertainty, conflict, and leaks 
played key roles in the expert discussion of the 1970s. Florin, in a review of the 
relationship between science and policy in relation to coronary heart disease prevention, 
aimed to assess the extent to which policy on health promotion in general practice 
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was based on evidence.59 She indicated that high levels of scientific uncertainty led 
to different interpretations of the evidence by those from different backgrounds. This 
was a problem in areas that lacked an independent system such as an expert committee. 
The literature raised relevant questions for a study of cannabis: did uncertainty over 
cannabis' effects also impact within the framework of expert committees and what 
impact did it have on advice and its uptake? What impact did domestic drug policy 
have on re-medicalization and did re-medicalization have an impact on discussion 
on cannabis more generally? How were expert committees and enquiries set up and 
how did they relate both to the changing views of cannabis and to the roles of the 
organizations concerned? 
The re-medicalization of cannabis 
Historical work on the medical use of cannabis has expanded since the late 1990s. 
Mathre provided an edited collection on the therapeutic use of cannabis in which she 
questioned the polemic division of 'good' and 'bad' drugs as a useful premise. GO In the 
same volume, Aldrich, a cannabis historian, contributed an account of the therapeutic 
use of cannabis from ancient times through to the 1990s. One section in particular 
provided a helpful narrative and brief analysis of the re-interest in medical marijuana 
in the US, after the 1970s.61 With a focus on scientific discoveries, and the role of user 
activists, namely AIDS patients, he concluded that science, in the case of cannabis, had 
not been linked to policy. The different treatment of cannabis derivatives and the crude-
plant product emerged as an important consideration. Aldrich's work raised interesting 
questions over the medical history of cannabis: who makes decisions over that which 
is considered to be a useful drug - politicians, lawyers or scientists and what influences 
that decision? 
By the turn of millennium additional popular histories emerged, this time with 
a greater focus on medical use. The Emperor Wears No Clothes pressured for the 
right to smoke cannabis and questioned the science over the issue of brain damage 
allegedly caused by cannabis use. 62 It advanced the theory that cannabis policy in the 
form of the Marihuana Tax Act was related to industrial interests protecting their trade. 
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The wine writer Patrick Mathews reported on the 'cannabis culture' in England and 
revealed some of the pressure provided by user activists for access to cannabis. He 
offered an interesting, popular account of the role of industry in the moves to\vards re-
medicalization of cannabis through interviews with the founder of GW Pharmaceuticals 
, 
a company licensed in the UK to grow cannabis and carry out research into cannabis-
based medicines.63 Booth's Cannabis: A History, though focused on the US, offered 
some UK comparisons and provided a useful narrative chapter on the re-interest in 
cannabis as a medical product after 1960. He raised the dilemmas faced by doctors 
when weighing up the benefits and risks of the medical use of cannabis, the results of 
clinical trials, the problems of synthetic cannabinoids and the role of user activists. 64 
One of the few popular books dealing specifically with the medical use of cannabis 
is that by Alan Bock, editorial writer for the Orange County Register. He delivered 
a journalistic-style review of American politics surrounding medical cannabis and, in 
particular, the implementation of Proposition 215 which allowed for compassionate 
access to cannabis.65 These popular histories offer an interesting start point but 
are primarily anecdotal, brief introductions to the field. Issues such as the role of 
industry and user activism raised by these texts would benefit from a more in-depth 
archival and oral history approach to ascertain how they impacted on the process of 
re-medicalization. Documentary histories have also appeared publishing key primary 
texts from the nineteenth and twentieth centuries on a range of issues, including the 
development of prohibitive policy, to campaigns for medical access to cannabis. 
Musto's documentary history focused on aspects of drugs in America.66 Belenko's 
collection, focused on three key themes; that of periodic concentration on specific 
drugs; tensions between medical or punitive approaches to drug use; and shifts in policy 
attributable to politics rather than science.67 These documentary collections provide 
access to useful documents but provide little by way of analysis and the texts published 
are obviously selective and without their broader historical context. 
Additional literature emerged reviewing major developments in the science 
around cannabis since the 1960s, in particular, the production of synthetic drugs such as 
Marinol and the endogenous cannabinoids and receptor sites.68 Reviews have emerged 
on the development of certain aspects of scientific discussions surrounding cannabis, 
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such as the controversial stepping-stone and gateway theories, which gained currency 
in the 1950s. The gateway theory implied that there was a sequence of drug use and 
that cannabis led to the use of other 'harder' hallucinogenic drugs and the theory was 
often used in policy discussions to justify strict controls and penalties on cannabis use. 
Historical reviews of these theories, such as that by John Witton and Sarah Mars, have 
clarified some of the debates around cannabis' impact and have also been used to inform 
contemporary policy.69 A better understanding of the role of and trajectory of scientific 
knowledge is necessary to understand the process ofre-medicalization, the fluctuating 
perceptions of cannabis and resultant policy. 
Russo, senior medical advisor to GW Pharmaceuticals, provided a short history of 
cannabis' medical role, in the book The Medicinal Use afCannabis and Cannabinaids, 
edited by Dr Guy, Director of GW Pharmaceuticals. Russo's chapter imparted a 
perspective on the problems of research into plants and the negative impacts of 
legislation upon research.70 Histories, written by scientists involved in research and/or 
with industry, may provide useful insights into the problems of scientific and industrial 
research and production, but may also lead to questions of bias and objectivity. In 
the twentieth century, the history of therapeutics is inseparable from the rise of the 
pharmaceutical industry. Since the 1990s, industry has become an important location 
for research into new cannabis products. Historical literature, however, on the role 
of industry in the re-medicalization of cannabis in the twentieth century, especially 
in the UK context, is limited. That which does exist focuses on the development of 
synthetic products, such as nabilone in the USA, rather than the development of the 
herbal product, which has been the focus of UK industry.7! There is limited independent 
historical discussion ofthe role of industry in this field and the techniques for studying 
industry raised by existing literature need to be applied and developed in relation to the 
re-medicalization of cannabis. 
There is a range of historical and sociological literature which provides 
conceptual modules for understanding the role of the pharmaceutical industry in the 
twentieth century. A number of studies have looked at the long history of therapeutics, 
highlighting the brevity of synthetic drug usage, as opposed to a long, herbal tradition.72 
The influence of factors, such as regulatory processes and scientific advances in drug 
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development, has attracted attention.73 Pickstone traced the growing intersection 
of industrial and scientific interest in the interwar years, whilst others focused on 
developments in the pharmaceutical industry in the immediate post-war years, a time 
of great optimism surrounding the advent of new drug treatments. 74 The changing 
focus from infectious to chronic disease and the relationship with industry has attracted 
attention, as have research flows between countries and the impact on industry.75 In 
the initial development of the pharmaceutical industry historians cite the importance 
of a greater understanding of vegetable and mineral substances used as medicine.76 In 
this, the isolation of an active principle was important. Major discoveries included 
the isolation of morphine from opium, aspirin from willow bark, and later quinine 
from cinchona. Authors writing about the pharmaceutical industry and pharmacy have 
highlighted the importance of accessibility to research material and how it can shape 
social and cognitive developments.77 Histories of pharmacy and the pharmaceutical 
industry divide its development into between three and five stages: kitchen physic; the 
rise of commercial remedies; development of pathology and microbiology; growth of 
multinational pharmaceutical companies, acquisitions and mergers and the elimination 
of small-scale industry; and the emergence of small biotechnology companies.78 The 
emergence of small biotechnology companies, such as GW Pharmaceuticals, provided 
the opportunity to exploit the gaps left unexplored by 'big pharma.' A study of the 
effect of small biotechnology firms, with a focus on GW Pharmaceuticals, provides 
an ideal case study of industry/science/policy relationships. Although histories have 
emerged from those involved in the pharmaceutical field, there is limited discussion of 
its role in the cannabis field. Furthermore, available historical literature introduces, but 
does not fully answer, questions as to the importance of supply, the controversy over 
synthetics versus plant products, and synergism (the combined effect of two or more 
components of a plant) versus the use of isolated single active principles. This thesis 
therefore considers the impact of an initial lack of industry interest, followed by its 
involvement from the late 1970s and the emergence of biotechnology firms from the 
1990s. Within this context, it considers the impact of changing drug technology and if 
the ability to produce oral cannabis medicines was important as a delineator of medical/ 
non-medical boundaries. Other issues include, what role have synthetic products, such 
as nabilone, and extracts of cannabis such as Sativex played in the transition and \vhat 
has been the impact of an interest in the 'botanical route'? 
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The rise of specific disciplines: psychopharmacology and 
phytomedicine 
A review of the literature reveals that there are deficiencies in taking account of 
the rise of specific disciplines, in particular, psychopharmacology(the branch of 
pharmacology that deals with the study of the actions, effects, and development of 
psychoactive drugs) and phytomedicine, (the study of plants for medical applications). 
Cannabis, while often viewed solely as an illicit drug, needs to be viewed as a plant 
and the revival of interest in its use as a therapeutic, needs to be considered within 
the context of the revival of interest in plant-based medicine. 79 Historical research 
on medicinal plants has concentrated on three aspects. First, there are the histories of 
the disciplines of botany and herbalism. Works centre on the early history of botany 
and herbals, particularly, in the Middle Ages.8o Those who have looked at 'medical 
history from below' have stressed the nineteenth-century popular interest in medical 
botany and subsequent commercial development.8l Second, a more recent trend has 
been the study of the development of ethnobotany, that is, the study of medicinal plants 
and indigenous knowledge. 82 Third, there are the histories of individual plants.B3 The 
discovery of Artemisia annua (A.annua) inspired a few thought-provoking, short pieces 
of historical writing including Dobson's examination of quinine and Artemisinin.84 
Some writers stress the role of competing interests. Power's study of drug resistance 
looked briefly at the history of A. annua s discovery and use, viewing the acceptance 
of both in terms of 'contested knowledge.'85 Goodman and Walsh's study of Tax 0 I 
traced the 'cultural biography' through which a plant became a commercial product.86 
Therefore what issues associated with cannabis are related, not to its framework as an 
illicit drug, but as a plant-based medicine? Historians have traced the development of 
pharmacy and pharmacology. In terms of the development ofpyschopharmcology, a 
witness seminar on Drugs in PsychiatriC Practice organised by the Wellcome Trust in 
1998 and Healy's book The Creation of Psychopharmacology traced the development 
of psychopharmacology and in particular looked at the role of industry, the rise of the 
'magic bullet' approach, the importance of standardization, and the tensions between 
disciplines.87 The rise of these disciplines is important for understanding the process of 
the development of drugs from a plant. Russo argued that Europeans were important 
for the development of cannabis-based drugs as although the National Institutes of 
Drug Abuse (NIDA) provided the majority of funding into cannabis and introduced 
cannabis-based medicine, Europeans had not' strayed quite so far from the realm of 
materia medica' .88 Many of the debates raised over plant medicine are transferable to 
an investigation of cannabis and allow the medical use of cannabis to be placed in the 
broader context of the development of phytopharmacy. 
Lay knowledge, advocacy, and user activism 
Lay knowledge and the role of user activists have been important for the re-
medicalization of cannabis. There is considerable historical literature on the self-help 
and mutual aid societies that flourished in the nineteenth century and the post-war 
period is seen as a new period of self-help. Health activism in the post-war period has 
been studied and focus has fallen upon the role of AIDS activism.89 This has been in the 
context of the rise of interest in the growth of single issue activism, and a small number 
of studies relate to activism in relation to cancer, animal rights, the environment, 
anti-nuclear movements, and, within this, the growing importance of internet-based 
activism.90 The growth of grass-roots knowledge and the relationship between lay 
activists and professional groups has been of particular interest to sociologists and 
historians.91 Institutional history has been helpful in providing insights into this 
arena. Mold, for example, has reviewed the history of the drug voluntary organisation, 
Release.92 Texts, however, often review how activism led towards stricter control over 
drugs such as tobacco. This thesis looks at the reverse: the role of activism in attempts 
to regain access to drugs like cannabis for medical purposes, recreational use and to 
attenuate control systems. 
In relation to cannabis, popular histories have explored the role of popular 
pressure and cannabis cultures. In relation to medical cannabis use there are a 
number of accounts by individual activists of their experiences. Steve Abrams, a 
cannabis activist and founding member of SOMA, has written on the development of 
SOMA and the impact of reports such as that of the Wootton inquiry and subsequent 
media responses upon activist groupS.93 Randall provides an account of his legal 
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battle to use cannabis for the treatment of his glaucoma.94 In the UK, lay activists 
have been important in pressuring for further research, access to cannabis. and have 
collaborated with members of the medical profession and have contributed their views 
and experiences to a number of government enquiries and reports. But the role of 
lay advocacy in relation to cannabis, particularly the role ofMS sufferers in the UK. 
has received little attention in the historical literature, despite the roles played by the 
Alliance for Cannabis Therapeutics and the MS Society. The nature of user activism 
and its impact needs closer scrutiny and opens up questions as to whether 'respectable' 
MS patients were more influential than other groups. The different groupings involved, 
from drug user activists in the 1960s, to the multiple sclerosis patients in the 1980s and 
1990s, offer the opportunity to analyse the nature of 'user activism' and its impact. The 
thesis considers to what extent and in what ways pressure from user activists helped 
cannabis cross the boundary from illicit drug towards licit medicine. 
'Peculiar' and 'borderline' substances 
Cannabis means many things to many different people and can be framed within 
concepts of public health, and drug control depending on one's view point. Some 
authors have provided useful avenues for research into such substances. Star and 
Griesemer in an historical study of Berkeley's Museum of Vertebrate Zoology, 
introduced the concept of 'boundary objects' in relation to records or documents and 
showed how different groups, such as amateur collectors, professional scientists and 
administrators, placed different interpretations upon the same sources. 'Boundary 
objects' were able to bridge the differences between the different understanding and 
goals of the different groups.95 This concept of boundary objects has been adopted 
for many different situations. For instance, in the medical history field it was adopted 
by Epstein in relation to AIDS.96 In his study of the relationship between activism 
and science, he showed that a boundary object could be a virus or a medication, but, 
in essence, the object was one that could cross social networks, having a subtle. but 
significantly different meaning, depending on from where it was vie\\ed. This concept 
of a border crossing substance has been considered in relation to drugs. Berridge. in her 
study of the shifting understandings of substances, focused on opiates and tobacco and 
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she showed how the boundary between licit and illicit is a shifting and negotiable one.g~ 
In looking at the concept of borderline objects, studies of various substances such as 
tobacco, opium and alcohol are useful. Berridge has provided a social history of opium 
tracing its development from a widely used treatment for various illnesses, and to the 
emergence of prohibitive legislation in the early twentieth century. She investigated 
some of the interests involved in the changing perceptions of opium. In relation to 
tobacco she considered how it portrayed an indeterminate nature - food, medicine or 
drug?98 The same can be asked of cannabis. In looking at these borderline substances 
she considered 'altered states' or 'the cultural and policy milieu' in which drugs are 
regulated and the social and political factors which drive change.99 This thesis considers 
the processes that altered the milieu around cannabis and its medical use. Sherratt in 
writing on the history of narcotics and stimulants, analysed how we define drugs, in 
particular, psychoactive substances, and viewed cannabis as one of a group of 'peculiar 
substances' which can cross the line from being a widely consumed substance to a 
dangerous drug. IOO Fluidity of these substances has invoked a considerable degree of 
controversy around them. The fluidity ofthis peculiar substance has been crucial in the 
story of the re-medicalization of cannabis. 
Different methodologies have been applied to the study of cannabis ranging 
from standard narrative and thematic historical methods to sociological approaches. 
Goode took a sociological approach to looking at why we have controversies, and 
through a case study of cannabis investigated the impact of bias. He argued that the 
controversy over cannabis was due to political not scientific debate, and resultant more 
on previously held ideological commitments than on any new scientific arguments. 101 
Ungerleider and Andrysiak have written on bias and the cannabis researcher. They 
looked at the impacts on research and policy emanating from the scientists themselves, 
funding bodies, and the roles of industry and government. They raised the issue that 
chemicals have been seen as moral as well as pharmacological substances.102 Thus the 
existent literature goes some way in considering how we understand such "peculiar 
substances' and raises questions as to, if cannabis is to be deemed a 'peculiar substance,' 
what is the process whereby boundaries shift between 'drug' and 'medicine' and what 
are the issues and interests involved in that transaction? How has cannabis' identity as 
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a boundary substance, and the resultant controversies, impacted on the process of re-
medicalization of cannabis and vice versa? 
Cannabis within public health 
Cannabis' role as a peculiar substance means it is also important to consider the process 
of re-medicialization within the changing natures of the frameworks within which it has 
been considered. Over the period understudy cannabis was framed under drug control 
policy but also within the context of changing concepts of public health. Berridge has 
explored the tensions between the coercive tradition and systematic gradualism and the 
rise of harm reduction. It is advantageous to consider discussions of cannabis in the 
context of tensions in public health and drug control policies through prohibition and 
harm reduction. 
Evidence-based medicine and the rise of the clinical trial 
One of the key components largely missing in the historical literature on cannabis 
is the influence of the development of the clinical trial on the re-medicalization of 
cannabis. Historians and social scientists have shown various reasons for the growth 
of the Randomised Controlled Trial (RCT): the development of statistics; experimental 
epidemiology; the professional and organizational interests of the Medical Research 
Council (MRC); the relative importance of key individuals including Bradford Hill; 
to the consolidating influence of fears over medical technology in the 1970s that 
produced a climate that encouraged funding ofRCTs.l03 Rosser Mathews placed the 
birth of modem clinical trials in the context of the search for quantification. 104 Tracing 
the developments from early nineteenth century Parisian medicine and the quest for 
quantification, to the rise of the British biometrical school and bacteriology, to the 
central role of the MRC and Bradford Hill, Mathews charted the forerunners of clinical 
trials to its eventual dominance. He revealed how the merging of statistics and medicine 
was an attempt to move medical decision-making away from an art to a science. His 
work raised issues ofthe impact of the clinical trial on the doctor-patient relationship, 
and ethical questions, as to where the balance lay between treating a patient and the 
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need to further develop scientific knowledge/treatments. The methodology of clinical 
trials became increasingly sophisticated, from the addition ofrandomization, to 'double 
blinding', and to cross-over trials. Specific developments in techniques have attracted 
attention, Kaptchuk, for example, has written on the development of the concept of 
'blinding' patients and the use ofplacebos.105 Archie Cochrane, a British medical 
researcher and proponent of social medicine, campaigned for more effective use of 
medical resources and he highlighted the importance of the randomised controlled 
trial. l06 Historians have shown how clinical trials began to impact on health policy, as 
well as the provision of therapeutics. Meldrum has demonstrated how RCTs became 
a tool of policy-making in the US where clinical trials became the route for passing 
medicine through the newly established Federal Drugs Agency in the post-thalidomide 
era.
107 Clinical trials have not been without their critics. Ethical considerations have 
always been important in clinical trials, ranging from the ethics of withholding potential 
treatment to concerns over the safety of participants when pushing at medical frontiers. 
Troth has shown in a PhD thesis on the history of clinical trials, concerns have been 
raised over ethics, problems of outcome measures especially in studies of pain, and the 
post-modernist arguments that trials can not be truly objective as they are interlocked 
into their social context, citing in particular, investigations into analgesics. l08 Questions 
raised in the historiography of clinical trials need to be applied to the study of cannabis. 
Potential cannabis drugs are dependent on successful outcomes in clinical trials and 
major RCTs of cannabis' medical utility for pain and MS have been carried out since 
2000 in the UK. What impact has the benchmark double-blind, randomised, cross-over 
trial had on the medicalization of cannabis; as well as on the delivery methods, and form 
of cannabis trialled and for what applications? And lastly how does a drug move from 
success in a clinical trial to a licensed and available medical product? 
This chapter has demonstrated that there is a considerable literature on cannabis. 
However, this literature is focused on specific topics or chronological periods and apart 
from a few texts published around 2000, there is limited historical work specifically on 
the history ofthe medical use of cannabis in the UK since 1973, a period when major 
developments in the scientific understanding of cannabis and its medical use took place. 
This study therefore extends historical and social science work to focus on the 
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re-medicalization of cannabis in the UK in the period 1973-2004, though it also 
follows the story before and after as necessary, to demonstrate important changes or 
developments. 
Existent literature was supplemented by primary research with a variety of sources 
which are described below. 
Primary Manuscript Material 
The study was heavily archival-based. The following archives were utilized. 
The National Archives, (TNA) 
The National Archives provided a rich source for a range of material. Records included 
files of the Medical Research Council, (MRC), Ministry of Health, (MH) and the 
Home Office, (HO). In particular, material was located on the expert groups of the 
Advisory Council on the Misuse of Drugs. Some material was closed under the thirty 
year rule and access to these files was applied for, and received, under the Freedom of 
Information Act. 
The Wellcome Library 
The Wellcome Library had considerable relevant holdings. Papers held at Wellcome 
included: Sir WDM Paton 1930-1993, (PPWDP). These files included personal 
correspondence, newspaper cuttings, minutes of committees and expert groups on 
cannabis. The Wellcome Library holds also the archives for the MS Society from 1953-
1977. 
The WHO Library and Archive 
The WHO Library and Archive, Geneva provided relevant reports and documents 
produced by the WHO specifically on cannabis and general reports on drugs. of which 
cannabis was a paI1. These included reports on drug dependence and cannabis since 
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the 1950s. Although the Archive does not hold minutes of these reports it does hold 
other relevant documentation. Among relevant files in the Archive were: documents 
of the Expert Committee on Habit Forming Drugs (404-1-1), Expert Committee on 
Dependence Producing Drugs, (A2/S1/16*) and general files on cannabis, (A2/447/ 
c/6/J.l) and applications for research on cannabis (A2I1S1111). 
Personal papers 
Key informants and those involved in the cannabis field proved helpful in providing 
additional information to that which could be located in libraries and archives, 
including personal papers, notes, correspondence, minutes, media cuttings and funding 
applications. These included papers from Professor Anita Holdcraft, Ms Claire Hodges, 
and Professor Roger Pertwee. 
Archives of professional institutions 
The archives of professional institutions, such as the Royal Pharmaceutical Society, 
yielded reports and minutes of the professional institutions that were involved in crucial 
events. 
Reports and other printed material 
Key reports of organizations involved were analyzed including the House of Lords, 
BMA, WHO, INCB, and the Department of Health. Reports and printed material 
were available in the DrugScope library, which is now closed. Many reports are now 
available on-line through the organizations' websites. 
Hansard 
A time-line of major events was developed early on and the parliamentary record was 
reviewed focusing on key events such as the debate on the House of Lords Report. and 
the reports of the Advisory Council on the Misuse of Drugs. 
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Press 
Media responses were surveyed again using the time-line of major events. Reviews 
focused on two quality papers, (The Times and the Guardian); two popular dailies 
(Daily Mirror and the Daily Mail); and one Sunday paper (The Independent on Sunday). 
Other sources included periodicals, such as the Economist. 
On-line resources 
The development of the internet has added a valuable research resource. Many 
documents are now digitised and available to researchers on-line such as the tobacco 
industry documents available through the BAT archive and utilised by the Centre for 
Global Health, at the London School of Hygiene & Tropical Medicine. Reports and 
press releases are available on-line, which is particularly useful if research travel is 
constrained. Websites in themselves can provide a useful historical source. Many 
organizations, especially activist or self-help groups, can be heavily internet-based. 
This 'virtual world' however presents a new set of research problems. PDF files, 
and web pages can disappear without trace, their http address change, or simply be 
withdrawn. In recent years there have been calls for the archiving of web sites. This is 
slow to arrive and would perhaps focus on larger organizations. It is possible to print 
webpages, but if these documents are not stored in an accessible archive, they are not 
necessarily accessible to researchers at a later date. 
Interviews 
Oral history interviewing is a useful technique for contemporary history and is a 
valuable means to add insight and knowledge to archival and documentary resources. 
Oral history provides the opportunity to gain accounts by interviewees of their 
experience of events. Oral history has generally focused on life histories but in recent 
years has expanded to develop the 'elite interview' for contemporary public health 
history. Virginia Berridge has used oral history techniques for a history of tobacco, 
as has Stuart Anderson for the history of pharmacy. Graham Smith provides a useful 
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history of the development of the method. lo9 Two training courses on oral history 
interviewing and elite interviewing provided by the British Library and Centre for 
Contemporary British History were undertaken. 
In social sciences more generally the aim is often to utilize random sampling 
techniques and anonymised interviews. Instead for this thesis interviews focused on 
key informants. A list of potential interviewees was drawn up and was snowballed 
through further research and interviewing. Interviews covered a range of actors 
including scientists, clinicians, science and policy figures, policy-makers, and activists. 
Fifteen interviews were carried out in total. Access was straightforward in most cases 
and participants were generous with their time. 
Ethical approval for research techniques such as interviewing has become of 
greater importance and interest in recent years. Approval was obtained from the 
LSHTM Ethics Committee. Interviewees were sent an information sheet explaining the 
proj ect and they were provided with a consent form which offered interviewees various 
ways in which their information could be utilized. l1O 
Various methodologies for carrying out and analyzing interviews have been 
discussed. 111 The standards set by the Oral History Society were adopted. All 
interviews were semi-structured. A topic guide was prepared for each interviewee 
but the questions were left open to follow-up interesting angles generated in the 
interview, and or to understand the story from very different perspectives. This basic 
list of questions was altered throughout the research to take account of new themes 
and questions as they emerged from documentary and interview research. Interviews 
require a facilitative approach to provide a balance between probing to encourage 
elaboration but to avoid leading or judgemental questioning. Interviews ranged in 
time from thirty minutes to three hours, with careful consideration taken of the setting 
to take into account the needs of both the interviewee and interviewer. Interviews 
were recorded to provide a reliable record and future resource and then transcribed. 
Interviews were analyzed for key themes. Framework analysis or grounded theory of 
qualitative data is often used in the social sciences utilising computer programmes such 
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as NVivo to assist with coding and theory building. For this smalI number of intervie\\ s 
with key informants analysis was carried out by hand, highlighting emergent and 
interrelated themes in a method similar to that required by such computer programmes 
and quotes are provided in text under relevant themes. The process was iterative. 
Interviews with individual key witnesses were supplemented through the 
organization of a witness seminar. The mechanism of a witness seminar is a useful 
tool to draw together those involved in a field to discuss developments, highlight 
tensions, debates and networks. The technique has been developed by the Institute of 
Contemporary British History (ICBH) and the History of Twentieth Century Medicine 
Group, part of the Wellcome Trust's Centre for the History of Medicine at UCL. 
The idea for a witness seminar on the medical use of cannabis was submitted to the 
Wellcome Centre which was co-organized with the Centre for History in Public Health 
at LSH1M, held in 2009. A topic briefing was provided for the Chairs. The seminar 
provided additional useful perspectives to the one-on-one interviews. 112 
As with any research method oral history has some constraints and in the past 
has faced criticism as a method. It can be limited by the availability of interviewees 
and especially, if interviewees are elderly, it can be difficult to carry out interviews. 
Issues of memory and recall are an issue for all interviewees, as is the influence of the 
interviewer. There are issues of bias, and the need to move beyond 'the official line' . 
However, such issues are not unique to oral history and can equally be a problem with 
printed and archival sources. Triangulation of research methods can help alleviate 
some of these concerns. As with all the primary data, interview material was cross-
referenced with that from other interviews, the witness seminar, and documentary and 
archival research. The sources were weighed and assessed against hypothesis and lines 
of argument. Through the examination of this wide variety of source material, this 
thesis demonstrates the complexity ofthe argument around such 'peculiar' substances 
and seeks to contribute to a greater understanding of the process ofre-medicalization 
beginning with the re-interest in cannabis in the late 1960s. 
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Chapter Two 
Understanding cannabis, 1968-1982 
The early 1970s saw the development of parallel worlds around cannabis. International 
and national drug control policies were tightened and cannabis was dropped as a 
medical product by 1973. Yet, as these moves took place, scientific interest in cannabis 
re-emerged. A PubMed search reveals that only thirty articles referred to cannabis in 
the 1950s, in contrast to the one hundred and thirty published between 1960 and 1970. 
When cannabis was introduced to Britain as a medical product its use was limited for 
several reasons: an undiscovered active principle, the inability to use it within new drug 
delivery systems or to standardize the product, questionable efficacy and fears over its 
side effects. When cannabis was removed as a medical product in 1973 certain of these 
problems had been solved and the door was opened to the re-introduction of cannabis-
based medicines. In order to understand the trajectory of research post 1973 it is 
necessary to review the events that took place in science, policy, funding and supply in 
the 1960s which enabled research into cannabis and its therapeutic potential to emerge 
in the 1970s. In the UK, scientists began to answer key pharmacological questions 
about cannabis. This chapter focuses on the role of one eminent British pharmacologist, 
Sir William Paton, as a means of analyzing the impact of changing scientific knowledge 
on the process of re-medicalization. It charts the re-emergence of interest in cannabis 
stimulated by breakthroughs in the understanding its chemistry, and advances in 
understanding its pharmacology. It considers how the growth of recreational use led 
to a need for a greater scientific understanding of cannabis to provide the evidence-
base to underpin drug control mechanisms. It considers how hindrances to research 
were partially overcome which enabled laboratory research on the chemistry and 
pharmacology of cannabis to go forward. It concludes by considering the impact of 
the pharmacological research on the re-medicalization of cannabis and demonstrates 
how that laid the groundwork for later research into medical applications of cannabis to 
emerge. 
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Opening the door to cannabis research. The discovery of the active 
principle 
Research into the pharmacology of cannabis took off in the 1970s primarily due to a 
breakthrough in understanding the chemistry of cannabis that took place in 1964. The 
lack of an isolated, pure active principle had been a major hindrance to cannabis' use 
as a medicine. The early history of research into the chemistry of cannabis and the 
isolation of cannabinoids has been reviewed. I By the late 1950s the United Nations 
organization, the Commission on Narcotic Drugs (CND) had called for governments to 
encourage research into the active principles of cannabis, most notably, to assist with 
the accurate and speedy identification of dangerous parts of the plant, to assist the fight 
against illicit traffic.2 This problem was overcome by the work of medicinal chemists, 
Raphael Mechoulam and his group in the Hebrew University in Jerusalem, Israel. 
Mechoulam was interested in the chemistry and biological activity of natural products 
and synthetic drugs and, at the Weizmann Institute, he had investigated several natural 
products including cannabinoids found in cannabis. As he delved into cannabis he was 
surprised to find that unlike the chemistry of morphine and cocaine which were well-
known, the active compounds in cannabis had never been isolated in pure form, nor was 
their structure really understood.3 As he worked on its chemistry, Mechoulam made 
a major breakthrough: the isolation of the major psychoactive principle of cannabis, 
delta-9-THC.4 This enabled him to elucidate its structure and stereochemistry.s The 
next stage was the synthesis of the natural or phytocannabinoids. Mechoulam was 
able then to synthesise the active principle and THC became available both in natural 
form via the plant and by way of synthesis. Researchers no longer had to rely on 
the plant material or on extracts of cannabis with unknown constituents. THC could 
be produced from laboratory-made chemicals, which allowed the production of a 
standardized product which was crucial for research and re-medicalization. These two 
steps, at a time when recreational use of cannabis was increasing, sparked interest into 
cannabis research and opened up funding possibilities that had not previously existed. 
Mechoulam noted a change in funding options. 
When we started nobody was interested. We couldn i get a penny to do 
research on it ... ... The Americans told me that it:S a south American 
52 
problem, we are not interested. Then everyone was interested in it, and 
I was supported in my research for nearly forty years by the National 
Institutes of Health (NIH) in the us. They were interested in the chemistry 
of course '" we supplied them with materials in the beginning, .... . gave them 
the first ten grams and on this material quite a lot of work was done in the 
US in the I960s and probably the 70s. 6 
The National Institute of Drug Abuse (NIDA) created in 1972 as part of the NIH, began 
supplying cannabis to scientists and provided eighty-five percent of the world's research 
dollars for cannabis research.7 Despite the discovery, little else was known about 
cannabis and the effect of the new cannabinoids such as THe. Research was necessary 
on the pharmacology and epidemiology of cannabis. Furthermore, new cannabinoids 
posed problems for drug control policies as they were outside the control mechanisms, 
having been discovered subsequent to the 1961 Single Convention on Narcotic 
Substances. 
Stimulation of cannabis research in the UK. Drug control, the MRC 
and Sir William Paton, 1968-1970 
William Paton, a noted pharmacologist, was one of the first serious researchers in the 
UK to expand the pharmacological knowledge around cannabis and cannabinoids and 
he published significant texts throughout the 1970s. Although the method of biography 
and a 'great man' approach to history has its criticisms, a study of Paton's work on the 
pharmacology of cannabis provides a lens into understanding some of the pivotal issues 
around cannabis research. Paton, who kept prolific notes of his work, is important not 
only for his contribution to the expansion of scientific knowledge around cannabis, but 
because of his endeavours to transfer that knowledge to policy. 
Sir William Drummond Macdonald Paton was born in Hendon in 1917, and later 
trained in medicine at Oxford. After successive bouts of pneumonia he moved away 
from the clinical field to pharmacology. He became a member of staff at the National 
Institute for Medical Research between 1944 and 1952 and went on to become Reader 
in Pharmacology at University College London and UCH Medical School bet\\een 
1952 and 1954. He then became Professor of Pharmacology. at the Royal College of 
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Surgeons until 1959 and was made a Fellow of the Royal Society in 1956. His early 
work in experimental pharmacology led to important breakthroughs while he worked on 
methonium compounds with the pharmacologist Eleanor Zaimis and his collaboration 
with anaesthetist Geoffrey Organe led to important discoveries in the drug therapy 
of hypertension, and the pharmacology of smooth muscle relaxants.8 He moved on 
to become Professor of Pharmacology at Oxford University, and a Fellow ofBalliol 
College between 1959 and 1984. His early work in the 1940s and 1950s had focused on 
decompression sickness on which he acted as a consultant to the Royal Navy. As part 
of this work he was interested in anaesthetic mechanisms and during his time at Oxford, 
Paton was able to overcome some of the problems of deep sea diving through his work 
on physiological properties of gases at high pressure, which led to the development 
ofTri-Mix (oxygen, helium and nitrogen) for divers. This interest in anaesthetic 
mechanisms later informed his research on cannabis. Much of his work at Oxford 
focused on drug dependence and in particular the pharmacology of cannabis. Sought 
after by government and professional bodies, he sat on over seventy comm ittees. 
Significantly for the direction of research on cannabis, he came to the study of 
its pharmacology via an interest in drug dependence.9 Concepts around drug use were 
fluid. They had shifted from the concept of habit forming drugs to addiction in the 
post-war period and they again shifted in 1964 when the WHO recommended the use of 
the term drug dependence rather than addiction. 1o The term addiction was associated 
with the idea of withdrawal symptoms and the development of tolerance as seen with the 
use of opiates. The concept of 'dependence' merged the concepts of habituation and 
addiction. It was viewed as a broader model and referred to drugs which maintained 
some hold on the user with either physical or psychic characteristics. Prior to the 1960s, 
drug dependence was primarily considered in relation to alcohol and tobacco, but in 
the 1960s non-medical drug use of illicit drugs expanded considerably in the UK and 
illicit drug use became of major concernY Paton, an early proponent of dependence, 
considered cannabis to be a drug of dependence ofthe 'psychic type'. He recognized 
that critics might view this as an over-reaction, '1 am sure it is true that the dependence 
is not normally strong and some might think 1 make too much of it' but he viewed it 
as one of the most dangerous of the dependence producing drugs because he thought 
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it was innocuous enough to enter general circulation, unlike drugs such as LSD which 
had side-effects which he considered would deter most potential users.12 When Paton 
entered the cannabis field he found only limited research on the action of the drug. 
When he wrote on drug dependence in 1968 he emphasized that cannabis was not 
understood well enough to inform policy. For this reason, in his advisory capacity he 
consistently pressured for the maintenance of the status quo in the legal situation around 
cannabisY Much of Paton's early work had been funded by his Department in Oxford 
but in 1969, Paton applied for and received funding for two years from the Medical 
Research Council (MRC) to investigate the actions and toxicity of cannabis. 14 But why 
were Paton and the MRC interested in researching and funding cannabis research? 
The incentive to study the pharmacology of cannabis was driven by drug control 
imperatives, not medical need, and medical use and research was constrained by 
control policies introduced to restrain recreational drug use. In the 1960s and 1970s 
the policy environment around drugs and especially cannabis was in flux. The UN 
Single Convention on Narcotic Drugs of 1961 simplified earlier control regimes and 
expanded controls to cover plants from which 'narcotic' drugs were produced. IS It 
was a continuation and consolidation of the 'dominant supply control mentality.' 16 It 
introduced a scheduling system with substances placed within four schedule, Schedule I 
and Schedule IV representing the most restrictive. The convention meant that controlled 
drugs could only be used for medical and scientific purposes, though countries that had 
'traditional use' were exempted for twenty-five years. 
Medical use was an important delineator for placement of a drug within the 
system. Cannabis was drawn into this convention but its medical use had slowly been 
eroded. Analysis of documents and reports of the international agencies shows how, in 
drafting the new drug legislation, policy impacted for the first time on the medical use 
of cannabis. 17 The documents indicate that the World Health Organization, (WHO) the 
health body of the UN responsible for advising the Commission on Narcotic Drugs, 
(CND) the central policy-making body of the UN for drug related matters, was hostile 
to medical cannabis. This was significant because the WHO was responsible for 
making recommendations to the CND on the level of international control to be applied 
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to 'dependence producing drugs'. In 1952 a WHO Expert Committee informed the 
CND that there was no justification for the medical use of cannabis. 18 This decision 
was important for it was the first time cannabis had been officially declared to have no 
medical role, rather than simply falling out of widespread use. The harms of cannabis 
were brought to the forefront. When, in 1953 the CND asked the WHO to consider the 
mental and physical effect of cannabis the WHO condemned the drug unequivocally 
and the UN Economic and Social Council urged governments to discontinue its use 
as a medicine. This advice paved the way for the CND to severely curtail the use of 
cannabis and by 1957 the CND had requested the prohibition of all but traditional 
medical use. 19 This was critical because it meant that when the regulatory position 
of cannabis was considered cannabis was differentiated from heroin and its medical 
derivative diamorphine, which was seen as having some medical properties despite 
attempts to ban its medical use.20 
Yet whilst these international control mechanisms around cannabis were being 
tightened, research on cannabis had continued and research in Eastern Europe indicated 
some potential medical uses, for instance, as an antibiotic.21 Such research filtered 
through to the CND which expressed concern that the draft of a planned new drug 
control convention might limit medical uses and as a result requested the WHO to 
re-examine the issue of cannabis' medical utility.22 But when the WHO reviewed 
the antibiotic properties of cannabis it found no reason to backtrack on its original 
assessment.23 Cannabis tincture and extracts and cannabis and cannabis resin were 
placed in Schedule I of the Single Convention. This placed it in the same category 
as morphine and permitted medical use. However, cannabis and cannabis resin were 
also placed in Schedule IV on the grounds that medical use was 'obsolete' and its use 
was allegedly widespread. For Schedule IV drugs the convention required parties to 
prohibit, except for research purposes, cultivation, production, manufacture, export and 
import of, trade in, possession and use.24 Penalties for misuse were left under the control 
of domestic laws. This led to different interpretations of the convention in different 
countries. But cannabis was left in a vulnerable position because its medical utility had 
been officially discounted by the WHO. 
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Governments were required to implement punitive legislation for drug misuse. 
It led to the establishment of the 1964 Dangerous Drugs Act in the UK and the 1965 
Dangerous Drugs Act that consolidated previous legislation. This replicated the 
schedules of the UN convention. It regulated the import, export, manufacture and sale 
and possession of cannabis, morphine and opium and extended controls to cannabis and 
coca leaves, and by 1967 subsequent legislation had introduce police powers to stop and 
search drug suspects. These policy measures created incentives to better understand the 
drugs under control and the impact of control. Cannabis, in particular, seemed to pose 
a problem for legislators, especially, as in the 1960s there were large numbers of young 
people receiving criminal convictions, and consequently around the world commissions 
developed in the late 1960s and early 1970s which delved into the impact of the 
criminal control of cannabis use. 25 In the UK, where recreational use had been limited 
prior to the 1960s, its use increased despite increased controls and cannabis become a 
priority for drug regulators and expert committees. 
One expert committee in particular drew attention to the problems that cannabis 
posed to the drug control systems. In 1967 an expert committee the Hallucinogens 
sub-committee of the Advisory Committee on Drug Dependence, chaired by Baroness 
Wootton, a leading British sociologist and criminologist, had delved into the available 
evidence on the pharmacological, clinical, pathological, social and legal aspects of these 
drugs and produced a report focused on cannabis. It raised issues that re-occurred in 
debates over cannabis in future decades. The Wootton report concurred that in terms 
of physical harm cannabis was a dangerous drug but the sub-committee questioned 
cannabis' relationship in terms of harm compared to other drugs both licit and illicit. 
In terms of physical harmfulness, cannabis is very much less dangerous than 
the opiates, amphetamines and barbiturates, and also less dangerous than 
alcohol. 26 
Moderate use was not seen as especially harmful. Flexibility in the drug control system 
was deemed necessary. 
Wi.' do not ·wish to make anyformal or absolute statement on a comparison 
(~f cannabis and the other drugs in common social use. All we H'ould wish 
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to say is that the gradations of danger between consuming tea and coffee at 
one end of the scale and injecting heroin intravenously at the other, may not 
be permanently those which we now ascribe to particular drugs. 27 
Furthermore, it concluded that there was no convincing evidence for the' gateway 
theory'. The report recommended that in the interests of public health it was necessary 
to maintain restrictions on the availability of cannabis but argued that the law should 
be re-cast to give more flexibility of control over individual drugs. It called for new 
legislation to deal separately with cannabis, isolating it from drugs such as the opiates. 
It questioned the perceived dangers of cannabis use and the penalties applied to 
cannabis under the criminal justice system. 
We have no doubt that the wider use of cannabis should not be encouraged. 
On the other hand, we think that the dangers of its use as commonly 
accepted in the past and the risk of progression to opiates have been 
overstated, and that the existing criminal sanctions intended to curb its use 
are unjustifiably severe. 28 
The report recommended that imprisonment be removed as an offence for the 
possession of small quantities of cannabis. In this context, police powers of stop and 
search were questioned and it was recommended that these powers be investigated by a 
sub-committee of the Advisory Committee on Drug Dependence. 
Cannabis medicines were not deemed a problem by the committee. The sub-
committee saw no problem with an increase in the use of cannabis as a prescribed legal 
medicine. 
We see no objection to this and believe that any new legislation should be 
such as to permit its continuance. 29 
The new synthetic versions of cannabinoids such as THC had opened up a 
new dimension to the debate and they were seen as worthy of investigation. 30 The 
committee's recommendation for a re-consideration of drug policy and its call for an 
improved scientific base and reduction of constraints on research, stimulated research 
into cannabis which indirectly stimulated research into cannabis therapeutics.3 ) 
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The Wootton report was quickly rejected by the government. Some elements 
of the report were accepted and the problems caused by the police powers of stop and 
search were viewed with concern and discussion of this aspect was passed back to 
the ACDD. However, the recommended reduction of penalties and a potential move 
toward decriminalization were rejected both for national and international reasons. The 
government response stated, 
To reduce the penalties ... would be bound to lead people to think that the 
Government takes a less than serious view of the effects of drug-taking ... It 
would be entirely contrary to Government policy to allow this impression. .. 
nor would such a view accord with the resolution of the United Nations 
Commission on Narcotic Drugs, which the Government accepted last year. 32 
The extent to which the government could change legislation was limited since it was a 
signatory to the UN Single Convention on Narcotic Substances 1961. James Callaghan, 
the Home Secretary, whilst he rejected calls for decriminalization, did accept the 
need for cannabis research and called for the subsequent involvement of the Medical 
Research Council (MRC). 
Ifully accept that more comprehensive andflexible powers of control are 
needed to check drug abuse ... We also accept that there is a needfor wider 
research and we are bringing this to the notice of the Research Council. 33 
Cannabis remained a controlled drug but the penalties associated with its use came 
under scrutiny in the following years and the MRC became deeply involved in cannabis 
research and in time the report became seen as a sensible report.34 
The MRC had its origins in the search for solutions to the threat of tuberculosis 
(TB) at the tum ofthe twentieth century and it had come into independent being after 
World War One with a remit to fund research into public health threats. When the 
focus of public health shifted from infectious to lifestyle disease the MRC's attention 
fell on the problems associated with growing recreational drug use. But its interest in 
psychopharmacology, a discipline that was developing by the 1970s, developed from 
a long standing interest in basic laboratory work.35 The MRC had outlined its policy in 
1969 and indicated it was, 
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... . most anxious to foster a comprehensive research programme on the 
various aspects of drug dependence: worthwhile applications for support 
under the temporary research grant scheme for work in this field always 
received sympathetic consideration by the Council and indeed not 
insubstantial support had already been given under this scheme to various 
workers. In addition however there were probably a number of specific 
problems which could be solved relatively easily and which once identified 
could be carried off with Council s support on a contractual basis. 36 
The MRC had called a conference in 1967 to detennine avenues for future research 
and subsequently established three working parties to consider the research needs 
around drug dependence: the Working Party on Biochemical and Pharmacological 
Aspects of Drug Dependence; the Working Party on Evaluation of Different Methods of 
Treatment of Drug Dependence; and the Working Party on the Epidemiology of Drug 
Dependence.37 
The Working Party on Biochemical and Pharmacological Aspects of Drug 
Dependence which met for the first time in 1969 was chaired by Sir William Paton. 
It was composed of leading academics in their field, including Dr Marley, from the 
Institute of Psychiatry, Maudsley Hospital; Professor AH Beckett, from the Department 
of Pharmacy, Chelsea College; Dr Graham, at the Department of Pharmacology, at the 
Welsh National School for Medicine; Professor Gray, at Kings College, a Ministry of 
Health observer, Dr Johnston, a Scottish Home and Health Department observer, and 
GS Geoffrey, a Home Office observer. Its terms of reference were: 
To consider the needfor research on the biochemistry and pharmacology 
of drug dependence in particular to indicate those aspects of the problems 
that should be given priority or which are ripe for exploitation and to make 
recommendations to the council on specific research projects which should 
be encouraged. 38 
During its operation it was asked to comment on some of the recommendations 
made by the Wootton Report. By the late 1970s there was pressure for additional 
drugs legislation and a draft proposal was produced. Existing legislation was seen as 
'uncoordinated, inflexible and inadequate '. New legislation was desired to control 
availability of any drug the misuse of which caused both ill effects to the individual 
60 
and which constituted a public health and social problem, • and to make particular 
drugs subject to particular controls according to their comparative harmfidness 
and circumstance attaching to their misuse.' It was expected most of these would 
be pharmaceutical products with accepted medical or scientific uses but also those 
that might be used for non-therapeutic use.39 It was not expected to apply to alcohol, 
tobacco, tea or coffee as Paton later queried. The Home Office prepared a confidential 
report and asked the MRC for comments, which, in turn, passed the report onto 
the Chairmen ofthe Sub-Committees.4o Paton's response to the report which was 
subsequently forwarded to Mr Turner at the Home Office, provides an interesting 
insight into the debates over the drug control framework. 41 
Fundamentally I think the approach is sound and as I understand it would 
allow much more flexibility in dealing with a situation liable to change 
rather rapidly .... I find myself in a dilemma. On the one hand, I think 
it is probably sensible to be able to separate the more harmful from the 
less harmful drugs. On the other hand I am not sure that it is easy to do 
operationally ... 42 
Paton raised prescient points in terms of assessing harm and the separation of drugs. 
Flexibility of the system he deemed important citing the changing knowledge over 
amphetamines. He also queried where the lines could and should be drawn between 
derivatives. Where, for example, would the line be drawn in the sequence of opiate 
based drugs? Cannabis, Paton expected, would be placed in the least harmful category. 
Finally I am sure that cannabis and derivatives would be placed in the less 
harmful category but of course this is only just starting and I have little 
doubt that synthetic cannabinoids for intravenous administration will in due 
course appear and since I doubt if these could be regarded as less harmful 
than say a casual oral dose of pentazocide one might have got things the 
wrong way round. 43 
Flexibility of movement within the drug mechanism would become of greater 
importance in later decades as scientific understandings expanded and the social use 
of drugs changed. In looking for a solution to the problem of control of drugs Paton 
queried if drug delivery methods were the more pressing and controllable point, 
. accordingly I wonder ll'hether it is possible to incorporate controls over more or less 
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harmful methods of use. '44 The issue of drug delivery would be critical in the process of 
re-medicalization providing a method by which medical cannabis could be differentiated 
from recreational use. The development of new methods of administration of cannabis 
would prove equally important in the process of re-medicalization. 
The Working Party on Biochemical and Pharmacological Drug Dependence looked at 
a variety of drugs and reported to the MRC in 1970. It had found that knowledge was 
lacking in many areas: the determination of drugs in body fluids; methods for detection 
of heroin in the blood; and the biochemistry and pharmacology of heroin in man. It 
became clear that cannabis was the least studied and understood drug of dependence and 
it was this that triggered further calls for research into cannabis.45 One area of particular 
concern was the lack of reliable tests for cannabis in the blood, 'cannabis consumption 
is evidenced either by testimony or circumstantially; a reliable biochemical test would 
be of value primarily for diagnosis. '46 Such tests were available for morphine, cocaine 
and amphetamines and so research on this aspect was deemed essential in the light of 
penalties imposed by the Dangerous Drugs Acts. It was this that stimulated the MRC to 
fund and attract researchers to the cannabis field. 
The Working Party on the Epidemiology of Drug Dependence was chaired by 
Professor M. Roth ofthe University Department of Psychological Medicine, Newcastle, 
and aimed, 'to consider the needfor research on the epidemiology of drug dependence 
and in particular to indicate those aspects of the problem which should be given 
priority and to make recommendations to the Council on specific research projects 
which should be encouraged. '47 It held three meetings and also set up a subcommittee 
to review the supply of drugs giving rise to dependence. The working party concluded 
there was insufficient research directed to the problem of how and where drugs became 
available to the addict and that a focus on special groups such as adolescents in borstal, 
and young people at universities was desirable. There was also a need to develop 
methodology in the field, for example, simple and reliable interview schedules.48 In 
a joint meeting of the working groups, prior to submission of the final reports, Roth 
raised the point that he wondered if the drug of dependence was unimportant and that 
dependence related to . damaged personalities ll'ho lI'ould become dependent on any 
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drug. '49 The Working Party on the Evaluation of Different Methods of Treatment 
of Drug Dependence, chaired by Professor AC Dornhorst of St George's Hospital 
Medical School focused on the treatment of heroin dependent patients as new centres 
for treatment offered new ways of evaluating the methods used to treat patients.5o 
Once the working parties reported in 1970 they disbanded and a new working party 
chaired by Dr Owen was established to facilitate action on their recommendations. 
The interest in the biological aspects of drug dependence in relation to substances such 
as cannabis, nicotine and alcohol remained important and was deemed to warrant the 
establishment of their own working party which became the Working Party on the 
Biological Aspects of Drug Dependence, established in 1971. It was chaired by Paton 
and aimed to consider the pharmacological issues that had not been covered by earlier 
working groups.51 It was to consider the state of knowledge on the biochemistry and the 
pharmacology of dependence on drugs. It was also to identify suitable teams already 
working or who might work in the area and therefore to identify problems on which the 
MRC should contract research. 52 The working party again pushed for further research 
on cannabis, most notably to ascertain the fate of cannabis in the human body, and for 
the development of reliable biochemical tests to assist with the criminal prosecutions. 
The MRC was to be critical in funding the clinical trials into therapeutic cannabis in 
later decades but its interest in cannabis began by funding research to improve the 
fundamental understandings of cannabis.53 
This necessitated pharmacological research. Pharmacology, the study of the 
effects of a drug on the body and the means by which it exerted its influence, had 
become the cornerstone of drug development. The British Pharmacological Society had 
been established in 1931 and a branch of pharmacology, psychopharmacology, had been 
developing since the 1950s. The discipline of pharmacology expanded in the 1960s and 
psychopharmacology became of greater significance in the 1970s. Berridge showed 
that psychopharmacology, which focuses on psychoactive substances and their chemical 
interaction in the brain, became important to public health and eventually re-introduced 
the role of 'laboratory medicine' .54 Paton was a firm believer that pharmacology was 
an intrinsic route to understanding psychoactive drugs. 55 When the Wootton Report had 
been released in 1968 suggesting that cannabis should not be included in the Dangerous 
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Drugs Act, Paton, had been against these conclusions on the grounds that there was 
little hard scientific evidence on which to make such a decision. It was Lady Wootton's 
retort to Paton, 'if there isn i that much pharmacology isn't it about time you did someT 
that Gill, a colleague of Paton's, remembered triggering the Oxford group's work.56 
Paton and his team in the Department ofPharmaco)ogy at Oxford funded by the MRC 
would go on to carry out laboratory work and answer vital unanswered pharmacological 
questions around cannabis during the 1970s. 
Overcoming problems of the supply of cannabis for research, 
1969-1973 
The availability of the cannabis tincture was important for emergent research. 
Controlled drugs could be made available as medicines but the 1960s had seen raised 
fears around the safety oflicit medicinal drugs. Rachel Carson's Silent Spring published 
in 1962 had awoken people to the impact of the use of DDT. 57 The thalidomide disaster 
of 1962 revealed how medicines previously thought safe could pose an appalling threat 
to patients and this shook confidence in drug therapy and existing regulation. Tn the 
UK the government determined to exert greater control over the provision of medicine 
and introduced the Medicines Act of 1968 to take account of the more potent medicines 
developed during the therapeutic revolution of the 1950s and 1960s. This Act gave 
government the power to license pharmaceutical companies, products and clinical trials. 
The issue of the development of safety controls around medicines has been discussed 
by historians and it proved important in the process of re-medicalization. 58 Under this 
new licensing system, medicines were given 'Product Licences of Right (PLRs) which 
allowed drugs to be prescribed. These were granted automatically to products already 
on the market when the Act came into force. Controlled drugs with medicinal value 
therefore came under control of the Medicine Act 1968 as well. Cannabis tincture 
automatically received a PLR leaving it under the auspices of controlled drugs and 
medicines, and as such it was available to researchers. Edward Gill, a chemist who 
worked with Paton recalled 'there was afirm called Ransom .... that had the country's 
entire stock of tincture of cannabis. So my job .. lVas simply to isolate a sample of pure 
THe '59 But to isolate THC from the tincture was a time consuming process. The 1970 
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annual report of the MRC discussed the problem. 
The extraction of significant quantities of pure derivatives from crude 
cannabis is a laborious undertaking and although it can be carried out in 
any good laboratory it is wasteful of time and manpower. 60 
The synthesis ofTHC had partially solved the problem by providing a standardized, 
industrial product, but supplies ofTHC were difficult to obtain.61 Paton was mystified 
by Mechoulam's ability to source THC and he wrote in 1969, 
I was fascinated by your remark about the relative availability of delta-9-
THe ... when I looked into it a year ago there seemed to be none available 
and a notable silence on the topic, it shows again how one must know where 
to gO!62 
THC was not included in the 1961 Single Convention and a Home Office licence 
was not required for import but it still remained difficult to source.63 The inclusion 
of cannabis in the 1961 UN Single Convention on Narcotic Substances had made 
the situation complicated. Mechoulam, for example, wished to send Paton some 
extracts but Paton had to organize licences before the material could be shipped.64 The 
alternative was to circumvent the bureaucracy and risk prosecution in order to maintain 
an informal supply between researchers. 
Problems intensified with the introduction of the 1971 Convention on Psychotropic 
Substances. This convention brought in more comprehensive drugs regulation that 
amended the 1961 Convention which had generally been seen as a compromise and as 
superseded by drug development such as through the development of pyschotropics, 
non narcotic substances synthetically produced such as barbiturates, and which often 
rapidly entered the medical sphere.65 The 1971 Convention kept the idea of schedules 
but altered their significance. Schedule 1 took the place of Schedule IV as the most 
stringent and included substances 'whose liability to abuse constitutes an especial( .... 
serious risk to public health and which have very limited if any therapeutic usefulness.' 
Parties to the 1971 Convention were required to have punishable offences but the 
Convention also reflected a greater focus on the study of the nature of addiction and 
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treatment. Thus cannabis-based drugs including phytoTHC appeared in Schedule I and 
parties were therefore obliged to ban them' except for scientific and very limited medical 
purposes by duly authorized persons.' Schedule I products were not acknowledged as 
having medical value. How this worked in practice could vary between signatories. 
The US, for example, had already placed cannabis in the most restrictive category 
Schedule I of the domestic Controlled Substances Act 1970 which included drugs 
deemed to be dangerous and without recognized medical use, whereas countries such 
as the Netherlands, Canada and some Australian states, took a more liberal approach 
to the treaty obligations. Britain introduced the Misuse of Drugs Act of 1971 which 
became the cornerstone of UK drug policy. It focused on the supply and possession 
of 'dangerous or otherwise harmful drugs' which became known as 'controlled drugs'. 
Schedule 1 of the Act created the Advisory Council on the Misuse of Drugs (ACMD) 
and Schedule 2 of the Act listed the controlled drugs. The Act which came into force 
in 1973 was complex because it had to create a balance between permitting the 'correct 
use' of medically or scientifically useful controlled drugs as well as preventing their 
misuse.66 Under Schedule 2 of the Act controlled drugs were classified into three 
classes. Cannabis-based drugs such as cannabinol (CBD) and THC were highly 
controlled and placed in Class A. Herbal cannabis was listed as Class B. To avoid 
having to amend the MDA there was provision for subordinate legislation to allow for 
amendments through its regulations. Regulations, for example, permitted exemptions 
for legitimate activities such as the medical use. Drugs were placed into Schedules 
under the regUlations. Cannabis, certain psychoactive cannabinoids and derivatives 
were not deemed to have medical use and therefore they was not exempted under the 
regulations and were placed in the most restrictive schedule and required a licence 
from the Home Office for research purpose. In contrast substances such as morphine 
could be exempted under the regulations and did not require a licence from the Home 
Office for clinical trials. If a cannabis-based drug, for example, cannabinol was to be 
made a commercially available licenced product the drug needed to be transferred to a 
less restrictive schedule of the regulations of the MDA. Cannabis medicines were no 
longer permitted when the Produce Licences of Right (PLRs) provided under the MCA, 
were reviewed and the regulations of the Misuse of Drugs Act 1971 were enacted in 
1973. With no acknowledged medical use, cannabis lost its PLR and could no longer be 
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prescribed by doctors or dispensed by pharmacists, though it could be used for research 
purposes with a Home Office licence. This move meant that by 1973 cannabis came 
under the sole control of illicit drug regulation. 
MRC funded projects ground to a halt through insufficiency of research material. 
A domestic source of cannabis or synthesized THC would have simplified the problem. 
But when the MRC attempted to encourage a commercial firm to supply cannabis 
under contract to the Council there was little optimism.67 It was especially problematic 
because the supplies required were small-scale and likely suppliers such as Miles 
Laboratories refused to become involved. 68 The next avenue was to tum to an overseas 
source. The National Institutes of Mental Health (NIMH) in the US had begun to fund 
research projects into cannabis initially on the assumption it would provide an evidence 
base for the harms of cannabis use and underpin control policies. It was prepared to 
supply material free of charge. But UK researchers perceived this as a major problem 
as it potentially left them reliant on agreements with a foreign authority and one with its 
own policy and research agenda. Furthermore, the US supply of cannabis was rich in 
THC but lacked cannabidiol (CBD) another important component of cannabis. Paton, 
was deeply unconvinced about this supply chain and complained to the MRC in 1971.69 
It seems to me there is something wasteful .... 1 do not care for leaving the 
decision whether a project is worthy, not to the MRC but to NIMH ... 1 do 
not consider consulting Dr Collier as adequately exploring the possibilities 
in industry.... if it becomes established that the MRC will not make its own 
arrangements for supply then there is another possibility, that they negotiate 
an agreement with NIMH whereby the latter makes available to the MRC a 
quantity for distribution at the MRC s discretion. 70 
Hopes were briefly raised when it appeared that Imperial Chemical Industries (ICI) 
might be interested, particularly, as its Research Director, DG Davey, had been co-opted 
onto the MRC. But it was to no avail as ICI found the complexity ofthe operation did 
not justify the investment.71 Issues of expense and expertise waylaid other industrial 
alternatives. Davey had suggested an alternative - Koch Light Laboratories, a maker 
of industrial fine chemicals in Suffolk. Paton rejected the idea of using Koch Light on 
the grounds of expense, time constraints and their lack of expertise.72 The inability to 
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procure a supply left three potential sources: via the UN, through Dr Olav Braenden, 
Chief Scientific and Technical Section of the Division of Narcotic Drugs; from Dr 
Monique Braude, Acting Chief, Biomedical Section of the Centre for Studies of 
Narcotics and Drug Abuse, (NIMH); or via an Israeli producer, Makor Chemicals. 
None of these sources appeared ideal. The UN source appeared to fall by the wayside, 
using NIMH was advantageous in term of costs but problematic in that there were 
conditions attached to the supply but the Israeli source involved a commercial 
transaction.73 As time went on the cost and practicalities outweighed the concerns of 
obtaining supplies from the NIMH. Paton became more resigned to a US supply though 
he remained dissatisfied and he wrote to the MRC of his desire to source material from 
Europe. 
I have reservations about the work becoming wholly centred in the USA and 
wish there was an adequate source of supply in Europe. But the fact is the 
NIMH is willing to give it away. 74 
The MRC had secured supplies from NIMH by 1972 and began to act as the 
central liaison and distribution point. 75 Problems arose over how to obtain the necessary 
import licences from the Home Office. Additionally, the solution ignored non-MRC 
funded researchers.76 Although MRC researchers received their supply there remained 
some dissatisfaction. Researchers were irritated as they could not supply other 
colleagues directly and the NIMH system was viewed merely as an interim solution. 
When the MRC wrote to MRC researchers in 1973 to ask if they required additional 
material, researchers feared that the MRC wished to divest itself of this distributive role. 
Gill expressed his frustration with the system to the MRC. 
Research groups ... .. are inhibited by the difficulties in obtaining small 
quantities of pure materials ..... research groups could approach the NIMH 
directly but if a body with the authority and administrative resources of the 
MRC find it tiresome to complete the port formalities then the burden on 
individual departments is even more severe. The Misuse of Drugs Act makes 
it illegal to provide ... with samples unless one goes to the considerable 
trouble of obtaining a Home Office licence .... it would ... appear that the 
MRC is contemplating abandoning its role as an intermediary ... if that is 
the case it is a most unfortunate decision. 77 
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Finally, the MRC agreed maintain its role and act as a clearing house for all UK 
requests. This was fortuitous as when in 1973, cannabis tincture's PLR was not 
renewed, the structure was in place for supplies ofTHC to enable research to continue. 
This early period opened the door to cannabis research, providing both incentives and 
systems to study cannabis. But it also revealed the serious consequences of a lack of 
domestic industry interest; a gap which stakeholders would prove to be keen to fill 
in later decades. The banning of cannabis tincture also impacted on the direction of 
research. Roger Pertwee, a pharmacologist and colleague of Paton in the early 1970s, 
recalled, 
In the early i970s tincture of cannabis was banned. It was no longer a 
medicine. It had ceased. And the main interest then for research was why is 
cannabis bad for you? Why is it taken recreationally?78 
Research by psychologists expanded, with researchers such as Adele Kosviner, at the 
Addiction Research Unit, also funded by the MRC, focused on the prevalence and 
impact of cannabis use amongst university students. 79 The main emphasis however 
remained on establishing the pharmacology of cannabis, which in this period focused on 
the potential harms of cannabis use. 
Understanding cannabis: experimental pharmacology, the research of 
Sir William Paton, and the problems of cannabis use 
Basic pharmacological questions remained unanswered over cannabis in the early 
1970s: What was its pharmacology? What kind of impact did the structure of cannabis 
have? Was THC the main psychoactive ingredient? What were the physiological 
effects of cannabis and cannabinoids like THC? Paton argued that the role of the 
pharmacologist in understanding psychoactive drugs was to provide an overall 
description of a drug's actions to 'act as insurance against adverse reactions in human 
practice' .80 Throughout the 1970s Paton and the group at Oxford started to answer 
some of these questions by introducing in-vitro studies of cannabis. in-vitro studies 
provided a controlled environment for studying the effects of cannabis. Roger Pertwee 
a pharmacologist who worked closely with Paton described the initial focus of research. 
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Early pharmacology was descriptive because so little was kn01I'n and 
you could go in any direction you liked and there would be new stuff to 
learn about what THC and cannabis were doing. A lot of interest was in 
confirming that THC was the main psychoactive constituent of cannabis by 
comparing the two pharmacologically. 81 
Research sought to establish the effects of cannabis and individual cannabinoids on 
biological systems, and compared cannabis with other drugs, and especially cannabis' 
ability to cause dependence. 82 Paton and his group at Oxford published preliminary 
results of their research in Nature in 1970 in which they confirmed that THe was the 
main psychoactive constituent of cannabis, and they found six other pharmacological 
effective components of cannabis. 83 They discovered that the effects of cannabis 
ranged from lowered body temperature, catalepsy, analgesia and the extension of the 
sleeping time when used in combination with barbiturates. In the early 1970s cannabis' 
interaction with other drugs had become an important area of research. Paton and 
Pertwee continued to look at the effects of cannabis constituents on pentobarbitone 
sleeping time and phenazone metabolism. Building on the work of Professor 
Sigmund Loewe in the 1940s and 1950s on pharmacological studies on cannabis' 
structure-activity they investigated the effect of cannabis on sleep induced by certain 
barbiturates.84 They researched the mechanism of action of this effect in m ice and 
sought the constituents of cannabis responsible for this effect. Detailed results of the 
research were published in 1972. They found that cannabis extract prolonged sleep time 
and that the effect was dose-related. They concluded that cannabis extract inhibited 
microsomal activity of the mouse liver through the cannabidiol content. This was a 
significant finding because it was thought probable that human cannabis consumption 
could lead to interactions with other drugs, through the altered metabolism of many 
other drugs, not just barbiturates, taken for medicinal or recreational use. 
The group developed new technology for studying cannabis. Pertwee had become 
interested in inert gas narcosis after doing a diving course with the military whilst at 
university. He went on to do his PhD under Paton on diving-caused gas narcosis and 
took a post-doctorate on cannabis as it appeared to act similarly to the anaesthetics.85 
Pertwee developed a new quantitative method to assay cannabis biologically: a 
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bioassay for cannabis. Bioassays measure the pharmacological activity of substances 
and were a prerequisite for establishing modes of action, a facet of cannabis that was 
not understood.86 This bioassay tested the cataleptic effect of cannabis by measurin o 
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the percentage of time a mouse spent completely immobile on a horizontal wire ring. 
Pertwee established that responses were dose related, and concluded that THC was 
largely responsible and that cannabidiol had no effect. This test was demonstrated at 
a meeting of the British Pharmacological Society and was published in 1972Y This 
test, along with three others, was to form the Tetrad tests which became a mainstay of 
experiments on animals. This was significant because bioassays tended to open up new 
research avenues as had occurred in the tobacco and nicotine field. 88 
In the early 1970s a focus was on the harmful effects of cannabis. Gill described 
the legislative imperative. 
I think the main thrust of the work that was being done then was trying to 
establish there was a clear-cut case for decriminalizing cannabis. It is 
clearly difficult to prove a negative ie to demonstrate that THe was not 
harmful and one rather got the feeling that a lot of the work that was being 
financed was really to establish whether you could clearly demonstrate a 
harmful effect. If that was the case then that would really take care of the 
legislative problem ... the stuff was dangerous so it ought to be controlled. 89 
Research highlighted cannabis' potential problems and provided a degree of 
evidence to underpin fears that had been raised in the nineteenth century. Although 
cannabis was not known to cause death there were concerns over its physical effects. 
Paton raised fears over toxicity in a 1972 research report for the MRC. Paton found 
THC to be the most toxic constituent of cannabis but that other cannabinoids, such as 
CBD were also active and had observable effects. Animal experiments showed that the 
administration of cannabis caused weight loss from which some animals adapted whilst 
others died. Paton noted the development oftolerance to cannabis and the existence of 
withdrawal symptoms at high dosages in animals, though not to the same degree as to 
barbiturates but he felt that this could still be sufficient to predispose continued use. It 
was significant because tolerance and withdrawal symptoms were considered diagnostic 
criteria for substance dependence. Importantly, Paton's work raised fears that toxicity 
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was likely to be cumulative, a result of its fat-soluble (lipophilic) properties. This 
was seen as having serious implications for cannabis use, especially for long-term 
use.
90 For Paton research that appeared to show cumulative and teratogenic effects in 
animals meant that the use of cannabis in humans was not acceptable until there was 
'unequivocal evidence' that humans were not susceptible to the effects as seen in animal 
research.91 
Paton worked hard to publicize the results of his research and to carry his 
concerns to a wide audience. Cannabis and its problems, presented at the Royal Society 
of Medicine and published in the Proceedings of the Royal Society of Medicine in 1973. 
drew together a review of existing literature on the adverse effects of cannabis. Paton 
highlighted particular areas of concern: teratogencity, carcinogenicity, and the impact on 
mental health.92 He expanded upon the behavioural effects on neurophysiology. These 
varied effects he put down to the 'disinhibiting action' which affected concentration 
and memory. In analysis of the psychopathological problems his paper raised the issue 
of 'cannabis psychosis' and he argued that though the literature on this was rarely cited 
in contemporary debates around cannabis, it should be taken into account. However, 
he did draw distinctions between 'effects due simply to cannabis .... and exacerbation 
of a personality disorder, precipitation of psychosis and the exacerbation of pre-
existing psychosis '.93 A key concern for Paton was the effect on young people. Work 
on cannabis smoking and young people had indicated neurological impacts, and Paton 
was particularly concerned due to the potentially cumulative effect of cannabis use on 
developing bodies. Some of Paton's work was criticized for inferring effects on humans 
from animal studies, and the level of dosages used being greater than those that would 
be found in cannabis smoking. But experimental pharmacology was largely focused on 
animal experiments and Paton was a proponent of research on animals, and throughout 
his career highlighted their continued value to science.94 
Paton was troubled with the way in which pharmacological knowledge was 
utilized in the formation of policy. He was concerned with the inconsistency of the 
science-policy transfer. for example, the way in which knowledge could be applied 
to policy in respect to different drugs, such as in the case of cyclamates, DDT, and 
barbiturates. He argued, 
72 
One might venture a nai"ve pharmacological comment on the odd fact that 
cyclamates are being banned never having done any damage to any human 
and only with difficulty to animals, while in millions of bathroom cupboards 
there lie a lethal or near lethal doses of barbiturates. 95 
Paton argued that for the formation of reputable policy there needed to be consistent 
criteria by which to assess substances, criteria which seemed to be non-existent. A few 
years later he reiterated this point that there seemed a split between the treatment of 
products developed through industrial processes, such as DDT and saccharin, which 
were coming under attack as dangerous products, and a natural product like cannabis, 
which many argued was not dangerous.96 Paton questioned where responsibility lay for 
all drugs whether medical or recreational. Attitudes towards the mechanism of control 
of cannabis could swing between paternalism and permissiveness. For Paton, one way 
to avoid these extremes was to rely upon accepted principles of public health and social 
legislation. For a drug to be made available it needed to meet criteria similar to those 
used for medicine or food additives and to take into account its risks, and the number 
of consumers vulnerable.97 Though Paton was not involved in some of the main expert 
committees of the Advisory Council on Drug Misuse of the 1970s, he tried to influence 
the public debate over cannabis and called for a precautionary approach to legislation 
in relation to cannabis. In 1978 he published an article on the impact of laboratory 
research on social policy. Drug policy, he argued was made up of evidence and attitudes 
welded together. The article case studied cannabis and considered the inter-relationship 
of science, medicine and policy. He saw policy decisions around cannabis as critical 
because he believed that they had the potential to set a precedent for the treatment of 
other substances. 
It was with such a background that those interested in preventive medicine 
must consider the question of control of cannabis ... , one must ask whether 
a government would successfully control any chemical again, if it approved 
for general distribution a chemical substance known to be cumulative, 
found to be teratogenic in three species and possessing a wide variety of 
biochemical and cytotoxic actions ..... 98 
Unlike many proponents of decriminalization, Paton attempted to draw distinctions 
between cannabis and other substances like tobacco and alcohol. Cannabis, he 
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considered, to be more dangerous than alcohol on the grounds that alcohol was ingested 
and therefore was not an irritant, it was usually ingested with food and \\ as less 
cumulative. In contrast, he noted that cannabis was inhaled for its intoxicant effect, and 
was often diluted with tobacco. Cannabis could result in non-obvious intoxication had , 
a serious toxicology dossier, with an unknown chronic dose level, and for Paton this 
was of much greater concem.99 But it was difficult to apply consistent criteria when 
cannabis' role in the body remained unclear. 
How cannabis impacted on the body was still a mystery. A key question of 
pharmacology is pharmacodynamics: the explanation of how a body interacts with 
a drug. Understanding of the mechanism of action (MOA) of drugs was important 
as it also helped to explain the working of the body, for example, through the role of 
receptor systems. But in the 1970s the MOA of cannabis was not understood. Paton 
had previously worked on the mode of action of anaesthetics and he had argued that 
they were non-specific in action and had detailed a case for properties of fat soluble 
(lipophilic) substances.lOo In seeking the MOA, of cannabis, Paton predicted that active 
principles like THC which were also fat soluble had a resemblance to the anaesthetics. 
Pertwee found that THC mimicked the anaesthetics which seemed to support this 
hypothesis. It was thought that this would account for some of cannabis' actions such 
as hypotension, depression of cortical activity and analgesia. This led Paton to consider 
that cannabis, like the anaesthetics, was also non-specific in action. Such findings led 
Gill and another member of the team, Lawrence to argue that there was no 'goodness 
offit' into a specific cannabinoid receptor and that the mode of action was quite 
different. 101 This hypothesis moved research away from the idea of the specific action 
of cannabinoids and away from the idea that cannabis acted on receptors. Mechoulam 
later attributed this interpretation due a supply of impure THC and commented on the 
impact for cannabis research. 
A very prominent group in Oxford .... had done some work on cannabis, 
and ... thought that its activity was not specific ..... it was based on some 
work with ... synthesized THe which was not very pure . .... so Bill Paton 
thought maybe these compounds act non-specifically ... This was accepted ... 
ft turned 0111 there 11'as a mistake in the chemistry ... The people who had 
synthesised it (had) ... not obtained very pure material. .. that blocked 
investigation for almost twenty years. 102 
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This avenue for research was not re-opened until the late 1980s when the hypothesis 
was disproved and a new understanding of cannabis' mode of action re-opened the 
cannabis field and changed the understanding of how cannabis could act as a specific 
therapeutic. 
Paton and the therapeutic use of cannabis 
Paton's concerns over the potential harms of cannabis and his fear of decriminalization 
contributed to his disinclination to use it as a therapeutic and he argued in 1968 that he 
would 'defend the case that there is no valid therapeutic use for cannabis. ' 103 He was 
skeptical about the anecdotal reports of cannabis' medical value. Whilst ancient and 
nineteenth century use of cannabis was often cited to support claims for therapeutic 
applications, Paton rationalized that with so few drugs available anything that offered 
hope was seized upon. Furthermore, cannabis as a therapeutic lacked clinical trial 
evidence and for Paton this meant cannabis had no contemporary proof of value. 104 But 
whilst clinical trials were the route to drug testing and licensing, large-scale trials on 
cannabis would not take place for decades. In this context Paton argued that there were 
more potent, more specific modern drugs to employ. 
Today it is proposed as an analgesic, antidepressant, hypnotic .... diuretic 
or antibiotic, for treating glaucoma ... psychiatric aid or treatment of 
withdrawal symptoms. For each of these uses there are more potent 
modern drugs. It is of greater significance that its modern rivals are also 
more specific, even though cannabis or THe has some particular action, 
its therapeutic use all entails the production tachycardia, conjunctivas, 
psychic changes, ..... or depression, euphoria .... itsfat solubility and 
pharmacokinetic properties too present difficulties for sustained use, 
although if its toxicity were acceptable, methods could be devised for 
dealing with these, as with other drugs. 105 
Since research indicated an apparent non-specificity of cannabis, the widespread effects 
of cannabis were deemed a problem by Paton and a limiting factor for any medical 
application. 
The issue of medical cannabis became politicized by the mid 1970s. Potential 
medical use of cannabis became caught up in campaigns for decriminalization. Lester 
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Grinspoon, an American psychiatrist, became an early medical activist for medical 
cannabis and he wrote Marihuana Reconsidered in which he illustrated anecdotal 
reports of cannabis' value as a medicine. In stark contrast to Paton he downplayed 
cannabis' dangers. Grinspoon had previously taken an anti-cannabis stance but, 
when his son who suffered from cancer found cannabis alleviated the symptoms of 
the chemotherapy, he began to take an altered view of the substance and became an 
advocate of legalization. This case and others I ike it raised the profi Ie of cannabis' 
therapeutic potential and the need for legal flexibility to cater for patients who had no 
other recourse. This triggered a response from anti-decriminalization scientists such as 
Gabriel Nahas, an anaesthetist pharmacologist at Columbia University in the US. Paton 
corresponded with Nahas and they were united in their concern over the pressure that 
had developed for legalization in their respective countries. As with Paton, Nahas was 
concerned about the aspect of the debate that tried to draw cannabis closer to licit drugs 
like alcohol and tobacco. He commented, 
1 believe that every effort has to be made to turn the tide and prevent as 
much as possible the widespread usage of cannabis, especially among 
adolescents. 1 am sure that it will take a good deal of time to dispel the 
widely spread new myth that marihuana is less toxic than alcohol or 
cigarettes. 106 
Nahas feared popular opinion was shifting against the precautionary principle that 
kept cannabis more closely aligned with drugs such as heroin rather than those such as 
alcohol. 
All these observations seem to have been performed a little too late in order 
to offset the momentum of the attractive but completely erroneous claims of 
Charles Kaplan and Grinspoon. 1 believe their claims correspond exactly to 
what many people want to hear today. 107 
Paton agreed with the aim of Nahas' book, Keep off the Grass and contributed its 
foreword in which he argued, 'the innocuousness of cannabis is being overstated and its 
dangers underestimated.' J08 Despite some differences of opinion Paton was pleased to 
see this kind of work appear. 109 
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But the book did not sell well.llo Popular texts on the anecdotal benefits of 
cannabis seemed to receive greater publicity and find a greater market. Indeed, 
problems with publishing cannabis texts dogged Paton.11l Furthermore Gill recalled 
that' by the time we got to the middle of the 1970s, the effects were at best marginal, 
second-rate; there was no overwhelming case that could be made against cannabis on 
the grounds of toxicity. It was at that point that the subject lost momentum.' 112 Gill 
argued that Paton took an asymmetrical view of cannabis literature, 'he applied all his 
very considerable skills to a lot of what you might call the positive evidence (ie that it 
was not harmful) and was much more tolerant about the negative evidence.' 
Paton and Nahas feared that the claims of therapeutic use and comparisons to licit drugs 
such as alcohol would override research that suggested harmful effects in humans. 
Paton found cannabis useful for providing hints to synthesizing related molecules 
because of its interesting structure and not as a medicine in its own right. 113 In 
comments to a publisher on Mechoulam's idea for a new book on the therapeutic uses 
of cannabis in 1980 he argued that in light of cannabis somewhat scattergun impact on 
the body it was useful only as a lead. 
There is ... a tendency ... to show that cannabis ... is therapeutically useful 
instead of. .. trying to use the hints it provides to produce some really 
unexceptional remedies by synthezing related molecules. My own view 
is that the only therapeutic use of significance so far is as an anti-emetic 
in cancer therapy. Its effect in glaucoma and in bronchodilation and 
with cannabidiol in epilepsy ... aren't really useful as they stand ... ..... The 
significance therefore I take to be potential rather than actual for the most 
part. 114 
Paton did not condemn completely cannabis as a medicine as he assumed it would be 
possible to deal with its cumulative problems if its toxicity was regarded as acceptable 
as was the case with other medical drugs.1I5 To Mechoulam he wrote of the link of 
therapeutic cannabis with politics. 
I was surprised that nabilone being excludedfromfurther trial .... I still 
think THC points to something interesting and exploitable but its all 
bedeviled by politics and the pot lobbies desire for THC to be the winner. 116 
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In 1983 he commented on the dilemma , 
If your view is that it is harmless then the psychic effects and general 
somatic effect which would appear as side actions get discounted. If on 
the other hand its action and its cumulative potential have worried you in 
recreational use then they continued to do so in therapeutic use. Il7 
For Paton there was a considerable gap between potential therapeutic use and the 
advisability of using it as such. 
Conclusion 
At the time at which cannabis research re-emerged cannabis fell under the 
administration of both 'controlled' drugs and the regulation oflicit medicines. But 
when cannabis tincture was removed as a licit medicine in 1973, cannabis was left 
firmly in the arena of illicit drug regulation. Whilst this move might have seemed 
to have ended cannabis' career as a medical substance, pressure to obtain a better 
understanding of cannabis as a controlled drug indirectly opened the door to re-
medicalization. 
The isolation and synthesis ofTHC, the active principle of cannabis, had removed 
a hindrance that had stunted cannabis' use as a phannaceutical product, and pennitted 
cannabis research to develop in a way that had not previously been possible. Interest 
originated from different scientific communities: sociologists and psychiatrists seeking 
to establish the epidemiology and the impact on mental and social health. Experimental 
pharmacologists like Paton, investigated these compounds for physiologic activity, 
and demonstrated various effects of cannabis. Research was mainly animal-based 
laboratory work. It confirmed that THC was the main psychoactive constituent but that 
there were a number of other previously unknown active constituents. Other significant 
findings indicated that cannabis could interact with other drugs, had potential toxic 
effects, and because of its fat-solubility could be cumulative. 
Supply issues, in terms of availability, access and quality, hindered research in this 
period. Although problems were partially overcome, the situation was never ideal and 
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it drew attention to the problems encountered without a domestic supply and limited 
industry involvement. The quality of supply could be crucial in influencing research 
and the interpretation placed on research results which in turn influenced developments 
within the field. The lack of an independent domestic supply and industrial involvement 
were issues that would have to be revisited in later decades. 
Nonetheless, the background knowledge to cannabis that would allow therapeutic 
applications to develop in later decades was explored in this period. As Paton himself 
explained, 
There is a misunderstanding of the role of 'basic' laboratory work. This 
may, if one is lucky, yield results with immediate application. But its 
real function is longer term, to provide the background knowledge and 
understanding and the rational framework in which opportunities for 
practical advance can be created and grasped. 118 
By the mid-1970s many of the main chemistry and pharmacological questions had been 
answered. It was the interpretation of pharmacological findings in animals that was 
important because it raised concerns over the possible effects in humans and appeared 
to give credence to earlier vague fears over the harms to individuals and to society 
especially over mental health and long-term effects particularly to young users. 
In this period science and policy became increasingly interlinked and Paton 
articulated concerns to the scientific community, the public and to policy-makers. The 
interpretation of results on laboratory animal work led Paton to campaign vigorously 
again the recreational use of cannabis. He emphasized the need for the precautionary 
principle in relation to cannabis, and pressed for preventative approaches to cannabis 
by the maintenance of the status quo around existing legislation. However, he also 
raised the need for flexibility in the mechanism of drug control, to allow for changes in 
knowledge. 
Through international science networks Paton was aware of research into therapeutic 
use such as that by Mechoulam for glaucoma and epilepsy and he did see cannabis 
as useful as a palliative in the treatment of cancer chemotherapy. But on the whole, 
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Paton denied cannabis' usefulness as a medicine because of its potential long term toxic 
effects, and possib Ie encouragement of recreational use but he did concede its potential 
usefulness as a lead. Paton's research had put into place the building blocks that would 
allow research into cannabis' medical applications to go forwards. Paton in a discussion 
of the importance of pharmacology explained, 
Pharmacology studies the response of biological system and their control 
by chemical substances with the special aim of improving therapeutics. 
Pharmacology underpins the pharmaceutical industry. 119 
With the basic pharmacology better understood other pharmacologists began to write 
more positively about the drug, and clinical pharmacologists, clinicians, and the 
pharmaceutical industry began to study cannabis' therapeutic applications. 
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Chapter Three 
Re-discovering the therapeutic use of cannabis: Clinical 
pharmacology and the therapeutic applications of cannabis, 
1973-1982 
The interest of the medical profession is slowly reviving. It is not impossible 
that a limited but respectable niche will be establishedfor it (cannabis) in 
therapeutics by the end of the century.! - JDP Graham, 1976. 
Whilst Paton wrote on the potential harms of cannabis a change in attitude amongst 
some pharmacologists towards cannabis became discernable. Pharmacologists such 
as JDP Graham emphasized potential therapeutic applications and questioned the 
interpretation of the harms of cannabis. This chapter traces the emergence of potential 
therapeutic applications of cannabis for glaucoma, epilepsy, as a pre-anaesthetic, and 
as an anti-nausea drug in cancer chemotherapy. Forces of necessity in the clinic led to 
some degree of acceptance of cannabis as a therapeutic. In particular, the application of 
cannabis as a palliative for the treatment of nausea caused by chemotherapy provided 
stimulus and legitimacy to the cannabis field. But whilst previous cannabis therapeutics 
had focused on cannabis extracts by tincture, the 1970s saw a very di fferent focus on 
the form and delivery system used to confer cannabis' therapeutic properties. After 
the removal of cannabis tincture's Product Licence of Right (PLR) in 1973, cannabis 
therapeutics focused on synthetic, single entity chemicals which attempted to improve 
on the active principle of cannabis in order to increase its efficacy and reduce its 
psychoactive effect. A few small-scale clinical trials were carried out on versions of 
THe some of which made the leap through the regulatory processes in the US and UK. 
Within ten years of cannabis being removed as a medicine in the UK, the argument 
that cannabis had no medical value was being overturned as emergent synthetic 
cannabis-based drugs were licensed for limited use in the UK and US. In contrast, 
investigations into smoked cannabis acted as a lightening rod to controversies over 
cannabis, herbal medicines and smoking. Interest in cannabis' therapeutic potential 
infiltrated policy discussion by the 1980s with debates focused on the benefits versus 
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the harms of cannabis. Over this period medical cannabis remained deeply interlinked 
with discussion around recreational use. The newly introduced licit cannabis-based 
drugs were poorly tolerated by patients, and were not widely marketed as a result of the 
stigma around cannabis and their placement within drug control systems. In addition, 
public health focus began to shift away from cannabis to other illicit drugs and with no 
development in the understanding of the mode of action of cannabis, the field began to 
contract. 
International research and the therapeutic use of cannabis 
Whilst experimental pharmacologists such as Paton concentrated on the harms of 
cannabis as demonstrated in animal studies, others started to investigate cannabis' 
potential in the clinic. With the chemistry of cannabis better understood both 
pharmaceutical firms and academic laboratories began projects into cannabis-
based drugs.2 Two areas opened up for cannabis therapeutics: one that utilized the 
psychologic effects of cannabis, including its application as a sedative, analgesic, 
pre-anaesthetic and anti-emetic; the other that avoided the psychologic impacts and 
focused on cannabis as a bronchodilator, in intraocular pressure reduction, as an anti-
convulsant and in tumour growth reduction.3 As is discussed in detail in chapter six, 
patient pressure in the US encouraged research into cannabis for glaucoma.4 Glaucoma 
is a condition of the eye in which the channels through which the fluid flows gradually 
become blocked, and the intraocular pressure (lOP) gradually increases causing 
increasing damage to the optic nerve and gradual deterioration of vision. Standard 
treatments were limited. Emergent reports of cannabis' benefit were largely anecdotal 
but some scientific research began. Hepler and Frank carried out work on cannabis 
smoking and intraocular pressure and found that cannabis reduced intraocular pressures 
in normal subjects for four to five hours with 'no indications of any deleterious 
effects ... on visual function or ocular structure. '5 They concluded that cannabis 
might be more useful than conventional medications because it worked by a different 
mechanism. Hepler found later that when cannabis was smoked for months at a time 
by glaucoma patients, the effect on intraocular pressure stayed constant and there was 
no deterioration of vision.6 Mechoulam was particularly keen to push work on the 
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therapeutic applications of cannabis in glaucoma.7 He had some success with local 
applications ofTHC on rabbits for glaucoma and wrote to Paton in 1976 about his 
research on cannabis and glaucoma as well as epilepsy. 
We have gone ahead with the glaucoma thing but unfortunately although we 
have very good results in rabbits we have no idea what relevance our work 
has for humans . ... we are doing a double blind-clinical experiment 1i'ith 
cannabidiol on epileptics with results so far much better than expected. 8 
It was difficult to transfer research into the clinical environment due to a dearth of 
toxicity trials on cannabis and THC. Furthermore, Mechoulam's project hit snags, 
similar to those that had plagued Paton and the MRC in the early 1970s, that of being 
unable to secure industry involvement. Mechoulam complained to Paton, 'Industrial 
companies do not consider a new glaucoma drug worth the enormous expense of 
introducing it into the market so we are stuck!,9 Whilst researchers demonstrated some 
potential applications there were only a few that were deemed worthy of research and 
development especially for a 'controlled' substance. Paton, for one, was not convinced 
over the application of cannabis for glaucoma. He responded to Mechoulam that he 
found it had interesting cellular effects but that interest was mainly focused on the 
impact on intraocular pressure and that people tended to miss the link with changes 
in blood pressure. 10 The National Eye Institute in the US supported research studies 
from 1978 to 1984 in an effort to determine whether cannabis, or drugs derived from 
cannabis, might be effective as a treatment for glaucoma. The studies demonstrated that 
some derivatives of cannabis lowered intraocular pressure when administered but there 
were also side-effects and that they did not compete favourably with other available 
drugs. ll Research also emerged on cannabis as an analgesic though reports were 
inconsistent and revealed a narrow window between beneficial and adverse effects.12 
It was as a drug in the management of cancer that cannabis's benefits were 
perceived to outweigh its harms and to justify involvement in cannabis-based 
drug development. It was this application that contributed most to cannabis' re-
medicalization during this period. The side-effects of cancer chemotherapy presented 
a distressing problem with new cytotoxic drugs such as Taxol causing nausea and 
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vomiting, sometimes to the extent that the treatment was viewed as worse than the 
d· J3 I . lsease. n some cases patIents were forced to stop treatment. In the 1970s, it was 
a relatively new but increasing problem. Available cancer chemotherapy palliatives 
were unsatisfactory. Phenothiazine was used but its benefits diminished with use 
and it had unwanted side-effects. Other treatments, such as Metoclopramide, were 
often ineffective. As a clinically induced problem, and one that seriously limited 
the viability of chemotherapy as a tool, it was critical to find a solution. Anecdotal 
observations of cancer patients in the US had revealed that patients who used illicit 
herbal cannabis were less troubled by chemotherapy. Herbal cannabis, however, was 
in no way considered a suitable therapeutic and chemists attempted to improve the 
efficiency of cannabis constituents by molecular manipulation with the aim of retaining 
the activities ofTHC but without the undesirable side-effects. Mead has argued that 
attempts to divert patient pressure from herbal cannabis in the US during the 1970s led 
to research funded by the National Cancer Institute, part of the NIH, on both smoked 
herbal cannabis and THC. Pre-clinical and clinical research was carried out into THC 
delivered in tablet form.14 Sallan et el reported on trials with THC capsules given to 
twenty patients before and after chemotherapy, fourteen of whom found their symptoms 
of nausea were alleviated. 15 Chang et al demonstrated that THC was superior to a 
placebo, and other experiments showed that it was equivalent to, if not better than, other 
available treatments. 16 Not that it was without side-effects, some of which appeared 
worse than competitive drugs to clinicians, but patients seemed to prefer it. Six US 
states began trials that involved seven hundred and forty eight patients who smoked 
cannabis and three hundred and forty five who were given THC capsules. These trials 
indicated that smoked herbal cannabis could alleviate symptoms of nausea and vomiting 
following cancer chemotherapy.17 Legal restrictions made further research difficult 
but popular pressure led twenty one states to legislate to permit its use with cancer 
chemotherapy. Mechoulam, for one, was enthusiastic over this application, and viewed 
it as a 'real blessing' for chemotherapy patients, and pointed out that others found it to 
be the drug of choice. 18 These early experiments filtered through to British researchers. 
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Clinical pharmacology: J.D.P. Graham and the therapeutic use of 
cannabis 
One notable UK pharmacologist with an interest in the clinical applications of cannabis 
was Professor J.D.P. Graham. Graham had qualified in medicine and had developed 
an interest in the pharmacology of the autonomic nervous system during his time at 
the Nuffield Institute of Medical Research, in Oxford. After war service he had moved 
to Glasgow and later to Cardiff as Senior Lecturer in Pharmacology and Lecturer in 
Toxicology and later became Professor of Pharmacology at the Welsh National School 
of Medicine in Cardiff. He wrote extensively on the pharmacology of therapeutics 
and toxicology. He became Secretary of the British Pharmacological Society in 196 L 
at a time when the Society was expanding and in his role there he sought deeper links 
with the pharmaceutical industry. A clinical section of the British Pharmacological 
Society was established in 1970 and the Society introduced a new specialist publication 
in 1974, the British Journal of Clinical Pharmacology. The discipline of clinical 
pharmacology linked the laboratory and the clinic and assisted in the re-evaluation of 
cannabis as a therapeutic. Throughout the 1970s and 1980s Graham published on the 
study of pharmacology and the effects of cannabis on the respiratory and cardiovascular 
systems and its potential as a medicine in those fields. 19 Graham was described as an 
excellent communicator and he became an influential figure in pharmacology and policy 
circles through his involvement in advisory committees. He became important to the 
process of re-medicalization not only for his research but for his advocacy of cannabis 
therapeutics within policy circles. One obituary in 1990 summarized his approach to life. 
Typically Scottish down to-earth approach to everybody and everything 
but very much his own person, not intimidated nor daunted by obstacles or 
difficulties but clear and decisive in pursuing the path he saw to be right. 20 
Graham's interest in the central nervous system led to work on narcotic analgesics, 
hallucinogens and drug dependence. Early work had led to structural activity profiles 
of a-adrenoceptor blocking agents, anti-histamines and cannabinoids.21 By the time 
he moved to Cardiff he had a particular interest in the effects ofTHC. Graham and 
his group worked by way of an MRC grant on the physiological effects of e:xtracts 
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of cannabis and THC, and they studied the cardiovascular and respiratory effects of 
cannabisY Initial experiments by Graham focused on the cardiovascular effects of 
cannabis extracts and purified constituents of cannabis on laboratory animals including 
cats and rats.23 Experiments were able to use tincture of cannabis, produced by William 
Ransom & Sons, from which THC was extracted. THC itself was obtained from 
Makor Chemicals Ltd. Results appeared to demonstrate the ability ofTHC to reduce 
systematic blood pressure, pulse and respiratory rate. Other constituents, including 
cannabinol and cannabidiol, were found to have no effect in rats. 
Graham went on to investigate the impact of cannabis on human subjects in the 
clinic. Respiratory diseases, including bronchial asthma which had a rising fatality 
rate, were a growing problem. Early concepts of asthma as a psychosomatic disease 
had been overturned during the 1960s, for one with a physical component. Asthma 
was shown to have an inflammatory component and the search began for drugs to treat 
the inflammation. Pharmacology, in particular autonomic pharmacology, had become 
a strong field in Britain and it was important in the development of bronchodilatorsY 
Isoprenoline had been used but had cardiac side-effects and benefits were short-lived. 
Other treatments included barbiturates but more effective, less harmful treatments were 
sought. An analogue of isoprenoline, the British salbutamol (Ventolin) was introduced 
in 1968.25 Many of the effective therapies for asthma were originally derived from 
natural substances so it was not out of context to consider cannabis as a therapeutic.26 
Furthermore, unlike glaucoma, asthma had a high death rate, so there was pressure for 
the development of alternative treatments. In the US, research had shown that cannabis 
could cause an increase in the volume ofthe bronchial tubes. In the UK, Davies and 
Weatherstone, at the Chest Disease Research Unit, Sully Hospital, Glamorgan, Griffiths 
from the Department of Psychological Medicine at the Welsh National School of 
Medicine, Cardiff and Graham carried out small-scale double-blind clinical trials on 
ten volunteer asthmatic in-patients providing them with a placebo, THC, or salbutamol. 
The study revealed that THC and salbutamol significantly improved ventilatory 
function. The delivery method chosen for THC was via a metered dose by pressured 
aerosol, a new route of administration for THC. Nebulizers had been developed at the 
turn of the century using aqueous solutions. and this was superseded in the mid 1950s 
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by the pressurized metered dose inhaler.27 By this method researchers found THC was 
effective in an amount too small to alter mood or be detectable by radioimmunoassay. 
In 1976 when they published the results of the study they concluded that THC had 
potential as an adjuvant medicine for asthmatics.28 
The mode of action ofTHC differs from that of sympathomimetic drugs, and 
it, or a derivative, may make a suitable adjuvant in the treatment of selected 
asthmatics. 29 
The broncholidation effect ofTHC gained international acceptance as a 
potential area for cannabis therapeutics by the mid-1970s. A United Nations Office 
of Drug Control (UNODC) review of 1977 written by Nahas, usually more noted for 
his opposition to cannabis, acknowledged research in this area and accepted that it 
provided a novel approach, though he concluded there were problems with the method 
of delivery and potential side-effects.3o When Graham reviewed the work on the 
bronchodilator actions of cannabis for Mechoulam's book Cannabinoids as therapeutic 
agents in 1982, he was able to conclude that cannabinoids had a different effect to 
other bronchodilators.31 He found that other constituents of cannabis had effects 
similar to THC with few cardiovascular or psychological effects, though cannabinol 
and cannabidiol were ineffective. In contrast inhaled THC caused an increase in 
airway conductance increasing the lungs capacity to absorb oxygen.32 Although this 
application for cannabis did not develop to the extent as cannabis for anti-nausea, 
the development of new delivery methods was important in the process of the re-
medicalization of cannabis. Developments in metered dose, oral-mucosal spray by the 
British pharmaceutical industry in later decades would prove important for the delivery 
of cannabis extracts. 
Cannabis derived anti-emetics were also an aspect of Graham's work. Earlier reports of 
cannabis' psychic and somatic effects, combined with numerous anecdotal reports of the 
effect of smoked cannabis, meant it was seen as having potential benefits for patients 
with incurable diseases such as bronchogenic carcinoma, undergoing radiation therapy 
which caused distressing side-effects. Pilot single-blind clinical trials were carried out 
on patients with inoperable bronchogenic carcinoma being treated by radiation and 
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who were suffering distress. Two groups of six patients on a cross-over pattern \\ere 
investigated. Patients were administered oral THe or a placebo. Records of mood, 
sleep, pain, temperature and cardiovascular parameters were kept. The study found 
that THe caused drowsiness, improved night sleep, reduced pain, reduced elation 
and vigour, and increased fatigue and confusion. It caused slight tachycardia and 
hypotension as did the placebo.33 Overall it was concluded that the aim to determine 
whether or not THe could be given readily and safely in a hospital setting and establish 
an active but not toxic dose had been achieved and that' the management of stressful 
patients was considered to have been improved by the drug. '34 It was seen also as 
having wider implications for additional therapies. 
The state of passivity and relaxation shown in the above patients suggests 
that the anodyne (a medicine that relieves pain) may find a place in the 
management of patients undergoing psychologically disturbing therapy or 
investigation. 35 
With cannabis showing potential as an anti-emetic and able to ameliorate distressing 
medical treatments, Graham was to publicize the results of this research. 
Graham was a good communicator and was keen to take the research on cannabis 
to a wider audience. Graham's research in the 1970s led him to take a more positive 
and pragmatic approach to cannabis. Whilst Paton's research led him to a cautious 
approach towards cannabis, Graham, though he agreed cannabis had toxic properties, 
played down the dangers of toxicity and its ability to cause dependence. Graham 
published two books on cannabis. One, Cannabis and Health, was an edited collection 
on cannabis published in 1976 to which Paton wrote the introduction. In Cannabis 
and Health Graham presented a chapter on 'if cannabis was a new drug', in which he 
compared it to other available licit medicines, and he argued that all medical drugs had 
their individual problems, and that cannabis was not unique in that respect. He pointed 
out that other important medicines, such as aspirin and digitalis, would not have made 
it to trial if they were investigated in the 1970s.36 In the text he drew attention to the 
revival of interest by the medical profession and foresaw a time when cannabis might 
operate as a niche drug. As with Paton, he argued that approaches to drugs needed to 
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be flexible in order to take account of changing evidence. He drew attention to the fact 
that it was never wise to consider any drug permanently established as a therapeutic and 
he cited the experience of thalidomide and rauwolfia an evergreen tree from which an 
antihypertensive drug is made. As a clinical pharmacologist he was keen for trials to 
take place and argued that scientific evidence was changeable. and with that in mind, he 
argued that sufficient research had been carried out to justify trials on cannabinoids . 
... . .Insofar as the medical use of cannabis is concerned a submission 
would be perfectly feasible in so far as it applied to individual cannabinoid 
chemicals which can be produced synthetically from precursors which do 
not involve cultivation of the plant, in a pure form to which quality control 
can be applied ..... most of the workfor THC has been completed. .... There 
is no reason now to deny a clinical trial certificate for a single chemical. 37 
Cannabis therapeutics, however, remained closely linked to recreational use. As seen 
in the different approaches between Nahas and Grinspoon in the early 1970s arguments 
took place over the position of cannabis in society, in particular the legal implications. 
Graham waded into the debate over cannabis when he wrote Cannabis NolV. published 
in 1977. Graham took a rather more relaxed view than Paton about occasional, 
moderate use of recreational cannabis. In his book published for a non-specialist 
audience, he reviewed the current state of knowledge about cannabis, the history of 
social responses to cannabis, and the debates over its legal status. In the book, which 
generally received favourable reviews, Graham expounded his understanding of 
cannabis. 38 
It is not a drug which causes physical dependence and only rarely is it likely 
to cause a complete desire for it, but one can readily become more than a 
little fond of it. 39 
He accepted Paton's evidence that it could remain in the body for some time but he 
regarded its moderate recreational use as less of a problem. 
Moderate smoking is not likely to damage the brain or destroy the 
personality of the smoker but it would be preferable to confine the habit to 
the weekends as cannabinoids linger in the body. 40 
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Moderation rather than prohibition and abstention was deemed a more appropriate 
approach by Graham, a factor he drew into policy discussions. Berridge described the 
two strands of public health that co-existed in the 1970s and beyond, abstention the line 
that Paton pursued in relation to drug use and the second, risk reduction, which became 
known as harm reduction and moderation of substance use, an approach favoured by 
Graham.41 Intent on rehabilitating cannabis as a therapeutic he tried to draw the medical 
use of cannabis away from the recreational debate. In his opinion, it was not cannabis 
per se that was dangerous, simply people's utilization of it. This was an interpretation 
similar in some ways to Paton's early query of proposed drug control legislation - was it 
more feasible to control the use or administration of a drug rather than the drug itself? 
Furthermore, Graham was against the argument of denying medical use of a drug 
because it might drive recreational drug misuse and argued that misuse of a drug was 
not a reason to withhold trials. 
Highly accumulative drugs such as digitalis are used therapeutically, 
admittedly the need for this drug digitalis is urgent, there are no 
alternatives .... It is by no means certain that THe will not prove to be 
uniquely useful as it is distinctly unusual in its actions.... a trials certificate 
is not usually withheldfrom a new drug ofpromise because there is 
potential for danger if people mishandle the drug. 42 
Graham saw the potential benefits of a new drug for diseases which lacked effective 
treatments as outweighing the dangers of either its side-effects, or its potential for 
misuse. He posed the question as to whether the scientific community was being ultra 
cautious, and through fears of misuse, failed to take an opportunity of discovering a 
potentially unique medicine which had novel actions. 
These views were important because he brought them into the policy discussions 
of the 1970s and 1980s. These discussions are considered in detail in chapter four, but 
briefly, during this period a number of governmental expert groups were set up to advise 
on cannabis, and divisions within the scientific communities were played out within 
this framework. As with Paton, Graham was involved with science-policy transfer 
and was a member ofthe Advisory Council on the Misuse of Drugs (ACMD) from its 
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inception in 1972 until he resigned in 1984. Whilst Paton had been at pains to argue 
for the legal status quo, Graham took a somewhat different philosophical approach to 
the discussions surrounding the law and took a very different view of the implications 
oftoxicity.43 He was cautious in accepting the right of government to impose law upon 
its citizens in that he felt that people should have more freedom to make up their own 
minds on such issues. Within the discussion of the ACMD he downplayed the dangers 
of cannabis, brought therapeutics into the discussion and he pressured to make changes 
to the law.44 His attitudes led to heated discussions in the committee.45 As well as being 
influenced by his patients, his pragmatic approach and desire for immediate action 
rather than the status quo was also a character trait. His desire to get things done was 
reflected in his committee work on cannabis in which he pressed members to be more 
proactive in making decisions based on available evidence rather than merely calling for 
more research and as a consequence delaying any decision-making.46 These committees 
were significant for the process of re- medicalization as they provided an early arena 
for discussion on the therapeutic use of cannabis. They gave Graham, a pharmacologist 
with a professional interest in the therapeutic use of cannabis, a platform to influence 
the debate over policy. Significantly, arguments by Graham and others allowed initial 
attempts at drawing the discussion of cannabis therapeutics away from concerns over 
the misuse of drugs. This move created an environment more receptive to the re-
medicalization of cannabis. Cannabis' therapeutic potential was an inconvenience 
to drug control policy and meant that in later decades attempts would be made to 
disassociate the two concepts and encouragement given to the development of licit 
cannabis-based medicines. 
Mainstream medicine started to take more note of cannabis therapeutics. An editorial 
in the Lancet published in 1975 considered the therapeutic potential of cannabinoids and 
Graham's work was referenced. Though the article indicated problems and doubts about 
some ofthe research, including the development oftolerance to THC, the article raised 
the profile of cannabis as a legitimate therapeutic possibility. Pharmacological properties 
highlighted included sedatation, analgesia, anticonvulsant, hypothermic and hypotensive 
effects, stimulation of appetite, lowering of intraocular tension, relaxation of smooth 
muscles, and immunosuppressive actions. The article concluded, 
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THe or more probably some derivative may well find a place as an 
adjuvant to isoprenaline, since the action on bronchial smooth muscle 
differs from that of isoprenaline, or as an anodyne in the management of 
terminal carcinoma. 47 
The attitudes of some international organizations also showed signs of a shift. Both 
the UNODC and The National Institute of Drug Administration (NIDA) two agencies 
more noted for their hostility to cannabis acknowledged cannabis therapeutics.48 
But throughout 1970s, medical use remained largely interlinked with concerns of 
recreational use and impeded re-medicalization. The UNDOC report of 1977 illustrated 
the fears, 
If marijuana products are proven to be useful therapeutic agents, their 
usefulness might well be attenuated if marihuana is widely used as a 
recreational drug. 49 
It did, however, note that THC might be useful in the treatment of asthma, glaucoma 
and that cannabidiol might be useful for epilepsy. NIDA was more positive and a report 
published in 1976 summarized contemporary research on cannabis and in a section 
specifically on the therapeutic use of cannabis indicated areas of potential interest. 
Although much more testing is needed there is promise that certain of the 
pharmacological actions of cannabis and its derivatives can be helpful 
for specific conditions .... The further study of cannabinoids for various 
therapeutic applications seems worthwhile. 50 
Possible applications noted included cannabis for use in glaucoma and for 
bronchodilation. Particular benefits of cannabis therapeutics were described: the 
cannabinoid configuration which provided a wide safety margin between effective 
and lethal doses and crucially, the mechanism of action which appeared to differ from 
known mechanisms.51 This different mechanism of action would become critical for 
the process of the re-medicalization of cannabis. The concept of therapeutic cannabis 
was back on the research agenda but it took a breakthrough in laboratory research and in 
understanding this mechanism to re-invigorate the process of re-medicalization. In the 
meantime practical difficulties and controversies remained. 
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Form and delivery: smoked herbal cannabis or cannabis-based 
derivatives 
The question by the 1980s was in what form should cannabis be used. Should only one 
single active principle be used, or should it be synthesized or was it preferable in herbal 
form or was it only valuable as a lead? Paton's correspondence revealed differences of 
approach between different researchers within the scientific community. Frances Ames, 
a South African researcher who worked on cannabis with animals, found that baboons 
refused an extract of cannabis which forced her to work with herbal cannabis, a concept 
which appealed to her.52 Mechoulam experimented with both extracts and synthetic 
compounds. But on the whole, acceptance was for derivatives of cannabis rather than 
herbal cannabis or its extracts. Herbal cannabis was not accepted due to two concerns: 
its effect as an irritant and the properties of smoke. Focus fell on specific cannabinoids 
and the ability of synthetic chemists to modify them. In the United States, NIDA 
suggested that active cannbinoids could be improved, and that it should be possible 
to remove the psychoactive element and provide a longer shelflife. Development 
of synthetic derivatives without the psychoactive element and administered through 
alternative methods to smoking had the advantage of separating therapeutic cannabis 
away from recreational cannabis. At this point from NIDA's point of view there was no 
interest in moving cannabis or its derivatives through the drug control schedules until 
they had passed through the regulatory processes of the FDA.53 
Smoked herbal cannabis, Dr Rose and cannabis controversy 
In the UK the reports of cannabis' and THC's anti-emetic properties stimulated a new 
avenue of clinical research and a handful of doctors applied for, and received, licences 
to investigate cannabis for this role in the early 1980s. On the whole research focused 
mainly on the provision of cannabis in the form of oral THC. Clinical researchers 
included Professor JS Malpas at St Bartholomew's Hospital, Dr Speed and Dr Smith 
from the Royal Marsden, Dr J Pritchard of Great Ormond St. and Professor JW 
Thompson a pharmacologist at Newcastle, all of whom were licensed to administer oral 
THC in a study of the psychological effects. 
Interest arose also in researching herbal cannabis. As a 'peculiar substance· it 
was far from straightforward to carry out such cannabis research especially in a clinical 
environment. Clinical application was controversial not only with the continued linkage 
to recreational cannabis use but for technical reasons: Trialing of herbal cannabis was 
controversial because the method of administration was via smoking. Cannabis smoke 
was considered to contain many similar carcinogenic substances as tobacco smoke and 
there was increased opposition to smoking, the BMA for instance would begin high 
profile anti-smoking campaigns in 1984. The experiments of a Dr Michael Rose, a 
haematologist at St George's Hospital, Tooting and St James' Hospital, Balham in the 
1980s, illustrate some of the controversies of researching this form of cannabis in the 
clinic.54 Rose was convinced that the investigation of cannabis derivatives and herbal 
cannabis was worthwhile. Rose applied for a licence to study oral trials of cannabis, but 
later changed the application to include smoked cannabis. 
The discussion became political when Rose publically complained that the legal 
situation constrained research and he placed public pressure on the Home Office to 
facilitate research. In an article in the Lancet in 1980 Rose argued it was time to bring 
cannabis back into the clinic. 
There seems to be a population of cancer patients who may benefit from 
treatment with cannabis derivatives .... this is a pressing and important area 
for research. Yet, currently the Home Secretary has issued only one or two 
licenses for prescription of cannabis or its derivatives. I believe that failure 
to give cannabis to patients on cytotoxic therapy could be considered a 
matter of professional negligence. 55 
For Rose, cannabis research was a question for the medical profession not one for the 
law. In his view any problems related to the mode of administration, for instance, 
smoked cannabis, were technical rather than social issues. Rose complained bitterly of 
the effect of policy on research and medicine. 
What seems to be at issue is neither the therapeutic value nor the 
detrimental reputation of cannabis which have been disputed since 1839 .... 
It is the state of public affairs which is mn)'.56 
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In particular Rose was irritated by the actions of the Department of Health and Social 
Security (DHSS). Rose argued that it was the interpretation of the law rather than the 
law itselfthat was the cause of the problems. He claimed that although the law allowed 
for research, problems originated from the negative attitude of the DHSS towards 
cannabis. 
The law in the Misuse of Drugs Act 1971 makes provision for the clinical 
administration of cannabis ... .. the Department of Health meanwhile without 
authority implicitly repudiates the public evidence of clinical potential 
supported no doubt by such ex cathedra sources as the British National 
Formulary ... in which cannabis is dismissed as having no valid medical 
use. 57 
Because of the Misuse of Drugs Act licences for research on cannabis had to be 
obtained from the Home Office. Dr Rose's application to the Home Office was 
approved after agreement by the DHSS. The DHSS agreed to permit the use of a room 
at Balham for the treatment to take place and cannabis derived from the plant extract 
was obtained from the government chemist. But in practice it proved difficult to carry 
out the research. Licences took time to obtain and there remained the issue of cannabis 
supply. Rose became upset by what he perceived as hindrances to clinical research 
and in particular bureaucratic wrangling. After having battled through a complicated 
licensing system, he continued to criticize policy and in 1981 he condemned the process 
in the Lancet. 
The licence was issued after almost six months of wrangling, pursued by 
florid attention in the press. Having issued the licence apparently under 
duress the Home Office disclaimed authority to provide the cannabis 
indicating officials at the Department of Health as a source of supply. They 
in turn put it blandly that .... release of cannabis for therapeutic purposes in 
the UK was more or less out of the question. 
The DHSS responded that the question of therapeutic cannabis was under consideration 
and could not be answered in the interim. In the meantime, Rose's licence expired 
before he received any cannabis material. 58 
99 
The issue of therapeutic cannabis in relation to such as emotive issue as the 
alleviation of side-effects of chemotherapy brought into question the precautionary 
principle as had been advanced by Paton. Rose called this approach into question in 
certain circumstances. 
Awaiting definitive conclusions, authorities behave with conviction that 
they are already available. Draconian regulation debars patients with 
intractable vomiting caused by chemotherapy from receiving cannabis as a 
potential source of relief That seriously calls into question the claim that 
officialdom is acting with caution out of concern for the sick. These people 
are already bedeviled with problems: the calculation of risks and benefits 
must make allowance for their exceptional circumstances. 59 
Fears of cannabis toxicity and psychosis on which this precautionary principle were 
based were downplayed with some asperity by Rose. 
There is a disparity between the notable absence of danger associated with 
cannabis, and the behaviour of authority. The legions of insane, wrecked by 
their youthful ingestion of cannabis are not exactly in evidence. 60 
The exceptional circumstance generated by cancer chemotherapy provided a wedge 
into the precautionary principle and increased the pressure, particularly on the Home 
Office and DHSS, to allow research. This placed the DHSS in awkward position. Even 
those individuals, who had reservations or a more cautious approach towards cannabis, 
considered that, in the light of constraints placed on cancer chemotherapy, the situation 
warranted further research. The debate continued in the Lancet when an editorial in 
1981 observed the desperate need for new anti-emetic and acknowledged that despite 
problem cannabis-based drugs might have role to play. 
An effective anti-emetic would revolutionize cancer chemotherapy ... 
There must be serious reservation about the use of a drug which produces 
alteration in mood and perception even if these applications are likely to 
be beneficial to some cancer patients ..... Nevertheless further studies on 
the anti-emetic properties ofTHC and related cannabis derivatives are 
desirable. 61 
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Ongoing medical research called into question the scheduling of drugs. JT DuQuesne 
from the Psychopharmacology Research Committee, London questioned the position of 
cannabis and LSD and the reasons for the discouragement of research. In response in 
the Lancet in 1981, he acknowledged the need for research on cannabis. 
It is truly bizarre that cannabis is juxtaposed with lysergide (LSD) .... 
Whatever one s view of the possible adverse effect of cannabis, whether 
or not one believes, on the evidence, that it is habituating or holds other 
dangers, is it not absurd that Dr Rose and others are actively discouraged 
from undertaking serous clinical research, for example, such as may 
improve the quality of life for cancer sufferers?62 
Healy has shown how a number of drugs used in psychiatry were feared as their 
social use was deemed to have political consequences. In the 1960s LSD also became 
increasingly prohibited and had been placed in the same schedule as cannabis in the 
US.63 But in the case of cannabis the need for additional therapeutics called into 
question the existing policy on illicit drugs, both in relation to the inclusion and position 
of drugs within the control system. 
These public attacks on the system and reports that also appeared in the Guardian 
and The Doctor provoked concern within government departments and pressure to 
defend government policy necessitated a note from the Chief Medical Officer to justify 
policy.64 The note pointed out that cannabis was considered worthy of investigation 
in this instance and that four consultants in oncology held Home Office licences to 
evaluate the effect. It clarified the process whereby the Home Office referred to the 
DHSS for advice on the suitability of applicants to hold licences. Licences were 
granted by the Home Office, on the recommendation of the DHSS, who established the 
doctors' credentials and bonafide nature of research. The response highlighted problems 
of dealing with a drug that crossed the boundaries between a medical and recreational 
substance and the likely cultural acceptance of cannabis in this instance. In relation to 
Dr Rose it was remarked, 
Officials do have some anxiety about Dr Rose and his activities but on 
balance it isfelt that his present study is very limited and tightly controlled 
under Home Office regulations. There is a need to conduct studies of 
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cannabis in patients with cancer and any move to revoke his HO licences 
would be counterproductive because of the inevitable emotive publicity this 
would generate. Dr Rose 5' activities will be closely monitored. 65 
The Lancet reported the position of the Minister of Health, Dr Gerard Vaughan who had 
been forced to respond to Rose's complaints in September 1981. 
... . Dr Rose :s original application to the HO was for oral trials but he later 
changed his research to include smoking cannabis ... the HO agreed to this 
but requested further information ... and evidence exists to indicate that 
smoking cannabis may be more carcinogenic than the smoking of tobacco .... 
The Department is not opposed to research into cannabis or its therapeutic 
potential but there are constraints under the law and a responsibility to 
avoid harmful side-effects. 66 
The route of administration was a key factor in the debate over medical use of cannabis. 
It seemed that orally administered, extracts of cannabis or synthetic THe in exceptional 
circumstances were acceptable but smoked herbal cannabis was a step too far, especially 
in light of the anti-smoking campaigns. Graham and Rose corresponded over the 
mode of administration of cannabis. Rose wondered if the aerosol method used in 
Graham's research with asthmatics would be transferable for anti-emetic purposes.67 
Developments in drug delivery systems remained important for the process of re-
medicalization and were further developed in the 1990s. 
The process was confusing for researchers such as Paton and Mechoulam. In 
1981 Mechoulam wrote to Paton that he had several hundred grams of cannabidiol but 
that he found it difficult to initiate trials for epilepsy and he asked Paton ifthere were 
suitable groups in England that might be interested. Paton wrote to the Home Office, 
and the query was forwarded to the DHSS.6s The DHSS explained the system. There 
were two route to research. The more usual system was for researchers to apply to 
the Home Office for a licence to possess and administer the drug. Such requests were 
then forwarded to the DHSS who considered the suitability of the research worker and 
project design before licences were issued by the Home Office. Alternatively, if the 
Department wished to promote research in a particular field suitable research workers 
would be informed and encouraged to submit protocols. But this route \\as for areas of 
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priority and 'until the Minister has received recommendations of the Advisory Council 
regarding the priority of research into the therapeutic potential of cannabis the latter 
procedure could not be initiated. '69 As is discussed in chapter four the ACMD did 
give later cautious consideration to the therapeutic benefits of cannabis as growing 
acceptance of synthetic cannabis-based drugs offered greater legitimacy to the concept 
of cannabis as a medicine. 
Cannabis derivatives become licenced medicines 
Urgent necessity to alleviate symptoms which were in themselves being created by 
medical intervention meant that cannabis as a therapeutic was given a legitimate role 
beyond that of a drug of misuse. Suggestions for the study of extracts of cannabis 
or synthetic THC instead were extended. Whilst researchers were able to carry out 
research on cannabinoids for various applications to bring cannabinoids to patients on a 
large-scale was another matter. Any cannabis-based medicine required a licence from 
regulatory bodies, at that time the Medicines Control Agency in the UK or in the US, 
the Federal Drug Administration (FDA). Unlike the trials of cannabis for respiratory 
and cardiovascular problems which did not lead to a licenced medicine, it was for the 
alleviation of symptoms caused by cancer chemotherapy that licenced cannabis-based 
drugs were produced. 
Synthetic THC presented the acceptable solution. A single chemical entity, 
orally administered version ofTHC was able to pass through regulatory systems in the 
US and UK. The pharmaceutical company Eli Lilly brought to market, nabilone, an 
h . 70 analogue ofTHC, branded as Cesamet and targeted at cancer chemot erapy patients. 
As an analogue ofTHC it was hoped nabilone would avoid the psychoactive properties 
ofTHC, and the associated concerns over misuse. The role of industry in bringing 
nabilone to market is detailed in chapter five but nabilone was licensed in 1982 for 
prescription-only hospital-only use against nausea arising from chemotherapy and 
unresponsive to other treatment in the UK and was licenced in the US by the FDA in 
1985. It appeared initially to offer an acceptable way forward. As Leslie Iverson. a 
pharmacologist with an interest in policy later explained, 
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The result of properly controlled clinical trials in the 1970s and 1980s 
indicated that the two cannabinoid drugs, dronabinol and nabilone 
appeared to offer an potential important advance over the relative 
ineffective anti-sickness medicine available in the 1980s. 71 
Nabilone was not widely marketed and was withdrawn in 1989 in the US althouoh 
b 
it remained available in the UK and Canada. Another drug, dronabinol (Marinol) 
synthetic THC, was given approval by the FDA for treatment of nausea in cancer 
chemotherapy in 1985. Marinol was never marketed in the UK. A decade after the 
removal of all cannabis-based medicines, cannabis derivatives based on the active 
psychoactive principle of cannabis, THC, were back in the medicine cabinet.72 
These derivatives had significant problems. The psychoactive effects which 
could not be totally avoided, remained of concern to doctors and patients, and this 
constrained their application. They proved unpopular with patients for several reason 
including, the 'high' produced as a side-effect, and the time lag between administration 
and effect. In addition their use was heavily restricted due to fears over potential 
diversion to recreational use. Competitor drugs emerged quickly, ones that were more 
effective, soluble in water and therefore usable as an IV injection at the time of therapy: 
a preferable administration method for patients with nausea. Furthermore, with no 
progress on the mode of action of cannabis, no one really understood how these drugs 
worked. However, despite their problems and limited uptake, the arrival of these 
synthetic cannabinoids into the clinic was critical for the process of re-medicalization. 
It marked the re-introduction of licensed cannabis-based medicines, and provided 
cannabis research with a degree of legitimacy which encouraged further investigation of 
cannabis from a therapeutic viewpoint rather than a continued focus on its deleterious 
effects. It also left the potential for research into herbal cannabis in later decades. 
The temporary slowdown in the cannabis field 
The sudden surge of interest in the pharmacology of cannabis that had developed from 
the 1960s proved short-lived and by the late 1970s and for most of the 1980s, the field 
ceased to develop. Pertwee described meetings of the British Pharmacological Society 
1()4 
in which cannabis was essentially ignored, with cannabis posters being relegated to 
the sidelines and cannabis talks to the last session of the last day. He commented later. 
'No one was interested. 'Why work on cannabis?' was a constant question. It got a bit 
depressing. '73 One problem was the absence of dedicated cannabis research societies 
and only occasional symposia which failed to motivate the discipline. Pertwee recalled. 
In the 1970s and 1980s there weren't any cannabis societies and there'd be 
the occasional symposia, but many of those were organised in a way that 
you always had the same speakers. It was all very constrained ... it wasn i 
very encouraging for the development of the field. 74 
Work had become descriptive, centred on the chemistry and pharmacology but, without 
any advance in understanding the mode of action, there was little opportunity to carry 
out exciting new research. Pertwee described the situation. 
We had run out of things to do. Very descriptive, just describing the 
pharmacology. There was no handle on the mode of action. ... All pharma 
was thinking about cannabis and then abandoning it. 75 
The report by NIDA in 1977 indicated the potential importance of discovering cannabis' 
mode of action for research and medicine. 
In addition to the possibility that therapeutic benefits may one day 
accrue another reason for studying the potential medicinal value of 
the cannabinoids is the possibility that their mechanism of action may 
be different from the currently available medicaments. In this case the 
elucidation of these mechanisms would be even more significant than the 
mere discovery of another therapeutic agent. 76 
Without a breakthrough in the mode of action the cannabis field began to contract as 
many researchers and funders switched to other fields. Furthermore, the cannabis threat 
was being superseded by other concerns including 'hard' drugs such as cocaine and 
heroin, and new public health fears over the emerging disease of AIDS. Additionally. 
interest shifted away from drugs such as cannabis to a greater focus on licit drugs 
including alcohol and tobacco. The Addiction Review Group of the MRC in 1978 
concluded, 'in view of the adequate amount of work on the pharmacology of addict in! 
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drugs there was no need to specifically encourage more in the future '77 By the 1980s 
comments in the House of Commons highlighted the economic and social costs of 
alcohol and tobacco as opposed to the illegal drugs. 78 Pertwee recalled the shift and the 
impact of changed incentives for researchers. 
People were running out of things to do and the thing was winding down, 
people were leaving the field ... going into amphetamines, or dependence, or 
ecstasy ... other drugs of dependence, especially in the States. They couldn l 
get funding basically, on can nab ino ids. 79 
The process ofre-medicalization was affected as well. Paton's analysis when he acted 
as a referee to Mechoulam's book Cannabinoids as therapeutic agents summed up the 
altered environment. 
One should resist the book being too long. I might add that I think there 
would be a reasonable but not enormous sale. I think the cannabisfield is 
getting less fashionable. 80 
Some individual researchers including Mechoulam and Pertwee maintained their 
own enduring interest in cannabis despite the general trend. This continued interest 
proved important for later developments in the cannabis arena. Pertwee later described 
his reasons to remain in a diminished field. 
I stuck with it and decided to develop this assay. Ijustfelt it useful to have. 
Very lucky for me that the receptor was discovered and I could be in at an 
early stage. 81 
Pertwee had moved from Oxford to Aberdeen to establish another research "cell" in 
1974.82 For his research he drew upon work in the opioid field. Hans Kosterlitz and 
his team who became famous for their discovery of opioid receptors in the brain and 
the endogenous morphine-like substance which they termed enkephalins were based at 
Aberdeen.83 This discovery explained why opiate worked. The discovery of the opioid 
receptor proved important for the concept of addiction and borderline substances like 
tobacco. This research eventually provided the rationale for understanding how the 
brain deals with pain and enabled the production of new analgesics. The techniques 
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for research used by Kosterlitz were important to cannabis research. Kosterlitz \\orked 
" d .c: 84 on opIUm usmg mouse vas elerens. Pertwee's experiments examined whether this 
process could be applied as a bioassay in the cannabis field and his research later proved 
fortuitous as it turned out to be a sensitive assay for the cannabis agonists that were 
developed later in the 1990s. As with the discovery of opioid receptors, a breakthrough 
in cannabis' mode of action and the discovery of cannabinoid receptors in the late 1980s 
would re-awaken the cannabis field and open up new avenues for cannabis research, and 
lead to new understanding of how the human body functioned. 
Conclusion 
Within a decade of the banning of cannabis tincture, cannabis-based drugs were 
back in the clinic. Pharmacologists provided a more detailed understanding of the 
pharmacology of cannabis itself and initiated more positive approaches to cannabis 
with discussion of its potential therapeutic benefits. Numerous potential applications 
were investigated but it was as a bronchodilator, an anti-emetic and for glaucoma that 
became the most widely accepted avenues. Focus fell not on 'whole cannabis' but 
on synthetic, single chemical entities, derived from cannabis, like THe. Synthetic 
cannabis-based products re-opened the therapeutic arena as they appeared to offer a way 
to improve the efficacy of cannabis and at the same time reduce undesirable side-effects. 
The search for solutions to new clinical problems related to cancer chemotherapy saw 
the move from anecdotal to evidence-based medicine with the provision of larger-scale 
clinical trials. Some clinicians such as Dr Rose pressed for investigation of herbal 
cannabis, but the use of smoked cannabis as the delivery method meant the use of 
herbal cannabis was interlaced with controversy. Clinical pharmacologists, like Graham 
expounded the potential benefits and played down the dangers of cannabis use and took 
this viewpoint to both policy-makers and the public. Even researchers with a more 
cautious approach like Paton and Nahas recognized the potential therapeutic avenues. 
As is discussed in the following chapter, expert groups in the UK began to take note of 
the importance ofthis developing area. But the perceived interaction between medical 
and recreational use remained a major stumbling block to medical use. Whilst sustained 
interest in cannabis therapeutics would not re-emerge until the late 1990s the period of 
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the mid-1970s to late 1980s re-awoke the concept of cannabis as a medicine. and began 
to overturn the WHO's 1951 pronouncement that cannabis had no medicinal value. 
Importantly, whilst cannabis remained firmly routed in illicit drug regulation cannabis 
derivatives through the involvement of the pharmaceutical industry re-entered the licit 
medical drug arena through the licensing of two cannabis-based drugs in the 1980s. 
As Paton had predicted cannabis acted as a lead to other drugs not as a drug in its own 
right. These, as pharmaceutically produced substances, entered drug control regulation 
and were still tightly controlled and rarely used, which left the door open to further 
industry involvement, the investigation of 'herbal cannabis', and patient pressure for 
access to herbal cannabis. It would take sustained pharmaceutical industry involvement 
and a breakthrough in understanding cannabis' mode of action to revitalise the cannabis 
field and lead to the next steps in the process of the re-medicalization. 
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Chapter Four 
Evidence-based policy? The development of expert 
committees and the re-medicalization of cannabis 1972-1982 
During the time that research into cannabis and its therapeutic applications was 
emerging, moves were taking place to make policy more evidence-based and this 
chapter traces the re-medicalization of cannabis within the context of the development 
of expert advice. Historical research has shown that 'the idea of rationality, that there 
could a rational relationship between research and policy was high on the agenda, ' 
by the 1970s.1 Berridge demonstrated how this trend impacted on dealing with both 
licit and illicit drugs, and where policy was in flux. She reveals how this shift in 
government advisory mechanisms opened doors between government and professional 
bodies allowing for interactions between specialists and policy-makers.2 Evidence-
based policy became the goal, emerging through a mechanism of expert committees, 
which formalized previous informal networks of advice. In the drugs field, previous 
ad hoc committees were reconstituted in 1972 as the statutory Advisory Council on the 
Misuse of Drugs (ACMD) with the aim of providing advice to government on drugs of 
misuse. This mechanism of an institutionalized statutory expert committee became an 
important forum for policy discussion around cannabis. Around the time the ACMD 
sub-committees on cannabis were created, cannabis, which had previously come under 
the jurisdiction of both illicit drugs and licit medicines, lost its 'product licence of right' 
and had become solely aligned with drugs of misuse. However, as research re-emerged 
on therapeutic use the implications ofthis research were drawn into the discussions over 
drug control policy and the expert committees became an early arena for discussion of 
the therapeutic use of cannabis prior to the therapeutic specific discussions and public 
reports of the 1990s. Three significant deliberations are considered in this chapter. The 
first of these was the ACMD's Working Group on Cannabis, 1972-76 which discussed 
research gaps, and legal issues and produced two interim reports. It saw animated 
discussion between committee members over the relative harms of cannabis and had 
the occasional reference to research on therapeutic cannabis. The second committee 
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studied was the ACMD's Working Group on Cannabis, 1977-1979, \\"hich focused 
on the impact of potential amendments to the Misuse of Drugs Act through proposed 
amendments to a Criminal Law bill. Its discussions led to a decision to recommend 
the downgrading of cannabis from Class B to Class C. The decision was based on 
heated and divisive discussions over the position of cannabis in the control system and 
the relative dangers of cannabis. The final committee considered was the ACMD's 
Expert Working Group on Cannabis, 1980-82. This group had a new membership, was 
less acrimonious and discussion of cannabis therapeutics featured more prominently, 
influenced, in part, by clinical trials of cannabis for the treatment of the side-effects of 
cancer chemotherapy. When the Expert Working Group on Cannabis released its report 
in 1982, it, too, recommended the downgrading of cannabis, and the encouragement of 
research into cannabis as a medicine.3 This chapter considers how these expert groups 
were established, the impact of their membership, the impact of therapeutic cannabis 
and it tracks the evolving discussion over therapeutic cannabis within the broader drug 
policy debate. 
The Advisory Council on the Misuse of Drugs and the Working Group 
on Cannabis, 1972-1976 
During the 1950s and 1960s expert committees had been established in the illicit 
drugs field on an ad hoc basis. The DHSS at the request of the Home Office set up the 
Interdepartmental Committee on Drug Addiction in 1958 to update advice given by the 
Departmental Committee on Morphine and Heroin Addiction in 1926 and to advise on 
the use of dangerous drugs of addiction.4 Chaired by Sir Russell (later Lord) Brain, 
President of the Royal College of Physicians, its brief had been to consider whether any 
revised advice should cover drugs liable to produce addiction or to be habit-forming; to 
consider whether there was a medical need to provide special, including institutional, 
treatment outside the resources already available for persons addicted to drugs; and 
to make recommendations, including proposals for any administrative measures that 
might seem expedient. The committee reported in 1960 and came down in favour 
of the status quo concluding that, in view of the small number of drug addicts in the 
UK further restrictions on heroin and cocaine were not necessary. The committee's 
, 
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report looked briefly at the issue of the medical use of cannabis and concurred with the 
WHO's position that cannabis had practically no therapeutic use and its control \\as 
not a medical matter within the committee's terms ofreference.5 This acceptance of 
no medical utility was important for the later placement of cannabis within regulatory 
mechanisms, differentiating it from heavily controlled drugs like morphine which were 
seen to have medical benefit. By the time of the second Brain report of 1965 growth 
in recreational drug use had led to a perceived need for greater drug control, and as 
a signatory to the 1961 UN Single Convention on Narcotic Substances, Britain had 
enacted the 1965 Dangerous Drugs Act.6 The Brain report recommended the creation of 
an advisory committee, to advise government on the social and medical aspects of drug 
use. In this context, an ad hoc body, the Advisory Committee on Drug Dependence 
(ACDD) was set up under Sir Edward Wayne, Regius Professor of the Practice of 
Medicine at the University of Glasgow. Sub-committees investigated specific drugs 
and, as discussed in chapter two, the Wootton Committee had focused primarily on 
cannabis. When the international framework around illicit drugs was tightened with 
the 1971 Psychotropic Drugs Convention, corresponding alterations to UK policy were 
required and resulted in the Misuse of Drugs Act 1971. With the need for an on-going 
specialist advisory body the earlier, ad hoc Advisory Committee on Drug Dependence 
was refigured as a statutory body and renamed the Advisory Council on the Misuse of 
Drugs. Its remit was to: 
Keep under review the situation in the United Kingdom with respect to 
drugs which are being or appear to them likely to be misused and of which 
the misuse is having or appears to them capable of having harmful effects 
sufficient to constitute a social problem, and to give to anyone or more of 
the Ministers, where either Council consider it expedient to do so or they 
are consulted by the Minister or Ministers in question, advice on measures 
(whether or not involving alteration of the law) which in the opinion of the 
Council ought to be taken for preventing the misuse of such drugs or dealing 
with social problems connected with their misuse, and in particular on 
measures which in the opinion of the Council, ought to be taken. 7 
The creation of the Council was an important development. Griffith Edwards, an 
eminent researcher on drugs and alcohol and a member of the ACMD later explained 
the power of the Council. 
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A statutory organization; its existence is embedded in the Misuse of Drugs 
Act so even when Mrs Thatcher was trying to get rid 0fQUANGOs (quasi-
autonomous non-governmental organizations) she couldn't touch it. 8 
Members of the committee were Home Office appointments. Ministers were 
obliged to consult the ACMD before laying Orders before Parliament or before 
making Regulations under the Misuse of Drugs Act, though they did not have to act 
upon its advice. It necessitated a working relationship between experts and government. 
However, from the time of its inception this was an uneasy relationship. 
Cannabis was a major initial feature of the ACMD's work, athough other drugs 
were investigated. Edwards recalled in 2009 how the Advisory Council became 
enmeshed with cannabis. 
The Advisory Council on the Misuse of Drugs was not a cutting edge 
organization for its efficiency and it could take six years for any 1-vorking 
party to report. It got bogged down with cannabis. 9 
The ACMD created a sub-group, the Working Group on Cannabis to advise the Council 
on cannabis in late 1972. Whilst the role of the ACMD was to provide expert advice, 
the available evidence on which to formulate any advice was limited. In essence the 
Working Group on Cannabis set out to investigate some of the major questions raised 
by the Wootton Report of 1968, including the harms associated with cannabis use, 
and the role and impact of criminal sanctions, especially police powers of stop and 
search. Cannabis policy and its implications were high on the agenda. A major focus 
of discussion was the legal situation around cannabis. Cannabis had been placed in 
Class B of the Misuse of Drug Act 1971, with a resultant set of penalties. Its placement 
had proved controversial and there were calls for decriminalization, either by changing 
the position of cannabis in the classes or by altering the penalties associated with each 
class. Measures for cannabis control that had emerged such as stop and search were 
particularly inflammatory and became a key area of debate for the Working Group on 
Cannabis. 
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The membership of the working group was important and brought together experts 
from the different sides of the debate. Berridge described how expert committees 
including the ACMD were viewed as part of the polite and gentlemanly relationships 
out of the public view which characterized government-medical interactions in health 
policy' but she made the additional point that as expert committees developed, they 
began to incorporate expertise from within and from outside government, and emphasis 
was placed on technical expertise and the role of research. 10 Members in this instance 
included: Bob Searchfield, a sociologist, and Director of the Standing Conference on 
Drug Abuse; Griffith Edwards, Director of the Addiction Research Unit, at the Institute 
of Psychiatry and IDP Graham who had sat on the Wootton Committee and whose 
pharmacological research into cannabis was examined in chapter three. The working 
group was chaired by Mr JC Bloomfield, a pharmacist. The composition of the working 
group proved critical to the way in which the discussions were framed. Expert advice 
of the period has been described as a mixture of 'the great and the good' with limited 
politicization and based on an 'ethic of politeness' but behind this, at least in relation to 
cannabis, lay critical differences in approach. II The different professional backgrounds 
of the members meant that behind the Working Group on Cannabis' reports lay mixed 
messages and different approaches, to both the scientific evidence around cannabis and 
the interpretation of what to do with such evidence. The working group comprised of 
strong personalities and reflected both sides of the debate. Graham, influenced by his 
research and perhaps the immediate needs of his patients, took a more benign view of 
cannabis and was keen to draw conclusions and make recommendations for action. One 
obituary described his forthright personality and approach to life. 
Jimmy was an energetic and forceful character. Always eager to get things 
done now rather than later. He was frank and forthright, blunt even. And 
would become impatient and even on occasion impetuous when, in his 
view, events were unnecessarily hindered by bureaucracy or more cautio liS 
individuals. These qualities were appreciated and endeared him to kindred 
sprits but occasionally rendered him vulnerable to those holding influential 
positions. 12 
Edwards later described Graham's approach to cannabis as, . asymmetry person(fied-
he believed that cannabis should be legalized. '13 In contrast Edwards \\as against 
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liberalization and reflected Paton's more precautionary approach to cannabis and its 
potential harms. 
The working group met for the first time on the 1 st of December 1972 and between 
1973 and 1976 produced two interim reports. The initial work was essentially an 
information gathering exercise to clarify basic information about cannabis and its use 
in the UK by examining current literature, analyzing the consequences of cannabis 
use for individuals and society, establishing what research was in progress and general 
epidemiological details.14 As discussed in the previous chapters, pharmacological 
cannabis research in the 1960s and early 1970s was primarily focused on animal 
research and the deleterious effects of cannabis. The impact on humans required a 
stronger evidence base. Reports presented to the working group, such as a paper by 
Graham in 1973 on the harms of cannabis use, indicated that research was still required 
on drug interactions, reproduction, and neurological damage. IS 
The working group had been established to consider facts relevant to the use of 
cannabis and other psychedelic drugs not normally in therapeutic use and to examine 
the need for further research. It was not constituted to report to ministers at this point 
but was rather set to provide the ACMD with a better understanding of cannabis in the 
context of growing international and domestic campaigns for a relaxation of controls 
on the drug. At the first meeting the group decided to consider the current literature 
on cannabis, its use within the UK, and the form and presentation of the debate on 
cannabis. Edwards attempted to introduce a consistent framework by which cannabis 
could be assessed and this informed much of the follow-up discussions. He presented 
a paper entitled, Cannabis and the criteria for legalization of a currently prohibited 
recreational drug in 1973.16 The paper identified criteria which might be employed to 
consider whether any drug should be legalized and applied them to cannabis. Edwards 
p laced discussion of cannabis within the context of the rise of regulatory frameworks 
controlling drugs, increased control of food additives, and a heightened awareness of 
previously under-rated dangers of already accepted substances. Edwards argued that 
stringent new regulations represented changed attitudes towards all drugs. 
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A move towards legalization of cannabis will be subjected to far more 
rigorous scientific and political scrutiny than would have been the case 
before 1963.17 
Within this context he argued that legalization of cannabis could not be justified, and 
indeed legalization was never on the agenda for the working group. Instead the question 
hinged upon how cannabis could be prohibited without bringing the law into disrepute; 
a major problem with an illicit but borderline substance. Discussion in the fifth meeting 
focused on the impact of control measures. Attitudes to the legal situation varied. On 
the one hand, Searchfield was concerned over the immediate impact of the social effects 
of penalties on individuals, such as fines for poorer members of the community. He 
argued that the use of 'drug squads' and increased numbers of arrests simply polarized 
positions, and that the' day to day social damage to individuals which was occurring 
as a result of prison sentences for first and seemingly trivial offences should not be 
overlooked'.18 On the other hand, Edwards, although he recognized injustices should 
be eliminated, was more concerned with the public health threat over a longer term. 
Edwards framed the question as a public health concern but one which necessitated a 
coercive legal framework. 
The Council s work was concerned with the long-term. Present injustices 
moreover might seem slight in relation to the possibility of irreversible 
health damage on a large-scale. 19 
The indeterminate nature of cannabis was reflected in the discourse of the working 
group. Though it was classified as a drug of misuse, research both in the UK and abroad 
had begun to raise the question as to whether cannabis should be viewed once again as 
a therapeutic drug. Therapeutic use of cannabis, which was being investigated by the 
broader scientific community, entered into discussions in this period to a limited degree 
both in its own right and as an adjunct to discussions around cannabis controls. Here 
the composition of the working group was important. Graham brought various areas of 
research to the attention members including his own work on the physiological effects 
of extracts of cannabis and ofTHC, as well as Paton's work on the effect of cannabis 
on the immune response, and other studies that had found cannabis to be an antipyretic 
as well as the need to look for therapeutic possibilities of cannabis.20 \\'hilst the 
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potential of therapeutic cannabis had become more acceptable, the advisability of the 
application of cannabis therapeutics was disputed because of perceived risks and moral 
implications. Edwards had taken note of the therapeutic research in his 1973 paper but 
he questioned where the balance between benefits and risks lay.21 Like Paton, Edwards 
was concerned with the broader effects of using it as a medicine and commented in a 
meeting in 1973. 
It was not per se a drug without therapeutic possibilities, such risk of 
damage as might be found should .... be weighed against any known benefit. 
Three areas would need to be examined, acute toxicity, chronic toxicity and 
any public health hazards envisaged as a result of the foreseen prevalence 
and frequency of use. 22 
A related issue that was raised in these early discussions and one that would later 
prove important for the therapeutic use of cannabis was the form in which cannabis 
might be utilized as a medicine. Splitting cannabis into its constituent parts was 
one method of moving re-medicalization forward. Standardized THC was deemed 
acceptable, herbal cannabis was not. In discussion, Dr Cahal from the DHSS drew 
attention to the lack of standardization of herbal cannabis, but he argued that THC 
should be approached as any new drug and that if indications of therapeutic qualities 
existed then clinical trials should be carried out to test its efficacy and safety.23 
The Working Group on Cannabis produced its first interim report in 1973 
which was approved by the ACMD which agreed that the report should be 
submitted to Ministers. The report considered the extent to which cannabis was 
harmful in terms of physiological and social effects, highlighted areas lacking in 
cannabis research and made recommendations for further research.24 Eight areas 
of research were to be encouraged: pharmaco logy of the constituents of cannabis 
and their interactions with other drugs; development of body fluid assay techniques: 
dependence potential; prevalence of use and characteristics of the user; association 
between cannabis and brain damage: identification of possible functional mental 
syndromes; the psychopharmacology of cannabis use and the impact on controls; as 
well as carcinogenic and teratogenic properties. The report \vas significant because it 
demonstrated the level of uncertainty around cannabis and therefore the inability of the 
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working group, and therefore the ACMD, to provide expert advice on issues of control. 
It concluded, 
Our study confirmed the case for alleviating the controls on cannabis is 
fraught with uncertainty, even if minor constituents were deemed safe many 
of the effects of prolonged and widespread use would remain. There is 
no likelihood of significant changes to the pattern of control until some of 
these uncertainties have been resolved ... the possibility that over-restrictive 
controls may give rise to social damage ... individuals and society can not 
be overlooked ... ... For present the aim ofreport is to draw attention to the 
need for research and give urgent consideration to stimulating research. 25 
But calls for further research on cannabis created concerns within the ACMD and policy 
circles that these conclusions, if made public and/or if acted upon, would generate the 
wrong message and boost calls for legalization. These discussions in the 1970s were 
intended to be kept out of the public domain, an approach that was not unusual at this 
time. Edwards and the chair were content to leave the report in the private arena, whilst 
Searchfield who tended to be in favour of legalization was keen to make the report 
public. Graham saw no problem in publication but did not make an issue of the point. 
The fear that the public might misunderstand the advice has been an often repeated 
explanation for the reasons for government rejecting expert advice on cannabis from the 
1970s onwards. As lasanoffhas shown that the 'evidence' of expert committees can be 
socially constructed and is not value free. 26 Certainly concern over social factors and 
wider debates over cannabis were embedded in the members' discussions. Fear of the 
media and the public response was the background to much of the discussion. 
Certain aspects of research were especially contentious, in particular, those related 
to the delivery methods, with concern raised over the possibility of experiments with 
smoked cannabis. A civil servant, Mr Stotesbury wrote, 
Some of the research is likely to involve the smoking of cannabis by 
humans ... in controlled conditions. The Misuse of Drugs Act 1971 and the 
Regulations enable the Secretary of State to approve premises for cannabis 
smoking ... for research proposed and we may in due course be making 
recommendations for the exercise of this paper. This could occasion some 
public interest. 27 
Carrying out research on smoked cannabis was contentious on two grounds. First. it 
was too close to recreational use methodology and second. it \\as in conflict with the 
anti-smoking campaigns. 
The report was not published. Correspondence within the Home Office in 1974 
revealed concerns that calls for research might indicate to the public that calls for 
decriminalization were being considered. A civil servant commented , 
I am glad that you do not wish to publish this report. I regard it as 
important that it is neither published nor leaked. A casual reader would 
infer from it that the whole question of whether the law against the misuse 
of cannabis should be relaxed was under consideration. It 11'ould be 
unfortunate if this got about, particularly in the present political climate . ... 
it may be necessary to consider the possibility of making public the 
commissioning offurther research. Whether or how this might be done will 
need to be considered against the climate of the time. 28 
Nevertheless, the recommendations were important in the process of re-medicalization 
because they provided pressure to research cannabis to facilitate a clearer scientific 
base on which to formulate control measures. Arrangements were made for a further 
research sub-committee of the Interdepartmental Co-Coordinating Committee to study 
the recommendations and to take steps to effect them through the appropriate research 
councilor by direct application to the Home Office or DHSS.29 
After submission of the first interim report, the Working Group on Cannabis 
considered its next move. The original terms of reference had included other 
psychedelic drugs but it was decided that the focus should remain on cannabis. Topics 
of discussion included, how to obtain data on cannabis users, data on stop and search. 
and the effect of control measures, for example, the impact of legal charges on students' 
careers, and the effectiveness and impact of statutory controls. 30 
Therapeutic use entered discussion to a greater degree this time and the balance 
in the risk-benefit analysis began to shift. Graham raised again the issue of therapeutic 
cannabis and took quite a different view to the stance taken by Ed\\ards in th~ previous 
discussions. Graham argued that cannabis' potential as a medicine out\\'eigh~d any 
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risks. He presented a paper in 1975 to the working group on the therapeutic potential of 
cannabis. In it he provided a brief history of cannabis use and highlighted its modem 
potential as a sedative. analgesic, appetite stimulant, immunosuppressiye and its role in 
reducing intraocular pressure. Citing his own work at Cardiff, he dre\v attention to the 
potential uses of cannabis in asthma and for cancer patients. 
Cannabis or more probably some derivative shouldfind a place as an 
acijuvant to established drugs: e.g. by inhalation when its action on the 
bronchial smooth muscle differs from that of isoprenoline or as an anodyne 
in the management of terminal carcinoma. 31 
How its potential would best be exploited remained uncertain, though Graham appeared 
to favour derivatives over herbal cannabis. 
However the Working Group on Cannabis' focus was on control measures. 
Throughout the 1960s and early 1970s cannabis use had increased despite increased 
controls and the apparent failure of the criminal justice system to deter cannabis use and 
the increased number of prosecutions, namely of young people, brought drug polic) 
into question. The concept of decriminalization, the idea of maintaining prohibition 
but reducing or removing penalties, was gaining ground. The harms of cannabis had 
taken on a new meaning - not the pharmacological impact on the body but rather the 
social impact of controls and the creation of a black market. The aim of drug pol icy 
was queried in the working group - was eradication still a possibility. or was the 
emphasis moving to discouraging new cases and influencing prevalence of use?32 On 
this point, the effectiveness of the current system. division in the group intensified. 
Edwards expressed his general satisfaction with current laws. Searchfield reiterated 
his concern over the policy offines and he drew attention to the fact that the concept of 
decriminalization was finding support despite the prohibitive moves of the international 
agencies.33 There could be no unanimity. The second interim report of 1975 considered 
the effectiveness of statutory controls and their impact at large and on the lives of 
individuals. It recommended that there should not be any changes to the la\\ in the 
light of uncertainty over long-term clinical and social effects of the drug, but it was 
accompanied by a minority report by Searchfield which fayoured liberalization.~4 There 
were no recommendations in relation to medical cannabis for the focus remained on the 
penal approach to drug control. 
At a meeting on the 19th December 1975 the ACMD considered and eventually 
endorsed the second interim report, but expressed disappointment about the absence of 
proposals for further action. It was endorsed only in the expectation that the working 
group would reconvene within twelve months to continue its work and yield more 
productive results.35 The issue of penalties was referred to other discussions on the 
penal system in connection with a study of maximum sentences. The report was 
submitted to Ministers but it was not published. The Home Office remained were wary 
of re-opening public debate or of risking the report becoming incorporated with calls for 
legalization.36 
The report was not allowed to fade away quietly however. Leaks had plagued the 
discussions, channeling private closed discussions into the public domain. Information 
about a debate over a loophole in the law relating to cannabis leaves and the stark 
divisions within the working group were leaked to the Guardian and to the New 
Scientist. 37 The report was leaked also to Release, a drug voluntary organization set 
up in 1967 to advise drug users on the law. There were fears within government and 
the ACMD that Release planned to publish an article and quote from the report.38 The 
issue of leaks featured prominently in the discussions during 1976. Searchfield who 
in private correspondence was deemed responsible for the leaks argued in favour of 
publication on the grounds that, 'interest reflects the public interest and suggests that 
it was better to seek publication from the outset in order to deflect criticism. 39 Graham 
perceived the public interest in cannabis had diminished and that therefore there was 
reduced political sensitivity. For Graham this made it the appropriate time to discuss 
the issue, though in his opinion publication was only worthwhile if the working group 
drew conclusions. Others like Mr PA Myers, Chief Constable of the North Wales 
Constabulary were afraid of re-igniting the controversy. Turner focused on the role of 
an expert group to advise, not to court public opinion. Edwards was against publication 
generally.40 Concerns were raised, not merely with the leaks but, that they were targeted 
at an organization associated with legalization. Mr GI de Deney of the Home Office 
Drugs Branch linked the leaks to Searchfield. 
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Release is an organization which does a lot of good work. But it argues for 
legalization .... Alarming the second interim report should have found its 
way to this organization ... Suspicion must, I'm afraid attach fairly strongly 
to Mr. Searchfield. 41 
The ACMD remained against publication citing the fact that the report was an interim 
report, not a final one, and that the cost of publication was an issue especially in the 
light oflimited conclusions.42 The report was never published and the working group 
did not reconvene again until 1977 after requests from the government for advice over 
potential amendments to the Misuse of Drugs Act of 1971. 
The Advisory Council on the Misuse of Drugs' Working Group on 
Cannabis and amendments to the Misuse of Drugs Act, 1977-1979 
The Working Group on Cannabis was re-convened in 1977 with the express purpose 
of advising on potential changes to the Misuse Use of Drugs Act 1971 through 
amendments to a Criminal Law bill. The amendments which if adopted would have 
removed from the Misuse of Drugs Act the power of the courts to impose custodial 
sentences on summary conviction for unlawful possession of cannabis and, in essence, 
would have implemented a major recommendation of the earlier Wootton Report. 
43 When the bill was proposed ministers sought the advice of ACMD which advised 
a delay pending the ACMD's re-evaluation of the general principles which governed 
control of drugs and the application of those principles to various offences around 
controlled drugs.44 Their actions were constrained, as the UK was signed up to the 
UN conventions and was obliged to prohibit non-medical use but there was some 
leeway within the control framework. The placement of cannabis in Class B or Class 
C of Schedule 2 ofthe Misuse of Drugs Act 1971, as opposed to legalization was the 
question. Three ACMD sub-committees were asked to consider the question. The 
Technical Working Group considered scheduling in relation to the pharmacological 
properties of cannabis and harm when misused, and was chaired by Graham. Another 
working group considered legal and administrative matters, and the Working Group on 
Cannabis, chaired by Bloomfield, considered the question of scheduling more broadly. 
In 1979, the ACMD on the advice of its working groups published its decision: that 
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cannabis and cannabis resin should be downgraded and re-classified from Class B to 
Class C and from Schedule 1 of the Regulations to Schedule 2. The recommendation to 
Ministers by ACMD was not based, however, on unequivocal advice from the workina 
:::0 
groups. 
Behind the 'performance' of an expert committee, which may appear to present a 
united decision, can lie division and bitter arguments between members. A follow-up 
report by the ACMD in the 1980s summarized the conflicts: 
Some members' appraisal of all the available scientific evidence so far 
leads them to conclude that some alleviation of the penalties for unlawful 
possession could be contemplated at the present time without undue 
concern ... others having regard to reports of current .... inconclusive 
scientific investigation are not satisfied that enough is known to make 
recommendations which would widely be regarded as implying that the risks 
of using cannabis and cannabis resin are less serious than was believed.-15 
Scientific uncertainty meant that evidence was open to interpretation by individuals 
representing different professions and who placed different emphasis on the available 
evidence. Divisions intensified when the working group on cannabis could no longer 
prevaricate as it had in the period 1972-1976 and was instead required to make 
recommendations in relation to Criminal Law bill. 
Divisions were clearly demonstrated in the interpretation of harms of cannabis 
use and their relationship to policy. For a meeting of the Working Group on Cannabis 
in 1977, Graham had prepared a paper on the long-term effects of cannabis on health.46 
As in 1972, he raised the issues of possible harms including foetal abnormalities, brain 
damage and mental health, but he drew out doubts over the validity of the data that led 
to these concerns and questioned their significance. 
Anti-pot scientists interpretfindings on cytotoxicty as indicating potential 
for damage. Then extrapolate from the laboratory to the sociological field 
and ignore the gross discrepancies between the concentrations of the dnlg 
... . in the laboratory to human science and advocate a ban. The cautious 
attitude is expedient, but I believe it is ill-founded. 47 
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Graham himself thought the research was problematic on harms and referred to 
Edwards on this matter.48 But Graham was also chair of the Technical Sub-Committee 
and in its meetings he had called for a reconsideration of cannabis and questioned why 
cannabinol and its derivatives had been classified differently. The explanation was 
offered that it was to discourage the illicit manufacture of synthetic cannabis, a transfer 
in interest which Paton had earlier feared. Graham called for the transfer of derivatives 
to the less restrictive schedules.49 With the harms of cannabis being brought into doubt 
so was the law and he brought these understanding to the Working Group on Cannabis. 
On these grounds the Working Group on Cannabis decided to recommend that cannabis 
be downgraded. 
The Criminal Law bill should be amended so as to provide that the penalties 
on summary conviction of simple possession involving any Class C drug 
should be subject to the condition that imprisonment could only be imposed 
in respect of second and subsequent convictions. In due course cannabis 
and cannabis resin should be transferred from Class B to Class C in order 
that offences of simple possession of those drugs could attract the revised 
penalties. 50 
This was a major development and instead of maintaining the status quo as had 
previously been the case, had the working groups' recommendations been accepted by 
government, it would have resulted in changes to policy. 
However, this initial decision was challenged. Edwards who placed more 
emphasis on potential harms, was not prepared to accept downgrading. Edwards had 
been absent at the meeting in which the decision to recommend downgrading had been 
agreed. In later correspondence with the chair, Edwards expressed the view that he 
could not support the working group's decision. 
I would not myself have felt able to support those recommendations and 
was rather surprised to hear that the recommendations seem to have been 
made in the light of an impression that there is no evidence that cannabis 
can damage health. ... . my 011'n beliefs that the scientific evidence which 
has been acculJlulating over the lastfe1l' years goes rather in the direction 
of suggesting that cannabis may well be a much more dangerous substance 
than that had previollsly been supposed. 51 
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Bloomfield, the chair, was forced on the defensive and he placed emphasis on the 
significance of Graham's report for influencing the decision to recommend the 
downgrading of cannabis. He wrote to Edwards, 
I think it is fair to say that one of the factors which influenced the group in 
coming to the conclusion it did was the report prepared by Graham on a 
review of the literature. 52 
At the following meeting, Edwards expressed his strong disapproval of the decision 
and re-iterated his view that cannabis was a threat to society. It also emerged that the 
Legal and Administrative Working Group had disagreed with the decision preferring 
the maintenance of the status quo. In Edward's view the uncertainty over harms 
necessitated the retention of the precautionary principle and justified the maintenance 
of the legal status quo. In a statement that illustrates how different professional 
standpoints can influence the end advice of expert committees, Edwards, argued that 
Graham's approach to the problem differed from his own in that Graham came from a 
pharmacological background whereas his own approach was epidemiological. Edwards 
expressed his concern with the sheer scale of the drugs problem and the effects over 
the long-term. He questioned Graham's use of evidence, and pointed out that Graham 
was open about this in his book, Cannabis Now, but not in the paper presented to the 
working group.53 Edwards argued that their decision should not be based 'on proving 
harm, but the possibility of harm. '54 Edwards suggested a further subgroup and more 
research to resolve the issue. But the tide was turning against more delays. Graham 
argued for a more pragmatic approach, and pressed for immediate action rather than 
the status quo. The chair recognized that there was little chance of agreement and was 
against the creation of another sub-group. 
It is unlikely that a consensus would ever be reached and they were further 
restricted by time constraints since the Criminal Law bill would go to the 
House of Commons for the second reading in mid April. 55 
Bloomfield appeared to have reservations about the initial decision but denied that 
legalization had been contemplated. Edwards changed the discourse. and moved the 
discussion away from the potential harms ofthe impact of the criminal justice system 
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and back to the harms of cannabis use. Bloomfield dissented from the decision of the 
previous meeting, and argued that the law protected first offenders from imprisonment 
and therefore there was no good reason to change the penalties. He argued additionally 
that problems might arise from public misunderstandings if changes to policy were 
suggested and commented, 'such an action might in the eyes of the public merely 
have the effect of devaluing the seriousness of misuse of the drug '.56 Searchfield was 
perplexed by the reaction of Edwards and Bloomfield to the cautious recommendation. 
Graham supported Searchfield though for different reasons commenting, 
It was merely a question of attitudes. If one was paternalistic, 'which he H'as 
not, then one felt justified in stopping people harming themselves. 57 
It appears that with inconclusive scientific evidence decisions depended less upon 
evidence relating to the potential harm of cannabis but more upon individual attitudes 
not only towards cannabis but to the role of science and government in society and 
depended greatly upon the personality and influence of those expounding a viewpoint 
on any particular day. 
These arguments continued into the joint meetings of the three working groups. 
The Technical Sub Committee which had examined the classification of drugs under the 
1971 UN Convention in relation to the pharmacological properties of drugs and their 
harmfulness when misused concluded: 
There is no compelling evidence that occasional moderate use of cannabis 
is likely to have detrimental physical effects on individual users .... we 
concluded that the '" relation between chronic use of cannabis and mental 
impairment was by no means proven and that there appeared too many 
compounding factors involved. 5& 
Graham's opinion that 'moderate smoking is not likely to damage the brain or destroy 
the personality of the smoker' seemed to be taking hold in policy discussion of the 
pharmacological evidence of cannabis's harm. The matter was somewhat different 
when social interpretations were introduced. The other two working groups had 
considered the evidence in relation to wider general principles and when the groups 
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came together the debate became more heated. Various options were discussed at the 
joint meeting of the three sub-committees: A separate class for cannabis; reclassifying 
cannabis as Class C; reclassifying cannabis as Class C and reducing penalties; or a 
reduction in all penalties. 
Edwards outlined three benefits of downgrading cannabis. One it would mean 
the law was less draconian, it would provide an educative effect by removing the 
mystique around cannabis and third it would make the letter of law compatible with its 
implementation. But in light of the disadvantages he remained against the amendment. 
The question was put to a vote, which marginally came out in favour of downgrading.59 
In the end, cannabis was split into its constituent parts. The sub-committees concluded 
that THC was a dangerous substance and there were no recommendations to remove this 
from Class A. This was not the case with herbal cannabis as evidence of harm remained 
inconclusive and a majority decision recommended reclassification of cannabis and 
cannabis resin from Class B to Class C.60 
Once the sub-committees had decided to recommend downgrading cannabis, the 
practicalities of carrying this out raised problems. As far as Edwards was concerned 
cutting penalties for possession, but not on supply, was illogical and he retained the 
view that the law had a part to play in educating people to realise that the use of all 
chemicals carried risks and therefore it would be best to leave the law as it stood. 
Graham argued that this was not the role of the criminal justice system and the minutes 
of 1978 recorded his comments. 
Whilst he supported Edward s idea that there should be an education effort 
to discourage cannabis use he did not agree that the educative function of 
the law warranted retention of heavy penalties in the absence of further 
evidence. 61 
The debate was going round in circles and the secretary was forced to intercede and 
remind members that they had accepted a decision to recommend the reclassification 
of cannabis to Class C. The final report of the ACMD argued that it was best to 
concentrate on limiting supply. The ACMD report argued that the use of these drugs 
should not be legalized and that a deterrent was still needed, but that cannabis should 
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be transferred from Class B to Class C and that the penalty of imprisonment on 
summary conviction for unlawful possession of all drugs in Class C should no longer be 
available.62 
Merlyn Rees, the Home Secretary, rejected the advice of the ACMD to downgrade 
cannabis. Dr Hardwick of the Ministry of Health wrote to members of the ACMD 
justifying this rejection not on scientific grounds but on the need to retain the deterrent 
effect. 
... The decision was taken both on grounds of principle and on practical 
grounds. The Home Secretary considers that any relaxation in control 
could be taken to mean that the health risks from using cannabis had been 
exaggerated, thus encouraging its use. 63 
Florin has argued that uncertainty comes in two forms, technical and socia1.64 When 
accepting or rejecting the advice of its experts government may act on more than 
scientific or technical knowledge, by taking into account social considerations. As 
Florin wrote, 'social uncertainty ..... not entirely solved by scientific evidence. Its 
resolution depends on political and other institutional interventions. ' She argued 
that in a study of general practice contracts that they were neither evidence-based nor 
evidence-free. Scientific factors interacted with social, political, and professional 
interests." This, Florin argued, takes value judgments rather than technical assessment. 
In the case of cannabis policy, rational decision-making was at risk at two points: in the 
production of that expert advice and in the uptake or avoidance of that advice. 
The report generated a degree of public interest and the Legalise Cannabis 
Campaign quickly published Trash Rehashed which criticized the ACMD on many 
grounds including: not going far enough in making recommendations concerning the 
law, the long time span of the review, the poor quality of the report and they emphasized 
the divisions within the committee.65 Legalization was never on the agenda though 
and a note from a civil servant in 1979 indicated the views within the Home Office, 'I 
11'ould not go to the stake to prevent cannabis being classified C instead of B. I can see 
no real advantage to this move which would doubtless be misinterpreted. I H'(wld resist 
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legalizing cannabis strongly. I doubt if the Home Office .... fill do anything 11'hich H·ill 
upset DHSS ministers. '66 Trash Rehashed had also raised the issue of access to cannabis 
for medical purposes on prescription, and whilst the points on legalization were 
dismissed further advice was sought on this point and the issue of therapeutic cannabis 
was raised later as a specific point in subsequent discussions.67 
The ACMD had provided an arena for discussion around cannabis to take place 
and allowed a more positive viewpoint from a pharmacological standpoint to influence 
debate over policy. Uncertainty, not only over understandings of cannabis, but what 
to do with the 'evidence', allowed scope for subjective decision-making within the 
working group and for government decisions on whether to take or ignore the advice. 
However, the process created a slightly more flexible and relaxed attitude towards 
cannabis within the policy network. It was this combination of more relaxed attitudes 
towards cannabis, research incentives, as well as a developing need to draw medical 
needs away from discussion of drug control, that was to allow the process of re-
medicalization to develop in the following decades. 
The Advisory Council on the Misuse of Drugs and the Expert Group 
on the Effects of Cannabis, 1980-1982 
The Expert Group on the Effects of Cannabis was established when the ACMD 
wanted to look again at the control of cannabis and cannabis resin under the Misuse 
of Drugs Act 1971 and required advice from scientists before it decided to what extent 
cannabis should be controlled 'Further evidence on all aspects of cannabis action 
continued to become available causing the Council to decide to establish an expert 
group to assist the Council in its consideration of the implications for future official 
policy on the use of cannabis and cannabis resin. '68 The previous working groups had 
opened up debates over the possible harms of cannabis and Griffith Edwards requested 
a separate group to look at the adverse effects of cannabis and he attempted to influence 
the group's composition and recommended that Paton be brought into the group. 
I actualZl' made the suggestion that .... re needed a 11'orking group specially to 
look the damage questions and I persuaded the Council to ask Bill Paton 
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to join use, because for some extraordinary reason he was never a member 
of that Council. We produced a report which I think was objective on the 
possible harms and many open questions. 69 
However, this time the expert group was chaired by JDP Graham. who had consistently 
questioned the harms associated with cannabis use, and brought research on the 
therapeutic use of cannabis to the attention of the working group throughout the 1970s. 
He continued to bring the issue of therapeutic cannabis to a more prominent position 
in discussions of the 1980s. This expert group included many members of the original 
Working Group on Cannabis, including, J Bloomfield, the previous Chair, and Griffith 
Edwards. Other members included, Professor W Cranston from St Thomas' Hospital: 
Dr B Hunt from the Department of Heath and Social Security, Dr McNicol, Principal 
and Vice Chancellor of the University of Aberdeen; Mr D Turner, from St Barts 
Hospital; Dr B Saunders, and Dr Harvey from Department of Pharmacology Oxford, 
and Sir William Paton.70 
The ACMD indicated that the expert group should look anew at the question 
of cannabis controls, and that it should "disabuse itself" of past considerations and 
recommendations. Under pressure from developments at home and abroad, the remit 
described the political background. It noted the government's obligations under the 
1961 UN Convention to limit the use of cannabis to legitimate medical and research 
purposes but the government was also facing the demand of a small but articulate 
section of the population for legalization and there was also pressure from some 
members of the UN to remove cannabis from the most restrictive categories. The task 
of the expert group was to assist the ACMD in forming a view of cannabis controls on 
the basis of scientific findings. 
F or the first time the issue of the medical use of cannabis was specifically raised in 
the remit ofthe expert group. 
The group should bear in mind that the constraints placed on a dmg hy 
the MDA related to its social use and misuse .... if the appropriate bodies 
decided that cannabis had value as a therapeutic agent it H'ould be possible 
to amend the regulation to authorize doctors to lise cannabis in this lray.71 
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The increased interest in therapeutic use by the 1980s had filtered more centrally into 
discussions of the expert group. The key issue was the developing use of cannabis 
for specific ailments most notably in the alleviation of symptoms caused by the 
chemotherapeutic treatment of cancer.72 The movement of cannabis into the clinical 
environment did not proceed without attracting controversy and concern. Any blurring 
of the boundary between recreational use and calls for legalization and medical 
applications was of particular concern, for example, as discussed in the previous chapter 
over the case Dr Rose. 73 It was viewed as more risky to prohibit access in certain 
circumstance as it was assumed that there was sympathy in the wider community for 
such research and this outweighed fears over any message of encouragement it might 
provoke for legalization. The Advisory Committee on the Misuse of Drugs set up an 
expert sub-committee in April 1980 to evaluate the science on the therapeutic use of 
cannabis. The social use of cannabis was not within the sub-committees agenda though 
it did consider toxicity.74 Attitudes too were altering in the international arena. The 
WHO by the 1980s had begun to move away from its previous stance that cannabis 
medicine was obsolete towards a cautious acceptance of cannabis' medical utility. 
Meetings and reports of the WHO, such as the joint report with the Addiction Research 
Foundation of Ontario in 1981 looked at cannabis and its problems but downplayed 
the threat of cannabis use.75 In the UK, whilst the earlier advisory committees had 
discussed the relative benefits or harms of therapeutic aspects of cannabis, by the 1980s 
the focus shifted to the technical issues surrounding such research.76 
By this time there was interest in the DHSS on the potential therapeutic uses of 
cannabis and it was against this background that a paper prepared by Dr B Hunt of the 
DHSS was presented on the therapeutic use of cannabis to the expert group. Dr Hunt 
highlighted the many avenues that had been investigated for cannabis and re-iterated 
that the most promising application was as an anti-emetic for patients undergoing cancer 
chemotherapy.77 The debate had moved on from one focused on the advisability of 
cannabis-based medicine to one focused on safety and efficacy for patients. 
The efficacy of cannabis as an anti-emetic was undeniable, but it could be 
questioned whether its efficacy outweighed it toxicity. It could only he lIsed 
for certain patients in certain circumstances. 78 
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But the dangers were not viewed as being so great, as to discourage research, even on 
additional applications. Hunt went on to comment, 
Great claims had been made for it treating glaucoma but a thorough 
topical examination of these claims was needed. The use of the drugfor 
epilepsy and asthma was interesting particularly the use of CBD in treating 
epilepsy but again more work needed to be done. The evidence for the use 
of cannabis as an analgesic was extremely equivocal, but it was certainly 
worth looking at. 79 
The expert group heard papers presented on a variety of other topics including the issue 
of cannabis dependence by Edwards; kinetic and metabolic information on cannabis 
and related compounds by Turner; the effect of cannabis on the lungs and respiratory 
system by Cranston; the effects of derivatives on cell division by McNicol; and cerebral 
damage in man and animals, by Corsellis Driver and Lantos; and cardio-vascular 
effects were described by Paton. The final report of the Expert Group on the Effects of 
Cannabis were of significant interest for the re-medicalization of cannabis. First, the 
Report placed the burden of proof on proving the harmful effects of cannabis which it 
argued had not been fully demonstrated. 
There is insufficient evidence to reach any intestable conclusions on the 
effect of cannabis on the human body, it affirmed that research undertaken 
so far failed to demonstrate positive and significant harmful effects on man 
solely due to the use of cannabis, and that areas where evidence suggested 
deleterious effects needed further research. 80 
It queried some of the key concerns over the use of cannabis therapeutics and in so 
doing helped open the way for further research in later decades. 
Second, the issue of therapeutics had become important enough to warrant specific 
discussion and recommendations instead, as had previously been the case, a sideline 
to the legal and social discussion. Importantly, the report acknowledged that scientific 
study had endorsed anecdotal reports of cannabis' medical applications and indicated a 
need for further research. 
Many traditional therapeutic uses of cannabis have been corifirmed 
by scientific research, but in most instances to date with no greater 
efficacy than existing modern drugs. Its use as an anti-emetic in cancer 
chemotherapy appears to be most promising and other possible therapeutic 
uses are in relation to glaucoma, epilepsy and muscle spasticity, but 
much more research is required before its use in any of these areas can be 
accepted as a standard method of treatment. 81 
The Hunt paper indicated the need for more research on nabilone.82 These conclusions 
provided some degree of legitimacy for therapeutic cannabis as an independent area 
of research instead of linking it to disreputable recreational use within the drug control 
framework. The report considered how potential cannabis-based medicines could be 
made available. 
If the appropriate bodies decided that cannabis had value as a therapeutic 
agent it would be possible to amend the regulations to allow doctors to use 
cannabis in this way. 83 
The Regulations allowed for amendments to the Misuse of Drugs Act of 1971 and 
it was possible that cannabis could be shifted from Schedule 1 to Schedule 2 of 
the Regulations which would have allowed research and medical uses. Work in 
the laboratory and the clinic was deemed sufficiently promising to justify further 
investigation and the report provided support for further research into cannabis' 
therapeutics by concluding that there was evidence 'to suggest that the therapeutic use 
of cannabis on certain medical conditions may after further research prove beneficial '.8-1 
The expert group recommended the downgrading of cannabis from Class B to 
Class C. and as it had in 1979 it reiterated the view that the penalty of imprisonment on 
summary conviction for unlawful possession of cannabis should be removed.85 Once 
again its advice was rejected by government, and again not on the evidence but rather 
the message that downgrading might portray. DJ Hardwick, of the Home Office wrote 
to members of the ACMD on the 16th March 1982 to explain the decision . 
... The Home Secretary has after careful consideration decided not to 
implement the recommendation of the Council for changes in the law 
relating to cannabis ... the decision has been taken both on grounds of 
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principle and on practical grounds. The Home Secretary considers that any 
relaxation in control could be taken to mean that the health risks from llsing 
cannabis had been exaggerated, thus encouraging its use. 86 
Fear remained over the potential 'misunderstanding' of the report and a draft press 
release deleted the sentence 'much of the research has failed to demonstrate the positive 
and significant harmful effects in man attributed solely to the use of cannabis. 'It did 
refer however, to the evidence that suggested that the therapeutic use of cannabis or 
substances derived from it 'may after further research prove beneficial. '87 
Despite the rejection of the report by government the discussions of the ACMD 
reflected a changing understanding of cannabis. Penalties for cannabis offences were 
reduced and in the 1980s there was a greater focus on cautioning and small on-the-
spot fines, rather than imprisonment. By the 1980s, attitudes towards cannabis as a 
medicine began to shift from hostility to one of cautious encouragement of research. 
The Report of the Expert Group on the Effects of Cannabis Use downplayed the dangers 
of cannabis, and put weight behind the possible medical benefits of cannabis.88 It had 
allowed initial attempts at separating discussion of cannabis therapeutics from the 
misuse of drugs, and altered the environment around cannabis to one more receptive 
to the re-medicalization of cannabis. Few contested cannabis's potential value for 
medical applications, where current licit medicines were not effective. At this stage in 
the process of re-medicalization of cannabis the quality of the evidence surrounding 
cannabis was inconsistent, and often contradictory. Calls for further research were 
a necessary step and shifted the discourse onto overcoming practical hindrances to 
further research including cost, and the limitations of supply. In 1982 a meeting on 
the therapeutic use of cannabis was arranged to discuss matters related to therapeutic 
use and to clarify where, within the DHSS, responsibility for policy on therapeutic 
cannabis should lie. Dr Wrighton, of the MRC argued that if increased use of more 
powerful cytotoxic drugs continued then cannabis would become of more interest 
to UK researchers. The law was not seen as a deterrent to research rather it was the 
cost and supply ofTHC, which no UK firm was prepared to synthesize, that \\as the 
problem. Furthermore, a product licence for manufacture had to be obtained but could 
not be granted prior to the Committee on Safety of Medicines being satisfied with 
136 
safety. This meant clinical research had to be repeated in the UK before cannabis-based 
medicines could be made available. To facilitate this, it was agreed that attempts should 
be made to encourage researchers to apply to the MRC with protocols, including the 
costs ofTHC. A split between medical use and misuse was also encouraged within 
the Department, as due to the use of cannabis in relation to cancer chemotherapy it 
was agreed that policy should 'properly rest with HSI and MED SEB. It was agreed 
desirable that responsibility should not rest with MED MHI or SHO in view of their 
concern for the misuse of drugs. '89 It was recommended that further work should 
be carried to identify the structure and specification of the effective components in 
cannabis. But interest in cannabis both in research and policy circles had shifted away 
to other drugs of misuse. When interest revived with the breakthrough in the mode 
of action, research, which up to this point had been driven primarily by an interest in 
the misuse of cannabis, became driven by a greater interest in the therapeutic use of 
cannabis. 
Conclusion 
The development of the mechanism for science-policy exchange allowed formal 
discussion of cannabis and the potential of therapeutic cannabis to filter through 
to policy circles. When formulized statutory expert groups began discussing drug 
control after 1973, cannabis was no longer regulated as a medical product. But 
cannabis functioned as a medical product in self-help circles for some patients and in 
the professional sphere, as a potential medicine in the laboratory and clinic. In this 
sense policy was running out of step with scientific developments and the issue of 
therapeutic cannabis was increasingly drawn into policy discussion providing a route 
for science-policy transfer. Drug policy and cannabis was discussed within the confines 
of the UN Conventions, but as a boundary substance and one slowly being re-drawn 
towards medical regulation, any discussion of cannabis as a drug of misuse and its place 
within the criminal justice system had to include discussion of emerging therapeutic 
applications. In this context discussions saw a change in focus over the period 191'2-
1982. Initially, between 1972-1976 expert discussion on cannabis began as an excrci~c 
in information gathering, with initial interest in understanding the state of cannabis 
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research, the use of cannabis and the effects of control measures which were in flux. 
Discussions drew out the paucity of the knowledge base on which to ground policy 
and added pressure for research. Whilst reference was made to therapeutic cannabis 
the main impact was to encourage cannabis research which would later indirectly 
lead to therapeutic applications. Whilst government was looking for expert advice. 
expert advice was guided by existent evidence, however up to and during this period 
the evidence was not clear cut and to some degree it became an issue of interpretation. 
Division amongst members emerged and resulted in no clear conclusions being 
drawn, instead further research and the status quo over the law was recommended. 
Between 1977-1979 a change was discernable. Though discussion of cannabis became 
increasingly acrimonious, in general the dangers of cannabis were played down, and 
eventually the working group and the ACMD decided to recommend downgrading of 
cannabis from Class B-C. Whilst the recommendations were ultimately rejected by the 
government cannabis harms were called into question and the working group, when 
left with no option but to make clear conclusions for the Criminal Law bill, adopted 
a more relaxed attitude to cannabis. The period 1980-1982 saw a further alteration in 
focus with discussion becoming less heated and less focused on cannabis harms, and 
conclusions backed up the previous recommendation to downgrade cannabis. Specific 
discussion on therapeutic use emerged and research into therapeutic applications rather 
than research into cannabis generally was encouraged. With cannabis derivatives 
entering the clinic and by 1982 medical drug regulation, therapeutic cannabis was 
accepted as a potential reality and discussion focused less on the wisdom of using it 
as a medicine but rather on the cost and practicality of doing so. Recommendations 
to downgrade cannabis were again rejected by government and there were no changes 
in respect to scheduling but penalties were in essence reduced. But the public health 
needs of cannabis as a therapeutic were more influential in driving discussion. In this 
period the issue oftherapeutic cannabis was not yet disassociated from discussion of 
recreational use and control measures as it would become to a degree in the 1990s. 
When by the end of the 1980s a breakthrough in the mode of understanding of 
cannabis emerged, cannabis as a medicine would become treated as a topic in its own 
right, and the door was open to provide justification to split cannabis as a medicine 
from discussion over the control of recreational cannabis use. Practical hindrances 
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to cannabis research would be considered by therapeutic specific, independent public 
committees that emerged in the 1990s, which paved the way for clinical trials and UK 
industrial involvement with medical cannabis. 
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Chapter Five 
Industrialising cannabis: The pharmaceutical industry and 
the re-medicalization of cannabis 1973-2001 
The pharmaceutical industry has been crucial in the process of the re-medicalization 
of cannabis and this chapter charts the gradually increasing interest of industry after 
the loss of cannabis tincture in 1973. This chapter overlaps slightly in time with other 
chapters but it provides an in-depth analysis of the role of pharmaceutical industry 
in the process of re-medicalization. It begins by describing the problems caused by 
a lack of industry interest pre-1973. In contrast, it then considers the importance of 
temporary industry involvement in the 1970s and 1980s which provided two boosts to 
re-medicalization. First, there was the development of compounds that never reached 
patients but were useful for scientific research, and second, the production of synthetic 
cannabinoids that entered the clinic and became licit, if unpopUlar, medicines. Then, 
from the 1990s, major scientific breakthroughs opened up two avenues of research 
and re-stimulated industry interest. One avenue was the investigation of drugs that 
could activate the newly discovered endocannabinoid receptor system; drugs that were 
not based on cannabis itself. The other avenue, and the one on which this chapter 
concentrates, was the investigation of extracts of cannabis. 1997 marked a new era 
when GW Pharmaceuticals, a small UK biotechnology company based solely on 
investigations into herbal cannabis, began cultivation of standardized cannabis plants 
for the production of cannabis-based medicine extracts (CBMEs) delivered via a new 
drug delivery system. The re-medicalization of cannabis is placed in the context 
of developments in the pharmaceutical industry and the rise of biotechnology; the 
interrelations between academic science and industry; the rise of phytomedicine, and the 
major scientific discovery of cannabis' mode of action via the endocannabinoid receptor 
system. 
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Cannabis in the laboratory: The pharmaceutical industry and 
cannabis prior to 1980 
In the twentieth century the history of therapeutics was inseparable from the rise of the 
pharmaceutical industry. Historical and sociological research provide frameworks for 
investigating the role played by the pharmaceutical industry. Histories of pharmacy and 
the pharmaceutical industry divide its development into several stages: kitchen physic 
or home remedies; the rise of commercial remedies often mixtures of secret ingredients; 
development of pathology and microbiology; growth of multinational pharmaceutical 
companies, acquisitions and mergers and the elimination of small-scale industry; 
and the emergence of small biotechnology companies. I These different stages of the 
pharmaceutical industry have been reflected in the process of the re-medicalization 
of cannabis. In the initial development of the pharmaceutical industry historians cite 
the importance of a greater understanding of vegetable and mineral substances used 
as medicines.2 The isolation of an active principle was essential. Major discoveries 
included the isolation of morphine from opium, aspirin from willow bark, and later 
quinine from cinchona. In the late nineteenth and early twentieth century, when these 
discoveries were taking place, cannabis, was more of a commercial remedy than a 
pharmaceutical grade medicine, and as discussed in chapter two its active principle was 
not discovered until 1964, and synthesised in 1965. Cannabis missed the 'cascade of 
medicine' which took place during the 'therapeutic revolution" of the 1940s-1960s and 
which led to the expansion of the pharmaceutical industry worldwide.3 In the UK, the 
development of the NHS and its subsequent mass market for drugs stimulated a flurry 
of new drugs, such as cortisone, beta blockers and the contraceptive pill. Aside from 
technical problems cannabis remained unattractive to the pharmaceutical industry as a 
result of its increasingly prohibitive legal status. 
This dearth of interest by a flourishing pharmaceutical industry had \\"ider 
implications for the understanding of cannabis: it caused problems for academic 
research. Authors who have written about the pharmaceutical industry and pharmacy 
have highlighted the importance of accessibility to research material and how it can 
shape social and cognitive developments. This was shown in the dc\elopmcnt of 
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the Taxol drug from the yew tree. One of the major issues for research into cannabis 
pharmacology was the lack of a ready supply of the active principle, THC.-l Industry 
was not interested in producing THC or in the development of cannabis-based 
medicines. Mechoulam later explained how the legal status of cannabis deterred 
companies. 
Many of the major pharmaceutical companies ..... had small groups working 
on cannabis. But as soon as it went up ... the bureaucratic ladder ... all ... 
decided not to go with cannabis because of the bad publicity. They were 
afraid of it .... 5 
Researchers at Oxford and at the MRC had unsuccessfully courted industry 
involvement in the early 1970s and the attraction of industry to the cannabis field 
remained a pre-requisite for the development of cannabis-based medicines and in the 
UK there remained an interest in the stimulation of domestic pharmaceutical industry 
involvement. 
Fleeting pharmaceutical industry interest proved important. Reacting to reports 
in the 1970s that cannabis and THe suppressed pain in experimental models, an 
international pharmaceutical company, Pfizer, developed a synthetic cannabinoid 
compound, Levonantradol, an analogue ofTHC, as a potential analgesic and the 
related compound CP55,940. These compounds proved more water soluble than 
THC and so more useful for research purposes. Pilot clinical trials were carried out 
with Levonantradol in suppressing postoperative pain and in preventing the nausea 
and vomiting associated with cancer chemotherapy. However, unable to separate the 
beneficial clinical effects from the intoxicant effects, Pfizer abandoned the project by 
1980.6 Throughout most of the 1960s and 1970s when interest in cannabis in academ ia 
was triggered, industry interest remained focused on alternative directions or showed 
only fleeting attention. The pharmaceutical industry itself was facing increasing 
restraints on its operations and undergoing a slowdown in development. Slinn 
explained the impact on the production of new drugs. 
When that took place not only was the therapeutic rerolution o\'(!r, but 
increasing regulation to ensure product safety ... 11'(7S making the time 
between the discovery of a new compound and its launch ... much lengthier, 
eating into patent life. The R& D process ... was ... becoming much more 
expensive. 7 
However while the Pfizer compounds were abandoned as medical products, these 
compounds later provided a useful tool for academic cannabis research. 
Cannabis in the clinic: The development of synthetic cannabis-based 
medicines, (CBMs) 1982-1987 
The 1980s heralded a major new development in the process of re-medicalization 
of cannabis. Pharmaceutical industry involvement in the US built on the research 
into cannabis-based drug in the 1970s and two cannabis-based drugs made it out of 
the laboratory and into the clinic and through medicine licensing systems. The main 
interest from the pharmaceutical industry'S perspective had been to find compounds 
that had the benefits of cannabis but without the psychoactive element. It was hoped 
that such products could circumvent the restrictive legislation around cannabis. Eli 
Lilly, had prepared cannabis preparations with standardized tincture of cannabis 
indica in the early 1980s and went on to develop nabilone, a synthetic cannabinoid, an 
analogue ofTHC. Whilst nabilone was not a naturally occurring cannabinoid it was 
pharmacologically very similar to phytoTHC. It was branded by Eli Lilly as Cesamet 
for prescription to cancer patients.8 With no other effective treatments for nausea caused 
by chemotherapy, nabilone was approved in 1982 for hospital-only prescription for 
'nausea and vomiting caused by cytotoxic chemotherapy unresponsive to conventional 
anti-emetics' in the UK where it was not a controlled drug.9 Cesamet capsules for the 
treatment of nausea and vomiting associated with chemotherapy were licensed by 
the FDA in 1985. \0 UNIMED, a newly established subsidiary of the Belgium based 
Solvay Pharmaceuticals, bought dronabinol, an isomer ofTHC, from the National 
Cancer Institute; part of NIH in order to bring the drug from research to market. I1 
Dronabinol was given approval for the treatment of nausea in cancer chemotherapy in 
1985 and dronabinol, in sesame oil, was marketed as Marinol. It was distributed by 
Roxanne Laboratories, an independent subsidiary of the German Boehringer Ingelheim 
Corporation by 1987 and later in 1992 its approval was extended in the US to cover 
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appetite loss related to AIDS in the US. Dronabinol (Marinol) was never licenced in 
the UK though it could be prescribed as an unlicensed drug on a named-patient basis. 
These were the first cannabis-based drugs introduced to market since the removal of 
cannabis tincture. 
These licit medical drugs faced two problems. First, they proved unpopular 
with patients, and second medical derivatives of cannabis posed problems for the 
drug control agencies as they re-introduced a dual role for cannabis. In discussing 
the development of the 1971 Convention on Psychotropic Substance, McAllister 
demonstrates that the pharmaceutical industry argued for a cost-benefit analysis 
of psychotropic substance arguing that under medical supervision the benefits of 
psychotropic substances outweighed their risks and therefore warranted less stringent 
control measures. 12 These arguments did not seem to work for pharmaceutically 
produced derivatives of cannabis. The US Drug Enforcement Agency concluded that 
nabilone was too closely related to cannabis and gave it a Schedule II classification 
under the US Controlled Substances Act, signifying that it was considered a dangerous 
drug, although having some medical usefulness. With cannabis as the lead, nabilone 
was not far enough removed from its source. This classification placed rigorous 
restrictions on the use of the drugY Eli Lilly upset by the strict classification lost 
interest and never marketed it though it was used in the UK for clinical research. 14 
This was a major problem when the marketing of drugs proved crucial to their success 
or failure. It was also expensive and was discontinued in 1989.15 Dronabinol had 
been placed in Schedule I of the 1971 UN Convention on Psychotropic drugs and this 
placement proved problematic for its wide-scale use as a medicine product in the form 
of Marino 1. In 1987, the US Government requested the UN to transfer dronabinol to 
Schedule II of the 1971 Convention and the WHO was requested to consider the matter. 
Recognizing some therapeutic benefit in certain instances but also the close relationship 
to the plant, it rated the abuse potential as 'high' but argued that dronabinol should be 
downgraded to Schedule II, 
The abuse liability of dronabinol is high and its therapeutic usefulness as 
moderate to high ... although few public health and social problems are 
currently associated 11'ith the therapeutic use of dronabinol, this substance is 
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the active principle of cannabis and is capable of producing the same effects 
as the plant material. 16 
The decision was not unanimous: two members of the WHO committee disagreed 
fearing that downgrading would send out the wrong message and would promote the 
abuse of cannabis and its extracts. Whilst the medical agencies were demonstrating a 
shift in attitude and were looking at cannabis medicines more favourably, drug control 
agencies were not. The Commission of Narcotic Drugs concurred with the minority 
view when it chose not to endorse the recommendation of the WHO committee and 
argued that cannabis' benefits did not outweigh its potential for abuse. 
Since the drugs failed to live up to expectations the pharmaceutical industry 
interest in cannabis tailed off. In general there was a dwindling in the numbers of new 
drugs feeding through the pipeline. There were a number of reasons for this. Drug 
discovery had become based upon an understanding of the underlying mechanism of 
disease, a process which took much longer than the accidental discoveries of the pastY 
The spiralling cost of health care, an ageing population, and the growth of chronic 
diseases encouraged governments to demand lower prices for pharmaceuticals which 
contributed to the restructuring of the pharmaceutical industry in the 1980s.18 The 
cannabis research field declined as researchers who had become involved in the 1960s 
shifted their research interests to emerging drugs like amphetamines, and cocaine, and 
funding on cannabinoids dried Up.19 In such an environment cannabis-based medicine 
might have remained dormant but for major discoveries that revitalized the whole field. 
Understanding cannabis' mode of action and the role of the 
pharmaceutical industry, 1988-1997 
After receptors were discovered .... cannabis became respectable ... Lots of 
drug companies still worried about drugs that activate receptors so they 
looked at blocking them ... for example for blocking appetite ... there was lots 
of money to be made out of that. 20 
In the mid 1980s researchers questioned the lack of stereo-specificity of cannabinoids 
and began to hunt for specific receptors for the psychoactive cannabinoids in the brain. 
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By the late 1980s interdisciplinary international research between medicinal chemists 
and pharmacologists working on cannabis yielded results which led to a breakthrough 
in the understanding of the mechanism of action of cannabis thereby clarifying the 
way in which cannabinoids worked on the human body. This research re-opened the 
issue of cannabinoid receptors, and led to the discovery of what is now known as the 
endocannabinoid receptor system.21 The interdisciplinary approach was vital. Steve 
Hill a Professor of Molecular Pharmacology at Nottingham University highlighted the 
importance of the interdisciplinary approach to pharmacology and drug discoveryY 
The power of collaboration between chemistry and pharmacology is 
immense and the success of this alliance has underpinned astonishing 
successes in the development of powerful therapeutic drugs. 23 
This interdisciplinary approach was particularly important in the process of the re-
medicalization of cannabis. 
Pertwee later expressed the importance of developments in pharmacology which 
provided an improved understanding of the mode of action of cannabis, for instance, 
signaling by G-protein-coupled receptors.24 Chemical signalling is the primary means 
to control biological functions and the role of the receptor is to recognise these chemical 
signals. Receptors have been described as lying at the heart of pharmacology and were 
important in medicine.25 Targeting receptors had became a focus for modern drug 
technology and therefore the emergence of research demonstrating that cannabis acted 
on receptors proved pivotal to cannabis' re-medicalization. 
Developments within the pharmaceutical industry provided the tools which 
ensured that research on the cannabis receptors could take place. This was a classic 
example of how industry could influence academic research.26 The cannabinoid 
compounds abandoned by Pfizer took on a new lease of life in academic circles. 
The Pfizer compounds proved to be a better tool than THC for researchers. Pertwee 
described later the importance of the compounds. 
It was those compounds that led to the discovery of the receptor. THe 
although it does bind to the receptor is so fat soluble, it:S vel}' d(fficliit 10 
shml' that it binds. Can i actually use it as a probe. 27 
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By radio-labeling the Pfizer compound to act as a tracer, it was possible to detect 
the recognition sites of receptors.28 It became almost certain that cannabinoids were 
specific in action and acted on a G-protein-coupled receptor, overturning Paton's 
original hypothesis that cannabis did not act on receptors. Dr Allyn Howlett. a 
pharmacologist at St Louis Medical School, who had done post-doctoral research at the 
University of Virginia involving the characterization of the first G-protein, along \\ith 
Bill Devane a graduate student at St Louis, provided conclusive evidence, published in 
1988, that cannabinoid receptors existed in the brain.29 Howlett's work was confirmed 
by the cloning ofthe CB 1 receptor in the 1990s.30 Evidence of a cannabis receptor was 
then confirmed through other developments at the time in the field of cloning. Pertwee 
described the inter-relations, 
It was lucky the field was developing in parallel with these important 
advances .... Cloning was really in ... so once it was cloned that H'GS it, the 
receptor must exist. 31 
Receptor cloning became a major preoccupation of molecular pharmacologists 
and by 2000 pharmacology had entered a new era.32 The distribution of CB 1 
receptors, found predominantly on central and peripheral nerve terminals, accounted 
for characteristics, described earlier by pharmacologists and the benefits described by 
patients in the 1970s and 1980s. A further receptor, a periphery receptor, eB2, was 
unexpectedly located by the pharmaceutical firm Sterling Winthrop in the UK in 1993, 
when it searched for an anti-inflammatory drug.33 This discovery of a receptor outside 
the brain was important because it opened up the possibility of achieving a cannabis-
like effect without the problems of cannabis, just as the pharmaceutical industry had 
tried to do with drugs like nabilone.34 
These discoveries led to the next crucial question: What was the role of this 
receptor system? Did the human body produce cannabinoid receptor agonists. 
chemicals that bind to the receptor, or did only the plant compounds affect the 
receptor?35 Mechoulam's group provided the next piece of the jigsaw. Mechoulam 
theorized that there must be a chemical that originated in the body (endogenous) and 
sought to identify it. He commented later on the search. 
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We assumed that these receptors are not found in our body because there 
is a plant out there but the brain forms some kind of compound that )I'ill 
activate these receptors when needed. So we started lookingfor these 
endogenous compounds. 36 
This was a complex process involving international and interdisciplinary co-operation, 
technological advances, and serendipity. Bill Devane moved to Israel to take up a 
post-doctoral position with Mechoulam and searched for the assumed endogenous 
cannabinoid. Devane, along with a Czech researcher Luis Hanus, synthesized a 
new radioactive probe, which they used to help identify the substance. A promising 
candidate was extracted from pig brain. Once they had material which seemed 
pure they utilized the advanced techniques of nuclear magnetic resonance (NMR) 
spectroscopy which provided the final formation of an endogenous cannabinoid, 
which was later termed Anandamide. Recent technological advances had made these 
discoveries possible as Mechoulam later elaborated, 
When we isolated A nandam ide ..... we had essentially nothing, we barely saw 
the material we isolated but the machines were happy with it . ... . couldn I 
have been done twenty years earlier. 37 
Technological developments in the field made it possible to work with much smaller 
amounts of material and to considerably speed up research. Rang, in a history of 
receptors, explained the importance of such technological developments. 
It took a full year to make the binding measurements, carry out the 
necessary controls and estimate the binding parameters - a task now 
routinely performed by a technician in less than a day. 38 
Once the potential substance was discovered it was necessary to establish if it could 
activate the CB I receptor, but Mechoulam's group lacked sufficient material to carry out 
the tests. Others within the cannabis network provided the solution. Pertwee's decision 
to stay in the cannabis field and develop bioassays proved advantageous. He later 
commented . 
... I felt it was the H'ay forward because you learn much more about 
the mode of actions ... if you want go in vivo .. it is n'1!' goodfor clinical 
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relevance but if you want to find out how something works you are better 
off in vitro because it s a much simpler system. We developed a little assay 
based on vas deferens from the mouse which as it happens turned out to be 
stuffed full of cannabinoid receptors ..... turned out to be very sensitive to 
cannab ino ids. 39 
By the early 1990s, Pertwee had shown he was able to work on mouse vas deferens 
with tiny amounts of material. He presented some of the initial vas deferens data 
at a cannabinoid meeting in Palm Beach in 1991 and this led to collaboration with 
Mechoulam. Here luck played a role. Mechoulam and Devane sent Pertwee some 
impure material. Pertwee was able to discover that it paralleled THC in activity. On 
sending the pure substance it was found inactive. This confusion was later cleared 
up when it was discovered that the pure material had oxidised and thus disrupted 
the experiment, whereas the impure material contained an anti-oxidant and was still 
effective for Pertwee.40 As a result, using the mouse vas deferens, Pertwee (with 
Graeme Griffin) was able to provide the first evidence that this substance, not only 
bound to cannabinoid receptors, but also activated these receptors, which strengthened 
the argument that Anandamide was an endogenous cannabinoid which acted upon the 
newly discovered receptors.41 Pertwee explained how it was serendipitous that they 
used the vas deferens assays as they had been working on other assays which could 
have provided a false trail. 
It was lucky we used this tissue, as gut chews up enzymes, so luckily, we 
used vas deferens. So we were able to detect something. 42 
The realization of the enormity of the impact of the discovery of the ECRS system 
had a range of broader implications. The excitement led to a re-emergence of funding 
for the cannabis research field. Pertwee described how a flow of research funding 
emergedY The new tranche of funding brought in new researchers to the field. Pertwee 
received Wellcome Trust funding in the 1990s on a re-entry scheme, providing him 
with two new staff. An MRC co-operative scheme provided additional funding. The 
discoveries led to the reinvigoration of the cannabis network and the establishment of 
international cannabinoid societies to advance the course of cannabis research. It led to 
the integration with a number of other scientific disciplines other than pharmacologists 
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and psychologists, for instance, immunologists such as Dr. Klein, professor of medical 
microbiology and immunology at the University of South Florida, who was \\ orking 
in a new field of psychoneuroimmununology, all finding areas of interest in research 
on cannabis. After the discovery of the ECRS new dedicated international societies 
and symposia that were much more open to new researchers were initiated. The 
International Cannabinoid Research Society was set up in the year the receptor was 
cloned. The Society met annually to exchange findings and to facilitate collaborations 
between scientists as well as with the pharmaceutical industry. A specific society for 
research into medical applications, the International Association for Cannabis Medicine 
was set up by a German clinician.44 These scientific networks consolidated the field in a 
way that had not previously been achieved. 
The discovery of the ECRS re-stimulated cannabis research and opened up new 
avenues. Dr Vincenzo di Marzio, a researcher on endocannabinoids in Italy, explained 
its importance for cannabis-based medicines. 
Some people view this issue as possibility separate from the re-
medicalization of cannabis but in fact we were getting many hints from 
knowing how the endocannabinodis are made and how they are regulated 
and how to use the plant cannabinoids. 45 
These developments provided cannabis therapeutics with a more acceptable face as 
they explained the mechanism behind anecdotal reports of cannabis' benefits, and the 
action of new cannabis-based drugs like nabilone. One reason the discoveries had such 
an impact on therapeutics was because the system impacted on so many aspects ofthe 
body. Mechoulam described the excitement around the discovery. 
There is almost no major physical activity in which this system is not 
involved .... It provided the basis for a huge amount of work. 46 
In later decades it would open up research especially on the modulation of pain, 
neurodegenerative disease, and anti-inflammatory action. Other research areas that 
were stimulated included immunity, leading to research on how the ECRS might help 
prevent re-occurring tumour growth; treatment for Post Traumatic Stress Disorder, 
153 
where it appeared it might playa role in emotions and memory function; as an anti-
inflammatory agent; in the treatment of schizophrenia, and for some cardiovascular 
diseases. Alternatively, when the endogenous cananbinoid system malfunctioned, it 
appeared that it could lead to obesity, fertility problems, and stroke. The possibility 
emerged of manipulating the system to alleviate these disorders: a possibility that was 
of great interest to industry. 
It was also important because it appeared to offer a way of avoiding one of the 
major hindrances to the use of cannabis as a medicine and one that had previously 
frightened off industry -the psychoactive properties of the drug. Iverson exp lained the 
significance. 
Using THC, or synthetic or cannabis extract was always limiting .... a 
narrow window between desired result and intoxication. THC would also 
go everywhere in the brain whereas the endocannabinoid system cOlild be 
much more specific. The discovery of the endocannabinoid system provided 
the potential for eliminating the intoxication element. 47 
That the CB2 receptor was located outside of the brain was of great interest to the 
pharmaceutical companies because of the possibility of achieving pain relief without the 
'high'. Other work by Pertwee's group in Aberdeen led to the discovery of the allosteric 
site on the receptor.48 This Pertwee described as acting rather like a volume control, 
allowing the activity of the receptor to be turned up or down.49 A new aim of research 
became an attempt to develop new drugs to enhance the activity of the receptor. The 
discovery ofthe ECRS meant that pharmaceutical companies finally discovered a 
sustained interest because they could look for either agonist or antagonists (receptor 
blocking) drugs which would affect the ECRS. Iverson explained later the importance to 
medicine. 
After all most of the drugs on the market ... the new drugs over the last 
twenty years .. , are based on being agonist or antagonist of receptors of 
endogenous compounds like dopamine and so on. 50 
The goal was to take this new understanding in the laboratory and to make it feasible 
for use in the clinic but the time lag between discovery and when patients received the 
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benefits could be considerable. Iverson later commented, 
Thirty years from lab discovery to useful medicine .... takes many decades. 
So research is at an interesting stage. Modern neuroscience development 
will take a long time to reach maturity. 51 
The discovery of the mode of action of cannabis, finally, caught the serious interest 
of pharmaceutical companies on two grounds. They could either produce a medicine 
directly based on cannabis, or they could move away from cannabis -based drugs 
to endogenous cannabinoids which would block (antagonists), mimic or augment 
(agonists) the endocannabinoid receptor system. Avensis, for instance. a leading 
pharmaceutical company, was attracted because of potential applications for treating 
obesity, potentially a high money earning applicaiton. The company developed 
synthetic antagonists and agonists such as SR 141716a known as rimonabant marketed 
as Acomplia. The targeting of obesity, Sanofi argued had became a major public health 
concern, and one with potential mass market appeal for industry. Rimonabant was not 
without problems as it became linked to depression and Sanofi had to withdraw it from 
the market. But the discovery of the endocannabinoid receptor system had brought 
a novel dimension to research as this understanding allowed some research to move 
away from directly cannabis-based medicines like the synthetic THe-based Marinol. It 
opened up a whole new arena and would lead to drugs that were well outside the remit 
of the Misuse of Drugs Act or the international drugs control conventions.52 Drugs 
developed from this new understanding were still a long way off from reaching the 
clinic and over the next decade many studies remained focused on the plant-based or 
synthetic cannabinoids. 
It was possible that the stigma around cannabis had created a glass ceiling for 
research, and permeated even these new approaches. Di Marzio commented how the 
stigma was difficult to dispel. 
There has always been this kind of preconceived idea that those working 
in cannabinoids were doing something wrong ... You can get an idea ... hoH' 
still the stigma is acting. There has been now - it s almost 15 years, it s 18 
),ears, 19 years - since the disco\'ery of the eB2 receptor. and there have 
'been several eB2 synthetic, eB2 selective agonistsfor this receptor which 
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are totally devoid of any psychoactivity so they could easily bypass all the 
problems of the psychotropic activity of cannabis and still we know I'ery 
little about this. 53 
Nevertheless, there was an alteration in attitudes towards cannabis-based drugs by 1990. 
Cannabis derivatives like dronabinol were viewed more leniently in some quarters. 
The CND requested the WHO to review the dronabinol issue. WHO presented a 
recommendation to downgrade dronabinol as it acknowledged dronabinol's medical 
properties were greater than the substance it had be classified alongside. 
It is nevertheless obvious in the assessment of the Committee that 
dronabinol has therapeutic usefulness that is definitely greater than that of 
the other substances in Schedule I which have very limited if any therapeutic 
usefulness and that it is comparable to that of a number of drugs in 
Schedule II. 54 
Furthermore, the WHO did not rate highly dronabinol's ability to adversely affect 
cannabis misuse as cannabis use was already widespread. 
Since cannabis is controlled under the Single Convention.. changes 
in the scheduling of dronabinol .... would not entail any change to the 
control status of cannabis. Nevertheless there might be a concern about 
the possibility that the official recognition of therapeutic usefulness of 
dronabinol might encourage the medicinal use of cannabis and thus its 
abuse. However cannabis is already the most widely abused illicit drug 
in the world ... it is unlikely that such recognition would make a significant 
difference. 
The CND was persuaded and at the 32nd meeting, recommended rescheduling 
dronabinol from Schedule I to Schedule II.55 This stiIlleft it a tightly controlled drug and 
pressure built later for it to be further downgraded. In the UK however it was moved 
to Schedule 2 of the Misuse of Drugs Act Regulations placing it alongside morphine, 
though it remained an unlicensed drug in the UK and had to be imported for prescription 
on a named-patient basis. This left the legal responsibly with the doctor. Arguments 
increased for it to be further downgraded to Schedule IV of UN Convention, the lowest 
schedule and in 2002 the WHO recommended its downgrading to Schedule IV. 
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The abuse liability for dronabinol is expected to remain very low so long 
as cannabis continues to be readily available ... the committee considered 
that dronabinol should be reschedule to schedule IV of the 1971 Convention 
on Psychotropic Substances, and to avoid placing stereochemical variants 
of the same substance under diffirent control systems the committee 
recommended that all stereochemical variants of delt-9-THC be moved to 
Schedule IV of the 1971 Convention. 56 
The 'stigma' of cannabis still operated and the recommendation was withdrawn on 
the recommendations of UNO DC. In 2006 the WHO recommended instead that it 
be transferred to Schedule III as a compromise but faced strong opposition.57 But the 
endocannabinoids especially Anandamide became major areas of study though none 
by this stage reached the clinic due to a lack of toxicity data. In the clinic the focus 
remained on THC, CBD and CBN. 
The emergence of GW Pharmaceuticals, 1998-2007. Cannabis-based 
medicine extracts (CBMEs) 
Another avenue for research was the re-investigation of herbal cannabis and this 
route took off in the UK with the development of a small biotechnology company 
based on the development of extracts of the cannabis plant. 1998 marked a new 
era in the development of cannabis-based medicines with the establishment of GW 
Pharmaceuticals in the UK, by the scientist entrepreneur, Dr Geoffrey Guy. GW 
achieved the first Home Office licence to cultivate, possess and supply cannabis for 
research. Cultivation began in August 1998 from which GW produced Sativex, an oral 
metered spray of a standardized extract from cloned cannabis plants. This marked a 
departure from the synthetic THC based medicines of the 1970s and 1980s. Sativex 
was based on the use of extracts and contained a mixture ofTHC and CBD in a 50/50 
mixture. 58 Although at the time of writing Sativex is not yet approved in the UK, the 
creation and development ofGW marked a watershed in the process of the medical use 
of cannabis, reflecting changes in the state of the pharmaceutical industry, relationships 
between industry, government, academia and patients, as well as developments in drug 
technology and clinical trial methodology. But why did 1998 see the entry and sustained 
development of a pharmaceutical company in the UK specifically based on cannabis? 
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Phytomedicine, the biotechnology industry and the role of the 
individual entrepreneur 
The decision by the UK Government to grant GW Pharmaceuticals the 
licence necessary to initiate cultivation and devise extraction procedures 
equal to the task of producing standardised plant extracts of proven content 
and stability was both timely and judicious coinciding as it did with a 
renewed interest generally in plant-based medicines. It is also relevant that 
many researchers and patients have concluded that the whole plant is more 
effective as medicine than THe alone especially in the form of synthetic 
analogues. 59 - Geoffrey Guy. 
Cannabis medicines in the nineteenth century had been based on herbal cannabis, 
usually in the form of a tincture, but these, in an era focused on active principles of 
plants, had fallen by the wayside. With the discovery of cannabis' active principle, 
THC, interest in cannabis had produced pills such as nabilone (Cesamet) based on 
one synthetic active principle of cannabis. OW was based on a different concept in 
which it aimed to capture something more akin to the whole plant. This alternative 
approach took place within the context of changes in pharmacy and developments in 
phytomedicine. For most of history, plants have been the main providers of medical 
drugs and even when pushed to the sideline there was a fluctuating but continuous 
interest in plant-based medicine.60 Plant medicine was important early on: quinine 
and pyrethrum were the lynchpins for malaria treatment and control. At the very 
time when synthetics were at their height, and medicinal plants marginalized in the 
West some uncertainty existed over the former's long-term sustainability and hence 
there remained a residual level of interest in plant-based medicine.61 By the 1970s, 
the continuing threat of old diseases such as malaria, increased focus on diseases like 
cancer, and newly emerging diseases such as AIDS, combined with increasing drug 
resistance provided impetus to find alternatives and this included re-investigation of 
plants and a greater interest in synergistic effects. Equally, in the wider community 
concerns over biomedicine, and a vague unease that life had become too divorced 
from nature, increased support for 'alternative' medicine. In addition countries such as 
Brazil and China had retained an ongoing and important relationship with traditional 
plant medicine. Whilst reservations remained over the potential value and usefulness 
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of plants, increased acceptance of plant medicine emerged within the public, scientific 
circles and regulatory authorities. Mead discussed the role of botanical medicine in 
relation to developing international controls on cannabis. 
The natural foods movement reinforced by patient advocacy and 
empowerment has also given new vigour to the interest in botanical 
medicine and dietary supplements. Renewed support for botanical and 
other natural products has been accompanied by an increased distrust 
of the pharmaceutical industry and its new chemical entities ... regulatory 
authorities have become more receptive to the concept of botanical 
medicines. 62 
Even though cannabis had lost its medical utility according to the WHO in the 1950s 
and cannabis tincture had been removed by 1973 in the UK, in some spheres there 
was a renaissance in the appreciation of plant-based medicine. This was reflected in 
the attitude of the National Cancer Institute in the US. Its screening programme for 
products, potentially helpful in the fight against cancer, initially excluded plants, but 
by the 1960s it was deemed advisable to incorporate them. Even with the advent of 
synthetic medicines, vast volumes of plants were used for drugs and new applications 
were emerging. For instance, two major developments, one in oncology with Taxol 
for cancer chemotherapy, and another around Artemisia annua for the treatment and 
prevention of malaria, encouraged the revival of interest in plant-based medicines and 
insecticides.63 Primary health care accorded traditional medicine, in which plant lore 
was critical, a higher place within health policy. The Alma-Ata Conference of 1978 and 
the WHO Health for All report (1981) brought about are-assessment of approaches to 
public health and one aspect ofthese changes was the increased consideration given to 
traditional medicine. A WHO report stated, 
The primary health care approach ... .... also emphasizes the need to make 
maximum use of all available resources. This is why the International 
Conference on Primary Health Care, in Alma-Ata in 1978, recommended 
that governments give high priority to the utilization of traditional medicine 
and the incorporation of proven traditional remedies into national drug 
policies and regulations. 64 
The refocus on traditional medicine meant that plant-based medicines sa\\ something 
of a revival from the 1980s onwards. In 1988 the World Conservation Union (lUCN) 
and the WHO collaborated to produce guidelines on medicinal plant conservation,65 and 
significantly the WHO published Traditional Medicine and Medicinal Plants , 
The recent decision to make the traditional medicine programme part of 
the global programme concerned with drug management and policies 
recognizes the importance of plants as sources of products of medicinal 
value, and the need for an adequate technological infrastructure to reali::e 
the potential. 66 
Plants, however, provided a set of particular problems for industry. 
Some of the problems of cannabis were related not only to its position as an 
illegal drug but to issues surrounding plant-based medicines in general. The problems 
highlighted in recent histories of plant-based medicines, like Taxol and Artemisia 
annua, can also be seen in the history of cannabis. These include issues over supply, 
isolation of active principles, standardization, and patents and these were a combination 
of negative factors that made pharmaceutical companies reluctant to invest. Goodman 
and Walsh's work on the history of Tax 0 I illustrates this. 
Few companies are capable of extracting and purifying large quantities of 
Taxol. Scaling up required capital investment and given the general lack 
of interest both in natural product medicine and anti-cancer agents among 
pharmaceutical manufacturers, there was probably a reluctance to invest. 67 
With regard to cannabis therapeutics and the reason for the creation of GW to fill this 
niche, Guy elaborated some of these issues, 
It was anticipated that one of the larger pharmaceutical companies would 
pick up the baton and use its vast drug development machinery to bring the 
project to fruition. Two major problems emerged. First, established 'big 
pharma ' is not comfortable generally with development of phytomedicines 
from starting materials that have a history of abuse ... .... It prefers an 
established drug development paradigm in which research is carried Ollt 
to define the 'active constituent' This is thought to ma_yimise intellectual 
proper(r rights . .... . second in an environment 11'here opinion is divided 
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on the ethics of developing a cannabis-based product the boards of major 
companies probably reflect this dichotomy. 68 
Established pharmaceutical companies, uneasy about working with cannabis left a space 
in the medical market place. The emergence of the biotechnology industry provided a 
new means to fill the space. The biotechnology industry, the industrial application of 
biological processes, took off after the discoveries around DNA in the 1970s in the US 
and developed in the UK after the 1980s.69 As research and development and the cost 
of bringing drugs to market spiralled, acquisitions and mergers were commonplace in 
the pharmaceutical industry in the 1990s. National governments especially in Britain 
and Germany had recognized the potential of biotechnology and had encouraged their 
development via government initiatives and finance. New small companies emerged 
focusing on niche markets. This had a number of effects including some on the 
structure of industry. Quirke explained the impact of the changed environment. 
It has brought back the inventor, in the person of the scientist-entrepreneur 
heading start-up companies. It has pushed big pharma into strategic 
alliances with start-up companies and academics and has led to the growth 
of what has been termed the bioscience industry. 70 
The new structures encouraged innovation and biotechnology firms contributed new 
therapies.71 It was in this context that an entrepreneur in the biotechnology industry 
could start up a company to fill the niche with a plant derived cannabis-based medicine. 
Geoffrey Guy, the founder ofGW Pharmaceuticals, a physician with a degree 
in pharmacology from University of London had been involved in the pharmaceutical 
development of chemical entities, biotechnology products, and drug delivery systems. 
He summed up why he was the man to do the job. 
There was no-one else who was interested in making, or thought it was 
remotely possible to make, a medicine out of cannabis ... I'd had twenty years 
in narcotic analgesics, drug delivery, plant medicines and had jllSt retired 
two days earlier. .. and had the time to think. 72 
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He had had a long term interest in plant-based medicines and had founded Phytopharm 
PLC in 1990 which developed novel products from medicinal plants, and \\ hich he 
floated in 1996. Guy explained the regulatory difficulties that had emerged when 
working on plant-based medicines in an era that concentrated on single chemical 
entities. 
Since the war, and certainly since the 1960s and the Dunlop Report and 
afterwards, the medicines regulation pertained to single chemical entities. 
The prospect of developing a medicine, which contains something like -IlO 
chemicals in the modern regulatory environment, was considered in the late 
1980s-mid-1990s, to be pretty nigh impossible. 73 
He became interested in building on his experience of plant-based medicine and 
aimed to 'bottle the essence of cannabis.' This meant the use of more than one active 
ingredient of cannabis and the use of herbal synergism. Scientists had been arguing 
since 1900 over the relative value of the alkaloids in cinchona and possible benefits 
of drug combinations. In the 1990s Kirby, a member of the Department of Medical 
Parasitology, at the London School of Hygiene and Tropical Medicine developed 
the argument that a herbal mixture was more effective than the use of a single active 
principle. Combination drug therapy, for instance, had been developed in the AIDS 
field. 74 The decision of GW to use a mixture of extracts from cannabis in order 
capture its essence, was in stark contrast to earlier industry moves. In following this 
route, GW set out to produce something closer to the plant-based product smoked by 
many patients. 
The establishment of GW reflected the relationship between industry and science. 
Historians such as Oudshoorn have shown how the demarcation between industry 
and universities has become increasingly blurred since the early twentieth century.75 
Lowy has demonstrated how the pharmaceutical industry in particular has historically 
developed through unusually close association with academic researchers. 76 In the case 
of cannabis this knowledge exchange between industry and academia proved crucial and 
active attempts since the 1990s were made to integrate the two worlds. By the 1990s, 
international networking and the development of symposia facilitated an c.'\change of 
ideas, and importantly opened a window to industry. The formation of societies on 
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cannabis such as the International Cannabinoid Research Society brought companies 
into contact with academics.77 Guy expanded on how one of these conferences re-
stimulated his interest in the subject. 
1 went to a conference in London.. and ... 1 thought: 'Ho hum, this is 
interesting. 1 thought it was ... very taboo. ' .... and there was the MCA 
(Medicines Control Agency), the Home Office, some very eminent 
scientists ... patients and patient groups, and a little smattering of 
pharmaceutical people ... keeping their heads way, way down, because they 
didn't want to be seen at a cannabis conference. The question arose: if 
research is to be done on cannabis, how do you standardize it? .... 1 stood up. 
spoke from the floor ... and said that it could be done as long as you got the 
agreement from the Home Office, from the MCA.78 
These meetings which were stimulated by the involvement of professional bodies 
are discussed in detail in chapter seven. As with many new biotechnology firms GW 
capitalised on networks between industry and academia. The company created an 
internal Cannabinoid Research Institute (CRI) directed by Philip Robson, a consultant 
psychiatrist from Oxford who in 1996 had provided a review on the therapeutic use of 
cannabis for the Department of Health. The CRI was designed to provide links between 
commercial enterprise and academia.79 GW Pharmaceuticals began collaborations with 
many of the major players in the field of cannabis research including Professor Roger 
Pertwee, who was engaged as Director of Pharmacology. Pertwee remained based at 
Aberdeen University but received funding from GW Pharmaceuticals to carry out work 
on plant cannabinoids. Further links were developed with Mechoulam, and di Marzio. 
These networks between science and industry allowed both to benefit from each others 
expertise. 
To start-up such a firm involved a high level of risk and nowhere more so than 
in the case of cannabis where fears over safeguarding intellectual property rights and 
overcoming difficulties related to international drug controls made most other people 
steer well clear of the subject. Robson described some of the risks involved. 
At that time in every country it was completely illegal. So in order for the 
thing to get off the ground yo II 've got to convince the Home Office to give 
1'011 a special licence which no one had done. Guy risked money before the 
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Home Office came round to his repeated requests. There was no guarantee 
this would happen ... he took the risk and put his own money up. 80 
The legal situation surrounding cannabis was still a major issue. But pressure from 
medicinal user activists provided incentives for policymakers to define the boundary 
between therapeutic cannabis and recreational cannabis, a division which the synthetic 
drugs like nabilone had failed to achieve. As is discussed in detail in chapter six, patient 
pressure that developed in the 1990s had kept the issue of therapeutic cannabis high on 
the agenda. Guy commented that' the government was very concerned about the MS 
patients being pushed up Whitehall as a campaign to have cannabis legalized. '81 By 
1997 industry and policy interests were beginning to move in a similar direction. 
Cannabis was a highly unusual substance in that it muddied the boundary between 
a medical and a recreational drug and one that already existed in herbal form for both 
uses, in the public domain. This scenario provided ammunition to both those in favour 
of medicalizing cannabis and those determined to prohibit it. Robson expounded the 
difference between bringing any new drug to market, in contrast to bringing cannabis to 
market and the potential benefits of doing so from a legal and public health viewpoint. 
The stuff is already out there in a totally unregulated way, manufactured 
by criminals whose quality control interests are not really at the forefront 
of their priorities. It s a paradox because if cannabis-based medicine was 
pharmaceutically produced and regulated a proportion of people currently 
running a risk by smoking illegal cannabis of uncertain strength and purity 
would switch to the pharmaceutical product and therefore even if there was 
a an inherent risk in cannabis-based medicine you would be teasing out all 
the additional risk of smoking an unstandardised, possibly adulterated drug. 
Also its illegal nature ... the simple fact they could be arrested, even if not 
harmed directly by the medicine. It s a total mystery to me why regulators 
wouldn't factor that into their calculations. 82 
Some of these considerations were being gradually taken on board. Guy had 
approached government previously about producing a cannabis-based medicine but had 
been advised to maintain his interest in opiate-based medicines research. He recalled, 
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In the early 1990s we'd approached the Home Office and said: '1 'd be 
interested in looking at cannabis, 'because, as you knOlv, li'e 'd dealt H'ith 
the opium plant with opiates. We got a bit of af/ea in our ear actualzv: 
the Home Office in the early 1990s said, 'No, you're going to stick with 
your opiates. 'And, like any other pharmaceutical company or chairman, I 
thought that we had other fish to fry, and so we did. 83 
However, as is discussed in chapter seven, attitudes had shifted by 1997 and a 
major report by the House of Lords on therapeutic cannabis pressured for industry 
involvement.84 As far as Robson was concerned the House of Lords report conferred 
credibility and was vital to give the confidence for industry involvement. 'I don i think 
there would have been a GW if there hadn i been a House of Lords. '85 The significance 
for industry was that it opened the way for clinical trials and potential licensing of a 
cannabis-based medicine. 
The need to split medical arguments from calls for legalization provided a spur to re-
medicalization. Confidence was boosted when David Blunkett, the Minister of Health, 
appeared supportive when he stated, 'should as I believe ... this programme be proved 
to be successful I will recommend to the Medicines Control Agency that they should go 
ahead with authorising its medical use. '86 Edwards described the pressure for additional 
pain medicines. 
So, I think the official mind-set would have been. .. was that one should be 
very willing to determine the therapeutic value ofTHC, even ifit were 
dangerous because we knew we needed better drugs for pain relief The 
pain specialists really made us feel a bit ashamed if we thought that 
morphine and heroin were enough they weren't. We needed better drugs. 87 
Guy described how the government position did not deviate from its overall aim: to 
facilitate research and see the development of a pharmaceutical grade product in order 
to eliminate the argument for legalization on medical grounds. 
If a product could be approved by the MCA as an approved medicine then 
the government would move to reschedule that product - not cannabis -
not the plant, not the rmll material, but that finished product - they would 
reschedule it to an appropriate schedule so that it could be llsed as a 
medicine. Therefore it was the government:S' position before 1 Cl'en got 
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involved with them because their concern was, if there is a medicine here, 
you have to separate it from the advocacy debate. That s what )j'as done, 
very, very straightforward and very quickly then ... The government was 
entirely consistent all the way through, and we got an enormous amount of 
support from the Home Office, even directly from Cabinet Office in the early 
days to ensure that this programme would run ahead smoothly. 88 
I f government had determined this was the way forward they needed to attract industry 
interest. Guy described how the doors were opened for his company at a witness 
seminar held in 2009 
Paul Boateng opened the meeting and said, 'Her Majesty s Government 
has no will to reschedule cannabis', at which point everybody s eyes went 
to the ceiling. 'However,' he said, 'we'd like the research to be done. 'At 
which point most people thought: 'Well, this is bizarre. 'But he did suggest 
that if one wanted to do the research, one should approach the Home Office 
Drugs Inspectorate (HODI). Having worked in one of the most highly 
regulated environments the previous 20 years with opiates and with a range 
of materials like that, when a minister says:, 'Go and see my officials' that s 
what we did. 89 
Guy met with the Home Office Drugs Inspectorate and was surprised at their rapid 
response. 
We presented .... to the Home Office in the January 1998, and I nearly 
forgot about it again, because I thought it would be buried in there for 
two or three years. About four weeks later I received a phone call from 
the Chief Inspector of the Home Office, whom individually is probably 
more responsible than anybody else in this room for the progress of our 
programme, and that s Mr Alan Macfarlane. He rang me up and said: 
"We'll do this. We don't know how we're going to do this: could you put a 
proposal in? "90 
GW was granted a Home Office licence to grow cannabis in June 1998 and was granted 
a clinical trial exemption certificate to conduct clinical studies with cannabis-based 
medicine extracts for numerous applications. With these permissions in place, GW 
was sufficiently confident to start the first large-scale, legal commercial production of 
cannabis for medicine in the UK. 
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Learning to grow cannabis: Standardization, security and patents 
Uniformity is king. Everything we do strives to produce batch after batch 
of plant material which is almost the same as the one before. 91 - David 
Potter, GW Pharmaceuticals. 
GW solved the problem of supply that had plagued cannabis research by turning to 
vertical integration, producing both the raw material and finished product. The main 
issue for GW was the need for standardization of the raw material. In describing his 
work, the chief botanist at GW Pharmaceuticals, Dr David Potter, highlighted the 
importance of standardization.92 Standardization was another reason why industry 
steered clear of plants. They were products where external and uncontrolled forces, 
climate, for instance, could make it difficult to achieve standardization of relative levels 
of active ingredients and therefore dose. Goodman described the problem for Taxol, 
'Yield and weather conditions were two elements that could not be controlled and had 
a considerable impact on the planning of clinical trials. 93 For G W one of the main 
aims became the production of pharmaceutical grade cannabis, through the growing of 
genetically identical material in optimum uniform conditions. 
Security issues had to be resolved. The placement of cannabis within the drug 
control mechanisms meant that special requirements for the site had to be met. A site 
was found where a security system was already in place and which also provided a 
well-equipped research glasshouse and half an acre of space. Apart from his botanical 
knowledge, Potter also brought with him useful police contacts built up in his earlier 
career in pesticides, and this facilitated the development of good working relationships 
with the police and Home Office. Providing the necessary security was feasible but 
expensive, and later the site was split to spread risk. The Home Office was particularly 
nervous of any diversion of plant material so traceability of plant material was critical. 
Any failure to trace a particular plant and tally numbers on any particular day during a 
regular visit by the Home Office resulted in nerve racking moments. Potter described 
the paperwork as phenomenal.94 Each plant had a unique number and any movement, 
harvesting, or destruction had to be logged. Failure to meet Home Office requirements 
could have resulted in the removal of the licence and failure of the project. Over time 
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the relationship with the Home Office and police settled down and a spin off was that 
the company could provide the police and the Home Office with specialist training 
courses on cannabis. 
A standardised product was a priority and for this botanical knowledge was an essential 
forerunner. The first employee Dr David Potter had seventeen years experience working 
for Shell on pesticides, and he was experienced in the process of registration of novel 
compounds. Suitable plant material had to be sourced and as this was the first time 
cannabis was grown commercially on this scale in the UK, intellectual knowledge about 
growing the plants had to be acquired. This is where a company called HortaPharm 
BV in the Netherlands proved useful. Staffed by expatriate Americans, banned from 
working in the United States, they had foreseen a time when there would be a demand 
for a range of cannabinoids, not just those producing high levels ofTHC. HortaPharm 
had combed the world for different seeds and created a seed bank from which they 
had cross-bred plants to produce varieties with high degrees of cannabinoids such 
as CBD. GW bought the rights to HortaPharm's collection and capitalised upon the 
firm's intellectual knowledge. International regulations forbade the movement of 
plants from Holland to the UK, and as there was no system for Home Office permits 
for plants, only seeds, which did not fall under international regulation, could be 
transported. HortaPharm was able to return to their parent plants to produce seeds 
that would produce similar progeny. These yielded eight packets of seeds of the most 
promising lines containing pure lines ofCBD and THC. Eventually, as OW established 
itself it was able to obtain licences for HortaPharm's collection of plants, which was , 
removed to the UK, providing a resource which could be dipped into when necessary. 
On the 24th August 1998 the eight varieties produced by HortaPharm were planted 
and ten days later yielded the first two thousand seedlings. HortaPharm provided the 
know-how to take the cuttings and GW developed the process. Plants with the highest 
cannabinoid concentration and purity were identified and ten genotypes selected and 
five recommended for trial. These five chemovars (chemical varieties) were selected 
for commercial cultivation. Thus GW had successfully bred the raw material and was 
therefore in a position to mass produce standardized or rather genetically identical plant 
material cloned from the original mother-plants raised by HortaPharm in 1984. 
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GW had to be able to be able to control the growing environment. Potter 
expanded on the need for standardization in phytomedicine. 
Medicinal cannabis must be of consistent quality. In striving to produce 
cannabinoids of uniform high quality commercially, the pharmaceutical 
company needs to ensure that plant material with the most appropriate 
genetics is selectedfor the propagation process ... the correct environment 
has to be found in which this material can be propagated, carefully 
harvested and stabilised by prompt drying. 95 
Growing the plants to maturity, GW fine-tuned information from HortaPharm and 
incorporated knowledge gleaned from illegal growers. Varieties resistant to pests, plant 
density, the growing medium and humidity levels were all factors to be ascertained and 
controlled. Optimum conditions were found for these via a process oftrial and error, 
and serendipitous discovery. One major issue was that the company needed to grow 
plants north of the equator whereas cannabis that produces a higher concentration of 
active ingredients does not grow naturally in light levels found in the UK, nor would it 
produce sufficient harvests per year needed for commercial mass production. Lighting 
in the glasshouse had to be supplemented to achieve standardized light levels and 
therefore yields. The timing of harvesting was critical: a week early or late affected 
yields. Plants were cultivated in accordance with Good Agricultural Practice (GAP) 
methods of the European Medicines Evaluation Agencies and in conjunction with 
the Medicines Control Agency, for the production of a Botanical Drug Substance.96 
Standardised cannabis plants were then processed to produce the medical product 
Sativex. 
Intellectual property right protection was essential for the company. In the past 
companies tended to steer clear of plants due to difficulties of obtaining patents, and 
those that risked involvement, faced debates over issues ofbio-piracy.97 There were 
fears raised over the 'hijacking of an ancient andfolk remedy 'and the patenting of 
traditional knowledge. 98 But standardization was a means of achieving property rights 
over the end product. GW was able exploit this because it could certify to a new variety 
as defined by the demonstration of distinctiveness, uniformity and stability, therefore 
gaining European Plant Breeders Rights. This process would normally be carried out in 
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the UK but because of security issues plants could not be assessed in the UK and had to 
be exported to Holland, incurring further difficulties over import and export licences, a 
process which caused some amusement at customs - carrying cannabis to Holland?!99 
Achieving standardization therefore provided the opportunity to obtain intellectual 
property rights, a necessity to make a high risk investment worthwhile, as it allowed 
GW to license chemically and genetically characterised extracts of Cannabis sativa L. _ 
CBD and CBN protected as Tetranabinex® and Nabidiolex. 
Was all the effort worthwhile? After three years GW was ready to test the product. 
Concerns over the impact meant that early tests on humans involved a ratio of one 
patient to thirteen doctors waiting to see what would happen. One patient became 'high' 
rapidly and described the medicine as powerful, like two joints of the best cannabis. 
Potter described the excitement, 'it told us we'd managed to capture the essence of 
cannabis in a bottle. '100 Whilst not the effect desired for a medicine it proved that GW 
had achieved an action more closely related to that of herbal cannabis. 
GW Pharmaceuticals' decision to develop a new delivery system rather than 
stay with the oral administration method used for dronabinol (Marinol) and nabilone 
(Cesamet) leads to the question as to how far technical change has helped to define 
boundary change? Producing oral cannabis medicines in the 1980s had been important 
as a delineator of medical! non-medical boundaries, and continued to be important 
especially in a climate increasingly against smoking. The spread of no-smoking zones 
to include hospitals, and fears over lung damage precluded the smoking route for 
acceptable evidence-based medicine. However oral medicines had their detractors 
and developments of alternative delivery methods have been important in the story 
of cannabis-based medicines. It appeared patients generally disliked available oral 
cannabis-based tablets as they had a long lag time and poor absorption. Nor was an 
oral route satisfactory for those suffering from nausea: this was one reason why tablets 
of dronabinol and nabilone were not well used. Intravenous and inhalation remained 
the quickest routes of absorption. But both had problems. Inhalation was initially 
proposed but presented technical problems. 101 Russo showed how GW modernized the 
nineteenth century technique of an extract in an ethanol base by utilising supercritical 
170 
C02 extraction. GW, therefore, piloted propellant powered aerosols providing a fluid 
extract of a metered spray under the tongue or inside the cheek. This method allowed 
for reliable and rapid absorption and one with which patients could self-titrate. Self-
titration was important. Notcutt recalled, 'J think that during the 1990s we also got llsed 
to the concept of patient-controlled analgesia after surgery. '102 It put patients back in 
control of dosage. Development of delivery methods has been historically important as 
delivery methods and technological developments could provide intellectual property 
rights. This was an essential aspect of working with botanical products. G W developed 
specialist security technology that could be incorporated in all its drug delivery systems 
allowing recording and remote monitoring of patient usage to prevent any potential 
abuse of its cannabis-based medicines. This technology enabled industry to further 
remove medical cannabis away from fears over misuse. By 2001 the company was 
ready to start clinical trials with Sativex. 
Conclusion 
Re-medicalization was intimately linked with developments in the pharmaceutical 
industry. Over the period under study the pharmaceutical industry developed a greater 
interest in cannabis as a potential medicine. Initially, academic research had struggled 
without an industrial supply but from the 1970s interactions between academia and 
industry boosted re-medicalization and the development of cannabis-based medicines. 
Nabilone and dronabinol set a precedent for the use of cannabis-based medicine and 
provided the cannabis therapeutics field with a new legitimacy. However, the relative 
failure ofthese synthetic, single chemical entity drugs left open the door to patient 
pressure for access to cannabis and later forced a re-evaluation of herbal cannabis. 
Pharmaceutical interest was re-stimulated when industry compounds contributed to 
new understandings of the mode of action of cannabis. This opened up two routes for 
industry involvement. First, drugs designed to manipulate the cannabinoid receptor 
system which moved drugs away from the use of cannabis itself. Second, industry 
involvement, stimulated by developments in phytopharmacy, moved research back 
in the direction of plant-based medical products, and linked it more closely to the 
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traditionally smoked herbal cannabis or the original herbal tincture of cannabis, whose 
mechanism of action had been revealed. 
In the UK, GW Pharmaceuticals and its development ofSativex spurred the 
re-medicalization of cannabis by the provision of a product more concurrent with 
developments in standardization, clinical trials and drug regulation. Development of 
a new drug delivery system, which was more effective and faster than the tablets used 
for the delivery of synthetic THC, and which steered clear of smoking, fitted within 
acceptable treatments but also took on board patient concerns. If a licence was to be 
achieved for Sativex in the UK it would be a remarkable development in the process 
of industrializing cannabis. First, it would bring a cannabis-based drug back into 
the medical marketplace after withdrawal of the extract. Second, although cannabis-
based drugs like Marinol (dronabinol) have been on the market since the mid 1980s, 
these were based on synthetic THC while Sativex consisted of extracts of cannabis 
not synthetic derivatives. Third, Sativex was based not on the use of one single active 
principle but on a combination of extracts of both THC and CBD, in an attempt to 
get closer the 'whole plant.' Fourth, a new delivery system had potential to provide 
the benefit of smoked cannabis without its negative connotations. By 2001, GW was 
ready to start large-scale clinical trials and was developing a portfolio of drugs and was 
working on a range of applications beyond its start point of MS. To bring its CBME 
product to market, Sativex had to pass successfully through the benchmark double-blind 
randomized clinical trial and through the UK regulatory and licensing mechanisms. 
The following chapters consider the factors that contributed to the development of 
GW pharmaceuticals and the process ofSativex products through clinical trials and 
regulatory mechanisms. 
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Chapter Six 
Forces of necessity: The role of lay knowledge, and advocacy, 
1973-2004 
Self-help and self-medication had always been important in health care and health 
activism, despite the increasing role of the National Health Service, became important 
in the health arena in the post-war period. This activism was part of a wider trend 
as activism in general took on a renewed format in the 1960s. The emergence of 
organisations and charities in particular in relation to poverty such as Shelter, and the 
environment such as the World Wildlife Fund, played an increasingly important role 
in society. Berridge has described the growth of single-issue health pressure groups 
like Action on Smoking and Health (ASH) established in the 1970s. These were 
single issue, media aware, national organizations. I Within this context cannabis and 
activism became increasingly intertwined from the 1960s. Medical activism was one 
aspect of cannabis campaigns. Grass roots knowledge of drugs proved important to the 
growing relationship between lay and professional spheres and as part of this trend lay 
knowledge around cannabis and subsequent patient activism was instrumental in the 
process of re-medicalizing cannabis. Medical activism in relation to cannabis evolved 
considerably during the period studied and this chapter charts its evolution and impact 
on the re-medicalisation of cannabis. Initially, activist focus was on legalization namely 
for recreational purposes, and medical use cited as one reason for this demand. In the 
US activism developed by individual patients by the 1980s and 1990s and later patient 
associations campaigned for medical access to cannabis. This time activists distanced 
themselves from calls for legalization on recreational grounds. Stimulus to calls for 
medical access first came from the growing acceptance of cannabis as a treatment 
for cancer chemotherapy. The AIDS crisis of the 1980s and the ensuing search for 
treatments brought added stimulus to debates over access to cannabis leading to the 
creation of new activist groups and co-operation with pre-existing cannabis activists. 
In the US it led to subsequent changes to policy with the setting up of compassionate 
programmes in some states and the licensing ofnabilone (Cesamet) and dronabinol 
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(Marinol). In contrast, in the UK, whilst activism has been as relevant to the re-
medicalization of cannabis as in the US, the impetus came from a different quarter. 
In the UK it was the pressure ofMS sufferers that had the most influence and led to 
MS becoming the major stimulus for cannabis research. Patient advocacy of cannabis 
in the 1990s became critical to the process of re-medicalization, both through patient 
associations that campaigned on cannabis as part of a wider policy and activist groups 
that were set up as single issue campaigning associations to campaign for access to 
cannabis. The development of cannabis as a medicine especially since the 1980s 
has been brought about to a large extent by patient-led demand driving the scientific 
community, policy advisors, and industry to build upon anecdotal and scientific 
knowledge. Despite major advances in the knowledge base and development of clinical 
trials, from the patient perspective, development of licit cannabis-based drugs remained 
limited and access to cannabis-based drugs constrained. This chapter considers the role 
oflay knowledge around cannabis and the establishment of patient activist groups. The 
role ofMS patient groups in influencing laboratory science, clinical research, the policy 
environment, and industry is examined. The complexities of the interface between 
these activist groups and the scientific and policy establishment in the advocacy of an 
alternative and illegal substance are highlighted. 
Early lay knowledge and activism: Cannabis and drug liberalization 
Cannabis activism in the 1960s focused on drug liberalization. In some cases it 
extolled the medical properties ofthe drug but medical arguments were subsumed 
within the larger campaign. In the UK, perhaps the most well known pressure group 
which campaigned for drug liberalization was SOMA, (Society of Mental Awareness) 
a campaign and research organisation founded by Stephen Abrams in 1967.2 At the 
point where cannabis was coming under scrutiny in the Wootton Committee, the Society 
attempted to influence policy via the media and public opinion with the placement 
of an advertisement in the form of a petition in The Times on the 24th of July 19673• 
The intention was to influence the terms of reference of the Wootton Committee into 
detailing the case for law reform.4 SOMA capitalised on its professional membership 
which included a medical network comprising a physician, pharmacologist, and a 
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research psychologist and the petition was signed by sixty five public figures. including 
Francis Crick, the co-discoverer of the structure of DNA, nine doctors, MPs including 
Brian Walden and Tom Driberg as well as the Beatles and Graham Greene. Such 
advocacy appeared to have little policy impact at that time, and the Wootton Report was 
rejected by government. 
These politicized campaigns for legalization failed in an increasingly hostile 
policy environment. Medical cannabis was overwhelmed by a combination of the 
link to recreational use and limited proof of medical efficacy. Against this backdrop 
activism had mixed fortunes. Single issue groups could be relatively short-lived and 
SOMA hampered by a lack of funds, folded.5 Other voluntary drug organisation such 
as Release continued and others emerged throughout the 1970s. In the US the National 
Organization for the Reform of Marijuana Laws (NORML) founded in 1970 lobbied for 
the decriminalization of cannabis. In the UK in 1978 the LegaJise Cannabis Campaign 
(LCC) was initiated to campaign for full legalization of the use and distribution of 
cannabis. As cannabis was no longer available as a medical product the campaign urged 
that cannabis should be available for prescription by doctors without special licensing 
requirements. Whilst ultimately groups like SOMA and the LCC had little success and 
placed emphasis on legalization they did use medical necessity as part of their argument 
and this raised awareness at the grassroots and in influential circles that there were 
possible medical uses of cannabis at a time when these uses were being denied and 
prohibited. But advocacy by patient associations for cannabis as a treatment for specific 
medical problems, disassociated from cannabis legalization, was to have a much bigger 
impact in the following decades. 
Lay knowledge and medical activism, 1975-1991 
Though side-lined, self-medication remained important despite the increased 
professionalization of medicine. With increased recreational cannabis use, lay 
knowledge developed around the therapeutic usages of the drug and activism related 
specifically to the medical use of cannabis emerged in the late 1970s and early 1980s. 
Health activism based around the concept of access to cannabis for medical necessity 
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became prominent in the us. The events in the US influenced later developments in 
the UK and UK campaigners developed links with US organizations. In the US Robert 
Randall, a glaucoma patient, defended his use of cannabis on the grounds of medical 
necessity and importantly won his case in court in 19756• Randall was provided 
with access to government grown cannabis. After the Federal Drugs Administration 
(FDA) attempted to block access, Randall brought a case against the FDA in 1978 and 
won. This legal victory meant that the US government had to create the Investigative 
New Drugs Programme (lNDP) in 1978 to supply National Institute of Drug Abuse 
grown cannabis to approximately thirty qualifying patients. This success encouraged 
patients to come together to campaign for legal access to cannabis for specific medical 
problems, creating a different agenda and separate from campaigns for legalization. 
Health activism became an increasingly important part of the story from the 1980s. 
Some potential medical uses for cannabis, for instance, in glaucoma had not attracted 
the same level interest as had the management of cancer treatment, yet were areas that 
lacked effective treatments. Consequently, user activism developed on a larger scale 
campaigning, not for access for a few individuals, but, rather, for reform of the laws that 
denied access in the first place. Robert Randall went on to found the patient association, 
the Alliance for Cannabis Therapeutics in 1981 along with Alice 0' Leary. The 
association was set up with the express aim to campaign for the reform of laws which 
prohibited medical access to cannabis.7 
Activism developed around diseases that lacked effective treatments and for 
which cannabis appeared to offer some hope but was yet to be investigated or deemed 
acceptable. The introduction of cannabis based-drugs in the 1980s contributed to a 
change in attitude towards cannabis therapeutics in policy circles in the US and the 
UK, from which activists benefited. In the UK, the findings of the 1980 Expert Group 
on Cannabis set up by the ACMD reflected a changed attitude towards cannabis. The 
dangers of cannabis were downplayed and attention began to focus on the possible 
benefits of the drug.8 It was work in one aspect of therapeutics that significantly 
contributed to this outcome and that was for the treatment of the side-effects of 
cancer chemotherapy. The urgent necessity to alleviate iatrogenic symptoms meant 
that cannabis gained its first modern instance of legitimacy. The need to use it in 
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this situation drew it away from discussion of recreational misuse. Significantly, it 
established a precedent from which other applications would later follow. However, 
the legitimacy was accorded to drugs based on synthetic THC rather than cannabis 
per se. Whilst the problems of cancer chemotherapy quickly stimulated research and 
acceptance yielding the licit drug nabilone licensed in 1982 in the UK, and shortly 
afterwards dronabinol as Marinol in 1985 in the US, there appears to have been limited 
activism in relation to cancer related drugs: there was no need as patients had licit 
access to cannabis-based drugs. 
The HIV/AIDS crisis of the 1980s and 1990s provided the next spur to activism 
around cannabis. Russo, an historian of the American medical cannabis experience 
commented on the importance of the AIDS epidemic on attitudes towards cannabis. 
The experience of desperate AIDS patients using medical marijuana helped 
to change the national perceptions of the drugs from menace to medicine. 9 
By 1993, the US Department of Health had listed AIDS as the most common cause 
of death for men aged 25-44. 10 The advent of AIDS has been shown to have had a 
considerable impact on many areas of health policy. As a deadly new disease doctors 
lacked knowledge of the causation and treatment and looked for solutions beyond 
mainstream medicine. II Even after the viral agent was identified patients faced the 
reluctance of pharmaceutical companies to become involved and with a dearth of 
treatment options, patients were forced to look to self-help methods of treatment. Russo 
has argued, 
The sudden emergence of the AIDS epidemic and the initial lack of effective 
treatment politicised the patient population into demanding quicker 
developments of, and access to, promising medication. 12 
Cannabis was one of the potential remedies and AIDS was 'a crucial influence on the 
growth of support for the medical marijuana movement. '13 By 1985, after pressure 
from the National Cancer Institute, more orthodox anti-viral treatment, including AZr, 
was developed for AIDS. However, a side-effect of AZT was nausea, leading to weight 
loss which exacerbated the problem of the wasting syndrome. Herbal cannabis became 
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popular in self-help circles as it acted as an appetite stimulate against the wasting 
syndrome, but its usefulness was compromised by its illicit status which forced patients 
into criminal activity. 
Activism by AIDS patients for medicines such as cannabis was led by an active 
and well-organised gay rights movement. The experience and ready-made network 
of campaign groups like the ACT proved invaluable for AIDS campaigners. Randall 
had set up the ACT to campaign to protect medical users from the law and had mainly 
focused mainly upon cancer and glaucoma patients but, by 1983, ACT turned its 
attention to the AIDS issue. Though cannabis-based drugs had entered the market, 
these were not available for applications other than as a palliative in cancer treatment 
and herbal cannabis remained illicit. The use of the pre-existing programme designed 
for Randall became a method through which AIDS patients could gain access to an 
otherwise illicit substance and a compassionate access programme was utilised for 
AIDS patients. But the programme was a slight concession rather than a right. It 
had limited coverage of patient demand, was subject to sudden closure and was not 
a change to federal law. The programme became so popular for AIDS sufferers that 
it was closed in 1991, apparently due to the large numbers of subscriptions and fears 
that it was sending the wrong message to the public. 14 Booth argued that the fury at 
the closure of the programme led to further development of the grass roots movement 
to protect patients and to the development of 'buyers clubs' for alternative and illicit 
remedies. IS However, the use of cannabis as an anti-nausea drug used in relation to 
cancer chemotherapy had already provided an example of a medical use of cannabis, 
and one that could be transferred to AIDS treatment. Dronabinol (Marinol) was 
therefore made available for prescription for AIDS patients in 1992 in the US. Patients 
who were already receiving herbal cannabis were allowed to continue but those who 
were in the process of being placed onto the compassionate programmes were provided 
with Marinol which enabled the US government to argue that smoked herbal cannabis 
for medical purposes was obsolete. 16 
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Cannabis, multiple sclerosis and the patient perspective in the UK 
1992-2007 
Pressure from HIV / AIDS activists was relevant in the UK but it was not this activism 
that led to a change in the environment around cannabis. In the UK, it was a different 
disease, perhaps one considered more 'respectable,' in the form ofMS and its associated 
patient demand which was to have a more influential and long-term impact on policy 
discussions and the development of cannabis medicine. A MS campaigner for access 
to cannabis commented, 'With AIDs - its your fault .... so in this country the focus 
was on MS. '17 In the UK a number of active self-help groups had been established to 
look after the interests of the approximate 85,000 MS sufferers. MS is a progressive, 
degenerative disease impacting on the brain and spinal cord nerves. Orthodox therapies 
included baclofen (Kemstro) and diazepam (Valium) for the treatment of muscle spasms 
and spasticity but their efficacy was limited and both had unpleasant side-effects. MS 
patients faced a variety of other medical symptoms for which there were no effective 
symptom control treatments, especially for pain. Some sufferers, often previously law-
abiding citizens, found they could self-treat with cannabis either in the smoked or oral 
form. 
This type of self help through 'kitchen physic' had yielded much anecdotal 
evidence of beneficial effects but there was limited scientific proof that cannabis was 
effective. In the early 1980s a few studies emerged in the US on the treatment ofMS 
with cannabis. For instance, in 1981, DJ Petro and Ellenberger published a paper on 
the treatment of spasticity with the active principle delta-9 THC and in 1983 Clifford 
published the results of an open trial with eight patients given oral cannabis which 
found that it reduced tremors. 18 In 1988 Ungerleider and colleagues carried out a 
study of twelve MS patients which, from the patient perspective, yielded significant 
improvements, but these improvements could not be backed up by objective observation 
by the medical staff.19 The numbers involved in the studies were small and results 
were ambivalent: only three double-blind placebo controlled studies involving more 
than one patient had been carried out and additionally some volunteers experienced 
a 'high', a reaction which was not considered acceptable in medical circles. These 
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experiments were promising leads but were not drug licensing exercises. and were not 
sufficiently large to provide proof of safety and efficacy which would be needed to take 
a drug through the regulatory processes. However, the discovery of the endogenous 
cannabinoid receptor system by the 1990s conferred legitimacy to the role of cannabis 
in the body and led to a snowballing of cannabis research. In tenns ofMS, articles 
appeared on the use of cannabis for fatigue, tremors, incontinence and pain. These 
publications, however, made little practical difference from the patient perspective but 
awareness was growing about patient self-medication of cannabis. A survey carried out 
by the MS Society revealed the widespread interest in cannabis amongst the Society's 
members.20 
A more educated and informed patient popUlation was taking an increasingly active role 
in treatment options.21 Since the 1990s different types of self-help groups became vocal 
in pressuring for research on cannabis for MS. Three societies influenced the cannabis 
story and each brought a slightly different perspective and emphasis to advocacy on 
cannabis but together they provided real pressure for research. 
The MS Society 
Formed prior to the rapid development of many patient groups after the 1980s, the 
MS Society was the longest established patient association that advocated research on 
cannabis. The picture was complex. The shifting opinions of the MS Society towards 
cannabis reflected wider debates in medico-scientific and policy circles from the 
1960s. Founded in 1953 it became a highly successful organisation in part due to the 
advantages that chronic disease associations have with long-lived members and public 
support. By 2000 the MS Society had become the largest charity for MS in the UK with 
55,000 members, 35,000 of whom suffered from MS. It had become the major funder 
of medical research into MS in the UK with a funding commitment of more than eleven 
million pounds.22 The Society mingled lay and medical membership, and had its own 
research scientists and science advisers. It had two major aims: to support patients with 
MS and their families and to support research into the potential elimination of MS. 
Cannabis became of interest in the 1990s. MS policy was that if cannabinoid-based 
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medicine proved safe and effective in clinical trials then it should be made available to 
patients through the NHS. The Society stipulated that research should be vigorousl) 
pursued and that cannabis had to be judged according to similar criteria which applied 
to the assessment of any proposal for a new drug therapy and normal standards for 
quality, safety and efficacy. During the 1990s the Society became involved in funding 
a number of clinical trials. Its policy was not to recommend the use of herbal cannabis 
prior to clinical trials, though it did urge authorities to deal sympathetically with people 
who self-medicated with cannabis. 
The MS Trust 
The MS Trust was set up in 1993 by Jill Holt and Chris Jones both of whom had 
personal experience of MS. They had previously been involved with Action and 
Research into MS (ARMS) an organisation which had been active since 1974 to make 
applied research into MS a priority. ARMS closed in 1993 leaving a dearth of money 
for its research programme. Holt and Jones purchased the ARMS trading company and 
aimed to find the money to continue the research programme. They argued that applied 
research remained underfunded, information for the newly diagnosed was inadequate, 
the image ofMS remained poor and that NHS services were limited. A small charitable 
trust was established with two MS researchers, and financial guidance. The Trust aimed 
to provide information, education, patient support and research funding. Clinicians 
described the Trust as 'a breath of fresh air' in their willingness to fund, though their 
funding ability was very limited.23 The MS Trust was more research driven than the MS 
Society but within this cannabis was merely one aspect of research. 
The Alliance for Cannabis Therapeutics, (ACT) 
In contrast to the MS Society and the MS Trust, the AIliance for Cannabis Therapeutics 
was created purely for the purpose to campaign for access to, and research into 
cannabis, mainly on MS but also for other applications. ACT was set up by Clare 
Hodges (Claire Brice), an MS sufferer, in 1992 at a time when many advocacy groups 
were developingY ACT was based on the US AIliance for Cannabis Therapeutics, 
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which had a long established tradition of campaigns for medical access. ACT in the 
UK was created as a single-issue, single activity, self-help group for medical cannabis 
users to campaign specifically for research into cannabis and access to it on the NHS. 
Hodges suffered from spasticity, loss of sensation, bladder problems, nausea and loss 
of appetite. Nine years of orthodox medicine had provided limited sustained relief and 
many unpleasant side-effects. After reading about the use of cannabis in the American 
Medical Journal she tried smoking cannabis and found that while it did not cure the 
problem, it alleviated some symptoms including bladder problems, pain, and sickness.25 
She remembered, 
As I was a middle-class mother of two young children I had a bit of problem 
obtaining cannabis ... eventually I found someone who helped me get some ... 
When I did try cannabis the physical relief was almost immediate . ... I was 
comfortable with my body for the first time in years. 26 
Wood has argued that patient associations are largely a middle class activity and Clare 
Hodges fitted into this mould, and this perhaps worked to her advantage and brought a 
not so respectable activity into a 'respectable' settingY She began to cultivate, smoke, 
and ingest herbal cannabis. With the introduction of nabilone she hoped to find a legal 
method of treatment, but instead found unpleasant side-effects, and that it failed to 
produce the beneficial effects of herbal cannabis. With the failure from the patient's 
perspective ofthe licit cannabis-based drug Hodges felt herself forced to revert to 
herbal cannabis. Her neurologist in 1992 put her in touch with others who were self-
medicating with herbal cannabis and they decided to form a group to campaign for more 
research and provide information to sufferers and the public about medical cannabis 
issues. Hodges explained her motivation. "Ifound out it was not just me ... so I raised 
awareness and let people know about it ... to let people know it helps. "28 Use of cannabis, 
however, posed problems from two points of view: first the threat of prosecution; and 
second a the lack of quality control and unknown dosage.29 
Since its formation, the ACT has aimed to encourage research into medical 
preparations of 'natural cannabis' and for these therapies to be made available on a 
doctor's prescription while research was ongoing. Hodges recalled later, 
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We are not campaigningfor the general legalization of cannabis. Indeed 
even if cannabis were legalized we would still be campaigning as we think 
seriously ill people should get their medication from their doctor and not 
have to provide itfor themselves. Similarly the objectives of the ACT would 
not necessitate cannabis being legalized. Preparations of cannabis could 
be available for medical use whilst still being illegal as is the case for 
diamorphine Iheroin. 30 
ACT argued that herbal cannabis had a long usage, was safe and available. It went a 
step further than the MS Society and argued that patients needed immediate relief not 
help at some undefined point in the future. In the interim ACT demanded that herbal 
cannabis should be made available to patients. These three societies each with different 
backgrounds and variant aims nonetheless significantly contributed to the process of 
re-medicalization. 
An important aspect of these patient associations lay in their ability to provide 
an interface between the patient view and researchers, thus drawing the lay and 
professional spheres closer together. Not all self-help patient associations were 
involved in educating and interacting with heath professionals but these were important 
activities of the patient groups associated with cannabis and MS.3! What was more 
unusual was the existence of the patient experience and knowledge of a botanical 
substance which they felt could help but which was illegal. The groups were able to 
filter these experiences through to the science field. ACT developed close connections 
with scientists and the medical profession and was able to provide laboratory scientists 
with access to patient perspectives. Clare Hodges described the membership of ACT as 
a loose affiliation of patients, including those with spinal injuries and cancer, doctors, 
hospital consultants, and health workers.32 Its role as an interface between patients 
and doctors meant that it helped research to take place. For the scientists working 
on cannabis-based products the patient association provided a ready pool of patients, 
many of whom were actively interested in the research. ACT worked with Pertwee 
at Aberdeen University on a project on the perceived effects of smoked cannabis on 
patients with MS. ACT assisted by distributing a questionnaire and providing access 
to users. The links to the US ACT provided access to American users.33 Similarly 
interactions were initiated with clinicians. Hodges developed links with an anaesthetist 
187 
Dr William Notcutt who was carrying out work on nabilone for pain. Through this 
relationship Hodges was able to obtain nabilone on a named-patient basis licitly rather 
than having to resort to the black market. Not many doctors were able or willing to 
prescribe nabilone on a named-patient basis and most patients were left to their own 
devices and in some cases turned to herbal cannabis. Hodges explained some of the 
difficulties involved in sourcing cannabis. 
You can't get it from the doctor. There are only a handful of doctors that 
can do it. Others get it illegally from the black market but people are 
scared. They wrote to ACT asking where can we get it? Most people just 
don't know where to get cannabis. 34 
Patient-doctor relationships provided a conduit for the patient perspective to reach 
the medical establishment. This was particular important over the issue of the 
unsatisfactory nature of nabilone in comparison to herbal cannabis. Hodges described 
her attempt to move to the licit nabilone and stay off the illicit cannabis. 
I had just been prescribed nabilone ... .J took this for four nights but it made 
me confused and clumsy. I persevered hoping it might be a substitute, but it 
wasn't. 35 
The evidence base for the use of cannabis in MS was lacking, as was research into the 
most effective form of cananbis. For both patients and clinicians it became clear that 
research was needed on other cannabis-based products most notably herbal extracts 
rather than a single chemical entity like nabilone. 
Interactions between laboratory scientists and the MS Society partially contributed 
to a breakthrough in scientific knowledge about the role cannabis could play in MS 
treatment. By the late 1990s, the MS Society had become interested in cannabis. This 
was important because the Society was an influential player. The Society described its 
role, 
One of the MS Society 5 main objectives is to promote andfund !vIS research. 
We fund scientific and applied research in order to make the maximum impact 
on MS, and the quality of life of people affected by i\lS. Our fundraisers work 
hard to pump around two million pounds into research each year. 36 
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In this search for treatments cannabis was merely one treatment option for the ~lS 
Society and one with serious implications. 
The Society placed emphasis on a respectable image and this image needed to 
be maintained especially if it was to deal with an illicit substance. This was achieved 
by maintaining a disassociation from legalization campaigns or demands for access to 
cannabis prior to clinical trials. Dr Layward, an immunologist at the MS Society, who 
had moved from academia to the charity sector and who had previously worked at the 
AIDS charity, the Terrence Higgins Trust, explained some of the initial concerns about 
an involvement with cannabis. 
Legalize Cannabis was the only strongly campaigning group at the time 
and we did not want be involved in the issue of legalization of an illegal 
substance. 37 
Legalization campaigns were re-emerging in the 1990s.38 The MS Society was keen 
not to be associated with this type of campaigning. It had been cautious about cannabis 
research and refused to fund trials in the early 1990s.39 The history of the MS Society 
provides some clues into its attitudes towards cannabis and its initial reluctance to be 
involved in related research. The early history of the Society showed that the Society's 
initial remit did not cover the sponsorship of scientific research mainly because of the 
antipathy of the medical establishment towards lay involvement.4o By the late 1950s, 
the Society had changed its position on funding basic science research, but this changed 
focus led to disagreements over the allocation of scarce resources. The dilemma was 
that on the one hand, the Society called for patience in waiting for effective therapies 
implying they were imminent, but on the other hand indicated that there was much 
research still to be carried out. Attention was directed into understanding the disease, 
finding a cure and the elimination of the condition rather than treatment and care. But 
with no cure in sight, the Society was forced to take a greater interest in the alleviation 
of symptoms. Their image was crucial to their choice and timing of funding options. 
Writers on the early history of the Society have argued that it was the social background 
of the Society's founding members and, in particular, its ties to neurology that made 
respectability especially important to the MS Society.41 The Society's network and 
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support base meant that it was very much positioned on the side of orthodox medicine. 
What is seen as orthodox or respectable however is part of the wider debate over 
orthodox versus alternative medicine. The Society placed great importance in its 
early days upon remaining orthodox and ignoring fringe medicine and the need to be 
against 'new, untried methods of treatment. '42 It received a constant stream of letters 
on alternative treatments and the Society saw MS as a disease that attracted a great deal 
of quackery and many extravagant claims of therapies. In relation to MS research and 
treatments 'being respectable meant a great deal. '43 
The Society's membership upset by the lack of available effective treatments 
started to look for alternatives. Cannabis research whilst by no means mainstream had 
become more acceptable. As time went on cannabis-based therapies could no longer be 
ignored and in the 1990s a new Chief Executive, Peter Cardy, initiated a review of the 
attitudes of the membership. An ex-MS Society scientist remembered his interest. 
He took it upon himself to go out and talk to MS people a lot before he 
decided what to do '" .he said this is what I'm hearing. 44 
Cardy asked Dr Lorna Layward to investigate the potential of cannabis. She explained 
later her initial response to Cardy's request, 
Talking to people with MS is where this story starts. One of the early things 
the Chief Executive said to me was, "Is there anything in this cannabis 
story?" and I was incredibly reluctant ..... my perception was that I did 
not want to get involved in legalization but wanted to focus on scientific 
evidence. 45 
But patient perspectives began to cut across these concerns. Dr Layward described the 
impact ofthe patient experience on her own attitudes after carrying out a survey on MS 
Society members and their reactions to cannabis, 'It is only when I started to speak to 
people with MS that I started to change my mind. '46 Layward never forgot one patient's 
response, 
I remember distinctly a comment ..... He/she said, 'Bugger research, one puff 
and I can straighten my leg. '47 
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With these patient voices filtering through to the leadership of the Society, the Society 
began to take a different approach to cannabis.48 
The Society applied pressure to shift anecdotal evidence onto a scientific footing. 
The discovery of the ECRS had given legitimacy to anecdotal reports of cannabis' 
medical usage but proof was needed of its value in specific applications such as MS. 
Layward believed that evidence of cannabis' effect on MS was required to provide the 
justification for clinical trials. When investigating existent research on cannabis and 
MS she made links with Pertwee, and Dr David Baker at the Institute of Neurology 
who though not working on cannabis, was working on long-term tolerization in animal 
models.49 Layward asked Dr Baker to carry out systematic research on the effects of 
cannabis on MS and she put him in touch with Pertwee.50 Layward described how a 
new project came about. 
If we were going to do anything about this in terms of clinical trials, we 
needed some sort of evidence. . ... On the back of a fag packet in a pub over 
a drink we cooked this Up.51 
It took about six to seven months to develop equipment to measure the effect but the 
project results showed cannabis had a significant impact on tremors in mice, similar 
to those experienced in MS.52 The experiment revealed the validity of the patient 
experience. Layward described the impact, 
It showedfor the first time objectively that cannabinoids could do what 
people with MS were telling us. What we had demonstrated was .... 'one 
puff and I can straighten my leg '.53 
The results were fed through to emerging discussion on potential clinical trials and were 
published later on the front page of Nature and this had a worldwide impact and gained 
much positive reportage in the media in the UK.54 This research was important because 
as Baker recalled it 'started to put biology behind the patient experience. >55 Laboratory 
research was a start but for patients to benefit changes had proven in the clinic. 
Patient need led to different approaches to the situation by the different societies. 
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The MS Society was keen to push for clinical trials to go ahead as the only method for 
getting cannabis-based drugs to their members. ACT was keen on clinical trials but 
recognised that there would be a huge time lag from clinical trials to the development 
of a medicine and it preferred to pressure for access to herbal cannabis in the interim. 
Hodges described the pressure for faster solutions. 
We want to see the problem addressed now as well as the research. You can 
do the two in conjunction. 56 
The MS Society explained the desire for a more cautious approach in 1997. 
Any proposal for therapy has to conform to stringent medical standards .... 
Unless and until such trials are undertaken and a therapeutic benefit is 
demonstrated the MS SOCiety would not support the prescription of cannabis 
for people with MS. 57 
With their concern for the long term, the MS Society echoed Paton's precautionary 
outlook, and argued that since MS was a long-term illness any drug had to be effective 
and safe over the long-term. In not advocating the use of cannabis, and not advocating 
any change to the law surrounding cannabis, they perceived themselves able to maintain 
their respectability and therefore their influence on the policy and medical environment. 
Clinical trials therefore became of critical importance for patient associations and 
especially the MS Society. Layward described the importance of trials, 
We had been aware of the anecdotal evidence of the benefits of cannabis for 
some time, but strongly believed that trials were essential to rigorously test 
the effectiveness of the drug and to develop safe and easy methods of use. 58 
Key to the initiation of the trials was the relationship between the MS Society and Tony 
Moffat, the Chief Scientist at the Royal Pharmaceutical Society. Layward explained the 
convergence of interest in clinical trials by patient associations and professional bodies. 
We both had the same sort of viewpoint. Not interested in legali::ation '" 
what 1I'e ll'ere interested in, was there any medicinal use? That marriage ... 
that relationship was absolutely pivotal to making all of this happen. 59 
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The MS Society joined forces with the Royal Pharmaceutical Society and the BMA and, 
as is discussed in chapter seven, jointly organised an influential conference in 1997 for 
scientists, patients, neurologists and industry representatives on the subject of clinical 
trials. 60 Nervous ofthe press response, and the risk to the reputation of the Society, 
the Society was still wary, but it seemed that the time was right for trials to proceed. 
Layward described the coalesce of factors that allowed research to go forward. 
We were pushing a time when there was a lot of resistance but over the 
coming year the resistance fell away. There was the discovery of the 
cannabis receptor system, MS and HIV patients talking about cannabis in 
terms of making them feel better ... there was a clamouring from different 
groups of people and anaesthetists were interested in pain relief61 
The symposium was critical in that it drew scientists, patients and most importantly 
funders together and focused their attention in the provision of protocols for trials on 
MS and pain. Importantly, it drew industry attention. 
ACT, in particular, actively sought out the pharmaceutical industry in an attempt 
to encourage the production of legal of cannabis therapies. It contacted several 
companies to no avail as cannabis therapies were seen as too controversial and not 
worth the investment. Hodges recalled, 
One company which I cannot name ... took it quite a long way ... and told me 
in confidence that it was too controversial, the scheduling was too difficult 
it just was not worth the investment. They took it seriously but they did not 
want to do it ..... at the Royal Pharmaceutical Society last summer I met a 
man who is an ex-chairman of a pharmaceutical company and he had tried 
to get a Home Office licence and hadpreliminary discussions with themfour 
years ago and he had been advised not to go ahead. Recently, I approached 
him and suggested that he had another go and he tried again. 62 
The meetings organised by the Royal Pharmaceutical Society were important because 
they allowed for interactions with Geoffrey Guy and other stakeholders. But for 
industry involvement to go forward it required the approval of the Home Office and the 
patient groups were important in placing pressure on government. 
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The MS Society and ACT sought to bring the patient perspective closer to 
policy makers. They did this in a mixture of ways. They developed relationships \\ ith 
professional bodies including the British Medical Association, (BMA). As discussed 
in chapter seven, influential reports on therapeutic cannabis such as that by the BMA 
that emerged in the 1990s absorbed evidence given by the ACT and the MS Society.63 
Such reports by professional bodies contributed to a change in the policy environment 
around cannabis that was taking place in 1997. ACT was especially effective at keeping 
the issue high on everyone's agenda through the media. In commenting on the role and 
significance of ACT, Layward reflected on the importance of this type of activism in 
applying pressure for change. 
We couldn't get anywhere without those sorts of groups for keeping the 
agenda high, for speaking to the press. 64 
Indeed press responses were largely positive towards medical cannabis use and it was 
a popular human interest topic, helping to keep the issue on the agenda.65 Hodges 
described the reaction to her first newspaper article on cannabis and her advocacy. 
Three hundred individuals wrote in about how much they had benefited 
from it. All grist to the mill, wasn 'tjust me. Doesn't take longfor it to get 
around.. The press very much like running stories about it because most 
people in the press use it and they liked stories like that. 66 
This publicity highlighted the problems of prosecuting patients for trying to alleviate 
their symptoms and increased public support for their cause. 
Links between activist groups and the policy community were important during 
this period.67 Whilst the MS groups were by no means so closely associated with a 
'network of influence' as organisations like Action on Smoking and Health (ASH) 
they did make a contribution to the policy environment. ACT, in particular, began 
to lobby government. It organised delegations which included MPs, scientists and 
clinicians, to the Department of Health in 1994 and 1997 and these stressed the need 
for medical preparations of herbal cannabis to be made available for research and 
they argued that in the interim that prescription on a named-patient basis should be 
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available.68 Hodges courted the support of sympathetic MPs such as Paul Flynn and 
MS groups were important in the All Party Parliamentary Group for MS. The group 
was made up ofMPs and peers with a specific interest in MS, and was established in 
1997 to promote the interests of people affected by MS. This interaction at the heart 
of government enabled the patient associations to raise the profile of the MS issue and, 
within that, the need for clinical trials.69 
Patient groups also contributed to parliamentary expert committees. The MS 
Society and ACT were the only two self-help groups invited to present evidence for 
the House of Lords Committee on therapeutic cannabis during the late 1990s. Their 
evidence provided the opportunity to place the patient perspective before the House of 
Lords and generate more public awareness of the issues. They raised concerns over 
the lack of treatments, the importance of clinical trials and the form of the drug to be 
trialled.70 ACT campaigned additionally for the need for access to cannabis whilst trials 
were developed. The MS Society through the evidence of Layward and Mrs Carlyle, 
the information and education manager, pressured for the development of clinical 
trials, raising awareness ofthe nature ofMS and its potential impact on clinical trial 
evidence. Whilst they accepted many of the points made by Clare Hodges they made 
it clear they were not prepared to accept anecdotal evidence, nor to push for interim 
access to herbal cannabis. They argued that clinical trial evidence for the efficacy of the 
new beta-interferon treatment was sufficient to justifY prescription and in the absence 
of comparative evidence for cannabis the Society could not support its use in clinical 
practice. However, they emphasised it was 'essential that further research is taken' 
and steadfastly pressed the case for cl inical trials. However, they were concerned that 
clinical trials, because of the nature of the disease, and the substance being tested, would 
pose complications. A large section of their evidence to the House of Lords Committee 
was given over to the methodology of potential clinical trials, predicting many of the 
problems that emerged later when trials were carried out. In contrast to the initial policy 
of the Society, they argued that disincentives to research were financial and attitudinal 
rather than legal and that they were happy to fund research to some degree.7l 
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Activists in giving evidence to the expert committees provided an effective 
conduit between grass-roots advocacy, practical know ledge of using the drugs, and 
policy-makers and lawmakers and helped to shape the form of the debate in a \\a\ 
that had not occurred in the closed expert discussions of the 1970s. Differences of 
opinion existed on the importance of the House of Lords Report in this process. Whilst 
some such as Philip Robson have argued that it was critical in allowing research to go 
forward,72 Layward argued that the trials would have gone ahead without the report and 
rather the report reflected the existent groundswell. 
We carried on anyway ... they came up with what we were doing anyway .... 
it was because there was a groundswell. Without it, it still would have 
happened. 73 
The ability of activist groups to potentially provide funding for clinical trials 
was particularly attractive to GW Pharmaceuticals as a newly established company 
when no government funds were forthcoming. Geoffrey Guy, the founder of GW 
Pharmaceuticals appeared hopeful when he gave evidence to the House of Lords 
Committee in 1997. 
I think also that the new research here, which is very much patient demand 
led will be accompanied by funding for research programmes ... the MS 
Society has already said they would support clinical trials . ... As yet there 
seems no prospect of any funding from government. 74 
Though no funding came to industry as the MS Society ploughed money into the proof 
of principle trials, their advocacy was significant in influencing industry research in the 
direction of MS. Robson ofGW explained the impact. 
MS is a major awareness group in this country. So, at the beginning, a 
focus on MS was sensible. 75 
It was also sensible for marketing reasons. Paton had previously argued that cannabis-
based medicines did not compete favourably with other available medicines but in MS 
it was hoped that 'CBME (cannabis-based medicine extract) would not mere~\' be equal 
in efficacy to standard drugs but rather offer tangible advantages in a difficult clinical 
context. '76 
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Activists with so much staked on the outcome of research were keen to influence 
its direction. One area of contention was the debate over the form of cannabis to be 
used, for instance, the use of herbal cannabis or drugs derived from single, active 
synthetic principles. Nabilone had been licensed for treatment in cancer chemotherapy 
but it could be prescribed for MS patients. MS patients with the experience of self-
treating with herbal cannabis found, as had been the case earlier with HIV/AIDS 
patients, that the synthetic THC legal drugs appeared inferior in terms of their efficacy 
and side-effects. This experience was noted in the House of Lords Report. 
Nabilone does not seem to be an effective substitute for cannabis used 
therapeutically ... . all those who have taken both nabilone and natura! 
cannabis say that cannabis is more effective and easier to control. 77 
ACT, in particular, campaigned for patient use and the study of herbal cannabis.78 
The MS Society, too, had concerns over the form of cannabis trialled. The Society 
argued that there might be many useful cannabinoids within cannabis or an interplay 
between cannabinoids. They pressured for a trial on herbal cannabis, and another on 
specific cannabinoids. They were keen to look for cannabinoids which lacked the 
psychoactive element. In its presentation to the House of Lords committee the Society 
argued for different arms to the trials. 
While a single cannabinoid which can be produced to a consistent standard 
may seem attractive, with a least sixty six cannabinoids to choose from this 
may be impractical. In addition there may be many individual cannabinoids 
which are beneficial with a possibility that an interplay between 
cannabinoids which possess a beneficial effect. Trials could take place in 
two phases. The first phase could consist of a trial of the whole cannabis ..... 
this would allow some results to become available at a reasonably early 
stage. The next phase could consist of trials of special compounds. 79 
Pressure originating from the practical knowledge and experience of user activists led to 
questions over the effectiveness of single extracts like nabilone and forced 
re-consideration of herbal cannabis. 
Patient associations were involved in discussions over the route of administration. 
Members of the MS Society, in a survey had expressed concern over the effect of 
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smoking on their general health and the Society doubted that any drug administered via 
smoking was likely to pass through the regulatory mechanisms. In this they concurred 
with established opinion. ACT offered a different perspective. 
With a disease so unpredictable, self-education seems more helpful than 
treatment with a regular dose of afixed strength ... People gain from treating 
themselves ... this probably explains why most people choose to smoke 
cannabis .... The advantages in taking cannabis via the lungs is that the 
effects are much quicker and therefore easier to regulate. 80 
Smoked cannabis was not however one of the ACT's demands and the scientific 
community was clearly against trialling any form of smoking. But while patient groups 
waited for trials to go ahead, they continued to campaign for compassionate treatment of 
cannabis users. An MS Society spokesman was reported by the BBC as pressuring for 
the end of criminalisation of patients who used cannabis. 
We want to see trials advance as quickly as possible ... in the meantime the 
reality is that there are people who suffer severe disability and painful 
symptoms for whom the only way of easing the pain is smoking or eating 
cannabis. 81 
Activists could claim some credit for the large-scale clinical trials that took 
place on cannabis for MS after 2000.82 Chapter eight discusses the development and 
outcomes of the clinical trials in-depth but with specific reference to advocacy, activists 
faced some disappointments with the results ofthe major clinical trials that emerged. In 
essence the results of the trials were inconclusive and failed to produce the evidence-
based proofs sought by the clinicians. Yet the majority of patients taking part appeared 
to find benefits to their lifestyles. The problem, in part, centred on the method of 
administration, which from the patient perspective, was an inferior model. Dr Layward 
suggested later that the trials were compromised in some sense from the start, 'The 
protocols got compromised so much. What, you would like to do, is often what you can I 
do in patients. '83 
Unusually patients had practical experience of alternative methods. As it was not 
possible to test these, investigations took place on more 'acceptable' delivery methods 
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but from the patient perspective these seemed to lack the effectiveness of smoked 
cannabis. Patient associations questioned the nature of evidence and the role of the 
patient perspective within clinical trials assessment when clinical trial results were 
published in 2003.84 Researchers found that cannabis had no significant effect on 
the key symptom measurement of muscle spasticity as measured by an independent 
assessment of clinical spasticity known as the Ashworth scale. The MS Society raised 
the question of how patient perspectives were weighed as evidence, and they argued that 
something of a small statistical value could radically change a patient's life. 
The results of this large trial show the difficulty in assessing treatments 
for a variable andfluctuating condition like MS Current methods of 
measurement do not always detect significant benefits patients may feel. 
Around two-thirds of those on the cannabis-derived medicines felt their 
spasticity was improved by them, even though that could not be shown 
clinically. More people on the drugs found relief from other very distressing 
symptoms like pain, spasm and sleeping problems than those taking a 
placebo. These improvements to quality of life can make a significant 
difference to people with MS, whose choice of treatments is very limited 85 
It was clearly feared that the patient perspective was lost in the data. 
The MS Society was particularly keen to bring the patient perspective to the 
notice of medical advisory bodies. The MS Society, along with other stakeholders 
including the manufacturers of the drugs under trial and health professionals' 
organizations, made submissions to the National Institute for Health and Clinical 
Excellence (NICE). NICE was the independent organisation responsible for providing 
national guidance on the promotion of good health and the prevention and treatment of 
ill health through health technologies. The MS Society urged NICE not to take a too 
narrow a view of the subject. 
We urge NICE to take full account of the views of people affected by MS. 
People with MS callfor members of NICE to shadow them for a day: to 
'walk in their shoes '. Only with this information do they feel that it is 
possible to understand the true value of these products. 86 
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In particular the MS Society highlighted concerns over existent outcome measures. 
Even if the trials show that the overall clinical benefits of the drug are small 
the impact this may have on quality of life for individuals should not be 
underestimated. We hope the trials will have data from the use of robust 
quality of life measures that have been developed and validated by people 
with MS. Clinically based outcome measures alone may not be sensitive 
enough to detect the changes that are important to people with MS. 87 
They were keen for NI CE to consider individual rather than universal benefits. 
The data may be 'muddied' by the variability in people s experience 
of symptoms of MS and the normal variation in people s response to 
cannabinoids. It is likely that some people will receive symptom relief, 
although not everyone will benefit. We are concerned that these significant 
improvements should not be 'lost' in the background noise. 88 
The Society advanced their case on more than medical grounds. They pushed the 
legality issue and argued that the production of a legal medicine would provide a clear 
split between recreational and medical use and remove the risk of self-treating patients 
becoming entangled in the criminal justice system. 
We are aware that some people with MS are already benefitingfrom the 
use of cannabis, but by beingforced to engage in illegal activity are 
experiencing great distress andfear. People have no choice but to put their 
health, personal safety and careers at risk in order to obtain some relief 
of their symptoms. Others deny themselves symptom relief because they 
fear prosecution. Offering cannabinoid-based treatments via the NHS will 
provide a much valued opportunity to use the drug in a safe and trusted 
environment. 89 
The submission highlighted the continued connection between medical use and 
criminalization, and the implication that this held for some patients: that the government 
position left them no option other than to deal with drug dealers. 
And that s what the Government are making you do ... deal with drug dealers 
who could be ripping you off or anything. 90 
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It highlighted some patients' perceptions that discussion on cannabis medicines \\as 
centred on political not scientific agendas. 
People with MS are concerned that the political issues around recreational 
use of cannabis may unfairly influence a decision about cannabinoid-based 
medicines. If a plant was discovered in the rainforest, then they probably 
would be called a miracle cure you know. It wouldn i have all this political 
baggage behind it. 91 
The patient perspective had helped take the process of re-medicalization so far. It had 
lobbied and pressured for research and access. Clinical trials had taken place but there 
remained a long time lag before any change would be seen from the patient perspective. 
Patient activism began to tail off after the turn of the millennium. ACT, for 
instance, began to cut back on its campaigning. Hodges explained the problems of 
advocacy faced by MS patients. 
People with MS are weary and ill and haven i got the energy to campaign. 
People with AIDS are often very active and angry and young and otherwise 
healthy. With MS you find out quite young that that s it and you lose the will 
to fight for yourself There s not much you can do about it. 92 
The MS Society had a structured organisation, including expert scientists able to 
campaign on behalf of its members, but it had other interests to campaign for especially 
whilst clinical trials, both proof of principle and industrial, were ongoing. Whilst 
Sativex made its way through the regulatory process it was made available on a named-
patient basis. At conferences, patients appeared to give positive reports of Sativex, 
but to what extent were these 'tame patients'?93 In 2009, at a witness seminar on 
the medical use of cannabis, the experienced activist, Hodges, queried the long-term 
side effects of cannabis and the impact ofSativex. Was longer term lay knowledge 
leading to an alteration in the patient perspective? It remains open as to what impact 
the introduction of Sativex will have on medical cannabis activism. As far as the 
membership of these societies was concerned perhaps not much had changed but 
through their lay knowledge and advocacy the process of re-medicalization had been 
taken forward. 
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Conclusion 
Lay knowledge and patient advocacy was critical in the process of re-medicalization. 
Medical advocacy of cannabis by patients became increasingly significant, altering both 
its own approach, and contributing to the changing direction of re-medicalisation. 
In the 1960s and 1970s pressure groups campaigned for the legalization of cannabis 
as part of a lifestyle choice. As part of their arguments these pressure groups raised 
the issue of medical cannabis which had arisen through the wider use of cannabis 
recreation ally, but with their main focus on the politically contentious issue of 
legalization for recreational use they had limited policy impact. As lay knowledge 
around cannabis' medical properties increased advocacy based purely on medical 
arguments became prominent especially in the US in the late 1970s and early 1980s. 
This resulted in the successful legal argument of medical necessity for the use of 
cannabis and the original development of patient associations for glaucoma and 
the initial development of compassionate access. These campaigns combined with 
developments in the scientific field provided much greater legitimacy for cannabis' 
medical use. The AIDS crisis then propelled the issue forward and achieved some 
changes with, for example, the expansion of compassionate access programmes but it 
did not lead to lasting changes in policy. These arguments filtered through to the UK, 
where they stimulated the development of equivalent UK Societies, but in the 1990s 
pressure emerged from a different quarter. In the UK the MS patient associations, 
in particular ACT (UK) and the MS Society, became examples of very active patient 
associations which interlinked with scientific and policy spheres. These societies had 
some differences of opinion and some different approaches but their combined advocacy 
provided a respectable face to medical cannabis use. Patients had limited power in 
their own right, their power lay in their knowledge and their ability to place pressure 
on other actors in the re-medicalization process especially after their experience had 
been validated to some extent by the discovery of cannabis' mode of action. They were 
successful in this and became interlinked and inseparable from the other main actors 
including, industry, media and clinicians, professional bodies, and government. Some 
patients had firsthand experience of the herbal product and or the derivatives of cannabis 
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and so they were able to have an impact upon not only the initiation of research but also 
its direction. They were the ones that brought herbal cannabis to the fore demanding 
a product much more closely related to their own experience than the synthetic single 
active principles which had previously made it to market. They also affected the 
policy environment, especially as they pulled cannabis use into a more 'respectable' 
framework and by keeping the issue in the minds of the press and public they created 
a groundswell of support for the issue. Through lobbying, parliamentary discussions 
and submissions to key reports of the period they kept the issue high on the political 
and scientific agenda and encouraged the shift from anecdotal lay knowledge to the 
facilitation of evidence-based knowledge with the initiation and development of clinical 
trials, both proof of principle and industrial. Funding was ploughed into the arena and 
fears over the loss of the patient perspective in clinical trials led to the reinvestigation of 
clinical trial methodology and the development of more subtle outcome measures which 
might lead to successful outcomes in future trials. 
Though lay knowledge and advocacy had an important impact on the process of 
re-medicalization how much changed from the patient perspective is limited. The 
production of a licit cannabis-based drug has often appeared to be almost within reach 
but never quite there. The following chapters consider the emergence of clinical trials 
and the process which took cannabis-based drugs through the licensing procedures. 
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Chapter Seven 
Establishing therapeutic cannabis: The role of expert advice 
in the process of the re-medicalization of cannabis, 1997-2005 
In analyzing the process of re-medicalization of cannabis this thesis has examined 
the science-policy interchange through a study of governmental expert committees 
and reports of professional bodies. Whilst an earlier chapter focused on the private 
committee discussions of the ACMD in the 1970s and 1980s this chapter explores 
the public reports on therapeutic cannabis that emerged from 1997 onwards. These 
reports ofthe 1990s focused specifically on the therapeutic uses of cannabis. They 
drew clear distinctions between the role of cannabis as a medicine and concerns over 
its recreational use. The reports contributed significantly to the legitimatization of 
medical cannabis and to a shift in attitude towards cannabis, which was downgraded in 
2004 from Class B to Class C under the Misuse of Drugs Act 1971. The chapter begins 
with a look at the initiation and impact of the British Medical Association's (SMA) 
report on therapeutic cannabis in 1997 that cited unmet medical need that could be met 
by derivatives of cannabis. The House of Lords Science and Technology Committee 
report followed a year later and called for research on herbal cannabis as well as its 
derivatives. These reports pressed for clinical trials, industry involvement and a re-
consideration of policy on cannabis. This chapter overlaps in time with chapters five 
and six but demonstrates how industrial interests and patient concerns discussed in those 
chapters were turned to put to practical effect. The chapter continues by looking at how 
pressure mounted for medical use and the rescheduling of cannabis, via the Runciman 
Report of 1999 and the House of Lords follow-up report of 200 1. The chapter 
concludes with the decision to downgrade cannabis from Class S to a Class C drug. 
Cannabis in Context: Changing attitudes to cannabis in the 1990s 
Before analyzing the expert advice ofthis later period it is worth considering the wider 
environment surrounding cannabis in the late 1990s. In the 1990s 'cautioning' \\35 
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taking over from prosecution and the concept of' harm reduction' \vas given greater 
acknowledgement in policy. I The government deemed that public opinion \\as more 
tolerant towards cannabis. Questions in the House of Commons increased over the 
issue of therapeutic cannabis for sufferers ofMS and cancer. MPs such as Paul Flynn, 
MP for Newport West, and a former industrial chemist, pressured in parliament for 
legal medical use of cannabis and delegations were received by government on the 
therapeutic use of cannabis. Emphasis was placed onto the outcomes of the clinical 
trials before any modification to the MDA would be considered.2 The Department of 
Health at the request of the ACMD had commissioned a series of unpublished literature 
reviews on cannabis in 1996.3 One on the clinical and pharmaceutical aspects of 
cannabis was by Professor Heather Ashton, Professor of Clinical Psychopharmacology 
at the University of Newcastle upon Tyne. A second on the psychological and 
psychiatric aspects was written by Dr Andrew Johns, from the Institute of Psychiatry. 
The third on the therapeutic aspects of cannabis and cannabinoids was produced by 
Dr Phillip Robson, Consultant Psychiatrist and Senior Clinical Lecturer, at Oxford 
University who went on to become Medical Director for GW Pharmaceuticals. 4 Paul 
Flynn, who had campaigned for access to cannabis for medical reasons, announced his 
intention to ask the All-Party Drugs Misuse Group to back new research to establish 
the risks and benefits of cannabis with the goal of directing parliamentary opinion in 
favour of reform. 1997 marked a watershed for cannabis as a therapeutic. Initially, the 
incoming New Labour government wished to appear to take a tough stance on the drugs 
issue, and appointed a US style 'Drugs Tsar' Keith Hellawell, a former chief constable 
of West Yorkshire and a liberal deputy, Mike Trace, formerly of the Rehabilitation 
for Addicted Prisoners' Trust. The incoming Home Secretary, Jack Straw, appeared 
adamantly opposed to cannabis decriminalization. But pressure was mounting for a 
re-evaluation of the situation. Popular support grew for decriminalization and public 
figures such Paul McCartney, Richard Branson, and Anita Roddick backed a change 
in status. In more liberal sections of the media, cannabis and its legalization was 
viewed positively. The Independent on Sunday, under the editorship of Rosie Boycott 
launched the Decriminalise Cannabis Campaign, in September 1997 and declared that 
the campaign would continue, 'until the law is changed and possession of marijuana 
for personal use is no longer an offence.'5 The medical use of cannabis focused 
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prominently and the paper reported that an anonymous poll taken of MPs revealed that 
70 percent said that there was a case for allowing doctors the right to prescribe cannabis 
for medical purposes.6 Senior figures within the legal system called for are-opening 
of the debate. The Lord Chief Justice, Lord Bingham, announced his support for open 
debate on the issue of legalization of cannabis in October 1997 and his comments were 
widely reported in the press. Some government members began to indicate a softer line. 
The Health Secretary, Frank Dobson, reportedly said that he would consider making 
medical cannabis legal, through a doctor's prescription, for sufferers of illnesses such as 
multiple sclerosis. In 1998, a ten year drug strategy was launched by government \vhich 
argued that government resources should focus on drugs that caused the most harm such 
as heroin and cocaine.7 
International agencies which had been more noted for their hostile approach to 
cannabis began to moderate their views to therapeutic cannabis in the 1990s. The WHO 
had been under pressure to review the literature on the health consequences of cannabis 
since the 1980s. It had established an Expert Group on Cannabis in 1993 and in 
December 1997 released the report, Cannabis: health perspective and research agenda 
aimed at policy-makers, and others concerned with public health.s The report included 
a section on the therapeutic use of cannabis. It recognized that the role of derivatives 
had been established in the late 1970s and early 1980s and this acceptance began to 
impact on attitudes to herbal cannabis. Whilst not enthusiastic, the WHO considered 
what issues had to be overcome in order to study herbal cannabis. 
The therapeutic uses ofTHC ... have led to discussion about the therapeutic 
potential of cannabis itself .. To explore possible therapeutic uses ... several 
scientific issues need to be considered ... the standardization of cannabis 
preparations ... the large number of patients which would be needed to 
study the comparative efficacy of smoking cannabis compared with other 
cannabinoids and other therapeutic agents, and the possibility of using 
alternative delivery systems which could avoid cannabis smoking. 9 
But the WHO remained concerned over the broader implications for drug control polk) 
and possible adverse effects of cannabis, particularly mental health, but these were 
not considered to outweigh potential benefits and the report called for further research 
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both in the laboratory and in the clinic.lO The report received more pUblicity than had 
been expected as it turned out to be rather controversial, not for what was included. 
but for what was left out. Reports emerged in the media in 1998 that evidence had 
been suppressed after pressure was placed on the WHO by the UN International Drug 
Control Programme, which had been created in 1990 to improve the efficiency of the 
UN's drug control structure. ll The material in question related to comparisons between 
cannabis and legal substances like tobacco and alcohol. The WHO was forced to issue a 
rebuttal, 'there was therefore no attempt to hide any information and the decision not to 
include such a comparison in the final report was based on scientific judgment and had 
nothing to do with political pressure. '12 The controversy highlighted tensions between 
the agencies and the problems posed for drug control by cannabis. The comparison 
between cannabis and alcohol and tobacco that had gained ground since the 1970s now 
raised more controversy than any endorsement of therapeutic cannabis and the issue of 
relative harms between licit and illicit drugs would be re-visited in domestic debates in 
the first decade of the twenty-first century. 
In the UK concerns over the implementation of existing drug policy had 
increased: stricter control and an increased number of prosecutions seemed to have 
limited impact on use levels; the cost of policing was rising and the impact on civil 
liberties remained a concern. But fears also remained over the relationship between 
cannabis and mental health, especially in light of claims of increasing THC content, 
and the uncertainty of reactions to changes in policy by the media and publicY Driven 
by these concerns between 1997 and 2004 professional bodies and expert committees 
began to study cannabis therapeutics and looked at ways to take forward the therapeutic 
use of both derivatives and herbal cannabis and they considered the question of the 
placement of cannabis within the drug control mechanisms. 
The Role of Professional Bodies. The BMA Report: Therapeutic Uses 
of Cannabis 1997 
This Representative Body believes that certain additional cannabinoids 
should be legalizedfor wider medicinal use. I.! BMA Report 1997. 
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It was against this backdrop that the BMA released its ground-breaking report the 
Therapeutic Uses of Cannabis, and added an influential, professional medical voice 
to the debate. It endorsed medical applications for the constituents of cannabis and 
indicated that the law surrounding them should be modified. IS The BMA, the UK body 
which represented the medical profession had, from its inception in 1832, commented 
upon key issues and sought to influence public health legislation. 16 The Association 
had an Annual Representatives Meeting, (ARM) which allowed members to debate 
motions and a Board of Science and Education, which acted as the interface between 
the profession, the government and the public. The Board established special working 
parties and steering groups and convened outside experts for specific scientific projects 
which had led to the publication of reports on a wide range of public issues, from the 
environmental risks of pesticides to drink-driving. 17 
A resolution was adopted at the ARM in 1994 that requested the Board of Science 
and Education to look at the relative risks of drugs of addiction, and advise on drug 
misusers who wanted to break their habit, drug misusers who wished to continue, and 
arrangements that did, or could, exist in the future for supplying drugs to either category 
of drug user. A third point was added to the resolution to consider the benefits or 
otherwise of decriminalization or legalization of some, or all, controlled drugs. 18 Sarah 
Mars, who part authored the report, explained that this final request "got tacked on at 
the end by one of the doctors at the BMA s Annual Representative Meeting and it was 
agreed that they should do it. 19 Legalization or decriminalization was a controversial 
area for the BMA to step into. The final report explained that the BMA had refined part 
three ofthe resolution to refer only to controlled drugs in relation to their 'therapeutic 
use, by patients under medical supervision, for particular medical conditions. ' 
Cannabis was chosen because it was of 'wide public and professional interest. '20 In 
addition, cannabis therapeutics was noted as attracting increased interest in the light of 
the 'increasing acceptance of herbal medicine and 'natural' remedies. '21 The report 
was published as a separate policy document to the larger and less well known BT\IA 
report The Misuse of Drugs. 22 It was possibly a way to assuage the issue. Sarah Mars 
explained the reason for a separate report. 
, .. 
L 
The Secretariat did not want to touch that issue .... The BMA is a very 
cautious organisation. They got round it by saying they would look into the 
therapeutic uses of cannabis as afudgy way of tackling the last sectionY 
The BMA commissioned an external expert to produce a report on cannabis. 
Professor Roger Pertwee, with his experience on the pharmacology of cannabis 
was asked in the first instance. Pertwee discussed the pharmacology of cannabis 
including the newly discovered endocannabinoid receptor system and went on to 
make recommendations which included that patients with terminal illnesses should be 
allowed to smoke cannabis on compassionate grounds. The recommendations created 
controversy on several fronts: smoking; the use of a herbal product; and the potential 
press response.24 Such reports were usually sent to two external expert referees whose 
comments were returned to the Secretariat who produced the final report. Pertwee's 
report was sent to Professor Heather Ashton. Concerned over the possibility of 
increased potency of herbal cannabis she suggested numerous changes. In light of her 
comments and her previous work, it was decided to abandon Pertwee's report and invite 
Ashton to write a more extensive report.25 
Others involved in the BMA report included Professor Jack Howell who was chair of 
the Board of Science and Education, but who had little involvement in its production, 
Vivienne Nathanson, Head of Professional Resources and Research Group, and Dr 
David Morgan, Head of the Science Department. Most of the writing was Ashton's 
work with contributions on some points from Pertwee; Dr Tony Moffat of the 
Pharmaceutical Society; Professor Patrick Wall, a pain specialist; and Sarah Mars. 
Clare Hodges of the ACT contributed on the patient experience, and Dr William 
Nottcutt, an anaesthetist, on his experiments with nabilone on pain and MS. 
The report made eleven recommendations. In direct contrast to most previous 
reports on cannabis, it drew a distinction between medical use upon which the report 
was focused and recreational use of cannabis which was outside the remit. The 
impact of medical use on drug control policy was not considered relevant to their 
investigations.26 The BMA report turned the previous situation on its head. Instead of 
the medical use of cannabis interfering with drug control policy. drug control policy \\ as 
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interpreted as interfering with legitimate medical use. It argued that the WHO. should 
advise the eND to reschedule certain cannabinoids and that the Home Office should 
amend the Misuse of Drugs Act accordingly. It recognized that major amendments to 
intemationallegislation were unlikely and recommended, instead that the government 
consider changing the Misuse of Drugs Act to allow the prescription of cannabinoids to 
patients with particular medical conditions that were not adequately treated and that a 
central registry be kept of the patients to follow-up effects over the long-term. 
Selected areas of research were to be encouraged and the pharmaceutical industry 
was to be drawn into the process. 
Pharmaceutical companies should undertake basic laboratory investigation 
and develop novel, cannabinoids analogues, and research on clinical 
indications for medical perscription should undertaken, especially for anti-
emetics, MS spinal cord injury and spastic disorders and pain, epilep!'y, 
glaucoma, stroke and immunological effects. 27 
To alleviate hindrances and facilitate research the report indicated that the Regulations 
should be altered. 
The regulation of cannabis and cannabinoids should be flexible to allow 
such compounds to be researched without a MDA licence issued by the 
Home Office. 28 
The form and mode of delivery of cannabis remained important questions. The 
BMA placed emphasis on cannabinoids, rather than herbal products with unknown 
concentrations of cannabinoids.29 Sarah Mars explained the cautious approach. 
The culture of the BMA meant they felt more comfortable with that. They 
were uncomfortable with leafforms. It didn i seem scientific. 30 
The herbal product was not considered as it was the choice of recreational drug users 
and nor was the use of a 'leaf' or herbal forms considered acceptable within the conte\.t 
of mainstream medicine. 
Critically, largely independent interests were drawn closer together with the aim 
of achieving a cannabis-based medicine. The BMA report helped to stimulate this 
process by urging all stakeholders to work together to develop clinical trials. 
The Clinical Cannabinoids Group, interested patient groups, 
pharmaceutical companies and the Department of Health should work 
together to encourage properly conducted clinical trials of cannab ino ids 
alone, or, in combination and, or, in combination with other dnlgs. 31 
Whilst new drugs were being developed the report urged that the police, courts and 
authorities should take account of medical reasons for unlawful use. 
The report was released in November 1997 with a press release which was careful 
to draw a line between recreational and medical use, but which also drew attention to 
some of the more emotive issues of medical cannabis use.32 
Therapeutic Uses of Cannabis draws a distinction between recreational 
misuse and using the drug to relieve pain. The report acknowledges that 
thousands of people resort to taking cannabis illegally ... to ease their 
distressing symptoms. 33 
The report generated considerable attention and it had to be re-printed. It was widely 
covered in the media: most coverage was positive with headlines such as 'Doctors' 
support for cannabis.34 As government had feared some sections of the media, 
including the Independent on Sunday linked medical arguments to policy change and 
re-opened calls for decriminalization. 
Its appearance under the name of the BMA will give the findings added 
weight. It will increase pressure on the government following the launch of 
the Independent on Sunday S campaign for the decriminalisation of cannabis 
and the call by the Lord Chief Justice, Sir Thomas Bingham, for a debate on 
the issue. 35 
The Independent on Sunday used the report to add weight to decriminalization 
arguments and commented, 'The publication ... of the BAL~ s report ... 1I'ill kill 0.[( the 
last arguments against the decriminalisation of the drugfor medica/use.- '36 Arter the 
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release ofthe report, the Independent on Sunday convened a conference, Cannabis: 
Should it be decriminalized? which included speakers such as Professor John Strang, 
Director of Addiction Research, National Addiction Centre; Anita Roddick, Body Shop 
owner; Mike Goodman, Barrister, Director of Release; Professor Colin Blakemore. 
Chairman ofthe British Neuroscientific Association; and Nigel Evans, Conservative 
MP. No spokesperson from the Home Office or the BMA attended. Rosie Boycott drew 
attention to cannabis therapeutics in her opening speech. 
A society ... that has denied a very benign drug to MS sufferers, to 
recreational users, and that has made people criminals. By choosing 
to stick to this ... 'just say no ' approach we have a wildly escalating drug 
problem. 37 
During the conference frequent references were made to the BMA's conclusions on 
therapeutic use. Austin Mitchell, MP, considered that the BMA report undermined the 
Misuse of Drugs Act 1971. 
I'm open minded about the question of legalization ... But I am concerned 
about the therapeutic case because in 1971 cannabis, which had been 
available on prescription, after that time was transferred to Schedule I of the 
Misuse of Drugs Act, defined as a drug which has no therapeutic value. And 
since then everything has been changed by this BMA report which actually 
says that cannabis has therapeutic value. 38 
Mitchell emphasized that a policy that led to the prosecution of patients brought the law 
into disrepute. 
The law s coming into disrepute, prosecutions are being abandoned, we 
know that the courts are imposing very lenient sentences but people still get 
a criminal record ... it is absolutely wrong that MS victims should be treated 
in that kind of fashion and driven to illegality. Something has to be done 
and quickly. 39 
Mitchell, prior to the conference had taken a delegation with the Alliance of Cannabis 
Therapeutics to the Department of Health but found he could make little progress. 
It S a chicken and egg situation in which the Home Office says it won i do 
anything because there is no research, but no research is done because 
it s illegal, and meanwhile thousands and thousands of multiple sclerosis 
sufferers are being forced into the backstreets into the illegal market to buy 
something that they know is helpful in the treatment of their condition. 40 
The conference raised the public profile of cannabis therapeutics and the controversy of 
the legal situation. The BMA report gave campaigners ammunition against government 
policy and the confidence to move the process of medicalization forwards. The press 
picked up on splits in government over best approach to cannabis. 
The Home Office Minister told Mr Flynn in the Commons there H'as no 
medical evidence that cannabis provided medicinal benefits. The Home 
Secretary Jack Straw has maintained a tough line in resisting all pressure 
for cannabis to be legalized ... ... but highlighted the change in attitude from 
Frank Dobson, the Secretary of State for Health, who indicated that if 
medical evidence could be found, he would have no objections to cannabis 
being legalizedfor medicinal use. Mr Flynn intends to challenge the Home 
Office again with the BMAfindings. 41 
The report was used by both campaigners for change and those in favour of the status 
quo. The conclusion, for example, whilst it recognized the potential therapeutic value 
of cannabinoids, steered clear of herbal cannabis itself and recommended further 
research prior to access being grantedY 
But the significance of the report was that a respected medical institution had recognized 
the potential of cannabis therapeutics. It legitimized research into cannabinoids if 
not cannabis and provided substantial pressure for a change in legislation for medical 
purposes. The House of Lords report which followed closely the publication of the 
BMA report was able to build on the BMA's acknowledgement of potential therapeutic 
uses of cannabinoids and provided pressure for action. 
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The Role of the Select Committee. The House of Lords Science 
and Technology Committee. Cannabis: The Scientific and Medical 
Evidence, 1998 
The House of Lords Science and Technology Committee report on the therapeutic 
use of cannabis marked a milestone when it was published in 1998. Where the BMA 
had accepted therapeutic use, the Science and Technology Committee made extensive 
recommendations to about what to do with that advice. Select committees operated 
in both the House of Commons and the House of Lords and monitored the work of 
government departments. The Science and Technology Committee established in 1979 
was one of the main investigative committees in the House of Lords with inquiries 
undertaken by two sub-committees. For each inquiry members were drawn from the 
main committee and additional members chosen for their relevant expertise. At the 
end of an inquiry a report, including evidence, findings and recommendations were 
presented to the main Committee and reports were published and debated in the House 
of Lords. The Committee worked independently of government and was free to choose 
its own topics. In February 1998, the House of Lords announced an investigation 
into the recreational and medical use of cannabis.43 It was the first time cannabis had 
come under the spotlight of a select committee. The report explained the decision to 
investigate cannabis. 
In the light of this heightened interest in cannabis, and particularly the 
report by the BMA, we decided to examine the scientific and medical 
evidence to determine whether there was a case for relaxing some of the 
current restrictions on the medical uses of cannabis. 44 
The interest of individual Lords was important in the choice of cannabis. Les 
Iversen, a retired Professor of Pharmacology at Oxford University, and the special 
advisor to the cannabis committee explained, 
That group is an interesting bunch of retired scientists, doctors, lawyers, 
all with some interest in science and technology ... They choose a couple of 
topics they 1I'ant to review entirely of their 01t'n initiative .... because the 
chairman of the sub-committee was a pharmacologist and had an interest in 
cannabis. 45 
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Lord Walton of Detchant, a fonner neurologist who had previously worked \\ith ~lS 
patients explained the focus, 'the Select Committee became aware that a number of 
well-meaning people with MS were being prosecuted. '46 The committee approached the 
problem from the patient perspective rather than from concerns generated by the misuse 
of drugs which had been the focus of earlier expert discussion. 
A sub-committee was established with Lords drawn from a range of disciplines but 
particularly from chemistry, pharmacology and neurology, some of whom during their 
careers had witnessed the use of cannabis by patients to treat intractable diseases. The 
Chair, Lord Perry of Walton, was a retired Professor of Ph anna co logy from Edinburgh 
University who had been instrumental in the development of the Open University. Other 
members included Lord Porter, Noble Prize winner for Chemistry; Lord Walton of 
Detchant; Lord Porter of Ludden ham, a chemist, Lord Butterfield, a medical researcher; 
Lord Rea; Lord Soulsby of Swaffham Priory, Emeritus Professor of Animal Pathology; 
Lord Butterworth, a lawyer and university administrator; Lord Carmichael of 
Kelvingrove; Lord Dixon-Smith, Lord Kirkwood, ajudge; and Lord Nathan, a solicitor. 
The tenns of reference were wider than those of the BMA report, and so the 
Committee inquired into, 'the science behind the arguments over the use of cannabis 
and its derivatives for medical and recreational purposes. '47 It also incorporated 
discussion of recreational use 'we have also considered whether the continued 
prohibition of recreational use is justified on the basis of the scientific evidence of 
adverse effects, , but it emphasized that it would not cover issues such as prevalence 
of cannabis use, behavioral or social aspects of drug taking, law enforcement, any 
relationship between drugs and crime, and the extent to which cannabis contributed a 
gateway to drug culture.48 
Iversen drafted questions for the committee and he was responsible for cal1ing a 
wide range ofwitnesses.49 Researchers, like Pertwee, provided the pharmacologist's 
viewpoint with evidence oflaboratory research and potential clinical applications. 
Clinicians, such as William Notcutt, presented on clinical research. and al1 provided 
positive feedback about clinical research. Professional bodies. such as the Royal 
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Phannaceutical Society, and BMA also contributed. Dr Geoffrey Guy provided the 
industry perspective and discussed his interest in setting up a small biotechnology 
company to investigate 'whole plant' cannabis. The patient perspective was included 
with patients and user activists, including Clare Hodges and representatives of the 
MS Society. Relevant government departments including the Home Office and the 
Department of Health provided additional witnesses. Funders such as the MRC were 
included, as were advisory groups, including the ACMD. The committee provided an 
important forum to bring disparate work and perspectives under one umbrella and its 
conclusions were based on a wide spectrum of stakeholders. 
The report made seven recommendations to stimulate research and change policy. 
The first recommendation urged that clinical trials of cannabis for the treatment of MS 
and chronic pain be mounted as a matter of urgency. Support for clinical trials was 
not unanimous. Professor Griffith Edwards, who had previously sat on the ACMD 
committees of the 1970s, provided evidence as a witness for the ACMD along with 
two other psychiatrists, Malcolm Lader, and Morfydd Keen. Edwards had always been 
wary of medical cannabis and he queried the value and ethics of diverting scarce MRC 
funding to large-scale clinical trials and argued, 'it would be reasonable to investigate 
the matter but I do not believe it would be reasonable to go through a controlled trial. '50 
If the ACMD delegation was wary of starting trials, delegates were also concerned with 
the misuse of drugs should cannabis-based drugs be developed and licensed. Edwards 
feared the potential for the misuse of prescriptions. However, the demand for clinical 
trials was overwhelming from most witnesses. The Department of Health accepted the 
legitimacy of demands for therapeutic cannabis and appeared keen to encourage trials. 
We do see that societies such as the MS Society do have a genuine interest 
in the potential/or therapeutic benefit .. .! hope I have made it clear that the 
Department 0/ Health would wish to do all it could to support and facilitate 
that initiative. 51 
The MRC was brought on board to solve funding issues and it appeared willing to speed 
up the process 'i/there was a need/or clinical trials in this area, In.> H'ould be prepared 
to consider them out of the usual round of consideration of clinical (rials. '52 The 
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feasibility of clinical trials was already being facilitated by the emergence of a Royal 
Pharmaceutical Society working party on clinical trials protocols, and the involvement 
of GW Phannaceuticals. With these aspects in place the Committee was keen to see 
trials go ahead, as Lord Walton explained, 
We did say that cannabis derivatives should continue to be controlled drugs 
because we did not approve the so called recreational use of cannabis .... but 
we were happy to approve properly designed studies of its medical use. 53 
One more contentious aspect was the fonn of cannabis to be studied and its 
delivery method. Conflict emerged between groups, such as the BMA, the Association 
of Chief Police Officers, and the Christian Institute, a charity which promoted the 
Christian religion in the UK, all of whom supported research into the constituents 
of cannabis, and those such as Guy and Professor Wall, who supported research into 
'whole cannabis'. The Minutes recorded, 
Professor Wall argues in favour of trials of cannabis rather than pure 
cannabinoids. He criticises the BMA report for recommending that trials 
be confined to synthetic cannabinoids; he considers that it would be 
premature ... to assume that the only active substance in cannabis is THe. 54 
The Royal Phannaceutical Society showed support for 'whole' cannabis and the MRC 
viewed the comparison as important, provided a standardized product was available. 
GW Phannaceuticals made this a possibility as the company indicated its willingness 
and ability to produce a standardized mixture. 55 The Lords, guided by Iversen's 
questions, pushed the issue of research into herbal cannabis, and pressed the issue 
when questioning witnesses. In particular, they appeared to accept the arguments of 
patient activists who complained about the synthetics in contrast to herbal cannabis. 
Subsequent clinical trials tested both synthetic THC and extracts of cannabis. OW 
Pharmaceuticals, the one UK company with a licence to produce cannabis-based 
medicines, was designed around the production of extracts of cannabis. 
The second recommendation related to the mode of administration of cannabis, 
Research should be promoted into alternative modes of administration ... 
which would retain the benefits of rapid absorption offered by smoking, 
without the adverse effects. 56 
Modes of administration of cannabis had long been a controversial subject. The BMA 
had clearly been against the use of smoked cannabis. The select committee, however, 
did not rule out initial experiments with smoked cannabis, but did not contemplate 
an eventual therapeutic based on this method and therefore placed pressure on the 
development of alternative modes of administration. Lord Walton explained' TTe could 
not condone smoking cannabis as we were carrying out a major campaign to ban 
smoking in public spaces, and there was good evidence that smoking cannabis was just 
as potentially carcinogenic as smoking tobacco '.57 But smoking was seen as a preferred 
method by patients and the need for a compromise stimulated research into other forms 
of administration, and preferably one that would divide medical from recreational 
use. GW Pharmaceuticals appeared to offer a solution to this problem through the 
development of a novel delivery system, the sublingual spray. 58 
The impact of policy on research was examined by the committee and its 
recommendation on this aspect may have contributed in part to a shift in the policy 
environment on cannabis in subsequent years. Whilst the committee maintained 
that cannabis and cannabis derivatives should remain controlled drugs it argued for 
amendments to legislation. A pragmatic approach was required to deal with patient 
pressure. The Alliance for Cannabis Therapeutics was particularly keen to see changes 
that would immediately impact on patients to mitigate the long drawn out process of 
research and regulation before any new drug would reach patients. Researchers also 
indicated that the legal situation hindered research. The committee took these concerns 
on board in making its third recommendation which was the most controversial in that 
it required the downgrading of cannabis under the Misuse of Drugs Act a move which 
would have permitted the prescription of cannabis. The reported suggested, 
The Government should take steps to transfer cannabis and cannabis resin 
from Schedule 1 of the Misuse of Drugs Regulations to Schedule 2. so as 
to allow doctors to prescribe an appropriate preparation of cannabis. 
albeit as an unlicenced medicine and on the named-patient basis and to 
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allow doctors and pharmacists to supply the drug prescribed. This 11'Ould 
also, incidentally, allow research without a special license from the Home 
Office. 59 
Amendments to the law surrounding cannabis would have allowed prescription of 
cannabis-based drugs and would have had the additional advantage of creating a 
boundary between medical and recreational use. It was argued that such as move would 
support rather than weaken the drug control system. 
Legalising medical use on prescription, in the way that we recommend, 
would create a clear separation between medical and recreational use ... 
We believe it would infact make the line against recreational use easier to 
hold. 60 
If government was to contemplate a shift of cannabis from Schedule I it was required 
by law to consult the ACMD and therefore the fourth recommendation was to do just 
that. The fifth recommendation related to the international policy and recommended 
that the issue of scheduling of cannabinoids should be raised with the WHO. To counter 
fears over the potential diversion of prescription drugs and any link to recreational use 
the final recommendation was that if doctors were permitted to prescribe cannabis on 
an unlicensed basis, the medical professional bodies should provide firm guidance on 
how to do so responsibly and that the professional regulatory bodies should set in place 
safeguards to prevent diversion to improper purposes. This would bring the 'ownership' 
of cannabis to medical bodies. 
The results of the select committee were made public and both the final report and 
the book of evidence were published. Government was expected to comment on Select 
Committee findings. The cannabis report created a stir when it was published on 11 th of 
November 1998, heightened by the fact that the government rejected the report on the 
morning of its publication. The government admitted that it had departed from the usual 
convention in case its silence raised speCUlation that it regarded the questions around 
rescheduling open, thereby inviting hints of policy change.61 
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The government made the case that to protect patients it was not prepared to make 
changes prior to potential drugs passing through the existent regulatory process and that 
no interim measures would be introduced. Iversen described the response. 
The government on same day, before the ink was dry, said they were not 
going to make any changes to the law. In other words they dismissed it out 
of hand. But that was no knee jerk reaction, everyone expected thatY 
The reaction was not unexpected. Previous reports that had called for re-classification 
had been rejected. The issue was debated in the House of Lords in December. Lord 
Perry criticized the government's reaction which appeared to be based on concerns 
already addressed by the Committee. Over the issue of efficacy and safety, Lord Perry 
argued that cannabis was already being used in the community and a more pragmatic 
response would be to regulate such use. 
The Government argues that prohibition protects patients ... Significant 
numbers of sufferers are taking cannabis ... in defiance of the law and 
without medical supervision or quality control; our recommendation 
would enable the health professions and the pharmaceutical industry to 
collaborate to provide appropriate preparations. 63 
The select committee questioned the nature of acceptable evidence and the 
interpretation of that evidence. In the committee's opinion enough evidence existed, 
even if it was largely anecdotal, and the committee added pressure to carry out clinical 
trials which remained the most accepted form of 'evidence.' Government concern, 
that a change in legislation, would reduce research was rejected as inaccurate and the 
opposite case was made that research was hindered by legislation. 
The Government argue that permitting prescription now would reduce the 
momentum of research. On the contrary, we found evidence ... that research 
has been held back by the stigma and bureaucracy associated with the 
status of cannabis as an illegal drug. 64 
The grounds on which the government rejected the advice were brought into question. 
First, if patients were the priority on what basis should decisions be made - safety or 
quality of life? Lord Perry argued, 
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Our report shows that if cannabis is used to treat patients on the 
prescription ofa doctor, the risk to the patient is vanishingly small .. many 
patients would regard their safety as only their second priority after the 
quality of their lives. Should not the Government share that vieH'?65 
Second, the transparency of the rejection was questioned with concerns raised over 
whether decisions were based on the scientific evidence or social grounds. Lord Perry 
asked, 
Is their attitude coloured by social, economic and criminological 
considerations to which our inquiry was not addressed? Those 
considerations are only pertinent to the recreational use of cannabis. 66 
The government demonstrated that it remained resolutely against re-scheduling or 
prescription prior to trials as it believed that 'such a move would be premature. '67 In 
particular, the government argued that to allow prescription of herbal cannabis would 
restrict research and it was able to refer to the BMA's conclusions on this aspect. Nor 
was the government inclined to consult the ACMD as it feared this would encourage 
speculation that policy change was likely when it was not. 
It would have been disingenuous to seek a view having already decided that 
the recommendations would not be accepted. 68 
The government's apparently intractable position drew criticism from different quarters. 
Mike Pringle, Chair of the Council of the Royal College of General Practitioners, 
declared, 'I think the government is being unnecessarily cautious. The main interest 
here is the care of patients and the relief of patient suffering. '69 Conflict rose over the 
meaning of the term 'care of patients' as for some GPs it meant that when faced with 
patients with intractable disease, it was the ability to offer some treatment and relief, 
while for government the focus was on provision of 'safe' medicines. 
The report attracted a degree of press attention. Iversen explained later the report. 
'caused some interest in the conclusion that there were genuine medical uses, Iii£' 
dangers had been exaggerated and more research 11'(7S needed.'-'o It reinforced the 
public perception that there were medical uses for cannabis and that an) dangers had 
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been exaggerated. The press picked up on the divisions between the BMA and House of 
Lords reports 
The BMA says it is not 100% behind a report by the House of Lords Science 
and Technology Committee backing the use of cannabis for medicinal 
purposes. The BMA, which has previously supported more clinical trials 
into the medical use of cannabis, says legalising cannabis is not the ans)!'er. 
It believes only cannabinoids - part of the cannabis plant - should be lIsed in 
medicine. 71 
But according to Iversen the report set the 'official seal of approval' for medical 
research into cannabis. Behind the scenes moves were taking place in regard to both 
therapeutic cannabis and cannabis within drug policy. Lord Walton later argued that the 
government, in time, took note of most of the recommendations including rescheduling. 
In general, the report was approved by government; they supported the 
needfor further research andfor reclassification of cannabis on which 
they consulted the ACMD. 72 
Whilst the recommendation to reschedule cannabis was rejected the government left 
an opening for the process ofre-medicalization. It gave assurances that if quality, 
safety and efficacy could be demonstrated, then cannabis would be permitted as a 
prescription medicine. In making the lack of clinical trial data the restraining factor it 
had to facilitate clinical trials. It agreed to license trials that involved cannabis as well 
as cannabinoids and the Home Office Drugs Inspectorate was described as willing to 
discuss research-related licensing issues. The frail evidence-base gave the government 
the opportunity to defer the issue but it also meant that clinical trials of both synthetic 
and herbal cannabis proceeded. Those involved in the Select Committee claimed some 
responsibility for the advancement of re-medical ization. 
Those involved in House of Lords would like to think it was some sort of 
response to the fact the House of Lords said there should be more research 
more proper trials ..... It was a sop towards saying we were doing something 
towards this. 73 
Even if it was merely a sop, it still forwarded the process of re-medicalization. Iversen 
commented, The report made some impact onfuture moves and helpC'd stimulate the 
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idea that there should be a proper controlled trial which the MRC took up and spon-
sored. >74 Importantly the House of Lords helped smooth the path for industry involve-
ment that took place after 1997.75 
The report contributed to a shift in the policy environment around cannabis generally. 
Certainly some of those involved in the Committee considered it had served a useful 
purpose. Lord Walton commented, 'partly as a result of our report, though I can l 
guarantee that, the Government downgraded cannabis. >76 Iversen pointed out that the 
report came at an opportune time, 
It happened to be at a time when the Government was beginning to think 
about relaxing the laws on cannabis. Blunkett, the Home Secretary in 200 1 
suggested to the Home Office they consider the evidence for downgrading of 
cannabis. 77 
Stakeholders had come together at a time when there was more flexibility in attitudes 
towards the control of cannabis and internationally moves were afoot to open the door 
to cannabis-based medicines. 
The UK and international policy 
Government may also have been influenced by the changing attitudes of the 
international drug control agencies. The INCB had been hostile to cannabis since its 
inception under the 1961 UN Single Convention.78 Presidents had taken a particular 
interest in the mental health aspect. Hamid Ghodse, Professor of Psychiatry and 
International Drug Policy at the University of London had been a Director of the 
International Centre for Drug Policy at St George's, University of London, a member 
of the INCB since 1992 and had held the Presidency in 1993, 1994, 1997, 1998 and 
2001. He became interested in cannabis from the mental health perspective in the 1980s 
which he continued through his role in the international arena.79 Despite concerns the 
INCB could not ignore the development in the medical sphere, nor the pressure for 
compassionate access to cannabis. The 1998 annual report admitted that· the Board is 
mvare that there is a need to investigate ... medical use and ... there is a growing inter"s! 
among the medical community, public and media. '80 
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Its changing attitudes to therapeutics may be because it viewed flexibility as a 
means to maintain the integrity of international drug policy. By 1998, Ghodse, by 
then President, encouraged the INCB to push for governments to carry out research 
into therapeutics in order prevent medical cannabis being hijacked by the legalization 
campaigns.81 Ghodse later explained the incentive, 
... to separate the political and medical aspects ... and to encourage 
governments to do serious, scientific research on the allege medical 
usefulness of cannabis so that ifits effectiveness is established, it will be a 
drug no different from most narcotic drugs and psychotropic substances. 
It can then go through the process of re-scheduling as with any other 
controlled medicine. If it is shown not to be effective it will not provide 
ammunition to those using medicine for different objectives. '" . 82 
However concern remained over the relationship between cannabis medicine and 
recreational use. 
The Board has noted with regret how possible medical usages of cannabis 
have been used to justify the legalization of call cannabis use. The Board 
welcomes and encourages serious scientific research on the alleged medical 
properties of cannabis ... but warns again misusing these research efforts for 
"blanket" legalization purposes. 83 
The treatment of cannabis appeared to have the power to disrupt the entire drug 
classification framework. In contrast to comparisons that were emerging of cannabis 
with socially acceptable licit drugs such as alcohol and tobacco, the INCB found it 
important to maintain cannabis' close ties to controlled, narcotic drugs. 
Should the medical usefulness of cannabis be established it will be a drug 
no different to most narcotic drugs and psychotropic substances. This 
means that cannabis used for medical purpose would be subject to licensing 
and other control measures forseen under the international drug control 
treaties. 84 
Ghodse' view was that the INCB stance gave the green light for research and stimulated 
research in the UK, such as the MRC clinical trials.85 Researchers in the UK denied that 
the INCB stance or indeed that of any of the international agencies had much impact. 86 
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Was it rather that the INCB wanted to catch up with events that had moved beyond its 
ability to control? But in the UK the government tone, if not policy, was changing. 
In the UK, clinical trials and industry involvement went forward after the House of 
Lords report and the following years saw the establishment of the clinical trials and 
the attempts at licensing cannabis-based drugs and in the process contributed to wider 
drug policy debates. But whilst the process of re-medicalization was to move forward 
potential changes to the classification system proved more problematic. 
Rescheduling cannabis: Drugs and the law, Report of the Independent 
Inquiry into the Misuse of Drugs Act 1971 
The issue of medical cannabis became more politicized and integrated with calls for 
re-scheduling in expert reports after 2000. One of the landmark reports that focused 
on the rescheduling debate was the Drugs and the Law, Report of the Independent 
Inquiry into the Misuse of Drugs Act 1971, otherwise known as the Runciman Report, 
released in 1999.87 This aimed to tackle issues that the House of Lords had not covered. 
Established in August 1997 by the Police Foundation with the assistance of the Prince's 
Trust, it was chaired by Viscountess Runciman, a long standing member of the Advisory 
Council on the Misuse of Drugs, Chair of the Council's Criminal Justice Working Group 
and Chair of the Mental Health Act Commission. Members included representatives 
from: drug service organizations, such as Alison Chesney, Chief Executive of the 
Cranston Drug Services; the legal profession including, Rudi Forston, Barrister at Law, 
Middle Temple and founding member of Release; the police service including, John 
Hamilton, the Chief Constable of Fife Constabulary and academics including Professor 
David Nutt, Head of the Mental Health and Psychopharmacology Unit at the University 
of Bristol' Simon Jenkins the former Editor of The Times; Ian Wardle, Chief Executive , , 
of Lifeline Project Limited, and Annette Zera, Principal of Tower Hamlets College, 
London. 
The Committee reviewed the 1971 Misuse of Drugs Act. It argued that the 
classification system needed to be more closely related to scientific evidence of relative 
harm. Cannabis was the focus of one chapter in which it was considered in relation to 
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the harms of other illicit drugs and it was concluded that cannabis was less harmful than 
the other illicit drugs and that therefore the current law was problematic. 
If our drugs legislation is to be credible, effective and able to support a 
realistic programme of prevention and education, it has to strike the right 
balance between cannabis and other drugs. 88 
The Committee concluded that there was little evidence that the law was effective as a 
deterrent. It, like the ACMD before it, urged reclassification of cannabis to from Class 
B to Class C and from Schedule 1 to 2 of the Regulations of the Misuse of Drugs Act, a 
move which would have allowed supply and possession for medical purposes. Within 
the discussion of cannabis, therapeutic use played an important part in relation to its 
impact on the Misuse of Drugs Act. 
We conclude that there is evidence that there are therapeutic benejits from 
the use of cannabis by people with certain serious illnesses and that these 
benejits outweigh any potential harm to themselves. We therefore agree 
with the House of Lords Select Committee that cannabis and cannabis resin, 
together with tincture and extracts not covered by the 1971 Convention, 
should be transferredfrom Schedule 1 to Schedule 2 to the 1985 regulations. 
That would automatically ensure that doctors who prescribed such 
substances were not criminally liable. The same would apply to their 
patients in possession and doctors or pharmacists who supplied cannabis. 89 
The Committee had little to add to the conclusions of the BMA and House of Lords 
report other than, on the whole, to endorse and further their recommendations. 
We appreciate the doubts of the British Medical Association over how 
to control and assess dosages of raw cannabis. But these seem to us 
insufficient reasons for preventing prescription where doctors, at their Olt'll 
risk on a named-patient basis, believe that their patients will benejit.90 
In the light of the medical conditions for which medical cannabis was being investigated 
attitudes to the form and delivery methods of cannabis were also undergoing change. 
While understanding the reservations expressed b.v the British ;\fedical 
Association and the House of Lords Select Committee about administration 
by smoking, this seems to us a Vel)' minor matter gin!l1 the seriollsness 
of the conditions for which prescription of cannabis seems likely to be 
beneficial. 91 
The report called for immediate changes prior to results of clinical trials. It rejected 
one government fear: that of the misuse of prescriptions, and noted that the ability to 
prescribe heroin for pain relief had not caused a problem. 
We do not share the Government's anxiety about the capacity ofGPs to 
withstand pressure for the prescription of cannabis. There is no el'idence 
that this has been a problem where the prescription of heroin for pain 
control is concerned. 92 
The Runciman Committee built upon the House of Lords demands for compassionate 
access to medical cannabis and called for a legal defence based on medical grounds. 
As the Government has rejected the House of Lords recommendations 
and it will be some years before a standard licensed cannabis product is 
available, we recommend that there should be a new defence of duress 
of circumstances on medical grounds for those accused of possessing, 
cultivating or supplying cannabis ... This approach wOllld comply with our 
international obligations under the United Nations conventions and enable 
spurious defences to be rejected. 93 
The Committee reported in March of2000 and the Home Secretary, Jack Straw, 
rejected reclassification. But he promised that the remaining recommendations would 
receive serious consideration. Meanwhile the report received considerable media 
attention and was generally well received. The Independent newspaper not surprisingly 
given its previous line on cannabis, reported the dismissive government response as 
did the BBC.94 The House of Commons Home Affairs Select Committee pressured for 
a full response from the Home Secretary, but when government responded in full in 
February 2001 it rejected most of the key recommendations. Viscountess Runciman 
expressed her confidence in the enduring quality of the report, 
Our recommendations on cannabis were byfar the mostfar-reaching and 
they were meant to be, because we think that that is where the lmv is, in 11 
sense, most defective .... this is a good report, has staying pOll'cr and that its 
time will come. 95 
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She appeared confident the recommendations would stand the test of time and policy 
change would be implemented at an opportune moment. When the report was discussed 
by the Home Affairs Select Committee in June 2000 it came in for criticism mer its 
independence and for its "soft" view on drugs.96 Runciman was scathing about the 
government's response and claimed, 'it also leaves us with a law that in relation to 
cannabis produces more harm than it prevents.'97 
Pressure continued to build for a rethink of drug policy and drug regulation. 
Therapeutic aspects of cannabis had again been headlined with the release in March 
2001 of the second House of Lords inquiry into therapeutic cannabis, a follow-up report 
to their 1998 report.98 This inquiry covered new research that had taken place since 
the initial report but also dealt with the legal situation and growing concerns over the 
prosecution of those using cannabis medically. The terms of reference were, 
To examine the current state of research into the therapeutic uses of 
cannabis, the roles of the Home Office and the Medicines Control Agency in 
the licensing of cannabis-based medicines, and more recent issues relating 
to the prosecution of therapeutic cannabis users. 99 
The 2001 report reiterated the points ofthe 1998 report but with clinical trials underway 
for the first time the role of regulatory and licensing bodies came under scrutiny. Once 
again reconsideration of regulatory requirements was urged. At that point there was 
more receptiveness to the concept. The report referred to an apparent change in attitude 
by the government to prescription of cannabis-based medicines. 
We are pleased to note that the Government now displays a more 
encouraging attitude towards the licensing of therapeutic preparations 
of cannabis ... In effect, the Minister assured us that once a safe, effective, 
cannabis-based medicine had been licensed by the Medicines Control 
Agency, the Government would actively co-operate in permitting it to be 
prescribed. 100 
The long timescale for the licensing of cannabis-based medicines was deemed to 
relate to the fear that medical use might stimulate greater recreational use rather than 
objections to medical cannabis itself. 
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Up until now we have sensed that the authorities have been dragging their 
feet, at least partly because they may have feared that permitting therapeutic 
preparations of cannabis to be prescribed would be interpreted by the public 
as a move towards allowing recreational use. 101 
But by 2001 government viewed the re-medicalization of cannabis as a means to 
provide a clear distinction between medical use and non-medical use. The development 
of clear medical and non medical structures for cannabis would weaken calls for 
decriminalization and make it easier for Government to clampdown on recreational use 
if desired. 
There is now a much sharper awareness of the distinction between 
medicinal use of cannabis and recreational use of cannabis in the public 
debate ... We are pleased, too, that the Minister now shares our view that, 
were the law relaxed on the therapeutic use of cannabis, the Government:S-
hand in suppressing illegal, recreational use would be strengthened. 102 
But the House of Lords had key concerns over this stage of the process ofre-
medicalization. The progress in clinical trials was slow and it appeared that the need 
for licences and a continued stigma around cannabis still inhibited research. In the 
meantime, it was viewed as undesirable to prosecute therapeutic users. In addition there 
were fears that the MCA had failed to take a balanced, objective view of cannabis-based 
drugs and that it needed to reconsider its position on cannabis-based drugs that had 
attempted to pass through the regulatory system. The report captured the attention of 
the press with headlines such as 'Lords back cannabis use. '103 
The General Election in June 2001 saw the re-election of the Labour government. 
The new government seemed more inclined to reconsider cannabis and in July 2001 
the incoming Home Secretary David Blunkett, was reported as wanting to re-open the 
drug debate. Pressure mounted when the Home Affairs Select Committee in July 2001 
announced its intention to hold an inquiry entitled, 'The Government:S Drugs Policy: Is 
it working? ' Later that year came an indication that policy change might be underway. 
At a Home Affairs Select Committee meeting the Home Secretary David Blunkett 
announced that he favoured the reclassification of cannabis and asked the ACMD to 
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review the classification in the light of the scientific evidence. At the meeting he made 
it clear that subject to the satisfactory outcome of the clinical trials, he \vould approve a 
change to the Misuse of Drugs legislation to enable the prescription of a cannabis-based 
medicine. 
Should this programme be proved to be successful, I will recommend to 
the Medicines Control Agency that they should go ahead with authorising 
the medical use of this for medical purposes. In the event of the successful 
completion of clinical trials and a positive evaluation by the MCA, we 
recommend that the law is changed to permit the use of cannabis-based 
medicines. 104 
The Home Affairs Select Committee signaled its agreement that the dangers of cannabis 
relative to other drugs had been overstated and the greater public health danger might lie 
in the loss of creditability of the entire drug control system. 
Whether or not cannabis is a gateway drug, we do not believe there is 
anything to be gained by exaggerating its harmfulness. On the contrary, 
exaggeration undermines the credibility of messages that we wish to send 
regarding more harmful drugs. We support, therefore, the Home Secretary s 
proposal to reclassifY cannabis from Class B to Class C. lOS 
Whilst these moves to reclassify cannabis took place therapeutic issues were brought 
back to the table with the government response to each of the House of Lords reports 
recommendations released in December of 200 1. The government reiterated its 
encouragement of clinical trials, 'The Government has consistently made it clear that 
it welcomes clinical trials into the therapeutic use of cannabis ." this remains the 
position. 106 The government appeared to take a relaxed attitude to the criminal justice 
system taking on a sympathetic view of medical users of cannabis. 
While the law can make no distinction on the criminality of the possession 
of cannabis for recreational or therapeutic reasons, while the efficacy 
and safety of the latter remain unproved, the Government believes that 
the criminal justice system does allow for a sympathetic approach to the 
genuine therapeutic user. 107 
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The government defended the MCA and the regulatory process. 
The Government accepts that it should be impartial in its approach 
tolicensing cannabis-based medicines .. Development of cannabis-based 
medicines poses a number of very difficult scientific and regulatory 
problems. The MCA is treating these products in the same way as any other 
drug, taking account of all the information available on the balance of risks 
and benefits including relevant human exposure, in making their decisions. 
Whilst acting within the appropriate constraints of regulations that protecl 
clinical trials subjects, the MCA is working closely with those developing 
these products to identify solutions to the specific problems. In doing so 
the MCA has contributed significantly to the progress of the development of 
these medicines. 108 
The ACMD presented its report to the Home Secretary in March 2002, recommending 
that all cannabis products be reclassified as Class C and moved from Schedule I to 
Schedule 2 of Regulations of the Misuse of Drugs Act 1985, on the grounds that 
cannabis was less harmful than other substances within Class B. The report made 
reference to a possible link between chronic use of cannabis and mental illness, but 
stated that 'no clear causal link has been demonstrated'. The impact on therapeutic 
cannabis was to split it from the drugs debate and to indicate that it could be treated as a 
separate issue. 
The Council is aware, however, that clinical trials of cannabis derivatives 
are in progress. If, at some future date, one or more cannabis preparations 
become available as medicinal substances then the Council would advise 
about which Schedule, under the Misuse of Drugs Regulations 2001, they 
should be categorized This matter, however, is entirely separate from the 
classification of cannabis under the Misuse of Drugs Act 1971. 109 
In October 2003 MPs voted to downgrade cannabis and its derivatives to Class C, 
though cannabis possession remained an arrestable offence as the power of arrest was 
extended to Class C drugs. Reasons given for this alteration included a more accurate 
assessment of the harm caused by cannabis relative to other drugs, the continued need to 
control cannabis use and as a signal that the government desired to focus on the misuse 
of the most harmful Class A drugs, such as heroin and cocaine. It marked a change in 
the allocation of scarce resources from the control of . soft' to 'hard' drugs. Debates in 
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the House of Lords featured consideration of the relative hanns of cannabis compared 
with licit drugs, Lord Rea stating, 
Although cannabis can precipitate some mental illness it causes nothing like 
as much harm as alcohol or tobacco. Alcohol can kill people acutely-if they 
drink a whole bottle of spirits-quite apart from causing lingering death and 
we all know what tobacco can do in the long term. Those two substances 
are not class A, Class B, or Class C- they are not classified at all. 110 
The amendments to the Misuse of Drugs Act 1971 came into effect in 2004 and 
the move attracted the ire of the INCB which reiterated it was against any moves which 
might weaken the international drug control framework. 
No government should take unilateral measures without considering the 
impact of its actions and ultimately the consequences for an entire system 
that took governments almost a century to establish. III 
Whilst the INCB admitted that downgrading did not contravene any convention, it went 
so far as to express its fear that the move might send the wrong message and described 
the decision as a ploy to grab headlines. The INCB's fear was that that individual 
countries might bypass rather than seek to change the international drug control 
mechanism.ll2 International moves to re-medicalize cannabis in particular came in for 
criticism. 
The Board has repeatedly expressed its concern that, without having 
reported conclusive research results to the WHO the Government of Canada 
and the Netherlands authorized the use of cannabis for medical purposes. 
The Board is also concerned that cannabis is usedfor medical purposes in 
some jurisdictions in the US without having definitive proof of its efficacy. 113 
It therefore welcomed the US Supreme Court's decision to 'reaffirm that the cultivation 
and use even if it s for medical use should be prohibited '114 This rul ing was intended 
to curtail individual states such as California which were taking a more liberal attitude 
to cannabis production. ll5 A backlash developed and criticism of the international drug 
control agencies and the 'war on drugs' intensified. \Vhen Canada permitted access to 
medicinal herbal cannabis it faced strong criticism from the INCB. Fazey argued that 
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the INCB criticisms of individual countries, in particular of Canada's pol ic). exceeded 
it role and that such criticism went, 'far beyond their remit. '116 Iverson contrasted the 
conservative nature of the UN narcotic agencies towards cannabis with the WHO's 
changing approach, and the impression that the agencies had lost respect in the western 
world.1l7 The problems inherent in the drug control agencies, like the Commission on 
Narcotic Drugs and the INCB, and the failure to respond to changing circumstances in 
the face of limited success in drug control, raised questions over their decision-making 
process. But whatever the criticism of the INCB, and their criticism of challenges to the 
international drug control framework, in order to justify control they had signaled the go 
ahead to medical research. The need to separate recreational and medical use in order to 
maintain the Conventions encouraged research and funding into what otherwise might 
have remained an obsolete field. 
Conclusion 
A major alteration in attitudes took place towards cannabis in the period 1997-2004. 
Research and acendotal reports filtered through to expert committees and professional 
organisations which released positive reports and the concept of cannabis as a medicine, 
rapidly replaced cannabis as a menace. As pressure mounted national and international 
agencies eased restraints on medical research in order to divide medical use from 
recreational use and funding and incentives again flowed into the field. Concerns 
shifted to focus on the form of cannabis utilised and its delivery methods. But the 
debates also opened up questions about the role and functions of the international 
control agencies and policies. The following decade would see the re-medicalization 
of cananbis hinge on success in clincal trials and regulatory systems and continued and 
intensified questions over systems of drug control. 
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Chapter Eight 
From anecdotal to evidence-based medicine. The role of 
clinical trials in the process of the re-medicalization of 
cannabis, 1980-2006 
Clinical trials have been integral to the process of re-medicalization of cannabis. 
Randomised controlled trials (RCTs) had become the benchmark in biomedicine and , 
cannabis had to successfully perform in trials in order to become a licenced medicine 
again. In the US clinical trials ofTHC tablets in the 1970s moved cannabis away from 
anecdotal medicine towards evidence-based medicine. In the 1980s, these trials led to 
the licensing of Marinol (dronabinol) and Cesamet (nabilone) as anti-emetics or appetite 
stimulants. These drugs had limited uptake and were largely superseded for these uses 
but the process set a precedent. There remained much scepticism, and up until 2000, 
reports on cannabis' medical use remained largely anecdotal or dependent upon single 
case reports or at best small-scale clinical trials. Work that had been carried out was 
primarily focused on synthetic THC, rather than herbal cannabis. This chapter charts 
the growing interest in clinical trials on cannabis in the UK from different stakeholders 
which converged in the 1990s in a desire to see the production of additional cannabis-
based drugs. Government was keen to see a distinct line drawn between illicit and licit 
cannabis use; MS patients were vociferous in their demands for access to a cannabis-
based medicine or herbal cannabis; a number of clinicians who worked on pain and 
MS developed an interest in the potential of cannabis; and professional organisations 
such as the BMA, and the Royal Pharmaceutical Society pressed for clinical trials and 
attempted to draw stakeholders together. Two avenues opened up for clinical trials: one, 
an academic route with 'proof of principle' trials and another by GW Pharmaceuticals 
which aimed to license an extract of cannabis. l These developments led to large-scale, 
randomised double-blind controlled trials. They had mixed outcomes and demonstrated 
the problems of working on cannabis, on health problems that were difficult to measure 
such as pain, as well as issues specific to clinical trials: recruitment retention and 
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outcome measures. At the time of writing trials had yet to lead to a cannabis-based drug 
licensed in the UK yet they were important in the process ofre-medicalization.2 
Cannabis and the importance of clinical trial methodology 
Discussion of the production and licensing of any new therapeutic drug in the later 
part of the twentieth century cannot be discussed without reference to the development 
of evidence-based medicine and the rise of the randomised controlled trial (RCT).3 
Clinical trials are broken down into four phases. Phase I establishes how a medicine 
works and dosage, and is based on healthy volunteers; Phase II tests safety and efficacy 
on small groups of patients with the relevant illness; Phase III tests both safety and 
efficacy in large groups of patients; and Phase IV is a post-licensing phase. If the 
drug successfully passes through the first three phases, it will normally be approved 
by a national regulatory authority, in the UK the Medicines and Healthcare products 
Regulatory Agency (MHRA, the Medicines Control Agency (MCA) prior to 2003) 
which is charged with ensuring that medicines and medical products work and are 
acceptably safe. If medicines are shown to be safe, and effective the MHRA will 
license a drug and provide a marketing authorisation (previously a product licence). In 
making regulatory and licensing decisions advice is sought from an advisory committee 
the Commission on Human Medicines (CHM), (the Medicines Commission and the 
Committee on the Safety of Medicines prior to 2005).4 There is an international 
element to trials, as in the 1980s, harmonization of clinical trial protocols was shown 
to be feasible across countries ofthe European Union. Coordination between Europe, 
Japan and the United States led to a joint regulatory-industry initiative on international 
harmonization known as the International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use (ICH). 
For cannabis to become a legitimate therapy again it had to pass the benchmark: 
double-blind randomised controlled trial. Above and beyond the difficulties of 
researching a controlled substance, the RCT presented a specific set of issues for 
cannabis. Healy has shown the importance of the development of RCTs in the history 
of the development of psychopharmacology and demonstrated that not all drugs were 
easily amenable to that form of evidence-based medicine, The match between dnlg 
therapies and RCTs is based on the idea that a dnlg embodied one active principle 
which had been isolated and could be delivered systematically. '5 In attempting to 
explain some of the problems RCTs posed for the development of antipsychotic drugs, 
he illustrated how not all drugs could be considered within the framework of "magic 
bullets" but instead were complex cocktails of compounds containing a number of 
therapeutic princip les. 6 These issues were particularly pertinent to the progress of 
cannabis through the licensing system. As a highly complex plant substance, it was 
difficult for researchers to ascertain the form of cannabis to research and develop. Up to 
the 1990s, the only area that had been seriously investigated was THC as an anti-emetic 
which led to the licensing of nabilone and dronabinol. These drugs, which it was hoped 
would provide a licit version of cannabis, failed to fulfill this expectation as the drugs 
were heavily restricted and patients appeared to prefer herbal cannabis. In this context, 
the door opened for further investigations and in particular a need to research something 
more akin to cannabis itself and for additional applications. 
The initiation and development of the UK clinical trials on cannabis. 
1995-2000 
Research began to support anecdotal evidence of cannabis' therapeutic role especially 
with the discovery of the endocannabinoid receptor system. Interest shifted out of the 
laboratory and into the clinic and gave a new legitimacy to cannabis. Cannabis had an-
ecdotal evidence of benefit in the treatment of MS and pain, and by the mid-1990s that 
was where interest focused. MS had few treatments and the area of pain had not seen 
the introduction of a new drug for twenty years. In MS, only six trials with a total of 
forty one patients had been carried out, insufficient to consider licensing cannabis based 
medicines. 
Individual clinician interest was a key factor in the focus of trials. Those 
clinicians who led the trials had an early interest in MS and, or pain and many had 
witnessed how the use of smoked herbal cannabis had been used by patients to alleviate 
their symptoms. Professor John Zajicek who led a MRC funded trial on MS, was a 
neurologist who had gained a PhD studying the cell biology of MS and he had wanted 
to move into the clinical aspects of MS. In 1995. he had moved to Plymouth where he 
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became involved in the clinical aspects of MS. Another clinician who began trials on 
MS and pain was Dr William Notcutt. Notcutt had qualified in Birmingham in 1970 
and he had come across cannabis being used as a bush tea for alcoholism and glaucoma 
whilst he worked at the University of the West Indies in Kingston, Jamaica. In 1982. 
he moved to the James Paget Hospital at Great Yarmouth as a consultant anaesthetist , 
where he focused on chronic pain. He set up a Palliative Care Service in 1985 and 
introduced Patient Controlled Analgesia (PCA) for patients with post-operative pain. In 
looking at the history of pain treatment, he had come across references to cannabis and 
had observed patients self-medicating with the drug. In 1994, he accompanied patients 
and Professor Patrick Wall, an eminent pain specialist, to Parliament to campaign for 
access for patients to medical cannabis. Notcutt had begun testing nabilone on patients 
suffering from pain and MS when nabilone became available on a named-patient 
basis.7 Dr Anita Holdcroft was another clinician who had also come across the use of 
cannabis by patients and she had investigated its usefulness prior to the development 
of the major clinical trials. Her focus however was on acute pain rather than MS. She 
was anaesthetist who had worked in West Africa in the 1980s and when she returned 
to the UK in the early 1990s, she retrained in pain medicine and set up a pain clinic 
at the Hammersmith Hospital. It was an era when the basic science of pain medicine 
was emerging and her interest in cannabinoids was triggered when she found herself 
dealing with 'very limited management strategies'S for problems that were inadequately 
described or that had inadequate treatments. Whilst she had read of advances in pain 
management she found that they were not put into practice in the clinical environment. 
This led to the development of small-scale trials.9 Holdcroft had one patient 
who suffered from familial Mediterranean fever, an inflammatory condition of the gut, 
and who used cannabis to reduce his symptoms. On discussion with the patient it was 
decided to develop a clinical trial. 1o The trial took a year to initiate. The patient had 
been prescribed oral morphine, but self-treated with herbal cannabis. Dr Holdcroft 
struggled to obtain cannabis for the trial. Marinol was considered difficult to import. 
and Holdcroft was aware that the patient preferred herbal cannabis to THe. Fred Evans, 
Professor of Pharmacognosy at the School of Pharmacy, worked on inflammation, and 
he was able to provide small amounts of cannabis as a capsule. The MS Society. wary 
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of the drug's illegal status, refused to fund the study. In contrast, the Home Office 
appeared keen on the trial and wanted it scaled-up. This proved not to be feasible as 
finding other suitable patients was problematic. 
The trial revealed issues that proved to be a problem with later clinical trials. 
Holdcroft's patient could obtain cannabis off the street and he knew that it helped with 
his pain. On the placebo he became irritable and he had to be persuaded to remain in 
the trial. This issue of retention would reoccur with a vengeance in later trials. But 
despite these problems the results of the trial were positive. The drug showed anti-
inflammatory properties and highlighted significant reductions in additional analgesic 
requirements.1l Holdcroft was able to show that cannabis use reduced the amount of 
morphine required to control pain. But this was only a very small scale trial (n= 1): the 
study of one patient was not proof on its own. Others have argued that n=1 trials such 
as those used in psychological research might be a suitable alternative method, rather 
than favoured large-scale trials. 12 The trials of cannabis in small-scale studies meant 
experience was gained in the UK around the application of cannabis to MS and pain. 
Moffat recalled, that 'the clinical trials that had been carried out were either too small 
20-30 patients or had no real objective end points. ' and pressure grew for large scale 
trials.13 The nebulous qualities of these health problems and complex therapeutic under 
investigation had both benefits and complications for the clinical trials and the licensing 
of resultant cannabis-based drugs. 
Individual clinical research interests were brought together by professional bodies 
in the mid 1990s. By that stage professional bodies were prepared to become involved 
with cannabis and their influence and expertise facilitated the initiation of large-scale 
clinical trials. In 1995, the Council of the Royal Pharmaceutical Society, the regulatory 
and professional body for pharmacists in England, Scotland and Wales, took an active 
role in stimulating cannabis research. The Pharmaceutical Society issued a statement 
that noted that more clinical research was needed to investigate the potential therapeutic 
uses of cannabinoids in specific medical conditions. It suggested that since it would 
be some considerable time before the results of such research were available, there 
was a case for allowing doctors to prescribe cannabinoids for serious named disorders. 
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To this end the Pharmaceutical Sciences Group of the Royal Pharmaceutical Society, 
in conjunction with the MS Society and with the support of the BMA, arranged a 
public meeting, 'The Therapeutic Applications of Cannabinoids " attended b) over 
one hundred and thirty people, at the School of Pharmacy in March 1997. The goal 
was to survey the evidence for the medical use of cannabinoids, to review the history. 
chemistry and pharmacology of cannabinoids and to clarify the legal position on using 
cannabinoids therapeutically.14 
The meeting highlighted the need and pressure for research into medical cannabis. 
Dr Anita Holdcroft recalled, 
Different vocal groups were there. They strongly advocated the medicinal 
use of cannabis. We could see that some patients were getting value olll 
of it. There were concerns ... they had no idea of the doses. They were 
probably taking too much. 15 
Medical use of herbal cannabis existed within the patient community, and it could be 
argued that one justification for trials was to ascertain an efficacious and safe dosage. 
The meeting was a catalyst to the development of clinical trials. Anthony Moffat of the 
Royal Pharmaceutical Society (RPS) and Professor at the School of Pharmacy described 
how discussions at the end of the meeting stimulated his interest to move the process 
forward, 
Anita Holdcroft and I, and the Dean of the School of Pharmacy were there 
together and she said 'Why doesn i somebody do some clinical trials' ... I 
thought well she :s absolutely right. 16 
But the question was whether trials were feasible in the political climate. It appeared 
there was support from enough quarters to allow trials to go ahead. Anthony Moffat 
and Vivienne Nathanson from the BMA, and the School of Pharmacy met with Kenneth 
CaIman, Chief Medical Officer, who agreed it was a good time to do trials. I? Alan 
Macfarlane, Chief Inspector of the Home Office Drugs Branch indicated that a study 
would be viewed favourably but stressed the necessity for good quality proposals. 
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In order to develop such proposals infonnal networks of interested researc hers 
such as the Clinical Cannabinoid Group convened by Dr Pert wee \vere put on a more 
formal footing and the Clinical Cannabinoid Working Group under the auspices 
of the Royal Pharmaceutical Society was established to bring all interested parties 
together to work out the means to carry out trials. The group comprised of influential 
stakeholders and was chaired by Professor Sir William Asscher, fonner Chairman of the 
Committee on Safety of Medicines. It included representation from the NHS Research 
and Development Directorate, the MRC, the MS Society and researchers including 
Professor Pertwee, Dr Zajicek, Dr Anita Holdcroft and Dr William Notcutt. Anthony 
Moffat, the RPS's chief scientist, explained the Society's involvement, 
The Society has a long-standing involvement with research into the 
medicinal benefits of cannabis and the publication of this work shows that 
cannabis has some therapeutic effect in the treatment of MS. The Society :\' 
policy on cannabinoids (the active constituents of cannabis) was to see 
clinical trials undertaken to show the therapeutic benefits. 18 
The working group met in July and August 1998 and had a clear remit: To prove the 
value of cannabis, not to bring a drug to market. Sir William Asscher explained, 
We were quite insistent we would have no involvement in the development of 
drugs, merely the proof of principle. The drug industry would have to take it 
up. 19 
The objectives of the working group were to produce guidelines by which future trials 
could take place with the aim of speeding up and facilitating the process of approving 
and funding trials, trial development and publication of results. The group met over 
the eighteen months to hammer out potential trial designs.20 Clinical trial design and 
objectives were written into a document called a clinical trial protocol. The protocol 
operated as the 'operating manual' for the clinical trial, and ensured that researchers 
in different locations perform the trial in a similar way on patients with similar 
characteristics and was particularly important in multicentre trials. 
Those eighteen months proved to be a significant period in the process of 
re-medicalization of cannabis, as other events were taking place which created a 
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changed environment around cannabis and which smoothed the path for clinical 
trials. In 1998, substantial pressure for clinical trials both by academia and industry 
emerged with the publication of the House of Lords Enquiry into the therapeutic use of 
cannabis.21 In its evidence to the House of Lords Report, which is examined in detail 
in chapter seven the Royal Pharmaceutical Society was unequivocal in its support for 
clinical trials. It recommended research should be encouraged into the mode of action 
of cannabis and the development of synthetic cannabinoids; and that the government 
should support clinical trials into therapeutic uses of cannabinoids for MS, nausea, 
pain, anorexia and epilepsy. In terms of the legal situation they stated that cannabinoids 
should be downgraded from Schedule 1 to Schedule 2 of the Misuse of Drugs Act 1985. 
Such a move would have placed them in the same context as opiates and bypassed the 
need for a Home Office licence for research. In relation to cannabis-based products 
that might emerge the Society recommended that they should be able to be prescribed 
by a GP.22 The House of Lords Committee took on board these recommendations and 
concluded, 
We therefore recommend that clinical trials of cannabis for the treatment 
of MS and on chronic pain should be mounted as a matter of urgency. 
We warmly welcome the fact that ... both Dr Geoffrey Guy and the Royal 
Pharmaceutical Society:S working group under Sir William Asscher have set 
off down this route. We welcome the Asscher :s group intention to compare 
the effects of a standardized preparation of natural cannabis with those of 
one synthetic cannabinoid already available, dronabinol. 23 
The House of Lords Report therefore stimulated both proof of principle trials, and also 
trials by industry which aimed to license cannabis-based drugs. Though the Report was 
rejected on the day of publication, attitudes in government towards the medical use of 
cannabis had shifted and it was indicated that the licensing process would be facilitated 
and few researchers found hindrances in this respect. Cannabis' illegal status provided 
political pressure and a flow of funding for research into cannabis, that many potential 
legal medicines did not attract. Zajicek commented on the background politics and the 
auspicious timing of the trials. 
It was luck really. A time when there were a number of factors that all 
conspired together. There was a big push to make cannabis legal. The 
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government wanted to test new treatments. New Labour didn i want to 
legalize. They wanted it to be tested. They were keen on getting results 
through scientific evidence. 24 
Patient experience and advocacy played an important role in the stimulation of trials. 
The patient perspective was particularly important in pain management. Holdcroft 
elaborated on the significance of pain and MS in the flexible attitudes in the UK towards 
cannabis. 
In pain you listen to what patient tells you ... its very much a subjective 
assessment. So it seemed reasonable to follow up on their experience. It 
was also what MS people saying. Only really happened in this country .. 
... . .1 think it was because there was some latitude in the use of cannabis (in 
the UK).25 
User activism was important and Holdcroft recalled, 'there was quite a lot of activity 
through the MS SOCiety. They were starting really to lobby,26 The UK governments 
interpretation of the international conventions meant that it was possible for clinical 
trials to go ahead. 
Funding clinical trials and the role of the MRC 
The government was especially keen to support research that could provide a licit 
cannabis-based medicine and therefore eliminate the use of the medical argument for 
legalization of cannabis. But to do this it was necessary to have a better evidence-
base, hence the need for trials. Zajicek argued that the illicit nature of cannabis and 
subsequent pressure from government helped direct funds into cannabis. 
We are lucky in that it s got a high profile in that it s a drug of abuse. If it 
wasn i I don i know if we would have funding now. I have a lot of colleagues 
that want to do clinical trials and can i. You need to have reasons to do 
one .... having politicians on your back is useful. It's good for us to some 
extent. 27 
Clinical trials have always been an expensive and complicated process. The support 
provided by the MRC was important both financially and to ease the burden of 
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multi-centre trials. Zajicek commented on the role of the MRC , 
We didn't have funding. So we approached the MRC. They were helpful in 
trying to make sure grant applications were successful .... And in facilitating 
the co-ordination of the study. 28 
The MRC was reorganized during this period and the cannabis trials benefited from 
the new structure. The MRC Clinical Trials Unit (CTU) was formed in October 1998 
to continue with research programmes in HIV and cancer and with its activities in 
statistical methodology, meta-analysis and quality of life research. In addition, the CTU 
directed by Professor Janet Darbyshire aimed to initiate trials in new areas where there 
were important questions but where there was either insufficient infrastructure or few 
clinical trials. A MRC Trial Development Group advised applicants on cannabis trial 
designs to ensure that applications were highly competitive in obtaining funding. The 
MRC participated in the Royal Pharmaceutical Society'S working party on therapeutic 
uses of cannabis. It reported to the House of Lords Committee that there was a shortage 
of high quality research proposals in the area and indicated that it would be supportive 
of funding clinical trials and would consider grant applications out of turn to speed up 
the process. 
It is particularly important that the potential for new medicinal drugs .... 
is not stifled by considering all cannabis-like compounds as medically 
unacceptable because of the abuse potential of the natural product . ... 
The MRC would be supportive of funding well-conceived clinical trials .... 
It is important to evaluate in a rigorous manner whether cannabis or 
cannabinoids do indeed offer any relief of symptoms in neurological 
disease. 29 
Holdcroft cited later the role of the House of Lords in encouraging the MRC to fund 
trials. 
The House of Lords put pressure on the MRC to do this study because 
they recommended trials. Normally trials are done by a pharmaceutical 
manufacturer rather than government and the MRC doesn [ normally fund 
them unless for spectfic purposes. 30 
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The result was that Zajicek's trial, CAMS, received an initial one and a half million 
pounds and Holdcroft's trial, CANPOP, half a million pounds from the MRC. Shortfalls 
were sought from specific disease charities such as the MS Society. 
The development of clinical trials: Cannabis form, supply and 
administration. 
A major question for the trials was the form of cannabis to study. Both the industry 
and proof of principle trials incorporated the study of extracts of cannabis as well as 
synthetic THC. GW Pharmaceuticals grew its own cannabis, and solved the problem of 
standardization and supply when it developed an oral-mucosal spray based on extracts 
of herbal cannabis. For the 'proof of principle' trials much debate took place over the 
forms of cannabis to trial. Zajicek explained, 
We had to work out which drugs we were going to use. We knew that THC 
was likely to be the most active ingredient. THC was already being used 
because in US it had a licence in the form of Marino I for nausea related 
to cancer chemotherapy .... IfTHC worked we would be able to get it out 
quickly because it was already being manufactured and used. We wanted 
to put THe in there. But if it didn i work and there was something else in 
cannabis then we would be criticized so we had to include an arm with a 
cannabis extract. 31 
The trials were focused mainly on THC. Marinol was an obvious choice, and UNIMED 
was prepared to supply it free of charge. 
But these trials marked a new avenue for clinical trials: extracts of cannabis. This 
was not without controversy as the use of an extract posed concerns. Some feared 
potential diversion of use, and others such as Professor Ashton and Professor Nathanson 
from the BMA were against the use of material other than a synthetic single entity 
chemical on the grounds that a botanical extract was a complex substance with unknown 
effects. Zajicek highlighted some of the difficulties involved in the investigation of a 
botanical extract. 
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It s very difficult to identifY every last component. THe is manufactured 
so we know what is in there. In an extract from a plant there are tens of 
different can nab ina ids and all other things such as flavinoids. 32 
Nevertheless, pressure was mounting for evidence-based research into something more 
akin to the herbal cannabis with which patients self-medicated. GW Pharmaceuticals 
had decided to go down the extract route, and Professor Asscher's working group was 
keen to see this area investigated believing it was possible 'to overcome problems of 
standardization, and reap benefits of the whole plant. '33 Professor Wall was also in 
favour of the investigation of an extract rather than pure cannabinoids and he criticized 
the BMA's position of testing only synthetic cannabinoids. Support for an extract was 
diverse: from the Royal Pharmaceutical Society, to researchers including Professor 
Roger Pertwee and patient groups like the ACT whose members were already using 
herbal cannabis and the MS Society which wanted to test all options. Holdcroft 
explained why those interested in pain wanted to pursue an extract. 
We were starting to know what compounds were in the plant. There was 
a big lobby to use the plant rather than THe. For pain it was obvious you 
needed to use more than one drug ...... so the use of something that had a bit 
of something ... no problem .... as long as we knew what was in it ... 34 
Technology had moved on and helped make clinical trials into extracts of cannabis 
feasible. The advent of mass spectrometry techniques in the 1980s made the original 
argument that it was not possible to define what was in a plant less powerful. Indeed 
instead of being viewed as problem, a mixture of substances was seen as potentially 
advantageous especially for pain and MS. On this basis, the protocols incorporated an 
arm that attempted to explore the effect of 'whole' cannabis. 
The provision of an extract was more complicated than provision ofTHC. The 
School of Pharmacy had for the previous twenty years produced cannabis under the 
guidance of Fred Evans who had grown cannabis for the Home Office. Evans who was 
head ofthe Centre of Pharmacognosy, (1994-98) specialized in the irritant phorbol 
esters with pro-inflammatory and tumour promoting activities, biologically active 
principles of cannabis and herbal medicine. However, the School was not geared up to 
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provide the quantity needed for multi-centre clinical trials. Such large quantities were 
usually provided by industry. Furthermore, standardizing the product remained an 
issue. Initially, those who designed the protocols hoped that GW Pharmaceuticals might 
provide the extract arm but financial and practical constraints intervened. Zajicek had 
met Guy in the 1990s and had discussed a supply of material but G W, in its formati \e 
stages, did not have a product to commit and Guy would have required payment.35 As 
in the 1970s, low or zero cost of research material was important. The presentation 
of the protocols at a Royal Pharmaceutical Society meeting in 1999 had presented the 
opportunity to introduce the project to potentially interested companies. A German 
charity, the European Centre for Immunological and Ontological Research produced 
Cannador, a standardized pharmaceutical preparation in the form of capsules which 
contained cannabis extract grown in Switzerland, and encapsulated in Germany. It 
agreed to provide the product free of charge. Ensuring continuous supplies of imported 
material however concerned researchers. Cannador depended on the ability of the 
charity to provide a continuous free supply, while Holdcroft raised the issue that the 
United States restricted THC production which might limit its usefulness for large-scale 
clinical trials.36 
Delivery systems related to the administration of herbal cannabis were a major 
stumbling block. The clinical trials ofTHC in the 1970s and 1980s were based on 
a capsule, but these had had problems in that those suffering from nausea found 
them difficult to take and the capsules had a long time- lag in comparison to smoked 
cannabis. Smoked cannabis however remained a pariah in an era of anti-smoking 
campaigns, though such trials were not totally ruled out. The House of Lords Report 
recommended, 'research be promoted into alternative modes of administration eg 
inhalation, sub-lingual and rectal '.37 The protocols however eliminated smoking as a 
delivery method. Zajicek explained the decision for the CAMS trial, 'It was decided 
at an early stage that the drugs would be administered in capsules by mouth because 
of the increased dangers of smoking such drugs. 138 The ultimate goal was a method 
of administration which provided the rapid absorption provided by smoking. G Vv' 
Pharmaceuticals hoped to solve the administration issue by the production of a new 
delivery system for cannabis. But Zajicek had concerns about that, . He knew;;-0111 
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conversations with other companies that this was going to be quite difficult because 
it s (a spray) quite an irritant. '39 As a result the CAMS trial remained with the THC 
capsule route. 
Ethical and bureaucratic issues had to overcome which were doubly difficult in 
the case of cannabis. In the UK a trial had to be approved by the Medicines Control 
Agency (MCA, which after 2003 became the Medicines and Healthcare products 
Agency, MHRA) and if approved a clinical trials certificate would be issued. Approval 
to study an illicit substance was also required in the case of cannabis. Because 
material had to be obtained from abroad, import and export licences had to be obtained. 
Normally, animal data would be expected from Phase I trials. Cannabis however was a 
'peculiar substance' and this for once worked in its favour. It had a long pre-history of 
use and illicit self-medication existed within the community. For the proof of principle 
trials it was hoped to begin with a cross between a Phase II and III tria1.40 However, 
initially the MCA wanted additional animal data and evidence on further aspects of the 
different cannabis extracts. This was a problem as there were no facilities in Plymouth 
for such work. A combination of events worked to the benefit of the trials as the issue 
was resolved pragmatically on the grounds that GW Pharmaceuticals was to review 
animal studies, and widespread use of cannabis in the community made it unnecessary 
to repeat the work. 
Cannabis posed particular concerns for obtaining trial licences. From the 
regulators point of view there were major concerns over the possible side-effects of 
cannabis. The risk of psychotic effects had always been an issue with cannabis and 
was a particular worry in clinical trials.4 ! Though clinicians were aware of a potential 
risk they calculated that the difference between medical dosage and recreational dosage 
mitigated the problem. Ziajeck described the implications. 
It s an increasing story that there is an association between psychosis 
and heavy illicit use. It s an association, and it may not be causative but 
evidence is becoming more convincing .... You can't shut your mind off to 
those issues but that is another reason to do a long-term study .... In illicit 
lise the amount ... is massive compared to licit medical use. lou don i go out 
to get high ... yoll try to lower the dose to avoid side effects. 42 
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Regulators were concerned over the extract arm of the trial especially CBD which was 
less well known than THe. A compromise was reached. It was agreed to carry out a 
pilot study in Plymouth with a psychiatrist on standby.43 The pilot started in Plymouth 
with twenty five patients who were contacted every three days in case of any psychotic 
episodes. No serious problems emerged. 
Other ethical concerns were issues common to all clinical trials. If a test drug 
proved successful, and patients found it helpful, what were the ethical implications of 
withdrawing a drug at the end of the trial period?44 In Zajicek's MS trial, a compromise 
agreement was reached to place patients back into treatment for an additional year. 
In the case of the GW Pharmaceuticals trials, Guy emphasized that any patient who 
believed that they had gained benefit during a study and who wished to continue to 
receive material beyond the end of the trial would be entered into a long-term safety 
extension. Guy explained, 'This is what politicians and ethics [committees} wanted. '45 
Support from the Department of Heath and Home Office was necessary for trials 
to take place on an illicit substance. Licences to possess any Schedule 1 drug for 
research had to be granted by the Home Office on the basis that there existed legitimate 
reasons for research. To be granted a licence researchers had to provide details of 
methodology and timescales, ethical approval and safeguards for safe custody and 
record keeping as well as delivery methods that allowed for controlled dosages. Twenty 
five licences for research projects on cannabis had been granted previously and the 
Home Office argued research was permissible under current mechanisms. 
Research into both cannabis and cannabinoids is possible within the 
existing policy and legalframework ... The Home Office and the MeA look 
sympathetically at ... research proposals and within the Department of 
Health we very much recognize the importance of research in this area and 
its potential value. 46 
It was hoped that the provision of' good practice' for trials would speed the process 
oflicensing and licences were granted for the trials. Clinicians spoke highly of the 
assistance rendered by the Home Office in licensing trials after 1997. Zajicek described 
the facilitation of the process, 
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Everyone s been fantastic. When you do this kind of stuff you've got all 
these hurdles to overcome. The Home Office were great. The "\iRe was 
fantastic. It was relatively easy ... as people were keen that it took place. r' 
The necessity of importing the drugs resulted in complications because international 
narcotics conventions required FDA export and Home Office import licences and both 
had to coincide which led to complicated logistics. But all these moves took time 
to initiate and co-ordinate and as discussed in chapter six this raised concerns over 
a long-time lag for patients. The MRC funded trials had not been developed to lead 
in themselves to the licensing of a cannabis-based medicine. If positive results were 
shown a pharmaceutical company was expected to license a related drug. This would 
take time. GW Pharmaceuticals had produced a therapeutic preparation in order to 
license it should it prove successful in trials. But what remained was the no small 
matter of passing that product successfully through the trials and for the drug to proceed 
through the UK/European regulatory system in order to see the provision of a licensed 
cannabis-based medicine. 
Trials and their outcomes. The results and emergent issues of the 
clinical trials and their impact on the re-medicalization of cannabis 
Both the 'proof of principle trials' and the industry trials demonstrated some degree of 
success and they showed few side-effects and some benefits. But they also highlighted 
a number of emergent issues associated with clinical trials in general, and some that 
were particular to the study of cannabis in the clinic. 
One of the main problems was the issue of recruitment. The first hurdle for 
the trials was to obtain the patient numbers required to run a large clinical trial: a 
necessity to overcome the criticisms over the evidence-base resting only on small-
scale studies. Recruitment problems stopped one trial from starting. CANPOP had 
aimed to investigate acute pain relief following tonsillectomy or abdominal surgery.48 
CANPOP suffered serious recruitment problems and was closed in October 2003 after 
only six patients had been recruited and randomized.49 The sample did not provide 
enough information to perform a statistical analysis. Issues of recruitment. often an 
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issue with clinical trials, posed special problems for a study of cannabis. Recruitment 
appeared subject to fluctuating public perceptions of the benefits versus the risks of 
cannabis.50 Holdcroft complained later, 'recruitment was so dependent on the media. If 
the media said something awful on recreational use we didn't get people on the trial. '51 
Holdcroft commented on frequent media reports linking cannabis use to mental health 
problems and she recalled, 'lobbyingfrom the psychiatrists emphasised the bad effects. 
It was this, the media picked up on. These reports used to come at regular intervals '.52 
The media has been noted as presenting an oversimplification of cannabis issue that 
polarised a highly complex issue and distorting appraisals of risks.53 Perceived medical 
problems attributed to recreational use impinged on clinical trials of therapeutic 
cannabis. 
This problem was especially significant in the area of pain where there was a 
desire to recruit 'naYve patients'. Previous trials had focused on 'cannabis aware' 
patients in order to overcome prescription problems but this in tum had caused problems 
due to lay knowledge and the ability of the patient to co-operate in placebo-controlled 
trials. Discussion with the MRC during protocol design had meant that trials focused on 
the provision of the drug to 'naYve' patients after surgery. Using drug-naYve patients was 
seen as advantageous in that it provided better compliance with study requirements but 
such patients proved harder to recruit. 
Retention posed further problems in the CANPOP trial as patients that agreed 
to take part initially dropped out after surgery. Holdcroft described the problems with 
consent. 
The trial had significant technical problems ... they (MRC) said .. had 10 be 
assessed on its(cannabis) own without any other drug and with someone 
in moderate pain .... this led to ethical questions ... Should we not be using it 
along with the opiates? We had to take consent prior to someone entering 
study ... in the cold light of day they could decide whether they wanted to be 
in moderate pain or not. .... so we had to consent a large number of patients 
who never did the study as ... they could not take the oral medicine. 5-1 
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Thus the trial recruited pre-operation but, in pain after surgery, or unable to take the 
capsules, many of those patients dropped out of the trial. In pain treatment it \\ as 
considered normal procedure to administer more than one drug, for example. in 
combination with the opiates. But for licensing purposes it was necessary to administer 
and measure only one drug: THC or an extract of cannabis. Holdcroft explained some 
of the problems that this approach engendered. 
Drug regulatory agencies only compare and consider a drugfor licensing if 
used on its own ... If we use ibuprofen and morphine separately they do not 
provide as much pain relief .. they enhance each others effect. ss 
Holdcroft's initial patient in the trial in 1995 used cannabis to reduce the amount of 
morphine required. But in the later trials cannabis had to be studied in isolation, which 
was in contrast to most pain management procedures. Trial design, which was designed 
to suit regulations, therefore failed to trial one potential cannabis application. 
When the trial closed early through to lack of recruitment, Holdcroft retained 
funding allocated for the main trial and she intended develop methodology for a new 
trial. But in the intervening period the medical environment changed. For instance, 
technological advances in surgery reduced the intrusiveness of surgery and resultant 
pain. Furthermore, the failure of the first trial had led to MRC concerns about funding 
another. Holdcroft commented on the MRC's decision, 
Having got the money, the MRC ... decided not to do it. The money went 
back to the MRC. They thought it had taken too long and that perhaps it 
was not worth the money. We started with 4 hospitals. In the end we had 
over 20 ... so we had all these ready to start, then the MRC pulled the plug. S6 
The failure of the first trial and loss of momentum weakened the pressure for additional 
trials in acute pain and interest swung away from acute to chronic pain.57 
The study of cannabis for chronic pain posed other problems. Because of the 
regulatory process it was necessary to test the drug for chronic pain for one disease, 
it could not be tested for chronic pain generally. This led to a guessing game 0\ er the 
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choice of illness to test, not to mention the unknowns around long-term treatment for a 
chronic condition. Holdcroft explained the concerns with the investigation of cannabis 
for chronic pain. 
It has to be licensed for a certain sub-group of patients. It~, like guessing 
who will benefitfrom it more. It can t be licensedfor chronic pain, it has 
to be for a specific incidence e.g. pain with stroke. I have concerns about 
long- term effects. there are no studies on long term usage and dosage. 58 
Though the main trial did not proceed, the interest in acute pain did yield some useful 
results. An aim of clinical trials had been to determine dosages and a dose escalation 
section ofthe trial was run successfully.59 This was a non-randomized dose-finding 
study to determine the dose of cannabis needed to achieve analgesia for post-operative 
pain in the main randomized trial. The study identified a dose of cannabis plant extract 
that could provide pain relief and possible therapeutic benefit and the trial researchers 
reported positive results on dosage in 2006.60 
Issues of recruitment were less of a problem for the MS studies but the time it 
took to recruit meant that clinical trials were long-term projects. A subsequent trial 
on MS, CUPID, took two years to recruit the full cohort of patients. The CAMS 
(Cannabinoids in MS) trial began in 2001 with 667 patients. Recruitment was an issue 
with the CAMS trial but not to the same degree as CANPOP. Unlike the CANPOP trial 
Zajicek found patients happy to take part in the trials, and less scared off by adverse 
media reports.61 
Retention posed particular problems for the study of cannabis and MS. Long-term 
trials for a progressive disease posed a particular set of problems. Zajicek highlighted 
problems. 'It remains difficult to keep people on studies if they think they are getting 
worse, even if (we) think the line (of progression) is less worse. '62 This led CAMS trial 
clinicians to improve measurement instruments in order to obtain statistically significant 
results in a shorter timescale and these were adopted for a follow up trial, CUPID. 
Lay knowledge of cannabis also posed unusual and major problems for the trials. 
A problem faced by clinical trials in general has been that patients often desired tl) ha\ e 
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the active drug not the placebo. This posed a particular problem with the cannabis 
trials. Lay knowledge meant patients were not 'blind' but rather became aware of which 
drug they were given in the trial and this posed two problems for the trial. Benchmark 
clinical trials were generally expected to be double-blind. This requirement posed 
a particular threat to cannabis trials. It was unusual to test a new drug about \vhich 
patients already possessed a good deal of knowledge and with which they may have 
been self-medicating with the herbal product. Patients were able to anticipate and 
recognise the side-effects of cannabis and tended to work out whether they were on the 
active drug or the placebo. It was possible for knowledgeable pro-active patients to 
take the drugs and have them tested for the active ingredients. Zajicek recollected 'one 
patient got the pills assayedfor THe andfound they were on placebo. People knew 
what they were taking. '63 The problem was compounded because cannabis was readily 
available on the black market, Zajicek commenting that it was 'more difficult to do long 
term trials if there are other sources.'64 This alternative availability encouraged some 
patients to drop out of the programme. It also caused problems for gaining statically 
significant results and opened the door to criticisms over trial evidence in relation to the 
trials validity. A major issue with any clinical trial is the placebo effect and unblinding, 
and the cannabis trials were no exception. Trials on cannabis were criticized on the 
grounds on these grounds as well as and efficacy. The report of the MCA on the GW 
trials highlighted some of the issues. 
The fact that a substantial proportion of patients had previously taken 
illicit cannabis as self medication increases these concerns, firstly, because 
this may have enabled them to recognize Sativex by its psychoactivity, and 
secondly because they might have greater expectations of benefit from 
Sativex treatment than would cannabis nai"ve patients ..... differences from 
placebo on efficacy measures were small and there was concern that such 
differences could be accounted for by unblinding and measurement bias. 65 
Patient selection became important. Patients wanted the active drugs. This knowledge 
had led to issues of patient selection and raised the concept of 'good patients.' CAMS 
clinicians found it important to select patients who were prepared to take part in a test. 
and they attempted to weed out patients who merely wanted access to cannabis. The 
problem had its humorous side as Zajicek commented on the selection of patients, 
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'most clinical trials have dropouts - few trials with dropins ...... It:5 about patient 
selection. It important to choose people who do not behave badly'. 66 The problems 
led some researchers to question the importance ofthe concept of un blinding in 
clinical trials. Zajicek argued unblinding was not so important in the instance of the 
MS trial and argued' if we can prevent patients becoming wheelchair-bound people 
aren't going to complain about some degree of unbinding. '67 The MHRA appeared to 
accept this compromise to a degree. In response to a similar problem in the GW trials 
it commented that unblinding was not a major concern in the face of a compelling 
treatment.68 The importance of un blinding appeared to be related to the efficacy of 
cannabis-based drugs, but proving efficacy was the biggest stumbling block for the 
trials and to the re-medicalization of cannabis. Steering cannabis into clinical trials 
was one thing, proving it was a valuable treatment for MS and pain was quite another. 
The CAMS trial, for example, reported a very small improvement in scores for all 
three treatment groups, and these improvements were slightly greater in the cannabis 
groups than the placebo group. However, none of these changes reached statistical 
significance. Results were published in the Lancet in 2003 and the study was criticized 
for similar reasons to the GW trials including unblinding, placebo effect, and efficacy.69 
But was cannabis not efficacious or were clinical trials not effectual in measuring 
cannabis' effect? 
Efficacy proved difficult to show partly due to the outcome measures and the in-
struments used to test them as specified in the protocols. This was compounded by the 
nature of the disease under study. Holdcroft summed up the problem, 
MS has been seen as the most acceptable disease in the UKfor trials of 
cannab ino ids. Unfortunately there are probably few diseases that are 
harder to conduct clinical trials on. 70 
The choice of disease under test was a problem as the symptoms proved difficult to 
measure. A pre-determined outcome measure is specified in a trial protocol and was 
expected to provide objective measurement: an instrument against which success or 
failure is measured. A major hindrance to these trials was the problematic outcome 
measures in existence for MS, and pain. A point in favour of the investigation of 
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cannabis for MS was the fact that MS had a raft of symptoms, and cannabis it seemed 
might have a raft of possible impacts on the body. Robson explained the impact of 
cannabis' properties. 
One of the great strengths of cannabis is its breadth of effect against a 
range of symptoms .... in the beginning we tried ... . to demonstrate that 
breadth of effect as one of the major assets of the drugs .... Unfortunately, 
the more you spread your target in a clinical trial the harder it is to get a 
statistically significant result. Also, because of the standard way of doing 
things in regulatory authorities ... they are lookingfor specific indications 
of drugs ...... the nearer you can get to a magic bullet the better. Cannabis 
is not a magic bullet. That breadth of effect which is so valued by patients 
with mult-symptom disease such as multiple sclerosis or HIVIAIDS has been 
a handicap in getting it through the trials. 71 
This breadth of effect was one of the reasons Paton had been wary earlier of cannabis as 
a therapeutic as opposed to its use as a lead. 
The lack of subtle outcome measures may have contributed to a failure to prove 
usefulness to the extent required by clinical trials. Both GW Pharmaceuticals and 
the Zajicek trials used the Ashworth Scale for measuring spasticity. It was a widely 
used scale because it was relatively simple and allowed for ease of reproducibility 
in experiments. The trials cast doubt on the measure's usefulness. Zajicek later 
commented, 
Measurement methods are not subject to scrutiny or if they have been they 
have fallen below acceptable levels ... If we had a decent symptom measure 
for example in cannabis, they would probably all be licensed. 72 
The scales lacked sensitivity especially over a short time-span. Zajicek elaborated 
further on the lack of sensitivity of instruments that were available for the initial trials. 
The problem is that particularly in progressive disease we don t have the 
measurement instruments that reliably detect potential small levels of 
change, but levels that might be important to individuals, H'e don I hal'£! the 
sensitive outcome measures to evaluate the treatment. There needs to be 
huge improvement ... 73 
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This proved a problem because the scales could not detect change over a short space of 
time, and this in tum impacted on recruitment and retention. Zajicek explained. 
The standard measurement is an awful measure. In order to see change you 
need three years .... deteriorating people don't want to stay in the study. 74 
The patient perspective however showed the trials to be more successful than the 
outcome measures indicated. Listening to the patient experience the clinicians hoped 
that they were onto something, despite the ambivalent results which would not have 
satisfied regulators. Zajicek recalled the disparity between results and the patient 
experIences. 
Patients were rating that they found significant effects '" ... The bottom 
line was the primary outcome measures .... that study was not regarded as 
suffiCient proof to use or license. We were left there with patients believing 
that the drug worked. 75 
The dichotomy between the patient experience and the results as demonstrated by the 
outcome measures caused clinicians to extend the trial for a further twelve months. 
This trial extension brought some of the first statistically significant results and ones that 
corresponded with new developments that had emerged from the laboratory in the 1990s 
on the role of cannabinoids in neuroprotection. 
Patients were followed up from the CAMS study for 12 months ..... After 12 
months we started to see positive results in the Ashworth score and other 
outcome measure of disability ... Rivermead mobility index ...... Over a year, 
we saw a spreading out of symptom benefit to other symptoms, like fatigue. 
To me this was very exciting but people took it with a pinch of salt ... But the 
suggestion was, there was something there. 76 
The results from the trial extension were seen as sufficiently promising to warrant 
a further trial on a new application of cannabis-based medicine; one that intended 
to overcome earlier criticisms, making trials longer and incorporating the new 
methodologies. Clinicians aimed not only to show symptom relief but raised an 
exciting new possibility and one which was in line with new laboratory research after 
the discovery of the endocannabinoid receptor system; that THe, might slow the 
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development of disability in MS. To this end a new trial was developed called CUPID. 
(Cannabinoid Use in Progressive Inflammatory Brain Disease) funded by the MRC at 
one and a half million pounds and another one and half a million pounds \vas provided 
by a mixture of funding from the Plymouth Medical School. the MS Society and the MS 
Tru st. 77 
Supply of cannabis-based products for the trials provided an ongoing problem. 
Reliance on a free industrial source of synthetic THC initially posed problems for the 
continuation of the CAMS trial and then for the CUPID trial, with acquisitions and 
mergers breaking the supply of Marinol. UNIMED which had provided the THC, to the 
initial MRC trials was bought out by the pharmaceutical firm. Solvay. It appeared that 
Solvay may not have been aware of the agreement with UNIMED when they bought 
the company.78 After discussion with the clinical trials team, Solvay and the MRC 
turned what had been a gentlemen's agreement into a firm contract intending to secure 
long-term supply.79 Solvay provided further funding to increase monitoring of the 
trial in case it proved possible to move to licensing if there was a successful outcome. 
'MRC trials tend to be proof of principle and the science level of monitoring less than 
in industrial. '80 But with the CAMS trial results ambivalent Solvay lost interest in 
the research and would not supply the CUPID trial. They were more interested in a 
small study related to migraine than work with the more complex MS.81 However, one 
of the employees, George Cattier who had previously worked for UNIMED, moved 
on to set up his own company, Insys. He agreed to provide the THC free of charge 
and he increased monitoring in the hope of moving towards licensing, if trials proved 
successful. Contracts were drawn up more tightly this time with the aid of the MHRA. 
The supply of cannabis extract was less complicated. The German charity which had 
undergone a name change to IKF agreed to continue supply and they set up their own 
separate substantial UK based commercial trials on MS symptom relief. 
New methodologies were developed. Zajicek and others began work on new 
outcome measures and borrowed methodologies, which included patient questionnaires, 
from the social sciences. Other new technological developments were brought into the 
trials. In CUPID, a host of other measurements including scanning and a ne\\ spasticit~ 
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scale were added to the trial protocol. The new scale aimed to split the concept of 
spasticity into separate entities including: symptoms; psychological effects; and the 
effect on movement and mobility.82 Zajicek argued that the trial was important for its 
methodological breakthroughs. 
Even if the drug does not work it will be a really important study in terms of 
the methodology ... we will be able to look at which bits of the measurement 
instruments are effective. 83 
In summary trials had been slow to start and the results somewhat ambivalent, however. 
they had been promising enough to warrant further large-scale, longer term trials and 
they also yielded outcome measures that it was hoped might stand a better chance of 
capturing cannabis' effects and enable clinicians to demonstrate efficacy. Crucially, 
they showed cannabis had few adverse side-effects, one of the primary fears around 
cannabis. The licensing of any cannabis-based medicine was left to industry. 
The OW Pharmaceuticals trials had been designed with the aim of bringing a drug 
to market. Phase I clinical trials began in late 1999 proceeding to Phase I II in 2001, on 
patients with MS and neuropathic pain and in 2002 pain associated with cancer. 
The proof of principle trials had concentrated on THC in the form of Marinol which 
was already licensed for another application. The process of making this available for 
MS and pain would therefore have been simpler if efficacy was proved. However, OW 
attempted to license Sativex, a Cannabis-based Medicine Extract (CBME) so the route 
to licensing was different and more complex than for a New Chemical Entity (NCE).84 
The form of cannabis used in Sativex caused concern to the regulators. As discussed 
in the previous chapter, the House of Lords Committee of2001 questioned whether 
the MeA was biased over this cannabis-based drug and called into question their 
judgement. 
The MCA s decision to insist onfurther toxicology data on CBD could de/en' 
the production of a cannabis-based medicine by G. W Pharmacelllicals 
by as much as 2 to 3 years. Were the MCA not to require further extensive 
toxicological studies on CBD, GW Pharmaceuticals claim that they could 
have a cannabis-based prescription medicine available for patients in ]003 
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We note that, according to GW Pharmaceuticals, the Canadian regula/DIY 
authorities have stated that they do not require additional animal toxicology 
studies for CBD. We put this to the MCA, who refused to comment, we 
found this refusal highly unsatisfactory. 85 
The problem was that GW Pharmaceuticals and the House of Lords committee argued 
that cannabis extracts should not be considered as a new medicine whereas the MCA 
was inclined to do so. Furthermore, the House Lords Committee argued that the MCA 
was not treating cannabis in the same manner as other potential medicines and placed 
undue emphasis on assuring safety to the detriment of providing a remedy for patients. 
The House of Lords Report explained, 
We are concerned that the MCA s approach to the licensing of cannabis-
based medicines, and their insistence on the provision of new toxicological 
data which could delay the approval of such medicines, place the 
requirements of safety and the needs of patients in an unacceptable 
balance. Patients with severe conditions ... are being denied the right to 
make informed choices about their medication. There is always some 
risk in taking any medication; patients and their doctors should certainly 
be informed about the toxicological concerns that the MCA have raised, 
but these concerns should not prevent them from having access to what 
promises to be the only effective medication available to them. Overall, we 
consider that the MCA s attitude means that cannabis-based medicines are 
not being dealt with in the same impartial manner as other medicines. 86 
The MCA denied any bias. But in the following year GW struggled to move Sativex 
through the licensing process. In 2003 GW submitted its licensing or marketing 
authorisation application MHRA. It was refused in 2004. The MHRA decided not to 
license Sativex in the UK as the Committee on Safety of Medicines was not satisfied 
with the efficacy of Sativex in the indication sought by the company stating that, 
In reaching its advice the Medicines Commission ... considered all the scientific 
data and arguments presented, and concluded that that the evidence of efficacy 
was insufficient to support granting marketing authorisations. 87 
Sativex was rejected not on grounds of safety, but on failure to detect useful effects. 
Concerns included the small-scale nature of the trials in comparison to most other 
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commercial clinical trials, whether the trials were adequately blind, and whether the 
trials showed any statistically significant effect.88 
But the patient experience had called this assessment into question. As discussed 
in chapter six, the patient community greeted the refusal of Sativex in the UK with 
disappointment. Commenting on the MHRA's decision not to grant a licence, Mike 
O'Donovan, chief executive of the Multiple Sclerosis Society, expressed the belief that 
there was enough evidence that Sativex could alleviate spasticity.89 Proving efficacy 
was reliant on the outcome measure and the patient perspective appeared to be sidelined 
by the measures upon which the decision was based. O'Donovan placed pressure on the 
Medicines Commission, which advised the MHRA, to be more flexible and he placed 
greater emphasis on patient relief 90 
However, though not approved in the UK, these clinical trials showed serious 
progress for re-medicalization. Iverson stated, 'the results with Sativex are clearly an 
important advance in the modern clinical development of a cannabis-based medicine. '91 
The trials resulted in the first licensing of a cannabis-based drug based on an extracts 
of cannabis in April 2005 when GW received regulatory approval for Sativex® from 
Health Canada for the symptomatic relief of neuropathic pain in Multiple Sclerosis later 
extended to adjunctive analgesic treatment in patients with advanced cancer. It attracted 
Big Pharma in the form of Bayer AG (later Bayer HealthCare) to enter into a strategic 
alliance with GW. Marketing of this new drug was critical. Drugs such as nabilone had 
struggled to establish themselves partially through limited marketing. OW announced 
that exclusive commercialization rights for the drug in the UK had been licensed to 
Bayer AG. This agreement also provided Bayer with an option to expand their licence 
to include the European Union and other world markets. 
But the licensing process proved more difficult in the UK. In 2005, OW 
Pharmaceuticals unsuccessfully appealed against the advice given by the Committee 
on Safety of Medicines to the MHRA but the MHRA agreed with the Committee and 
requested further clinical efficacy data.92 However a system existed in the UK \\ h~reb: 
drugs could be exempted from the licensing system and prescribed on a nam~d-patient 
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basis. Although Sativex was not licensed in the UK it was issued to patients \\ ho had 
been in trials on a compassionate basis. After Sativex was licensed in Canada, and 
under pressure from both patients and doctors, the Home Office and the MHRA. allowed 
the import of Sativex as an unlicensed medicine to be supplied on an individual patient-
basis for MS on a doctors' responsibility.93 A GW press release in 2005 announced. 
GWannounces that it has been informed by the Home Office that the Drugs 
Minister, Paul Goggins, has corifirmed that Sativex(Rl oromucosal spray. 
its cannabis-based medicine, may be imported from Canada to satisfy its 
prescription to individual patients in the UK as an unlicensed medicine. 
This development is in response to enquiries from a number of UK doctors 
and individual patients who have been in contact with the Home Office to 
request access to Sativex. 94 
The named-patient basis was a system used to provide off-licence drugs to particular 
patients and was most commonly used in oncology. This situation brought additional 
meaning to cannabis' borderline position, not quite approved, but sufficiently approved 
to permit its importation for use on a named-patient basis and provided a 'wedge' 
between a legal and illegal drug. Professor Holdcroft summed up the resultant situation. 
What I'm not sure is why the legal side hasn i changedfor medical 
cannabis. Guy used a wedge through..the named-patient basis. But it 
(Sativex) is quite expensive, not used everyday. 95 
The Home Office granted GW Pharmaceuticals a licence that permitted the company 
to import a product that contained a substance controlled under the Misuse of Drugs 
Act. Lack of efficacy was not considered grounds to refuse importation though the 
responsibility rested on the prescriber. 96 Whilst Marinol had also been available on 
a named-patient basis, Sativex became more widely used and was issued to over one 
thousand patients by 2006.97 
In order to have the product licensed in Europe, GW Pharmaceuticals resubmitted 
its application for Sativex in 2006 via the European Decentralised procedure of the 
European Agency for the Evaluation of Medicinal Products, (European Medicines 
Agency (EMEA) since 2007).98 The procedure involved the UK acting as the Reference 
269 
Member State (RMS) and if successful would have allowed licensing across the 
European Union. GW Pharmaceuticals however withdrew the application before the 
end of the procedure in response to requests for further data.99 The MHRA provided 
regulatory guidelines to GW Pharmaceuticals for further work in order to help it 
succeed in another application. loo 
But it also raised questions of the 'rule of evidence and the role of clinical trials in 
licensing procedures. In 2009 Edwards summarises the dilemma , 
I was wondering what the rule of evidence are ... I don 1 necessarily believe 
that controlled trials are everything and sometimes persuasive evidence 
of another kind is there before one s eyes ... there are also of course quite 
bogus claims made on single cases . .. .1 deeply respect what our patients 
say and I wish doctors would listen more often and more closely. But I also 
know that medicine was once founded on what doctors believed and patients 
told and that really wasn 1 enough. We also need the evidence of science 
and to control the placebo effect ... .1 am left puzzled that the controlled trials 
building on the brilliant laboratory work.. hasn 1 had its pinnacle in the 
application to clinical medicine .. .1 really would like to see more attention 
paid to the rules of evidence for our patients sake. 101 
Conclusion 
Clinical trials have become of crucial importance in the provision of medicinal drugs 
in the twentieth century. Clinical trials in the UK on cannabis emerged after the 
convergence of interests and scientific developments after 1997: lobbying from patients; 
developments in the laboratory, the interest of individual clinicians; the involvement of 
professional bodies and the government's desire to split recreational use from medical 
benefits all played their part. The clinical trials that began after 2000 had major impacts 
on the process of re-medicalization. The trials which struggled to show effectiveness 
did indicate limited adverse effects and some potential benefits. Additionally. the trials 
highlighted problems of clinical trial methodology, both those generally associated \\ ith 
clinical trials and issues that were related to studying a drug that was based on a readi Iy 
available illicit substance. The trials, both those by industry and the proof of principle 
trials, brought extracts of cannabis into clinical trials for the first time in the l:K. This 
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had been made possible by the emergence of standardised extracts, and a sufficient 
and regular supply and delivery of cannabis-based medicine. Trials began to move 
cannabis further through the process of re-medicalization. In terms of legal provision 
of cannabis-based drugs the industry trials resulted in one cannabis-based drug being 
licensed in Canada. This was the first cannabis-based drug licensed since dronabinol 
(Marinol) and nabilone (Cesamet) in the 1980s. This time the new drug was based 
on an extract rather than synthetic THe and though no drug was licensed in the UK 
Sativex was made more widely available on a named-patient basis and available on the 
NHS. In terms of methodology, the trials led to an acknowledgement of the limitation 
of available methods for the measurement of symptoms and problems such as chronic 
pain and to the development of improved patient-based outcome measures which could 
in turn could lead to more successful outcomes of cannabis-based medicines in future 
trials. In terms of the application of cannabis the successful licensing of Sativex in 
Canada, and also the proof of principle trials in the UK, extended the application of 
cannabis beyond the anti-emetic properties accepted in the 1980s to MS and pain and 
possibly towards neuro-protective aspects in the future. The development of clinical 
trials has left various options open for licit cannabis-based medicines either through the 
development of existent synthetic, products or through the emergent cannabis-based 
extracts such as Sativex. If Sativex was to pass successfully through the licencing 
system there would then be questions of availability, cost and access on the NHS to be 
resolved. 
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Chapter Nine 
Conclusion 
'MIST OPPORTUNITY - Does Sativex represent the future of medical 
marijuana-or the end?'} 
This newspaper headline from 2005 about GW Pharmaceutical's cannabis-based spray. 
Sativex, posed an interesting question. Sativex was expected to gain a licence in Europe 
in 2010, and synthetic cannabis-based drugs were seeing something of a revival. But 
how did we get to this point from the WHO's 1952 pronouncement that cannabis had no 
medical value and its removal as a medical substance in the UK in 1973, and what did it 
mean for cannabis, itself, as a medicine and its position in the drug control framework? 
Cannabis' role as a medical substance never disappeared entirely. Its medical 
role was maintained by some within the patient community and scientific research 
continued, albeit in very limited manner, even when its dual structure was denied 
by policy. During the period under study, many of the problems that had hindered 
cannabis' transformation, from a drug to a medicine in the nineteenth and for most of 
the twentieth century, were overcome, facilitating re-medicalization. 
Changing scientific knowledge contributed to a shifting environment around 
cannabis. Science had played a role in the post-war marginalization of tobacco, 
but, in contrast, science played an important role in the re-medicalization of cannabis. 
Medicinal chemists, pharmacologists, sociologists and psychiatrists, neurologists, and 
anaesthetists all contributed their expertise to the developing understanding of cannabis 
and to its application as a medicine. This took place within the context of the rise 
of more specialist disciplines, such as clinical pharmacology, psychopharmacolog) 
and phytopharmacy. Personal, and later professionalized, scientific networks pulled 
disparate researchers together and stimulated breakthroughs, any on~ of which, if 
missed, might have stopped re-medicalization. Major discoveries, including the 
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isolation of the active principle, THe, the synthesis of cannabinoids and the discov~n 
of the endocannabinoid receptor system re-invigorated the field at critical points. The 
discovery of the endocannabinoid receptor system conferred legitimac) to anc:cJotal 
reports of cannabis's therapeutic use, for example, it demonstrated the importance 
of this system in the modulation of pain and opened up new avenues for research. 
Advances in other fields, such as the opiates, and cloning, also contributed to advances 
in understanding. In addition technical developments, such as mass spectrometry, 
enabled research to progress at a faster pace, and allowed for more subtle analysis in 
experiments. But 'blue sky' research is rare and individual and disciplinary interest was 
supplemented by the broader, twin needs of drug control and medical necessity. 
Political and social fears over cannabis' recreational use and subsequent 
developments in drug control were paramount in the process of re-medicalization. In 
the search for solutions to the drug problem, countries, such as the UK, pursued, not a 
medical, but, a control-oriented approach. There was a global dimension to this, driven 
largely by the US. Medical utility was critical for the placement of drugs within drug 
control legislation, and cannabis' role as a medicine was eroded at the policy level. 
Though international and domestic drug control systems acted as a countervailing force 
against medical use of cannabis, they also provided a dual spur to re-medicalization. 
First, drug control imperatives directed funding to the cannabis field. Treating 
cannabis an illicit drug forced the need to improve the knowledge base for control 
purposes, pulling scarce resources into the cannabis arena. Though initial research 
focused on the deleterious effects, in the process of understanding the pharmacology 
of cannabis, research indicated some medical applications. Paton's work on cannabis' 
pharmacological relationship with anaesthetics indicated analgesic properties: an area 
investigated in-depth by clinicians from the 1990s. When scientific research emerged 
on cannabis' applications as an anti-nausea agent, and in the treatment of diseases, 
such as glaucoma, asthma and epilepsy, it began to overturn the viewpoint enshrined 
in policy: that cannabis' medical use was obsolete. But the question in the early 1970s 
was, whether, it was wise to utilize cannabis as a medical drug. In the light of its 
potential harms; its potential as a drug of misuse; not to mention it pharmacological 
complexity, researchers like Paton answered 'no'. Nevertheless by the mid 1970s 
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other pharmacologists were beginning to answer, 'yes', and it appeared that cannabis' 
potential as a medicine had begun to outweigh its possible harms. This \\ as the case 
especially where there was clear unmet medical need for high profile medical problems 
such as in the management of cancer. 
The transfer of this science to policy was enabled by the developing mechanism 
of expert advice via expert committees and the desire to place policy on a stronger 
evidence base, especially in the illicit drugs field. Cannabis's borderline position 
and widespread use within the community meant that considerable time was spent 
discussing cannabis, and the initial expert committees in the 1970s and 1 980s provided 
early discussion of cannabis' potential as a therapeutic. The drug problem had been 
framed under the criminal justice system but as the limitations of this were revealed 
and other pressures mounted, both from the focus on civil liberties and the practicalities 
of implementing a penal approach, new approaches were sought. Early public reports, 
such as the Wootton Report, downplayed the harms of cannabis and raised the profile of 
the therapeutic use of derivatives of cannabis in policy circles and the public domain. 
The closed discussions of the ACMD sub-committees also contributed to a shift in 
the policy environment. As cannabis had lost its dual structure, cannabis discussions 
inevitably had to cover emergent therapeutic indications. The use of cannabis by 
critically ill patients highlighted further some of the problems of a penal response and 
necessitated evaluation of where responsibility for medical cannabis lay. 
The UK had a more flexible attitude to the medical use of controlled drugs than 
the US. In the UK, for instance, diamorphine (heroin synthesised from morphine) had 
legal pharmaceutical status unlike in the US. Under the British system there existed 
medical and non-medical structure for the drug. Opium, existed under both legal 
proscription and medical prescription as its alkaloids, like morphine, retained their 
duality. Tobacco, on the other hand, moved further in the opposite direction. It had no 
medical value, and with evidence of harms increasingly accepted it became increasingly 
regulated and its cultural acceptability diminished. Cannabis, or, at least, its derivatives. 
retained the potential to return as a pre scripted product and to regain its dual structure. 
In turn, this research and emerging scientific legitimacy began to influence discussion of 
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cannabis policy more generally. Whatever policy was to be adopted and implemented, 
scientific research was required. Without this driving force to improve the knowledge 
base, cannabis might have remained a poorly understood herbal product. The policy 
structures around cannabis, including the ACMD, the Home Office and the DHSS all 
demonstrated shifts, towards acceptance of cannabis as a medicine in some form. As 
cannabis began to regain medical credibility, policy-makers saw the advantage to be 
gained by recreating the dual role for cannabis, as it offered the opportunity to split 
medical from recreational use of cannabis, and in the process weaken demands for 
legalization. 
Internationally, attitudes of the international agencies towards cannabis-based 
medicines underwent something of a change. Emergent therapeutic uses overturned 
the WHO's 1952 pronouncement that cannabis had no medical use, and, by the 1990s, 
the WHO began to take a softer line towards medical applications, for example, 
recommending the downgrading of dronabinol in the 1990s. Also, by the 1990s, 
the INCB had to concede some limited medical utility, if, perhaps only, to retain its 
authority and the integrity of the drug control framework. The stigma around cannabis 
was difficult to dispel as evidenced by the divisions between the UN agencies over 
dronabinol's placement within the UN 1971 Convention on Psychotropic Substances. 
Furthermore, herbal cannabis or medical marijuana, as advocated in some US states, 
and Canada, was in no way accorded a similar shift in attitude. 
In transforming the concept of cannabis, the drug, into cannabis, the medicine, 
the pharmaceutical industry was fundamental. The development of cannabis-based 
medicines by industry appeared to offer a way of accepting cannabis' medical 
utility, at the same time as transferring the ownership from 'illicit' drug users to the 
professional medical sphere by putting into place medical and regulatory structures 
around cannabis-based drugs. In the nineteenth and early twentieth centuries, with the 
professionalization of medicine, patent medicines were sidelined and self-medication 
attacked. Commercial products and treatments were shifted away from the control of 
pharmacists and patients, towards pharmaceutical products regulated by government. 
This avenue was deemed acceptable by policy-makers and the medical establishment, 
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unlike patient attempts to self-medicate with un standardized, herbal products. The 
isolation ofTHC encouraged the interest of pharmaceutical industry in the 1970s, 
which then provided the first licensed cannabis-based medicine since the removal of 
the tincture. Industry provided single, chemical entity synthetic drugs; chemically 
manipulated versions of the main psychoactive phytocannabinoids. Some of these 
proved to have too many side-effects and never made it to the clinic but re-stimulated 
academic research. Others were tested in the clinic and made the leap through the 
regulatory process in the 1980s though they did not reach a wide market. The drugs 
might have been introduced because of a focus on cancer, a high profile, and emotive 
disease, but with the stigma of cannabis still acting, and with strict controls and the 
advent of additional drugs for these applications, industry soon lost interest. The 
relative failure of the single chemical entity drugs left: the door open for demands 
for herbal cannabis and the development of additional cannabis-based medicines. 
In the 1990s the niche, left: open by synthetic cannabis-based medicine, stood ready 
to be filled. Cannabis therapeutics benefited from the changing structure of the 
pharmaceutical industry. The development of biotechnology firms to fill niche markets 
neglected by big pharma, allowed for the creation of a small firm, in the form ofGW 
Pharmaceuticals, to take an alternative route to the process ofre-medicalization: 
phytomedicine. To an extent, some of the constraints imposed by the stigma around 
cannabis for big pharma, were not relevant to a scientist entrepreneur, with a belief and 
expertise in phytomedicine. 
Phytomedicine, which had originally filled the medicine chest and then been 
marginalised as the pharmaceutical industry developed and concentrated on synthetics, 
began a comeback in the late twentieth century. It provided a route to integrate 
user activist's demands for access to herbal cannabis, but at the same time provide a 
standardized and regulated medicine. The myriad of constituents found in cannabis, 
as in any plant, posed problems in early research, but, in later years, looked to be a ke: 
benefit. The desire to create a medicine out of herbal cannabis raised heated debate 
over the form to be researched. developed and licensed: Should it be cannabis; THe, 
or other cannabinoids, either singularly or in combination? The thesis demonstrated a 
shift from the search and development of single chemical entities, usually synthetics, 
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to a re-emergence of interest in botanical cannabis. That change was facilitated by the 
rise of phytopharmacy and the biotechnology industry. Close relationships between 
industry, academia and government proved decisive in the 1990s as evidenced b: the 
story of GW Pharmaceuticals. Government licensed GW to develop cannabis-based 
medicines and it offered the long sought after domestic supply. GW was able to solve 
another key problem that had plagued cannabis: standardization of the raw material on 
an industrial scale. GW Pharmaceuticals' focus on a botanical substance, a traditional 
medicine, not a new chemical entity, meant that a product could be brought relatively 
quickly to market. This was a necessity when there was so much pressure to make 
cannabis available as a medicine. The relationship with big pharma was important. By 
the early twenty-first century, big pharma was showing an interest in the phytomedicine 
and a strategic alliance was formed between Bayer AG and GW for Bayer AG to market 
licensed Sativex medicines. The debates over form were important for the process 
of re-medicalization, as they impacted on attempts to draw a distinct line between 
recreational and medical use. Cannabis was a borderline substance but it was initially 
its derivatives that had more potential to be treated more flexibly. Once cannabis-
based medicine extracts were introduced it could be argued that there was no further 
requirement for the use of herbal cannabis, which was more likely to remain static 
within the drug control framework. 
The ability to deliver cannabis via a new delivery system was another factor in its 
re-medicalization. It was nineteenth century technological developments in drug 
administration systems that had helped marginalise cannabis, as it not water soluble, and 
therefore was not suitable for the new hypodermic syringe. The development of synthetic 
single entity chemical cannabinoids, delivered via tablet form whilst acceptable for policy, 
and to the pharmaceutical industry, proved less acceptable to patients, who maintained 
a preference for smoked herbal cannabis. In the 1990s, GW's new delivery system, 
an oral-mucosal spray, offered a number of advantages. It avoided smoked cannabis, 
a no-go for policy-makers and the medical community, and it bypassed the problems 
associated with oral administration that had beset the single chemical entity drugs, and 
provided patients with something more akin to the advantages of smoked cannabis. 
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Cannabis therapeutics in the UK after the 1990s would not ha\ t advanced as it 
did without the legitimacy conferred on the concept by influential professional bodies. 
such as the Royal Pharmaceutical Society and the BMA. When the BMA, produced a 
reasonably favourable report on cannabis therapeutics, it boosted cannabis' legitimacy. 
This was important in the context of the power of the medical profession and the 
close relationship between the state and medicine. The Royal Pharmaceutical Society 
provided the practical framework to build on the recommendations of the BMA report 
and brought researchers, industry, funders and policy-makers together with one aim - to 
carry out clinical trials on cannabis and hopefully lead to a cannabis-based medicine. 
The House of Lords Science and Technology Committee brought all the stakeholders 
together in an open forum and helped alter the policy environment around cannabis, 
and, most importantly, provided the momentum to force the concept into real it)'. 
The incentive to study cannabis as a medicine would not have taken place as it did 
without the role oflay knowledge. In this, cannabis' position as a botanical substance 
was important, as it meant that the general public had access to, and intellectual 
knowledge of, the drug in advance of it becoming a pharmaceutically produced product, 
in contrast to most other medicines. Despite increased controls on drugs there remained 
widespread illicit access to cannabis and a battle over the 'ownership' of cannabis 
emerged. Lay knowledge of cannabis drew attention to its medical properties for a 
raft of problems including; use as a palliative in the 1970s, for glaucoma; for AIDS in 
the 1990s, and also for MS and pain. Knowledge of cannabis' therapeutic qualities, 
combined with the illegal status of cannabis, led to the development of lay advocacy. 
Medical arguments emerged as a component of the 1960s legalization activism but, 
in the UK medical activism for research and access to cannabis for MS became , 
important in the 1990s. High profile advocacy, combined with high profile legalization 
demands, that developed in this period, placed pressure on policy. The result was the 
facilitation of clinical trials and the incentive for the pharmaceutical industry. in the 
form ofGW Pharmaceuticals, to risk the costs of research and development with the 
stated acknowledgement by government, that if an evidence-based drug could pass 
through clinical trials it could be licensed in the UK. Lay knowledge and advoc<.lC) 
was also critical in focusing the direction of research. This included the form of 
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cannabis to be studied and made research into extracts of cannabis imperative. It was 
important in forcing researchers, industry and regulators to take account of the patient 
perspective, no small point in medicine. Patient experience forced researchers to re-
evaluate outcome measures in clinical trials. Finally, when no drug was forthcoming 
after the development of trials, patient concerns contributed to the circumvention of the 
regulatory system by the import of Sativex, on a named-patient basis as a temporary 
measure. 
As these driving forces coalesced they resulted in a concerted effort to place 
cannabis into the clinical trial system, providing the opportunity to prove cannabis' 
safely, efficacy and quality, as demanded by the MHRA, under the Medicines Control 
Act of 1968. The trials that took place demonstrated safety, if not efficacy, and the issue 
of efficacy, it was argued, could be related not to cannabis, but, to the very methodology 
ofrandomised clinical trials themselves. The study of plant-based products, especially, 
for the treatment of subjective issues like pain, highlighted the inherent problems 
with the methodology of RCTs and the regulatory mechanisms. Although trials in 
the UK and the licensing of Sativex in Canada, and its introduction to the UK on a 
named-patient basis, represented another step in the process of re-medicalization, it 
remained un licenced in the UK. Therefore, there remained a wide gap between these 
developments and the provision to patients. 
If Sativex passed through the regulatory systems and was made available for 
patients what does did it mean for cannabis as a medicine or indeed cannabis itself? 
Will such developments be successful in re-creating the dual structures for cannabis? 
Will patients be satisfied with Sativex, and tum away from herbal cannabis or \vill 
Sativex not fulfill expectations and demand remain for access to herbal cannabis. The 
development of Sativex, also raises broader questions over the treatment of traditional 
knowledge, herbal medicines and raw materials and the patient experience. Synthetic 
cannabis-based medicines proved expensive and were used in small amounts only, 
so how accessible will Sativex prove to be on the NHS? Will new versions and 
applications be produced? Where will Sativex sit within drug regulation? What impact 
will developments in agonists and antagonists based on the ECRS have in future 
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years? What would the provision of a patient and regulatory acceptable cannabis-bas~d 
medicine mean for herbal cannabis within the drug regulatory system. 
By 2004 with cannabis downgraded, clinical trials ongoing and Sativex apparently 
set to emerge as a licensed medicine, it appeared that re-medicalization of cannabis 
could be achieved, without forcing a major re-evaluation of international and national 
policies. Re-medicalization was achieved to some extent but within constrained 
structures within professionalized medicine. The provision of cannabis, itself. was 
never really on the agenda and did not extend to giving patients 'ownership' of herbal 
cannabis, even on a compassionate basis, a move which would have had much greater 
impact on legal controls on cannabis. This opens up further questions of the role 
and position of herbal and traditional medicines within the medical market place 
and regulatory systems. The therapeutic cannabis- based medicines which emerged 
ultimately had little impact on the legal control of cannabis as recreational and medical 
use existed within separate networks within the drug control and regulatory systems. 
When scientific, medical and industrial networks regained 'ownership' of the medical 
aspects of cannabis, by the end of the period understudy, the medical use of cannabis 
looked to be back in some forms and able to exist in both controlled drug and medicine 
regulations. The emphasis then shifted from the place of cannabis within therapeutics 
and its potential impact on drug control to the broader question of the relationship 
between cannabis with other drugs, both illicit and licit, and the framework of drug 
control and the way psychoactive drugs are dealt with in society. 
Despite downgrading, cannabis' continued borderline status was about to create 
a backlash. Prior to downgrading concerns had been raised over the dearth of research 
in the addictions field on cannabis and others called for a more cautious approach 
and the need for additional information on such substances in light of the 'history of 
premature closure on social polices towards psychoactive substance our experience 
with alcoholic beverages, tobacco, heroin and cocaine. '2 Controversy did not evaporate 
but rather intensified and within four years government re-graded cannabis to Class 
B, on the grounds of the availability of more potent strains, and the threat to mental 
health. Robin Murray, Professor of Psychiatry at the Institute of Psyc h iatry, London, 
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drew attention to new evidence that heavy cannabis use appeared to be linked to serious 
mental illness. The government came under criticism for downgrading cannabis from 
the UN. The UNDOC chief, Antonio Maria Costa argued against policy reversals and 
the message they apparently sent to young people and he was reported as stating that 
countries received the 'drug problems they deserved. 'Costa argued that it was a mistake 
to dismiss cannabis as a 'soft' drug, a view that attracted increased attention in some 
sections of the media.3 
The rapid fluctuations of cannabis' position as a borderline drug drew attention to the 
validity or otherwise of the control system. Cannabis remained 'dangerous medicine' 
and cannabis harms included its threat to the stability or structure of the control 
framework. There were calls for the entire system to be re-evaluated and comparisons 
were drawn between cannabis and licit drugs, like alcohol and tobacco. The subsequent 
disagreements between the government and the ACMD drew attention to the role of 
expert advice, and evidence-based policy and transparency in the decision-making 
process. Writers have shown how little history has spoken to policy in the drugs control 
field or complained about the selective use of history in its formation. A knowledge 
ofthe history of drug control policies and the substances that these policies control is 
important for future policy around illicit drugs and medicines. What impact the debate 
will have on the later stages of re-medicalization remains to be seen, as, at the time of 
writing Sativex, is yet to pass through the final stages of regulation to provide a licensed 
medical drug in the UK. 
I D. Bienenstock, 'Does Sativex represent the future of medical marijuana--or the end? http://www. 
mindifidoaj .com/forum!f16/can _ sativex _brings _ about_end _ med-7985.html 
2 W. Hall, and T. Babor, ' Cannabis Use and Public Health: Assessing the Burden, Addiction, 95 (.t) 
(2000), p. 488. 
3 P. Johnston, 'UK 'too soft on cannabis dangers.' Telegraph 27 june 2006. http://www.telegraph.co.uk! 
news/uknews/ 15 223 99/UK -too-soft-on-cannabi s-dangers.htm 1 
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Appendix 1 
Search Terms: 
Boundary substance, peculiar substances, borderline substances 
Cannabis 
Cesamet 
Charvre indiene 
Dronabinol 
Drug addiction 
Drug control 
Drug dependence 
Expert advice 
Hashish 
Institutional histories: MRC, BMA, WHO, ACMD 
International agencies, WHO, INCB, UN 
Key reports such as Wootton, Brain, BMA 
Lay knowledge, user activism 
Licensing 
Marihuana 
Marijuana 
Marinol 
Medicine Regulation 
MS Society 
MS 
Nabilone 
Pharmaceutical industry, Pharmacy, Biotechnology, Pharmaceuticals 
Phytomedicine 
Pot 
Psyhopharmacology 
Regulation 
Sativex 
Synergism 
THC 
Terms were expanded as new areas of investigation emerged such as clinical trials and 
standardization. 
Appendix 2 
Re-Medicalizing Cannabis: Science, Medicine and Policy, 1960s-2003. 
Principal Investigator: Professor Virginia Berridge. 
Research Assistant: Ms. Suzanne Taylor: Tel: 078013655461 suzanne.taylor@lshtm.ac.uk 
Centre for History in Public Health, London School of Hygiene & Tropical :\ledicine 
University of London, Keppel Street, London, WCIE 7HT. ' 
Cannabis has been the subject of much policy and public attention in the last few years and the 
recent legal changes under the Misuse of Drugs Act in the UK have been widely, although 
incorrectly, presented as liberalisation or legalisation of the drug. Reports of potential 
therapeutic uses, especially for MS and cancer chemotherapy patients, possible harmful effects, 
in particular, psychosis, and fluctuating government policy, have all have brought cannabis 
more into the media and public discussion. 
Historical work on cannabis exists and has been used to inform current debates. Such history 
has tended to concentrate on the nineteenth century, on literary or alternative uses of the drug. 
Recent work has expanded our knowledge of colonial production and supply and initial 
international controls and many popular histories have been written contributing to the 
legalisationl prohibition axes of public debate. But, the contemporary history of cannabis has 
been little studied. This study is framed as a history of science and policy making with the 
overall hypothesis that the medicalisation of cannabis has been an important route for changes 
in the environment in which policy on cannabis has been made. By medicalisation, or rather re-
medicalisation, it is meant the introduction of medical uses and structures for the drug, as 
distinct from non-medical, illicit usage. 
The purpose of this research project is to study the process of medicalisation of cannabis since 
the 1960s and the interests involved, in particular, the role of scientific research and allied 
professions; of industrial interests; and of user activism. The project examines the interaction of 
science and medicine with policy at the national level and assesses the overall impact of 
medicalisation on the policy environment. A key part of the research is a series of interviews 
with 'key informants' with views on the therapeutic use of cannabis. These interviews will feed 
into articles for publication in a range ofhealthlmedical and historical outlets as part of a three 
year Wellcome Trust funded study. 
Your involvement. 
I hope that you will agree to be one of the 'key informants' for the res.ea~c? The !nterview can 
be as long or as short as you like. It will be conducted by Professor Vlrgmla Berr~dge, an 
historian with long experience of the drugs and alcohol field and health research m general, or 
Suzanne Taylor, her Research Assistant, a medical historian with pa~icular.interest in plant-
based medicine. If you would like this interview to be on a confidentIal baSIS, for b.ackground 
only, then please indicate this on the attached form. All interviews will be anonymlscd for 
publication if the interviewee wishes. 
Storage and ethical approval. 
Data will be kept in a locked filing cabinet and if material is held on a computer this will be 
password protected. 
The study has been approved by the LSHTM Ethics Committee. 
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Appendix 2 
Consent Form: Re-Medicalizing Cannabis: Science, Yledicine and PoliCY. 1960s-
2003. . 
N ames of investigators: 
Principal Investigator 
Research Assistant 
Professor Virginia Berridge 
Suzanne Taylor: Phone: 07801365546 
Email: suzanne.taylor@lshtm.ac.uk 
Centre for History in Public Health, London School of Hygiene & Tropical 
Medicine, University of London, Keppel Street, London, WCIE 7HT. 
The purpose of this fonn is to allow the use of your interview for research purposes. 
Please fill in the fonn according to your wishes. 
I hereby assign copyright of my contribution for research purposes to the Centre for 
History in Public Health at LSHTM. 
Name: 
Signature: 
Date: 
I pennit the use of my name with quotations from the interview. [] 
I wish to be consulted before publication of named quotes. [ ] 
I wish quotes to be used anonymously and for background only. [] 
Appendix 3 
Brief History of Drugs Legislation 
Year International UK Legislation Effect 
1868 Pharmacy Act Included schedule of 15 'poisons' of which 
sale or supply to be restricted to 
pharmacies. Included opium, strychnine, 
belladonna and mercuric chloride. 
1875 Food and Drugs Penalties for adulteration 
Act 
1908 Poisons and Revised schedules of 'poisons' and 'listed 
Pharmacy Act sellers' of non-medicinal poisons; limited 
companies controlled. Added further 
controls over the sale of opium and 
morphine. 
1912-1914 Hague Require parties to suppress production and 
Convention trade and prohibit import and export of raw 
and prepared opium. 
1925 Geneva Cannabis incorporated into international 
Convention legislation. It did not prohibit domestic 
cultivation, production or distribution of 
cannabis. 
Dangerous Controlled import and sale of addictive 
Drugs Act drugs, notably opium, cocaine and 
cannabis. 
1933 Pharmacy and Amendments to 'poisons' schedules and 
Poisons Act rules for labelling, packaging and selling 
medicines containing 'poisons'. 
1941 Pharmacy and All active ingredients of medicines for sale 
Medicines Act to be disclosed on labels; list of diseases 
for which advertising of medicines to treat 
made illegal; stamp duty repealed. 
1961 UN Single Maintained and strengthened existing 
Convention on controls. Extended controls to cover the 
Narcotic plants cultivated to product narcotic drugs. 
Substances Limited to medical and scientific purposes, 
with a 25 year exemption for traditional 
use. Introduced 4 schedules to classify 
drugs. 
1964/65/67 Dangerous Extended controls to cannabis and coca 
Drugs Acts leaves, effected controls O\cr LSD. and 
introduced police powers of stop and 
search. 
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Year International UK Legislation Effect 
1968 Medicines Act Consolidated list of diseases for which 
adve.rt~sing to the public is illegal; 
medIC me subject to safety quality and 
efficacy criteria before marketing 
authorisation graded three classes of 
medicine established, only general sales 
lists allowed to be sold from any shop. 
1971 UN 
Convention on 
Psychotropic 
Substance 
Misuse of Drugs Consolidates existing law and developed 
Act the term 'controlled drugs. Introduced new 
drug offences including possession with 
intent to supply, and extend the range of 
controlled drugs, increased penalties for 
possession, and allowed for future 
amendments. Regulations allowed 
modifications to the Act. Established the 
Statutory advisory committee the ACMD. 
Included a provision for the Home 
Secretary to encourage research into 
controlled drugs. 
1973 Regulations of 
the Misuse of 
Drugs Act 
1985 Controlled Increase maximum prison sentences for 
Drugs Penalties trafficking of Class A drugs 
Act 
2003 Criminal Justice Makes procession of cannabis or cannabis 
Act resin an arrestable offence to co-inside with 
the downgrading of cannabis from Class B 
to Class C and increased maximum 
penalties. 
Amended from M. Jepson, 'From Secret Remedies to Prescription Medicines: A Brief History 
of Medicine Quality,' in Anderson, S., Making Medicines (Pharmaceutical Press: London, 
2005), 
pp. 228-229 and Jason-Lloyd, Misuse of Drugs: A Straightforward Guide to the Law (Waterside 
Press, 2007), pp. Appendix 2. 
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Appendix 4 
United Nations system and drug control organs and their 
secretariat 
United Nations 
I 
General Economic and 
Assembly Social Council 
Functional Specialist 
Commissions Agencies 
WHO 
Expert Committee Commission on INCB Narcotic Drugs on Drug 
Dependence 
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Appendix 5 
Regulation of substances 1971 
Drugs 
Controlled 
Regulated 
medicines 
Medicines Act 
1968 
e.g. penicillin 
Appendix 6 
Prescribing of Cannabinoids 
Commercially Licensed for Subject to Misuse Basis of use in UK 
available use in UK of Drugs Act 
(and current 
status) 
Nabilone Yes Yes No A GP can prescribe but 
accepts responsibility for use 
for any unlicensed 
indications. 
Dronabinol Yes (USA) No Yes A GP can prescribe on a 
(Schedule 2) named patient basis but 
as is morphine accepts responsibility for its 
use. No need for licence for 
clinical trials. 
Cannabinol No No Yes If a commercial product 
(schedule 1) became available and 
cannabinol was rescheduled 
to Schedule 2, a GP could 
prescribe but accepts 
responsibility for use on a 
named-patient basis. 
Cannabidiol No No No If a commercial product 
became available and was 
licensed, a GP could 
prescribe. No rescheduling is 
necessary. 
Sativex Yes (Canada) No ? It is available as an 
unlicensed medicine on a 
named patient basis. 
Currently proceeding 
through regulatory 
mechanisms in Europe. 
The two compounds that are not commercially available are included to illustrate the following 
points: 
1 If Cannabinol was to be introduced as a commercially-available licensed 
product, then it would require to be moved from Schedule 1 to Schedule 2 
11 Cannabidiol is not included in the list of substances and products listed in 
Schedule 1 
Amended from the House of Lords Select Committee on Science and Technology Committee, 
Cannabis: The Scientific and Medical Evidence: Evidence (London: TSQ, 1998), p. 293. 
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Appendix 7 
Expert Committees 
Year Acts Expert Committee Sub committees t Reports 
1958 
1959 
1960 
1961 
1962 
1963 
1964 
1965 
1966 
1967 
1968 
Interdepartmental 
Committee on Drug 
Addiction (ad hoc 
committee) (chaired 
by Russell Brain). 
Advisory Committee 
on Drug Dependence 
(ad hoc committee) 
-7 
: 
! 
Hallucinogens 
Subcommittee 
Chaired by Lady 
Wootton-7 
, 
i 
i 
---------------------------------1 
i Ministry of Health Scottish 
Home and Health Department, 
Drug Addiction ([he Brain 
,Report) (London: HMSO, 
!1 961 ). 
i 
Ministry of Health Scottish 
Home and Health 
Department, Drug 
Addiction: The second 
report of the 
Interdepartmental committee 
on drug addiction (London: 
HMSO, 1965). 
Advisory Committee on 
Drug Dependence, 
Hallucinogens Sub 
Committee, Cannabis: 
Report by the Ad\'isOlY 
Committee on Drug 
Dependence (London: 
HMSO. 1968). 
1 ..... --------.. --.. --------.--------------------------.. -.. -----------.... ---t-----------... ------.--.------.. -.-.--------t---------- ------ ---- -------- ---
1969 
,-----.. -----------------------f----------
1970 
293 
Year Acts/bill Expert Committee 1 Sub committees Reports 
1971 ! Misuse of Drugs I 
---.-------J~~~-- ... -----.----.----L ___ . ___ . ______________ . ____ ~-------. _____________ +_I---_____ _ 
1972 I i 
iACMD~ 
--..... -.---.. -... ---.. ~ ..... ----....................... -........ __ ..................... --+ ....... --.... -------.-----.---......... --.... -.. --+ .. -----.. -------.---.-----io.--_ .. _. ____ _ 
i Working Group 
ion Cannabis~ 
1973 i , 
--......... ---.... --.----.. -.-.--.. ---........ ---.:-.--------.-.----.. -.--------t---------.. -----.---~-.- .. --
i I Advisory Council on Drug 
: Misuse, First Interim 
1974 
I Report of the Working 
I Group on Cannabis 
i (London: Advisory 
I i Council on the Misuse of 
! ! Drugs, 1982) . 
.. -....... -----.-.----~ ... -----..... ,.---......... ---..... ·····--..... ··----.... -.--1 ....... ---, ..... ---....... ----....... ----....... ---......... --- ...... ---.; ..... ----..... ----.. -.. ___ ........ ___ .. _ .. __ ._ .. ____ .. ~_-_ .. _ ... _____ .. _ ... ____ ....... ____ ... ___ . 
1975 ! j ! 
--.... " ... ---....... ---.. \ ...... ----." ... ---......... ---"·'·-··-··-· .... '·-.. --·······-~·t·······---··· .. -.--....... ----....... ----....... ---........... -.. . ..... ---....... -.. --........ ---....... ---......... --......... ----. ···----··t----······---······-·---··-· .----.... ----
1976 i i : Advisory Council on Drug 
! Misuse, Second Interim 
! Report of the Working 
: Group on Cannabis 
1 (London: Advisory 
i Council on the Misuse of 
i i Drugs, 1982). 
--........... ---.. -... -.. + .... ----... : .. -.. -.. ~ ..... --_ ......... _-_ ........ _-_ ....... _-.j-. ...... _-_ ......... _-_ ....... _--_ ... _ .. _---......... __ ..... --- . --- . ---- ---- --- .... _-_ .... __ .. _ ....... __ .. 
1977 ! Cnmmal Law ; i ACMD: 
I Bill I Technical 
! Committee; 
I 
I Working Group 
i on Cannabis; 
I Working Group 
! on Legal and 
! Administrative 
I ! Matters 
i ___ ._. __ : ________ . ______________ ~_!.. ________ _ 
--... -.... ---....... --! ...... ----...................... ---.... ---..... ----..... --+ .-.. ---.----.. -.----. ---- -- i 
1978 I '. _____ . ____ ._. _______________________________ : ______ .. _ .. ____ _._. 
-...... _ .._--....... _---;.. .... -.. --....... ---...... ---.. ····---·· .. ·----·-··--r···---···· ---. -.---- . i : ACMD releases 
1979 ! : 
recommendations 
-----------_.---.1-------_._-_._--_.- .. 
.... --- ..... -- --.. --- ··-r --- .. ---.- -.--.-- I ACMD Expert 
! Group on the 
-_·· .. ······ __ ·······--··-1· 
1980 
! Effects of 
1 Cannabis~ , 
-······----·······----f·····---·-·-·--····-···---·-··---····---·····--t-·-·----·---·---------·---+·---··---··---r----------.---
1981 ,I, : _ .. _. ___________ l ____________ i _________ _ 
--- .-.---."---.... --.t..~.--.. ----. -- - --
---·-·---·····----i····--- i Advisory Council on Drug 
1982 i Misuse, Report of the 
: expert group on the effects 
of cannabis use (London: 
Advisory Council on the 
, Misuse of Drugs, 1982). 
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Appendix 8. 
Clinical trials on cannabis in the UK 1999-2008 
Trial Name PI Dates Product tested Regulation and Marketing Comments 
CAMS: Cannabinoids Professor John Zajicek 2001 THC (Marino I) Proof of Principle Trial 
in MS Derriford Hospital Cannador (extract of 
Plymouth Medical cannabis.) 
School Placebo. 
I CANPOP: Trial of Dr Anita Holdcroft, THC (Marino I) Proof of Principle Trial This was planned as two stages. 
Cannabis for Acute Hammersmith Hospital Cannador (extract of As dose finding study and a main 
Post-Operative Pain London. cannabis) trial. The main trial never took 
Placebo place due to recmitmcnt 
problems. 
CUPID: Cannabinoid Professor John Zajicek, 2006- Proof of Principle Trial Planned as a three year study It 
use in Progressive Derriford Hospital, began recmiting in 2006 reaching 
Inflammatory Brain Plymouth full cohort in 2008. 
Disease 
William Notcutt. For William Notcutt, John Nabilone Proof of Principle Trial 
chronic pain conditions Paget Hospital Norfolk Sativex 
including MS. 
~-
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Trial Name PI Dates Product tested Regulation and Marketing Comments 
GW Pharmaceuticals 1999- Cannabinoids, with a Submitted to MHRA 2003 and 
Trials. focus on Sativex refused 2004. 
(CBD and THC) 
Licensed in Canada 2005 by 
Health Canada. 
I 
2005 Appealed MHRA 
decision. 
2005 Made available on an 
unlicensed, named-patient 
basis in the UK. 
2006 Regulatory submission 
to European Agency for the 
Evaluation of Medical 
Products. (now EMEA). 
Application withdrawn. 
2009 Resubmitted to EMEA, 
decision expected early 2010. 
- .. _- - ---
-------
L-. ___ 
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Appendix 9 
A Brief History of UK Medicines Regulation 
Date I Event 
1864 The first edition of the British 
Phannacopoeia (BP) set standards for the 
manufacture of common established drugs. 
1917 The Venereal Disease Act and later the 
Cancer Act of 1939 prevented the 
advertising and promotion of medicines for 
these conditions. 
1925 The Therapeutic Substances Act 
introduced regulations concerning the 
manufacture of biological substances. 
Consolidated 1956. 
1961 The thalidomide disaster. 
1963 The Committee on Safety of Drugs (CSD) 
established. 
1967 A White Paper recommended legislation 
rather than a voluntary system to control 
medicines. 
1968 Medicines Act received Royal Assent. 
1971 The Medicines Commission, an expert 
advisory committee, created to advise 
Ministers. The CSD became the 
Committee on Safety of Medicines (CSr-..l) I 
and later the Commission for Human 
Medicines (CHM). 
1989 Medicines Control Agency (MCA) created. 
1995 The European Medicines Agency (E:vlEA) 
was set up to co-ordinate and 
provide regulatory support to EU member 
states as was the European Medicines 
Advisory Committees for both human and 
veterinary medicines. 
2003 The Medicines Control Agency and the 
Medical Devices Agency - merged to form 
the Medicines and Healthcare products 
Regulatory Agency (MHRA). The CSM 
and Medicines Commission merged to 
form the Commission on Human Medicine 
(CHM) a committee of the MHRA. The 
MHRA is an executive agency of the 
Department of Health and is responsible 
for ensuring that medicines and medical 
devices work, and are acceptably safe. 
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